[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-7b_response": "The synonym of Acrokeratosis paraneoplastica is \"neoplastic acrokeratoderma.\"",
    "llama-7b_fact_raw": "1. Acrokeratosis paraneoplastica is also known as \"neoplastic acrokeratoderma.\"",
    "llama-7b_fact": [
      "Acrokeratosis paraneoplastica is also known as \"neoplastic acrokeratoderma.\""
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Acrokeratosis paraneoplastica is also known as Bazex syndrome.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-7b_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect the development of the brain and body. However, they are distinct conditions with different genetic causes and clinical features.\n\nWeaver syndrome, also known as Weaver-James syndrome, is caused by mutations in the NSD1 gene. This gene plays a crucial role in the development of the brain and other parts of the body. People with Weaver syndrome may have abnormalities in their facial features, hands, and feet. They may also have delayed development, intellectual disability, and behavioral problems.\n\nSotos syndrome, also known as 45,X/46,XY mosaicism, is caused by an abnormality in the sex chromosomes. People with Sotos syndrome have an extra copy of the long arm of the X chromosome (45,X). This extra genetic material disrupts the normal development of the brain and other body parts. Individuals with Sotos syndrome may have a distinctive facial appearance, including a prominent forehead, wide-set eyes, and a short nose. They may also have delayed development, intellectual disability, and behavioral problems.\n\nIn summary, Weaver syndrome and Sotos syndrome are different conditions with distinct genetic causes and clinical features. While both conditions affect the development of the brain and body, they have different genetic abnormalities and symptoms.",
    "llama-7b_fact_raw": "1. Weaver syndrome is caused by mutations in the NSD1 gene.\n2. Weaver syndrome can result in abnormalities in facial features, hands, and feet.\n3. Sotos syndrome is also known as 45,X/46,XY mosaicism.\n4. People with Sotos syndrome have an extra copy of the long arm of the X chromosome (45,X).\n5. Individuals with Sotos syndrome may have a distinctive facial appearance, including a prominent forehead, wide-set eyes, and a short nose.",
    "llama-7b_fact": [
      "Weaver syndrome is caused by mutations in the NSD1 gene.",
      "Weaver syndrome can result in abnormalities in facial features, hands, and feet.",
      "Sotos syndrome is also known as 45,X/46,XY mosaicism.",
      "People with Sotos syndrome have an extra copy of the long arm of the X chromosome (45,X).",
      "Individuals with Sotos syndrome may have a distinctive facial appearance, including a prominent forehead, wide-set eyes, and a short nose."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene, not the NSD1 gene.\n2. TRUE\n3. FALSE [correction]: Sotos syndrome is not known as 45,X/46,XY mosaicism. This term refers to a form of mixed gonadal dysgenesis, which is a different condition. Sotos syndrome is also known as cerebral gigantism.\n4. FALSE [correction]: People with Sotos syndrome do not have an extra copy of the long arm of the X chromosome (45,X). Instead, they typically have a mutation or deletion in the NSD1 gene on chromosome 5.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-7b_response": "The JASPAR database is a widely used repository of protein-protein interaction data. Here are the releases of JASPAR database:\n\n1. JASPAR 2004: This was the first release of the JASPAR database in 2004. It contained protein-protein interaction data for 14 eukaryotic species.\n\n2. JASPAR 2009: This release of the JASPAR database was released in 2009. It contained protein-protein interaction data for 20 eukaryotic species.\n\n3. JASPAR 2014: This release of the JASPAR database was released in 2014. It contained protein-protein interaction data for 25 eukaryotic species.\n\n4. JASPAR 2019: This release of the JASPAR database was released in 2019. It contains protein-protein interaction data for 30 eukaryotic species.\n\n5. JASPAR 2021: This is the latest release of the JASPAR database, which was released in 2021. It contains protein-protein interaction data for 35 eukaryotic species.",
    "llama-7b_fact_raw": "1. The first release of the JASPAR database was in 2004.\n2. The JASPAR 2009 release contained protein-protein interaction data for 20 eukaryotic species.\n3. The JASPAR 2014 release contained protein-protein interaction data for 25 eukaryotic species.\n4. The JASPAR 2019 release contained protein-protein interaction data for 30 eukaryotic species.\n5. The JASPAR 2021 release is the latest release and contains protein-protein interaction data for 35 eukaryotic species.",
    "llama-7b_fact": [
      "The first release of the JASPAR database was in 2004.",
      "The JASPAR 2009 release contained protein-protein interaction data for 20 eukaryotic species.",
      "The JASPAR 2014 release contained protein-protein interaction data for 25 eukaryotic species.",
      "The JASPAR 2019 release contained protein-protein interaction data for 30 eukaryotic species.",
      "The JASPAR 2021 release is the latest release and contains protein-protein interaction data for 35 eukaryotic species."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The JASPAR database primarily contains data on transcription factor binding profiles, not protein-protein interaction data.\n3. FALSE [correction]: The JASPAR database primarily contains data on transcription factor binding profiles, not protein-protein interaction data.\n4. FALSE [correction]: The JASPAR database primarily contains data on transcription factor binding profiles, not protein-protein interaction data.\n5. FALSE [correction]: The JASPAR 2022 release is the latest as of my knowledge cutoff in 2023, and it primarily contains data on transcription factor binding profiles, not protein-protein interaction data.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-7b_response": "The viral KP4 protein, also known as Kaposi's sarcoma-associated herpesvirus (KSHV) open reading frame 4 (ORF4) protein, is a viral protein that is produced by the KSHV virus that causes Kaposi's sarcoma (KS) in immunocompromised individuals, particularly those with human immunodeficiency virus (HIV) infection.\n\nThe KP4 protein is a multifunctional protein that plays a crucial role in the life cycle of the KSHV virus. The protein is synthesized as a precursor protein that undergoes post-translational cleavage into two distinct proteins, p40 and p34, which have distinct functions.\n\nThe p40 protein is a transcriptional regulator that binds to the promyelocytic leukemia (PML) protein, leading to the formation of a multiprotein complex called the PML-KP4 complex. The PML-KP4 complex represses the transcription of viral and cellular genes, thereby inhibiting viral replication and cellular proliferation.\n\nThe p34 protein, on the other hand, is a helicase that is involved in the uncoating of the viral genome during the early stages of viral replication. The protein also interacts with the viral replication machinery, including the viral DNA polymerase and primase, to facilitate viral DNA synthesis.\n\nIn summary, the KP4 protein plays a crucial role in the life cycle of the KSHV virus by regulating viral and cellular gene expression, inhibiting viral replication, and facilitating viral DNA synthesis.",
    "llama-7b_fact_raw": "1. The KP4 protein is produced by the Kaposi's sarcoma-associated herpesvirus (KSHV).\n2. KSHV causes Kaposi's sarcoma in immunocompromised individuals, particularly those with HIV infection.\n3. The KP4 protein undergoes post-translational cleavage into two distinct proteins, p40 and p34.\n4. The p40 protein is a transcriptional regulator that binds to the promyelocytic leukemia (PML) protein to form the PML-KP4 complex, which represses transcription of viral and cellular genes.\n5. The p34 protein is a helicase involved in the uncoating of the viral genome and interacts with the viral replication machinery to facilitate viral DNA synthesis.",
    "llama-7b_fact": [
      "The KP4 protein is produced by the Kaposi's sarcoma-associated herpesvirus (KSHV).",
      "KSHV causes Kaposi's sarcoma in immunocompromised individuals, particularly those with HIV infection.",
      "The KP4 protein undergoes post-translational cleavage into two distinct proteins, p40 and p34.",
      "The p40 protein is a transcriptional regulator that binds to the promyelocytic leukemia (PML) protein to form the PML-KP4 complex, which represses transcription of viral and cellular genes.",
      "The p34 protein is a helicase involved in the uncoating of the viral genome and interacts with the viral replication machinery to facilitate viral DNA synthesis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The KP4 protein is not produced by Kaposi's sarcoma-associated herpesvirus (KSHV). KP4 is a protein from Ustilago maydis, a type of fungus. KSHV produces a different set of proteins associated with the virus.\n2. TRUE\n3. UNKNOWN: Without specific scientific literature or data on the KP4 protein's cleavage into p40 and p34, it is not possible to verify this statement.\n4. FALSE [correction]: Since the KP4 protein is not associated with KSHV, it does not bind to the promyelocytic leukemia (PML) protein to form a complex that represses transcription of viral and cellular genes. This statement is incorrect as it pertains to KP4.\n5. FALSE [correction]: Given that the KP4 protein is from Ustilago maydis and not KSHV, it is not involved in the uncoating of the viral genome of KSHV or interaction with the viral replication machinery to facilitate viral DNA synthesis. This statement is incorrect as it pertains to KP4.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-7b_response": "Yes, DITPA (3,5-diiodothyronine) is a thyroid hormone analog that is utilized in both experimental and clinical studies. DITPA is structurally similar to thyroid hormones such as triiodothyronine (T3) and thyroxine (T4), but with two iodine atoms substituted for the hydrogen atoms at positions 2 and 3.\n\nDITPA has a higher affinity for the thyroid receptor compared to T3 and T4, making it a more potent thyroid hormone analog. It has been used in experimental studies to investigate the effects of thyroid hormones on various physiological processes, such as metabolism, growth, and development.\n\nIn clinical studies, DITPA has been used to treat hypothyroidism, a condition characterized by low thyroid hormone levels. DITPA is converted to T3 in the body, which can replace the deficient thyroid hormone and restore normal metabolism. However, the use of DITPA in clinical settings is limited due to its short half-life and the need for frequent dosing.\n\nOverall, DITPA is a valuable tool in the study of thyroid hormone action and has potential as a treatment for hypothyroidism, but further research is needed to optimize its use in clinical settings.",
    "llama-7b_fact_raw": "1. DITPA (3,5-diiodothyronine) is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA is structurally similar to thyroid hormones such as triiodothyronine (T3) and thyroxine (T4).\n3. DITPA has a higher affinity for the thyroid receptor compared to T3 and T4.\n4. DITPA has been used in clinical studies to treat hypothyroidism.\n5. DITPA is converted to T3 in the body.",
    "llama-7b_fact": [
      "DITPA (3,5-diiodothyronine) is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA is structurally similar to thyroid hormones such as triiodothyronine (T3) and thyroxine (T4).",
      "DITPA has a higher affinity for the thyroid receptor compared to T3 and T4.",
      "DITPA has been used in clinical studies to treat hypothyroidism.",
      "DITPA is converted to T3 in the body."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DITPA does not have a higher affinity for the thyroid receptor compared to T3; it has a lower affinity, which is why it can be of interest in certain clinical situations where a less potent effect on the thyroid receptor is desired.\n4. FALSE [correction]: DITPA has been used in clinical studies, but not primarily to treat hypothyroidism. It has been investigated for its potential in treating conditions like heart failure and high cholesterol, among others.\n5. FALSE [correction]: DITPA is not converted to T3 in the body; it is an analog of thyroid hormones and acts independently.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-7b_response": "The COUGER tool, also known as the Cougar tool, is a specialized tool used in the oil and gas industry for cementing operations. It is a high-pressure, high-temperature tool that is used to inject cement into the annulus between the wellbore and the casing, creating a seal to prevent fluids from flowing between the formation and the wellbore.\n\nThe COUGER tool is designed to withstand extreme pressure and temperature conditions, making it ideal for use in deepwater and ultra-deepwater wells. It is typically attached to the top of the casing and lowered into the wellbore, where it is activated to inject the cement.\n\nThe COUGER tool is a critical component of cementing operations, as it helps to ensure the integrity of the wellbore and prevent uncontrolled flow of fluids from the formation. It is also used in other well construction and maintenance operations, such as plug and abandonment operations.\n\nOverall, the COUGER tool plays a vital role in the safe and efficient operation of oil and gas wells, helping to protect the environment and ensure the sustainable production of energy.",
    "llama-7b_fact_raw": "1. The COUGER tool is used in the oil and gas industry for cementing operations.\n2. It is designed to inject cement into the annulus between the wellbore and the casing.\n3. The COUGER tool is capable of withstanding high-pressure and high-temperature conditions.\n4. It is used in deepwater and ultra-deepwater well applications.\n5. The COUGER tool is also utilized in well construction and maintenance operations, such as plug and abandonment operations.",
    "llama-7b_fact": [
      "The COUGER tool is used in the oil and gas industry for cementing operations.",
      "It is designed to inject cement into the annulus between the wellbore and the casing.",
      "The COUGER tool is capable of withstanding high-pressure and high-temperature conditions.",
      "It is used in deepwater and ultra-deepwater well applications.",
      "The COUGER tool is also utilized in well construction and maintenance operations, such as plug and abandonment operations."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the COUGER tool, which appears to be a specialized piece of equipment in the oil and gas industry. Without specific knowledge about this tool or a reliable source to verify these claims, it is not possible to determine the truthfulness of these statements. Therefore, the response to each statement is \"UNKNOWN\".",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-7b_response": "Tick-borne Encephalitis (TBE) is a viral infection that is transmitted through the bite of an infected tick. There are currently no drugs that have been specifically approved by the Food and Drug Administration (FDA) for the treatment of TBE. However, there are several antiviral drugs that have shown some effectiveness in treating TBE in clinical trials.\n\nOne such drug is ribavirin, which has been shown to reduce the severity of symptoms and shorten the duration of illness in some patients with TBE. Another antiviral drug that has been used to treat TBE is amantadine, which has been shown to reduce the severity of symptoms and shorten the duration of illness in some patients.\n\nIn addition to antiviral drugs, supportive care such as fluids and electrolyte replacement, respiratory support, and treatment of any complications such as meningitis or encephalitis, are important in the management of TBE.\n\nIt is important to note that the effectiveness of these drugs may vary depending on the strain of the virus causing the infection, the age and overall health of the patient, and the timing of treatment. Therefore, it is important to consult with a healthcare provider with expertise in tick-borne infections for the best management of TBE.",
    "llama-7b_fact_raw": "1. Tick-borne Encephalitis (TBE) is a viral infection transmitted through the bite of an infected tick.\n2. There are no drugs specifically approved by the Food and Drug Administration (FDA) for the treatment of TBE.\n3. Ribavirin has been shown to reduce the severity of symptoms and shorten the duration of illness in some patients with TBE in clinical trials.\n4. Amantadine has been used to treat TBE and has been shown to reduce the severity of symptoms and shorten the duration of illness in some patients.\n5. Supportive care for TBE may include fluids and electrolyte replacement, respiratory support, and treatment of complications such as meningitis or encephalitis.",
    "llama-7b_fact": [
      "Tick-borne Encephalitis (TBE) is a viral infection transmitted through the bite of an infected tick.",
      "There are no drugs specifically approved by the Food and Drug Administration (FDA) for the treatment of TBE.",
      "Ribavirin has been shown to reduce the severity of symptoms and shorten the duration of illness in some patients with TBE in clinical trials.",
      "Amantadine has been used to treat TBE and has been shown to reduce the severity of symptoms and shorten the duration of illness in some patients.",
      "Supportive care for TBE may include fluids and electrolyte replacement, respiratory support, and treatment of complications such as meningitis or encephalitis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no specific antiviral treatment for TBE that has been proven to be effective, and Ribavirin has not been shown to be effective for the treatment of TBE.\n4. FALSE [correction]: Amantadine is not a standard treatment for TBE, and there is no strong evidence to suggest that it reduces the severity of symptoms or shortens the duration of illness in TBE patients.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-7b_response": "There are several genome browser databases for DNA shape annotations available, each with its own unique features and benefits. Some of the most popular ones include:\n\n1. Ensembl Genome Browser: This is one of the most widely used genome browser databases for DNA shape annotations. It provides a comprehensive set of tools for analyzing genomic data, including DNA shape information.\n\n2. UCSC Genome Browser: The University of California, Santa Cruz Genome Browser is another popular genome browser database. It provides a user-friendly interface for exploring and analyzing genomic data, including DNA shape information.\n\n3. NCBI Genome Browser: The National Center for Biotechnology Information (NCBI) Genome Browser is a free genome browser database that provides access to a wide range of genomic data, including DNA shape information.\n\n4. ChEMBL: This is a database of bioactive molecules with pharmacological data. It includes data on DNA-binding molecules that may have an impact on DNA shape.\n\nOverall, each of these genome browser databases offers unique features and benefits, and the choice of which one to use will depend on the specific research question being addressed.",
    "llama-7b_fact_raw": "1. The Ensembl Genome Browser provides tools for analyzing genomic data, including DNA shape information.\n2. The UCSC Genome Browser is a genome browser database that includes DNA shape information.\n3. The NCBI Genome Browser is a free database that offers access to genomic data, including DNA shape information.\n4. ChEMBL is a database that contains data on DNA-binding molecules which can affect DNA shape.\n5. The choice of genome browser database for DNA shape annotations depends on the specific research question.",
    "llama-7b_fact": [
      "The Ensembl Genome Browser provides tools for analyzing genomic data, including DNA shape information.",
      "The UCSC Genome Browser is a genome browser database that includes DNA shape information.",
      "The NCBI Genome Browser is a free database that offers access to genomic data, including DNA shape information.",
      "ChEMBL is a database that contains data on DNA-binding molecules which can affect DNA shape.",
      "The choice of genome browser database for DNA shape annotations depends on the specific research question."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Ensembl Genome Browser provides tools for analyzing genomic data, but it does not specifically include DNA shape information.\n2. FALSE [correction]: The UCSC Genome Browser is a genome browser database that provides a wide range of genomic data, but it does not typically include DNA shape information.\n3. FALSE [correction]: The NCBI Genome Browser offers access to genomic data, but it does not specifically provide DNA shape information.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-7b_response": "EZH2, which stands for Enhancer of Zeste Homolog 2, is a protein that is involved in the regulation of gene expression. It is a part of the PRC2 (Polycomb Repressive Complex 2) complex, which plays a crucial role in the development and maintenance of stem cells. Mutations in the EZH2 gene have been associated with several syndromes, including:\n\n1. Wolf-Hirschhorn Syndrome: Wolf-Hirschhorn Syndrome is a genetic disorder that is caused by a deletion or mutation in a specific region of chromosome 4, which contains several genes, including EZH2. This syndrome is characterized by developmental delay, intellectual disability, and physical abnormalities such as heart defects, hearing loss, and abnormal facial features.\n\n2. DICER1-associated cancer predisposition syndrome: DICER1-associated cancer predisposition syndrome is a rare genetic disorder that is caused by mutations in the DICER1 gene, which is located on chromosome 19. This syndrome is characterized by an increased risk of developing certain types of cancer, such as lung cancer, ovarian cancer, and thyroid cancer. EZH2 mutations have been found to occur in some cases of DICER1-associated cancer predisposition syndrome.\n\n3. Acute Myeloid Leukemia: EZH2 mutations have also been found in some cases of acute myeloid leukemia (AML), a type of blood cancer that affects the white blood cells. These mutations may contribute to the development and progression of AML.\n\nIn summary, mutations in the EZH2 gene have been associated with several syndromes, including Wolf-Hirschhorn Syndrome, DICER1-associated cancer predisposition syndrome, and acute myeloid leukemia.",
    "llama-7b_fact_raw": "1. EZH2 stands for Enhancer of Zeste Homolog 2 and is involved in the regulation of gene expression.\n2. EZH2 is a part of the Polycomb Repressive Complex 2 (PRC2).\n3. Mutations in the EZH2 gene have been associated with Wolf-Hirschhorn Syndrome.\n4. Wolf-Hirschhorn Syndrome is caused by a deletion or mutation in a specific region of chromosome 4.\n5. EZH2 mutations have been found in some cases of acute myeloid leukemia (AML).",
    "llama-7b_fact": [
      "EZH2 stands for Enhancer of Zeste Homolog 2 and is involved in the regulation of gene expression.",
      "EZH2 is a part of the Polycomb Repressive Complex 2 (PRC2).",
      "Mutations in the EZH2 gene have been associated with Wolf-Hirschhorn Syndrome.",
      "Wolf-Hirschhorn Syndrome is caused by a deletion or mutation in a specific region of chromosome 4.",
      "EZH2 mutations have been found in some cases of acute myeloid leukemia (AML)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Mutations in the EZH2 gene have been associated with various cancers, but Wolf-Hirschhorn Syndrome is not typically associated with EZH2 mutations.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-7b_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition. Here are a few examples:\n\n1. Hemoglobin: Hemoglobin is a protein found in red blood cells that binds to oxygen. It exists as a dimer of two identical subunits, but can also form a tetrameric structure in which two dimers come together to form a larger unit.\n\n2. Actin: Actin is a protein that is involved in cell motility and muscle contraction. It exists as a dimer of two identical subunits, but can also form a tetrameric structure in which two dimers come together to form a larger unit.\n\n3. Tubulin: Tubulin is a protein that makes up microtubules, which are essential components of the cytoskeleton. It exists as a dimer of two identical subunits, but can also form a tetrameric structure in which two dimers come together to form a larger unit.\n\n4. Fibronectin: Fibronectin is a protein that is involved in cell adhesion and wound healing. It exists as a dimer of two identical subunits, but can also form a tetrameric structure in which two dimers come together to form a larger unit.\n\n5. Laminin: Laminin is a protein that is involved in the formation of basement membranes, which provide structural support to tissues. It exists as a dimer of two identical subunits, but can also form a tetrameric structure in which two dimers come together to form a larger unit.\n\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. There are likely many more proteins that have not yet been discovered or studied.",
    "llama-7b_fact_raw": "1. Hemoglobin is a protein found in red blood cells that can transition from a dimer to a tetramer.\n2. Actin is a protein involved in cell motility and muscle contraction that can form a tetrameric structure from two dimers.\n3. Tubulin is a protein that constitutes microtubules and can transition from a dimer to a tetramer.\n4. Fibronectin is a protein involved in cell adhesion and wound healing that can form a tetrameric structure from two dimers.\n5. Laminin is a protein involved in the formation of basement membranes that can transition from a dimer to a tetramer.",
    "llama-7b_fact": [
      "Hemoglobin is a protein found in red blood cells that can transition from a dimer to a tetramer.",
      "Actin is a protein involved in cell motility and muscle contraction that can form a tetrameric structure from two dimers.",
      "Tubulin is a protein that constitutes microtubules and can transition from a dimer to a tetramer.",
      "Fibronectin is a protein involved in cell adhesion and wound healing that can form a tetrameric structure from two dimers.",
      "Laminin is a protein involved in the formation of basement membranes that can transition from a dimer to a tetramer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hemoglobin is a protein found in red blood cells that exists as a tetramer, not as a dimer transitioning to a tetramer.\n2. FALSE [correction]: Actin is a protein involved in cell motility and muscle contraction that polymerizes to form filaments, not a tetrameric structure from two dimers.\n3. FALSE [correction]: Tubulin is a protein that constitutes microtubules and exists as a dimer called an alpha-beta tubulin heterodimer, not transitioning from a dimer to a tetramer.\n4. UNKNOWN: Fibronectin does form multimeric complexes, but whether it specifically forms a tetrameric structure from two dimers is not a standard description of its assembly and may require specific context or experimental conditions.\n5. FALSE [correction]: Laminin is a protein involved in the formation of basement membranes and exists as a cross-shaped trimer, not transitioning from a dimer to a tetramer.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-7b_response": "The protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2. Bcl-2 is a member of the Bcl-2 family of proteins, which are involved in the regulation of programmed cell death (apoptosis). Bcl-2 binds to and inhibits the activity of pro-apoptotic proteins such as Bax and Bak, thereby preventing the release of cytochrome c from the mitochondria and the activation of caspases. Additionally, Bcl-2 has been shown to interact with PLN, which is a cardiac muscle-specific phosphoprotein that regulates calcium uptake and contractility. The interaction between Bcl-2 and PLN may play a role in the protection of cardiac muscle cells from apoptosis.",
    "llama-7b_fact_raw": "1. Bcl-2 interacts with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.\n3. Bcl-2 is a member of the Bcl-2 family of proteins, which are involved in the regulation of apoptosis.\n4. Bcl-2 inhibits the activity of pro-apoptotic proteins such as Bax and Bak.\n5. Phospholamban (PLN) is a cardiac muscle-specific phosphoprotein that regulates calcium uptake and contractility.",
    "llama-7b_fact": [
      "Bcl-2 interacts with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein.",
      "Bcl-2 is a member of the Bcl-2 family of proteins, which are involved in the regulation of apoptosis.",
      "Bcl-2 inhibits the activity of pro-apoptotic proteins such as Bax and Bak.",
      "Phospholamban (PLN) is a cardiac muscle-specific phosphoprotein that regulates calcium uptake and contractility."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-7b_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. A meta-analysis of 25 randomized controlled trials found that vitamin D supplementation significantly reduced the risk of falls by 19% compared to placebo or control groups. Another trial conducted on elderly women found that vitamin D supplementation reduced the risk of falls by 22%. These findings suggest that maintaining adequate vitamin D levels may be an effective way to prevent falls and related injuries in older adults. However, it is important to note that vitamin D supplementation should be used in conjunction with other fall prevention strategies, such as exercise and balance training.",
    "llama-7b_fact_raw": "1. Clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people.\n2. A meta-analysis of 25 randomized controlled trials found that vitamin D supplementation reduced the risk of falls by 19% compared to placebo or control groups.\n3. A specific trial on elderly women demonstrated a 22% reduction in the risk of falls with vitamin D supplementation.\n4. Vitamin D supplementation is suggested as a method to prevent falls and related injuries in older adults.\n5. Vitamin D supplementation should be combined with other fall prevention strategies like exercise and balance training.",
    "llama-7b_fact": [
      "Clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people.",
      "A meta-analysis of 25 randomized controlled trials found that vitamin D supplementation reduced the risk of falls by 19% compared to placebo or control groups.",
      "A specific trial on elderly women demonstrated a 22% reduction in the risk of falls with vitamin D supplementation.",
      "Vitamin D supplementation is suggested as a method to prevent falls and related injuries in older adults.",
      "Vitamin D supplementation should be combined with other fall prevention strategies like exercise and balance training."
    ],
    "llama-7b_judge_raw": "1. TRUE: Clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people, although the evidence is mixed and some studies have not found a significant benefit.\n2. TRUE: A meta-analysis of randomized controlled trials has indeed found that vitamin D supplementation can reduce the risk of falls, although the exact percentage may vary across different studies and meta-analyses.\n3. UNKNOWN: Without specific details about the trial mentioned, it is not possible to confirm the accuracy of the 22% reduction in the risk of falls with vitamin D supplementation in elderly women.\n4. TRUE: Vitamin D supplementation is often suggested as one method to help prevent falls and related injuries in older adults, as part of a multifaceted approach to fall prevention.\n5. TRUE: It is widely recommended that vitamin D supplementation be combined with other fall prevention strategies like exercise and balance training for a more comprehensive approach to reducing fall risk in older adults.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-7b_response": "As an AI language model, I do not have access to the latest scientific literature or databases. However, I can tell you that the association between Jarid2 and miR-155 in Th17 cells is not clear from the available literature. While both Jarid2 and miR-155 have been implicated in the regulation of Th17 cell differentiation and function, their exact role in this process is still not fully understood. Further research is needed to determine any potential association between these two molecules in Th17 cells.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-7b_response": "The human HOXD cluster contains 13 genes, including HOXD1, HOXD2, HOXD3, HOXD4, HOXD5, HOXD6, HOXD7, HOXD8, HOXD9, HOXD10, HOXD11, HOXD12, HOXD13, and HOXD14.",
    "llama-7b_fact_raw": "1. The human HOXD cluster contains 13 genes.\n2. The genes in the human HOXD cluster include HOXD1 through HOXD13.",
    "llama-7b_fact": [
      "The human HOXD cluster contains 13 genes.",
      "The genes in the human HOXD cluster include HOXD1 through HOXD13."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains 9 genes.\n2. FALSE [correction]: The genes in the human HOXD cluster include HOXD1 through HOXD9, HOXD10, HOXD11, HOXD12, and HOXD13 are not part of the cluster.",
    "llama-7b_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-7b_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes such as cell division, differentiation, and apoptosis. CK1 can phosphorylate a wide range of substrates, including proteins involved in the cytoskeleton, transcription factors, and signaling molecules. Here are some of the phosphorylation consensus motifs for CK1:\n\n1. S/T-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X-X",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-7b_response": "The aspartate beta-hydroxylase (ASPH) gene encodes for a key enzyme in the urea cycle, which plays a crucial role in the removal of ammonia from the blood. The ASPH protein is a homotetrameric enzyme that catalyzes the conversion of aspartate to beta-alanine, releasing carbon dioxide in the process.\n\nThere are several isoforms of ASPH produced by alternative splicing of its mRNA. The most common form, known as ASPH1, is found in most tissues and is responsible for the majority of aspartate beta-hydroxylation in the body. However, other isoforms have been identified, including ASPH2, ASPH3, and ASPH4, which are primarily expressed in specific tissues such as the liver, kidney, and brain.\n\nThe different isoforms of ASPH have been shown to have varying levels of activity and specificity for different amino acids, including aspartate, glutamate, and cysteine. For example, ASPH2 has higher activity on cysteine than ASPH1, while ASPH3 has higher activity on glutamate than ASPH1.\n\nOverall, the different isoforms of ASPH provide important functional diversity to the urea cycle and contribute to the regulation of ammonia levels in the blood.",
    "llama-7b_fact_raw": "1. The ASPH gene encodes for an enzyme that is involved in the urea cycle.\n2. The ASPH protein catalyzes the conversion of aspartate to beta-alanine, releasing carbon dioxide.\n3. There are several isoforms of the ASPH protein, including ASPH1, ASPH2, ASPH3, and ASPH4.\n4. ASPH1 is the most common isoform and is found in most tissues.\n5. The different isoforms of ASPH are expressed in specific tissues and have varying levels of activity and specificity for different amino acids.",
    "llama-7b_fact": [
      "The ASPH gene encodes for an enzyme that is involved in the urea cycle.",
      "The ASPH protein catalyzes the conversion of aspartate to beta-alanine, releasing carbon dioxide.",
      "There are several isoforms of the ASPH protein, including ASPH1, ASPH2, ASPH3, and ASPH4.",
      "ASPH1 is the most common isoform and is found in most tissues.",
      "The different isoforms of ASPH are expressed in specific tissues and have varying levels of activity and specificity for different amino acids."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The ASPH protein catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of proteins. It does not catalyze the conversion of aspartate to beta-alanine.\n3. FALSE [correction]: There are not multiple isoforms of the ASPH protein designated as ASPH1, ASPH2, ASPH3, and ASPH4. The statement about these specific isoforms is incorrect.\n4. FALSE [correction]: Since the statement about the existence of isoforms designated as ASPH1, ASPH2, ASPH3, and ASPH4 is incorrect, the claim that ASPH1 is the most common isoform is also incorrect.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-7b_response": "Empagliflozin, also known as Jardiance, was approved by the U.S. Food and Drug Administration (FDA) on August 27, 2014, for the treatment of adults with type 2 diabetes. It was the first SGLT2 inhibitor to be approved by the FDA for the treatment of diabetes. SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, leading to increased excretion of glucose in the urine. Empagliflozin has since been approved in over 90 countries for the treatment of type 2 diabetes.",
    "llama-7b_fact_raw": "1. Empagliflozin, also known as Jardiance, was approved by the FDA on August 27, 2014.\n2. Empagliflozin was approved for the treatment of adults with type 2 diabetes.\n3. It was the first SGLT2 inhibitor to be approved by the FDA for the treatment of diabetes.\n4. SGLT2 inhibitors block the reabsorption of glucose in the kidneys.\n5. Empagliflozin has been approved in over 90 countries for the treatment of type 2 diabetes.",
    "llama-7b_fact": [
      "Empagliflozin, also known as Jardiance, was approved by the FDA on August 27, 2014.",
      "Empagliflozin was approved for the treatment of adults with type 2 diabetes.",
      "It was the first SGLT2 inhibitor to be approved by the FDA for the treatment of diabetes.",
      "SGLT2 inhibitors block the reabsorption of glucose in the kidneys.",
      "Empagliflozin has been approved in over 90 countries for the treatment of type 2 diabetes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Empagliflozin was not the first SGLT2 inhibitor to be approved by the FDA for the treatment of diabetes. Canagliflozin (Invokana) was the first, approved in March 2013.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-7b_response": "Loss of the protein Lon1 in the plant Arabidopsis has been shown to result in several changes in the cellular and physiological processes of the plant. \n\nFirstly, Lon1 is involved in the degradation of misfolded and damaged proteins in the endoplasmic reticulum (ER) of the plant cells. Without Lon1, the accumulation of misfolded proteins in the ER can lead to the formation of protein aggregates, which can disrupt cellular homeostasis and cause cell death. Therefore, the loss of Lon1 can result in an increase in the accumulation of misfolded proteins in the ER, leading to ER stress and cellular dysfunction.\n\nSecondly, Lon1 is also involved in the response to ER stress, which is triggered by the accumulation of misfolded proteins in the ER. The loss of Lon1 results in a reduced ability of the plant cells to respond to ER stress, leading to the accumulation of damaged proteins and cellular dysfunction.\n\nThirdly, the loss of Lon1 in Arabidopsis has been shown to result in alterations in the plant's immune response to pathogens. This is because Lon1 is involved in the degradation of viral proteins, and without Lon1, the plant cells may be more susceptible to viral infections.\n\nOverall, the loss of Lon1 in Arabidopsis results in a range of changes in cellular and physiological processes, including ER stress, accumulation of misfolded proteins, and alterations in the plant's immune response to pathogens.",
    "llama-7b_fact_raw": "1. Lon1 is involved in the degradation of misfolded and damaged proteins in the endoplasmic reticulum of Arabidopsis plant cells.\n2. The loss of Lon1 in Arabidopsis can lead to the accumulation of misfolded proteins in the endoplasmic reticulum.\n3. The absence of Lon1 in Arabidopsis results in a reduced ability of the plant cells to respond to endoplasmic reticulum stress.\n4. The loss of Lon1 in Arabidopsis can result in alterations in the plant's immune response to pathogens.\n5. Lon1 is involved in the degradation of viral proteins in Arabidopsis plant cells.",
    "llama-7b_fact": [
      "Lon1 is involved in the degradation of misfolded and damaged proteins in the endoplasmic reticulum of Arabidopsis plant cells.",
      "The loss of Lon1 in Arabidopsis can lead to the accumulation of misfolded proteins in the endoplasmic reticulum.",
      "The absence of Lon1 in Arabidopsis results in a reduced ability of the plant cells to respond to endoplasmic reticulum stress.",
      "The loss of Lon1 in Arabidopsis can result in alterations in the plant's immune response to pathogens.",
      "Lon1 is involved in the degradation of viral proteins in Arabidopsis plant cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are consistent with the known functions of Lon proteases in cellular mechanisms, including the degradation of misfolded proteins and involvement in stress responses and immune responses. However, the fifth statement about the specific role of Lon1 in the degradation of viral proteins in Arabidopsis plant cells is not a commonly established fact and would require specific scientific evidence to confirm, hence the response is UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-7b_response": "Yes, a linker histone does exist in the yeast genome. The linker histone H1 is present in all eukaryotes, including yeast. In fact, the H1 protein is one of the most abundant proteins in eukaryotic cells and plays a crucial role in the regulation of chromatin structure and gene expression. In yeast, H1 is involved in the formation of nucleosomes, the basic repeating unit of chromatin, and helps to maintain the chromatin fiber in a condensed and organized form. The H1 protein also interacts with a variety of other proteins, including transcription factors and DNA-binding proteins, to regulate the accessibility of the genome to transcriptional machinery. Overall, the presence of H1 in yeast is essential for the proper functioning of the cell's genetic machinery.",
    "llama-7b_fact_raw": "1. The linker histone H1 is present in all eukaryotes, including yeast.\n2. The H1 protein is one of the most abundant proteins in eukaryotic cells.\n3. In yeast, the H1 protein is involved in the formation of nucleosomes.\n4. The H1 protein helps maintain the chromatin fiber in a condensed and organized form.\n5. The H1 protein interacts with other proteins, including transcription factors and DNA-binding proteins, to regulate genome accessibility.",
    "llama-7b_fact": [
      "The linker histone H1 is present in all eukaryotes, including yeast.",
      "The H1 protein is one of the most abundant proteins in eukaryotic cells.",
      "In yeast, the H1 protein is involved in the formation of nucleosomes.",
      "The H1 protein helps maintain the chromatin fiber in a condensed and organized form.",
      "The H1 protein interacts with other proteins, including transcription factors and DNA-binding proteins, to regulate genome accessibility."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The linker histone H1 is not present in all eukaryotes; for example, most yeast species do not contain histone H1.\n2. TRUE\n3. FALSE [correction]: In yeast species that lack histone H1, it is not involved in the formation of nucleosomes. Other histones, such as H2A, H2B, H3, and H4, are involved in nucleosome formation in yeast.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-7b_response": "There is some evidence to suggest that tomato juice may have a positive effect on lowering cholesterol levels. Studies have shown that individuals who consume tomato juice on a regular basis have lower levels of LDL (\"bad\") cholesterol and triglycerides, which are both major risk factors for heart disease.\n\nOne study published in the Journal of the American College of Nutrition found that participants who drank 1 cup of tomato juice daily for six weeks experienced a significant decrease in their LDL cholesterol levels. Another study published in the American Journal of Clinical Nutrition found that individuals who consumed 2-3 servings of tomato products (such as tomato juice, soup, or sauce) per week had a 22% lower risk of developing heart disease compared to those who consumed fewer tomato products.\n\nHowever, it's important to note that while tomato juice may have a positive effect on cholesterol levels, it's not a substitute for a healthy diet and lifestyle. Additionally, the effects of tomato juice on cholesterol levels may vary depending on the individual's overall health and dietary habits. Therefore, individuals looking to lower their cholesterol levels should consult with a healthcare provider before making any significant dietary changes.",
    "llama-7b_fact_raw": "1. Consuming tomato juice on a regular basis is associated with lower levels of LDL cholesterol and triglycerides.\n2. A study in the Journal of the American College of Nutrition reported that drinking 1 cup of tomato juice daily for six weeks can significantly decrease LDL cholesterol levels.\n3. The American Journal of Clinical Nutrition published a study indicating that consuming 2-3 servings of tomato products per week is linked to a 22% lower risk of developing heart disease.\n4. Tomato juice is not a substitute for a healthy diet and lifestyle.\n5. The effects of tomato juice on cholesterol levels may vary based on an individual's overall health and dietary habits.",
    "llama-7b_fact": [
      "Consuming tomato juice on a regular basis is associated with lower levels of LDL cholesterol and triglycerides.",
      "A study in the Journal of the American College of Nutrition reported that drinking 1 cup of tomato juice daily for six weeks can significantly decrease LDL cholesterol levels.",
      "The American Journal of Clinical Nutrition published a study indicating that consuming 2-3 servings of tomato products per week is linked to a 22% lower risk of developing heart disease.",
      "Tomato juice is not a substitute for a healthy diet and lifestyle.",
      "The effects of tomato juice on cholesterol levels may vary based on an individual's overall health and dietary habits."
    ],
    "llama-7b_judge_raw": "1. TRUE: Consuming tomato juice has been associated with beneficial effects on blood lipid levels, including lower levels of LDL cholesterol and triglycerides, according to some studies.\n2. UNKNOWN: Without access to the specific study in the Journal of the American College of Nutrition, the details of the study's findings cannot be confirmed.\n3. UNKNOWN: Again, without access to the specific study published in the American Journal of Clinical Nutrition, the details of the study's findings cannot be confirmed.\n4. TRUE: While tomato juice can have health benefits, it is not a substitute for a comprehensive healthy diet and lifestyle.\n5. TRUE: The effects of tomato juice on cholesterol levels and other health outcomes can indeed vary based on individual health status, genetics, and other dietary habits.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-7b_response": "Hsp70 and Hsp110 are members of the heat shock protein family, which are involved in various cellular processes, including protein folding, trafficking, and degradation. These proteins have also been implicated in the regulation of mRNA stability.\n\nHsp70 and Hsp110 are thought to affect mRNA stability in several ways. Firstly, these proteins can interact with mRNA and stabilize it by preventing its degradation. This interaction occurs through the binding of Hsp70 and Hsp110 to the AU-rich elements (AREs) present in the 3' untranslated region (UTR) of mRNA. The binding of Hsp70 and Hsp110 to AREs inhibits the activity of the decapping enzyme, which leads to the retention of mRNA in the cytoplasm and its eventual degradation.\n\nSecondly, Hsp70 and Hsp110 can also promote the degradation of mRNA through their chaperone activity. By binding to and stabilizing unfolded or misfolded proteins, Hsp70 and Hsp110 free up cellular resources that would otherwise be used to fold and stabilize mRNA. This leads to the destabilization of mRNA and its eventual degradation.\n\nOverall, the effects of Hsp70 and Hsp110 on mRNA stability are complex and depend on the specific context in which they are acting. While Hsp70 and Hsp110 can stabilize mRNA in some situations, they can also promote its degradation in others. Understanding the precise mechanisms by which Hsp70 and Hsp110 regulate mRNA stability is an active area of research in the field of molecular biology.",
    "llama-7b_fact_raw": "1. Hsp70 and Hsp110 are members of the heat shock protein family.\n2. These proteins are involved in protein folding, trafficking, and degradation.\n3. Hsp70 and Hsp110 can interact with mRNA and stabilize it by preventing its degradation.\n4. The binding of Hsp70 and Hsp110 to AU-rich elements in the 3' untranslated region of mRNA inhibits the activity of the decapping enzyme.\n5. Hsp70 and Hsp110 can promote the degradation of mRNA through their chaperone activity by binding to and stabilizing unfolded or misfolded proteins.",
    "llama-7b_fact": [
      "Hsp70 and Hsp110 are members of the heat shock protein family.",
      "These proteins are involved in protein folding, trafficking, and degradation.",
      "Hsp70 and Hsp110 can interact with mRNA and stabilize it by preventing its degradation.",
      "The binding of Hsp70 and Hsp110 to AU-rich elements in the 3' untranslated region of mRNA inhibits the activity of the decapping enzyme.",
      "Hsp70 and Hsp110 can promote the degradation of mRNA through their chaperone activity by binding to and stabilizing unfolded or misfolded proteins."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN: While Hsp70 is known to be involved in various aspects of RNA metabolism, including potentially stabilizing certain mRNAs, the specific interaction with mRNA and the stabilization by preventing degradation is not universally established for all heat shock proteins, including Hsp110. More context is needed to confirm this statement.\n4. UNKNOWN: The specific mechanism of Hsp70 and Hsp110 binding to AU-rich elements in the 3' untranslated region of mRNA and its effect on the decapping enzyme's activity is not a widely recognized or established function of these proteins. More detailed information is required to verify this statement.\n5. FALSE [correction]: Hsp70 and Hsp110 are known to prevent the aggregation of unfolded or misfolded proteins, thereby assisting in their proper folding or targeting them for degradation. However, they do not promote the degradation of mRNA through their chaperone activity. Their primary role is in protein homeostasis, not in the active degradation of mRNA.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-7b_response": "Deiodinases are enzymes that catalyze the conversion of one thyroid hormone to another. In skeletal muscle, two types of deiodinases have been identified: type I (D1) and type II (D2).\n\nType I deiodinase (D1) is a cytosolic enzyme that converts the inactive thyroid hormone, T4, to the active thyroid hormone, T3. D1 is found in several tissues, including skeletal muscle, where it plays a crucial role in regulating thyroid hormone action. In skeletal muscle, D1 is localized to the sarcolemma, the plasma membrane of muscle fibers, where it converts T4 to T3, which can then bind to and activate the thyroid hormone receptor.\n\nType II deiodinase (D2) is a mitochondrial enzyme that converts the active thyroid hormone, T3, to the inactive thyroid hormone, T4. D2 is also found in several tissues, including skeletal muscle, where it plays a role in regulating thyroid hormone action. In skeletal muscle, D2 is localized to the mitochondria, where it converts T3 to T4, which can then be transported out of the mitochondria and into the cytosol.\n\nIn summary, both type I and type II deiodinases are present in skeletal muscle, and they play important roles in regulating thyroid hormone action in this tissue.",
    "llama-7b_fact_raw": "1. In skeletal muscle, two types of deiodinases have been identified: type I (D1) and type II (D2).\n2. Type I deiodinase (D1) is a cytosolic enzyme that converts the inactive thyroid hormone, T4, to the active thyroid hormone, T3.\n3. Type I deiodinase (D1) is found in several tissues, including skeletal muscle.\n4. Type II deiodinase (D2) is a mitochondrial enzyme that converts the active thyroid hormone, T3, to the inactive thyroid hormone, T4.\n5. Type II deiodinase (D2) is also found in several tissues, including skeletal muscle.",
    "llama-7b_fact": [
      "In skeletal muscle, two types of deiodinases have been identified: type I (D1) and type II (D2).",
      "Type I deiodinase (D1) is a cytosolic enzyme that converts the inactive thyroid hormone, T4, to the active thyroid hormone, T3.",
      "Type I deiodinase (D1) is found in several tissues, including skeletal muscle.",
      "Type II deiodinase (D2) is a mitochondrial enzyme that converts the active thyroid hormone, T3, to the inactive thyroid hormone, T4.",
      "Type II deiodinase (D2) is also found in several tissues, including skeletal muscle."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: In skeletal muscle, three types of deiodinases have been identified: type I (D1), type II (D2), and type III (D3).\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Type II deiodinase (D2) is an endoplasmic reticulum-associated enzyme that converts the inactive thyroid hormone, T4, to the active thyroid hormone, T3, not the other way around.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-7b_response": "There are several inflammatory caspase proteins, including:\n\n1. Caspase-1: Also known as interleukin-1 beta converting enzyme (ICE), caspase-1 is responsible for the processing and activation of interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a key role in the inflammatory response.\n\n2. Caspase-4: Caspase-4 is involved in the processing and activation of interleukin-18 (IL-18), another pro-inflammatory cytokine that contributes to the inflammatory response.\n\n3. Caspase-5: Caspase-5 is involved in the processing and activation of interleukin-16 (IL-16), a cytokine that promotes inflammation and immune responses.\n\n4. Caspase-6: Caspase-6 is involved in the processing and activation of interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a key role in the inflammatory response.\n\n5. Caspase-7: Caspase-7 is involved in the processing and activation of interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a key role in the inflammatory response.\n\n6. Caspase-8: Caspase-8 is involved in the processing and activation of interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a key role in the inflammatory response.\n\n7. Caspase-9: Caspase-9 is involved in the processing and activation of interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a key role in the inflammatory response.\n\n8. Caspase-11: Caspase-11 is involved in the processing and activation of interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a key role in the inflammatory response.\n\n9. Caspase-12: Caspase-1",
    "llama-7b_fact_raw": "1. Caspase-1 is responsible for the processing and activation of interleukin-1 beta (IL-1β).\n2. Caspase-4 is involved in the processing and activation of interleukin-18 (IL-18).\n3. Caspase-5 is involved in the processing and activation of interleukin-16 (IL-16).\n4. Caspase-6 is involved in the processing and activation of interleukin-1 beta (IL-1β).\n5. Caspase-7 is involved in the processing and activation of interleukin-1 beta (IL-1β).",
    "llama-7b_fact": [
      "Caspase-1 is responsible for the processing and activation of interleukin-1 beta (IL-1β).",
      "Caspase-4 is involved in the processing and activation of interleukin-18 (IL-18).",
      "Caspase-5 is involved in the processing and activation of interleukin-16 (IL-16).",
      "Caspase-6 is involved in the processing and activation of interleukin-1 beta (IL-1β).",
      "Caspase-7 is involved in the processing and activation of interleukin-1 beta (IL-1β)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-1, not caspase-4, is primarily known for its role in the processing and activation of interleukin-18 (IL-18).\n3. FALSE [correction]: There is no widely recognized association between caspase-5 and the processing and activation of interleukin-16 (IL-16). Caspase-5 is known to be involved in the inflammatory response, similar to caspase-1 and caspase-4.\n4. FALSE [correction]: Caspase-6 is not involved in the processing and activation of interleukin-1 beta (IL-1β). Caspase-1 is the enzyme primarily responsible for this process.\n5. FALSE [correction]: Caspase-7 is not involved in the processing and activation of interleukin-1 beta (IL-1β). Caspase-1 is the enzyme primarily responsible for this process. Caspase-7 is more commonly associated with the execution phase of apoptosis.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-7b_response": "Yes, there is a link between the aurora B kinase and the polycomb protein ring1B. The polycomb protein ring1B is a member of the polycomb family of proteins, which is involved in the regulation of gene expression during cell division and development. The aurora B kinase is also involved in the regulation of gene expression and cell division, and it has been shown to interact with and phosphorylate the ring1B protein.\n\nThis interaction between aurora B and ring1B is important for the proper regulation of gene expression during cell division. Specifically, it has been shown that phosphorylation of ring1B by aurora B leads to the formation of a stable complex between the two proteins, which is required for the proper localization of ring1B to the cell division plane.\n\nFurthermore, the interaction between aurora B and ring1B has been implicated in the development of cancer. For example, mutations in the ring1B gene have been associated with the development of certain types of cancer, and it has been proposed that the interaction between aurora B and ring1B may contribute to the oncogenic properties of aurora B.\n\nOverall, the link between aurora B and ring1B highlights the complex interplay between different proteins and pathways involved in the regulation of gene expression and cell division, and the importance of understanding these interactions in the context of normal physiology and disease.",
    "llama-7b_fact_raw": "1. The polycomb protein ring1B is involved in the regulation of gene expression during cell division and development.\n2. The aurora B kinase is involved in the regulation of gene expression and cell division.\n3. Aurora B kinase has been shown to interact with and phosphorylate the ring1B protein.\n4. Phosphorylation of ring1B by aurora B is necessary for the proper localization of ring1B to the cell division plane.\n5. Mutations in the ring1B gene have been associated with the development of certain types of cancer.",
    "llama-7b_fact": [
      "The polycomb protein ring1B is involved in the regulation of gene expression during cell division and development.",
      "The aurora B kinase is involved in the regulation of gene expression and cell division.",
      "Aurora B kinase has been shown to interact with and phosphorylate the ring1B protein.",
      "Phosphorylation of ring1B by aurora B is necessary for the proper localization of ring1B to the cell division plane.",
      "Mutations in the ring1B gene have been associated with the development of certain types of cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE: The polycomb protein ring1B is indeed involved in the regulation of gene expression during cell division and development.\n2. TRUE: Aurora B kinase is a protein that plays a critical role in the regulation of cell division, particularly during mitosis.\n3. TRUE: Scientific studies have shown that Aurora B kinase can interact with and phosphorylate ring1B protein, among other substrates.\n4. UNKNOWN: The specific role of phosphorylation of ring1B by Aurora B in the localization of ring1B to the cell division plane is a detailed molecular interaction that would require specific scientific evidence to confirm or refute.\n5. TRUE: Mutations in genes encoding polycomb proteins, including ring1B, have been associated with the development of certain types of cancer due to their role in regulating gene expression and maintaining cellular identity.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are known as the \"splice consensus sequences\". These motifs are composed of specific nucleotide sequences that are recognized by the splice machinery during the splicing process.\n\nAt the donor splice site, the most frequent non-canonical sequence motif is known as the \"donor splice site consensus sequence\". This motif consists of five nucleotides and is located immediately upstream of the splice acceptor site. The sequence of the donor splice site consensus sequence varies slightly between different species, but it generally contains the sequence \"5'-AG-3'\".\n\nAt the acceptor splice site, the most frequent non-canonical sequence motif is known as the \"acceptor splice site consensus sequence\". This motif consists of three nucleotides and is located immediately downstream of the splice acceptor site. The sequence of the acceptor splice site consensus sequence varies slightly between different species, but it generally contains the sequence \"3'-SA-5'\".\n\nBoth the donor splice site consensus sequence and the acceptor splice site consensus sequence are required for the correct recognition of the splice sites by the splice machinery during the splicing process. Non-canonical sequence motifs that deviate from these consensus sequences can result in aberrant splicing and the production of non-functional or defective proteins.",
    "llama-7b_fact_raw": "1. The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are known as \"splice consensus sequences.\"\n2. The donor splice site consensus sequence consists of five nucleotides.\n3. The donor splice site consensus sequence is located immediately upstream of the splice acceptor site and generally contains the sequence \"5'-AG-3'.\"\n4. The acceptor splice site consensus sequence consists of three nucleotides.\n5. The acceptor splice site consensus sequence is located immediately downstream of the splice acceptor site and generally contains the sequence \"3'-SA-5'.\"",
    "llama-7b_fact": [
      "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are known as \"splice consensus sequences.\"",
      "The donor splice site consensus sequence consists of five nucleotides.",
      "The donor splice site consensus sequence is located immediately upstream of the splice acceptor site and generally contains the sequence \"5'-AG-3'.\"",
      "The acceptor splice site consensus sequence consists of three nucleotides.",
      "The acceptor splice site consensus sequence is located immediately downstream of the splice acceptor site and generally contains the sequence \"3'-SA-5'.\""
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The donor splice site consensus sequence consists of nine nucleotides, typically represented by the sequence \"5'-AG|GURAGU-3'\" where | marks the exon-intron boundary.\n3. FALSE [correction]: The donor splice site consensus sequence is located at the beginning of the intron, immediately downstream of the exon-intron boundary, and generally contains the sequence \"5'-GT-3'\" at the intron side of the junction (not \"5'-AG-3'\").\n4. FALSE [correction]: The acceptor splice site consensus sequence is more complex and typically includes a polypyrimidine tract followed by the sequence \"3'-YAG|G-5'\", where | marks the intron-exon boundary and Y represents a pyrimidine nucleotide.\n5. FALSE [correction]: The acceptor splice site consensus sequence is located at the end of the intron, immediately upstream of the exon-intron boundary, and generally contains the sequence \"3'-AG-5'\" at the exon side of the junction (not \"3'-SA-5'\").",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-7b_response": "The event that results in the acetylation of S6K1 is the interaction between S6K1 and the p300/CBP acetyltransferase complex. The p300/CBP complex is a transcriptional coactivator that is responsible for the acetylation of a variety of proteins, including S6K1. The acetylation of S6K1 by the p300/CBP complex leads to the activation of S6K1 and its involvement in various cellular processes, such as cell growth and proliferation. The acetylation of S6K1 can also be regulated by other factors, such as nutrient availability, hormones, and growth factors, which can modulate the interaction between S6K1 and the p300/CBP complex. Overall, the acetylation of S6K1 is an important post-translational modification that plays a crucial role in regulating its activity and function.",
    "llama-7b_fact_raw": "1. The acetylation of S6K1 is a result of its interaction with the p300/CBP acetyltransferase complex.\n2. The p300/CBP complex is responsible for the acetylation of various proteins, including S6K1.\n3. Acetylation of S6K1 by the p300/CBP complex leads to the activation of S6K1.\n4. S6K1 is involved in cellular processes such as cell growth and proliferation following its acetylation.\n5. The interaction between S6K1 and the p300/CBP complex can be modulated by factors such as nutrient availability, hormones, and growth factors.",
    "llama-7b_fact": [
      "The acetylation of S6K1 is a result of its interaction with the p300/CBP acetyltransferase complex.",
      "The p300/CBP complex is responsible for the acetylation of various proteins, including S6K1.",
      "Acetylation of S6K1 by the p300/CBP complex leads to the activation of S6K1.",
      "S6K1 is involved in cellular processes such as cell growth and proliferation following its acetylation.",
      "The interaction between S6K1 and the p300/CBP complex can be modulated by factors such as nutrient availability, hormones, and growth factors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe statements about the acetylation of S6K1 and its interaction with the p300/CBP acetyltransferase complex are consistent with known molecular biology mechanisms, where p300/CBP is indeed responsible for the acetylation of various proteins. S6K1 is known to be involved in cell growth and proliferation, and its activity can be modulated by various factors. However, without specific context or a source, the direct effect of acetylation on S6K1's activation (statement 3) cannot be confirmed as true or false, hence it is marked as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-7b_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1S gene. This gene provides instructions for making a protein called the voltage-gated calcium channel subunit alpha1S, which is involved in regulating the movement of calcium ions into cells. \n\nCalcium is essential for the proper functioning of many cellular processes, including the transmission of nerve impulses. In EA6, mutations in the CACNA1S gene disrupt the normal functioning of the calcium channels, leading to abnormal calcium signaling and neurological symptoms. \n\nSpecifically, the mutations in the CACNA1S gene that cause EA6 affect the function of the alpha1S subunit of the voltage-gated calcium channel. These mutations impair the ability of the calcium channel to regulate the influx of calcium ions into cells, leading to abnormal calcium signaling and neurological symptoms. \n\nThe symptoms of EA6 typically begin in adolescence or early adulthood and are triggered by physical exertion, emotional stress, or sleep deprivation. The symptoms may include dizziness, loss of balance, speech difficulties, and muscle weakness. These symptoms typically resolve within a few minutes or hours, but in some cases, they can last for several days. \n\nOverall, episodic ataxia type 6 is a genetic disorder that is caused by mutations in the CACNA1S gene, leading to abnormal calcium signaling and neurological symptoms triggered by physical exertion, emotional stress, or sleep deprivation.",
    "llama-7b_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1S gene.\n2. The CACNA1S gene provides instructions for making the voltage-gated calcium channel subunit alpha1S.\n3. Mutations in the CACNA1S gene disrupt the normal functioning of calcium channels.\n4. Symptoms of EA6 typically begin in adolescence or early adulthood.\n5. Symptoms of EA6 can be triggered by physical exertion, emotional stress, or sleep deprivation.",
    "llama-7b_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1S gene.",
      "The CACNA1S gene provides instructions for making the voltage-gated calcium channel subunit alpha1S.",
      "Mutations in the CACNA1S gene disrupt the normal functioning of calcium channels.",
      "Symptoms of EA6 typically begin in adolescence or early adulthood.",
      "Symptoms of EA6 can be triggered by physical exertion, emotional stress, or sleep deprivation."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 (EA6) is caused by mutations in the SLC1A3 gene, not the CACNA1S gene.\n2. TRUE\n3. TRUE, but it should be noted that this statement is true in the context of the CACNA1S gene, not specifically for EA6, as EA6 is not caused by mutations in the CACNA1S gene.\n4. UNKNOWN: Without specific information on EA6, it is not possible to confirm when symptoms typically begin.\n5. UNKNOWN: Without specific information on EA6, it is not possible to confirm the triggers for symptoms.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add methyl groups to DNA, and they play a crucial role in various biological processes such as DNA replication, transcription, and repair.\n\nMethylation of DNA is an important mechanism for regulating gene expression, and chromomethylases are responsible for adding or removing methyl groups from DNA. In animals, there are several types of chromomethylases, including DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs).\n\nDNMTs are responsible for adding methyl groups to cytosine residues in DNA, while HMTs add methyl groups to lysine residues in histones, which are proteins that DNA wraps around to form chromatin. Both DNMTs and HMTs play important roles in regulating gene expression, and mutations in these enzymes have been implicated in various human diseases, including cancer.\n\nIn summary, chromomethylases are present in animal genomes and play a crucial role in various biological processes, including DNA replication, transcription, and repair.",
    "llama-7b_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases are enzymes that add methyl groups to DNA.\n3. DNA methyltransferases (DNMTs) add methyl groups to cytosine residues in DNA.\n4. Histone methyltransferases (HMTs) add methyl groups to lysine residues in histones.\n5. Mutations in chromomethylases have been implicated in various human diseases, including cancer.",
    "llama-7b_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases are enzymes that add methyl groups to DNA.",
      "DNA methyltransferases (DNMTs) add methyl groups to cytosine residues in DNA.",
      "Histone methyltransferases (HMTs) add methyl groups to lysine residues in histones.",
      "Mutations in chromomethylases have been implicated in various human diseases, including cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Chromomethylases are not present in animal genomes; they are typically found in plants.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Since chromomethylases are not present in animal genomes, they cannot be implicated in human diseases. However, mutations in DNA methyltransferases (DNMTs), which are present in animals, have been implicated in various human diseases, including cancer.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-7b_response": "Sure, here are some packages for transcription factor binding site analysis available in R/Bioconductor:\n\n1. ChEMBL: A database of bioactive molecules with pharmacological data.\n2. DAVID: A gene set enrichment analysis tool for functional genomics data.\n3. DESeq2: A software for differential gene expression analysis.\n4. edgeR: A software for differential expression analysis of RNA sequencing data.\n5. GEO2R: A software for differential expression analysis of gene expression data available in the Gene Expression Omnibus (GEO) database.\n6. HTSeq: A package for working with high-throughput sequencing data.\n7. RSEM: A software for accurate alignment of RNA-seq reads to the reference genome.\n8. TopHat: A software for spliced alignment of RNA-seq reads.\n9. TRANSFAC: A database of transcription factor binding sites.\n10. WGCNA: A software for weighted gene co-expression network analysis.\n\nThese are just a few of the many packages available in R/Bioconductor for transcription factor binding site analysis.",
    "llama-7b_fact_raw": "1. ChEMBL is a database of bioactive molecules with pharmacological data.\n2. DAVID is a gene set enrichment analysis tool for functional genomics data.\n3. DESeq2 is a software for differential gene expression analysis.\n4. GEO2R is a software for differential expression analysis of gene expression data available in the Gene Expression Omnibus (GEO) database.\n5. TRANSFAC is a database of transcription factor binding sites.",
    "llama-7b_fact": [
      "ChEMBL is a database of bioactive molecules with pharmacological data.",
      "DAVID is a gene set enrichment analysis tool for functional genomics data.",
      "DESeq2 is a software for differential gene expression analysis.",
      "GEO2R is a software for differential expression analysis of gene expression data available in the Gene Expression Omnibus (GEO) database.",
      "TRANSFAC is a database of transcription factor binding sites."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-7b_response": "Sure, here are some clinical trials for the prevention of sarcopenia:\n\n1. SARCOPREV: This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in elderly men.\n\n2. SARCOPREV-2: This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in elderly women.\n\n3. SARCOPREV-3: This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in elderly patients with cancer.\n\n4. SARCOPREV-4: This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in elderly patients with chronic obstructive pulmonary disease (COPD).\n\n5. SARCOPREV-5: This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in elderly patients with heart failure.\n\n6. SARCOPREV-6: This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in elderly patients with type 2 diabetes mellitus.\n\n7. SARCOPREV-7: This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in elderly patients with frailty.\n\n8. SARCOPREV-8: This is a randomized, double-blind, placebo-controlled trial",
    "llama-7b_fact_raw": "1. SARCOPREV is a randomized, double-blind, placebo-controlled trial focused on preventing sarcopenia in elderly men through resistance training and protein supplementation.\n2. SARCOPREV-2 is a similar trial to SARCOPREV but is focused on preventing sarcopenia in elderly women.\n3. SARCOPREV-3 is a trial aimed at preventing sarcopenia in elderly patients with cancer.\n4. SARCOPREV-4 is a trial designed to prevent sarcopenia in elderly patients with chronic obstructive pulmonary disease (COPD).\n5. SARCOPREV-5 is a trial that targets the prevention of sarcopenia in elderly patients with heart failure.",
    "llama-7b_fact": [
      "SARCOPREV is a randomized, double-blind, placebo-controlled trial focused on preventing sarcopenia in elderly men through resistance training and protein supplementation.",
      "SARCOPREV-2 is a similar trial to SARCOPREV but is focused on preventing sarcopenia in elderly women.",
      "SARCOPREV-3 is a trial aimed at preventing sarcopenia in elderly patients with cancer.",
      "SARCOPREV-4 is a trial designed to prevent sarcopenia in elderly patients with chronic obstructive pulmonary disease (COPD).",
      "SARCOPREV-5 is a trial that targets the prevention of sarcopenia in elderly patients with heart failure."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the SARCOPREV trials and their subsequent iterations, it is not possible to determine the accuracy of these statements. These trials are not well-known standard references like historical events or geographical facts, and without access to the relevant medical literature or trial databases, their details cannot be verified.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-7b_response": "The database of molecular recognition features in membrane proteins is called the Membrane Protein Structural Diversity Database (MPSDD). It is a comprehensive resource that provides information on the structural and functional diversity of membrane proteins. The MPSDD includes information on various types of membrane proteins, such as ion channels, transporters, and receptors, and provides detailed information on their molecular recognition features, such as ligand-binding sites, ion-selective channels, and pore-forming regions. The MPSDD is an invaluable resource for researchers studying membrane proteins and their role in various biological processes.",
    "llama-7b_fact_raw": "1. The Membrane Protein Structural Diversity Database (MPSDD) is a database for molecular recognition features in membrane proteins.\n2. The MPSDD provides information on the structural and functional diversity of membrane proteins.\n3. Types of membrane proteins included in the MPSDD are ion channels, transporters, and receptors.\n4. The MPSDD contains detailed information on molecular recognition features like ligand-binding sites, ion-selective channels, and pore-forming regions.\n5. The MPSDD serves as a resource for researchers studying membrane proteins and their role in biological processes.",
    "llama-7b_fact": [
      "The Membrane Protein Structural Diversity Database (MPSDD) is a database for molecular recognition features in membrane proteins.",
      "The MPSDD provides information on the structural and functional diversity of membrane proteins.",
      "Types of membrane proteins included in the MPSDD are ion channels, transporters, and receptors.",
      "The MPSDD contains detailed information on molecular recognition features like ligand-binding sites, ion-selective channels, and pore-forming regions.",
      "The MPSDD serves as a resource for researchers studying membrane proteins and their role in biological processes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Membrane Protein Structural Diversity Database (MPSDD) is not specifically for molecular recognition features in membrane proteins; it is a database that provides information on the structural diversity of membrane proteins.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-7b_response": "Yes, rivaroxaban is metabolized in the kidneys. After oral administration, rivaroxaban is primarily metabolized by the cytochrome P450 (CYP) 3A4 enzyme in the liver. The metabolites of rivaroxaban are then excreted in the urine. The kidneys play an important role in the elimination of rivaroxaban and its active metabolites. Therefore, renal impairment can affect the elimination of rivaroxaban and may increase the risk of its adverse effects. It is important to consider the potential impact of renal function on the use of rivaroxaban in patients with renal disease.",
    "llama-7b_fact_raw": "1. Rivaroxaban is metabolized in the kidneys.\n2. Rivaroxaban is primarily metabolized by the cytochrome P450 (CYP) 3A4 enzyme in the liver.\n3. The metabolites of rivaroxaban are excreted in the urine.\n4. The kidneys play an important role in the elimination of rivaroxaban and its active metabolites.\n5. Renal impairment can affect the elimination of rivaroxaban and may increase the risk of its adverse effects.",
    "llama-7b_fact": [
      "Rivaroxaban is metabolized in the kidneys.",
      "Rivaroxaban is primarily metabolized by the cytochrome P450 (CYP) 3A4 enzyme in the liver.",
      "The metabolites of rivaroxaban are excreted in the urine.",
      "The kidneys play an important role in the elimination of rivaroxaban and its active metabolites.",
      "Renal impairment can affect the elimination of rivaroxaban and may increase the risk of its adverse effects."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Rivaroxaban is primarily metabolized in the liver, not the kidneys.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-7b_response": "TRalpha2 is a member of the thyroid hormone receptor (TR) family of nuclear receptors, which are transcription factors that regulate gene expression in response to thyroid hormones and other signaling molecules. In the heart, TRalpha2 has been shown to play a critical role in the regulation of cardiac development, growth, and remodeling.\n\nStudies have identified several genes that are regulated by TRalpha2 in the heart, including:\n\n1. Nkx2.5: Nkx2.5 is a transcription factor that is essential for the proper development of the heart. TRalpha2 has been shown to bind to the Nkx2.5 promoter and enhance its activity, thereby promoting the expression of genes required for cardiac development.\n\n2. Gata4: Gata4 is a transcription factor that is involved in the regulation of cardiac muscle cell growth and differentiation. TRalpha2 has been shown to bind to the Gata4 promoter and enhance its activity, thereby promoting the expression of genes required for cardiac growth and remodeling.\n\n3. Col1a1: Collagen type I is a key component of the extracellular matrix that provides structural support to the heart. TRalpha2 has been shown to bind to the Col1a1 promoter and enhance its activity, thereby promoting the expression of genes required for cardiac remodeling and fibrosis.\n\n4. Tgfb1: Tgfb1 is a cytokine that is involved in the regulation of cardiac fibrosis and hypertrophy. TRalpha2 has been shown to bind to the Tgfb1 promoter and inhibit its activity, thereby reducing the expression of genes required for cardiac fibrosis and hypertrophy.\n\nOverall, TRalpha2 plays a critical role in the regulation of gene expression in the heart, and its dysregulation has been implicated in the development of cardiovascular disease.",
    "llama-7b_fact_raw": "1. TRalpha2 is a member of the thyroid hormone receptor family of nuclear receptors.\n2. TRalpha2 regulates the gene Nkx2.5 by binding to its promoter and enhancing its activity in the heart.\n3. TRalpha2 regulates the gene Gata4 by binding to its promoter and enhancing its activity in the heart.\n4. TRalpha2 regulates the gene Col1a1 by binding to its promoter and enhancing its activity in the heart.\n5. TRalpha2 regulates the gene Tgfb1 by binding to its promoter and inhibiting its activity in the heart.",
    "llama-7b_fact": [
      "TRalpha2 is a member of the thyroid hormone receptor family of nuclear receptors.",
      "TRalpha2 regulates the gene Nkx2.5 by binding to its promoter and enhancing its activity in the heart.",
      "TRalpha2 regulates the gene Gata4 by binding to its promoter and enhancing its activity in the heart.",
      "TRalpha2 regulates the gene Col1a1 by binding to its promoter and enhancing its activity in the heart.",
      "TRalpha2 regulates the gene Tgfb1 by binding to its promoter and inhibiting its activity in the heart."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true as TRalpha2 is indeed a member of the thyroid hormone receptor family of nuclear receptors. However, without specific scientific literature or context to confirm the exact gene regulatory functions of TRalpha2, the truthfulness of statements 2 through 5 cannot be determined. These statements require specific knowledge of the gene regulatory roles of TRalpha2, which can vary depending on the context and the current state of scientific research.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-7b_response": "There are several biomedical question answering systems available, some of which are listed below:\n\n1. Clinical Question Answering System (CQAS): This system is developed by the National Library of Medicine and is designed to answer clinical questions posed by healthcare professionals.\n\n2. Medical Subject Headings (MeSH): MeSH is a controlled vocabulary thesaurus maintained by the National Library of Medicine that is used to index articles in biomedical literature.\n\n3. Unified Medical Language System (UMLS): UMLS is a comprehensive lexical database that provides a standardized representation of biomedical terminology.\n\n4. Biomedical Ontology: Biomedical ontology is a standardized representation of the basic concepts and relationships in biology and medicine. Examples of biomedical ontologies include the Basic Formal Ontology (BFO) and the Simple Knowledge Organization System (SKOS).\n\n5. PubMed: PubMed is a database of biomedical literature maintained by the National Library of Medicine. It provides access to over 30 million citations from MEDLINE, including full text articles.\n\n6. ClinicalTrials.gov: ClinicalTrials.gov is a database of clinical trials maintained by the National Institutes of Health. It provides information on ongoing and completed clinical trials.\n\n7. DrugBank: DrugBank is a database of drugs and drug targets maintained by the University of Alberta. It provides information on drugs and drug targets, including chemical structures, pharmacological data, and clinical trial information.\n\nThese are just a few examples of the many biomedical question answering systems available.",
    "llama-7b_fact_raw": "1. The Clinical Question Answering System (CQAS) is developed by the National Library of Medicine to answer clinical questions for healthcare professionals.\n2. Medical Subject Headings (MeSH) is a controlled vocabulary thesaurus maintained by the National Library of Medicine for indexing biomedical literature.\n3. The Unified Medical Language System (UMLS) is a comprehensive lexical database for standardized biomedical terminology.\n4. PubMed is a database of biomedical literature that provides access to over 30 million citations from MEDLINE.\n5. ClinicalTrials.gov is a database of clinical trials maintained by the National Institutes of Health, providing information on ongoing and completed trials.",
    "llama-7b_fact": [
      "The Clinical Question Answering System (CQAS) is developed by the National Library of Medicine to answer clinical questions for healthcare professionals.",
      "Medical Subject Headings (MeSH) is a controlled vocabulary thesaurus maintained by the National Library of Medicine for indexing biomedical literature.",
      "The Unified Medical Language System (UMLS) is a comprehensive lexical database for standardized biomedical terminology.",
      "PubMed is a database of biomedical literature that provides access to over 30 million citations from MEDLINE.",
      "ClinicalTrials.gov is a database of clinical trials maintained by the National Institutes of Health, providing information on ongoing and completed trials."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information about a system called the Clinical Question Answering System (CQAS) being developed by the National Library of Medicine, it is not possible to determine the truth of this statement.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-7b_response": "The trancription factor that activates the betalain pathway has not been fully elucidated, but it is believed to be a member of the MYB family of transcription factors. The MYB family of transcription factors is known to regulate the expression of genes involved in secondary metabolism, including the biosynthesis of betalain pigments. In particular, studies have shown that the expression of genes encoding enzymes involved in betalain biosynthesis is regulated by a MYB-like transcription factor in several plant species, including potato, tomato, and eggplant. However, the exact identity of the specific MYB transcription factor that activates the betalain pathway in these plants remains the subject of ongoing research.",
    "llama-7b_fact_raw": "1. The transcription factor that activates the betalain pathway is believed to be a member of the MYB family of transcription factors.\n2. The MYB family of transcription factors regulates the expression of genes involved in secondary metabolism.\n3. The biosynthesis of betalain pigments is regulated by a MYB-like transcription factor.\n4. Genes encoding enzymes involved in betalain biosynthesis are regulated by a MYB-like transcription factor in several plant species.\n5. The specific MYB transcription factor that activates the betalain pathway in plants like potato, tomato, and eggplant has not been definitively identified.",
    "llama-7b_fact": [
      "The transcription factor that activates the betalain pathway is believed to be a member of the MYB family of transcription factors.",
      "The MYB family of transcription factors regulates the expression of genes involved in secondary metabolism.",
      "The biosynthesis of betalain pigments is regulated by a MYB-like transcription factor.",
      "Genes encoding enzymes involved in betalain biosynthesis are regulated by a MYB-like transcription factor in several plant species.",
      "The specific MYB transcription factor that activates the betalain pathway in plants like potato, tomato, and eggplant has not been definitively identified."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The specific MYB transcription factor that activates the betalain pathway would not be relevant in plants like potato, tomato, and eggplant, as these plants do not naturally produce betalains. Betalains are characteristic of the Caryophyllales order, and plants like beets and amaranth produce them, not the Solanaceae family (potato, tomato, eggplant).",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-7b_response": "There are several preferred technologies for the enrichment of phosphorylated peptides in quantitative phosphoproteomic analyses. These technologies include:\n\n1. IMAC (Immobilized Metal Affinity Chromatography) - IMAC is a widely used technique for the enrichment of phosphorylated peptides. It utilizes immobilized metal ions, such as Ni2+ or Co2+, to selectively bind phosphorylated peptides.\n\n2. TiO2 (Titanium Dioxide) - TiO2 is another popular technique for the enrichment of phosphorylated peptides. It utilizes the binding of phosphorylated peptides to the negatively charged surface of TiO2 particles.\n\n3. SMB (Strong Cation-Exchange Chromatography) - SMB is another effective technique for the enrichment of phosphorylated peptides. It utilizes a strong cation-exchange resin to selectively bind phosphorylated peptides.\n\n4. LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) - LC-MS/MS is a highly sensitive and specific technique for the identification and quantification of phosphorylated peptides. It utilizes liquid chromatography to separate phosphorylated peptides from non-phosphorylated peptides, followed by tandem mass spectrometry for the accurate identification and quantification of phosphorylated peptides.\n\nOverall, the choice of enrichment technology will depend on several factors, including the type of sample being analyzed, the abundance of phosphorylated peptides, and the specific research question being addressed.",
    "llama-7b_fact_raw": "1. IMAC is a technique used for the enrichment of phosphorylated peptides that involves immobilized metal ions.\n2. Titanium Dioxide (TiO2) is used for the enrichment of phosphorylated peptides through binding to its negatively charged surface.\n3. Strong Cation-Exchange Chromatography (SMB) is used for the enrichment of phosphorylated peptides using a strong cation-exchange resin.\n4. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is a technique for identifying and quantifying phosphorylated peptides, separating them from non-phosphorylated peptides using liquid chromatography.",
    "llama-7b_fact": [
      "IMAC is a technique used for the enrichment of phosphorylated peptides that involves immobilized metal ions.",
      "Titanium Dioxide (TiO2) is used for the enrichment of phosphorylated peptides through binding to its negatively charged surface.",
      "Strong Cation-Exchange Chromatography (SMB) is used for the enrichment of phosphorylated peptides using a strong cation-exchange resin.",
      "Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is a technique for identifying and quantifying phosphorylated peptides, separating them from non-phosphorylated peptides using liquid chromatography."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Strong Cation-Exchange Chromatography (SCX) is used for the enrichment of phosphorylated peptides using a strong cation-exchange resin, not SMB.\n4. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-7b_response": "The Palmini classification is used to rate a variety of disorders, including but not limited to:\n\n1. Anxiety disorders, such as generalized anxiety disorder, social anxiety disorder, and panic disorder.\n\n2. Mood disorders, such as major depressive disorder, dysthymic disorder, and bipolar disorder.\n\n3. Personality disorders, such as borderline personality disorder, narcissistic personality disorder, and avoidant personality disorder.\n\n4. Eating disorders, such as anorexia nervosa, bulimia nervosa, and binge-eating disorder.\n\n5. Sleep disorders, such as insomnia, sleep apnea, and narcolepsy.\n\n6. Substance-related disorders, such as alcoholism, drug addiction, and smoking addiction.\n\n7. Trauma and stressor-related disorders, such as post-traumatic stress disorder (PTSD) and acute stress disorder.\n\nOverall, the Palmini classification provides a comprehensive system for rating a wide range of mental health disorders.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-7b_response": "No, viruses are not involved in the etiology of human subacute thyroiditis. Subacute thyroiditis is an autoimmune disorder in which the body's immune system attacks the thyroid gland, leading to inflammation and pain in the thyroid region. While viral infections can sometimes trigger autoimmune disorders, there is no evidence to suggest that viruses are specifically involved in the cause of subacute thyroiditis. Instead, it is believed to be triggered by a combination of environmental and genetic factors.",
    "llama-7b_fact_raw": "1. Viruses are not involved in the etiology of human subacute thyroiditis.\n2. Subacute thyroiditis is an autoimmune disorder.\n3. The body's immune system attacks the thyroid gland in subacute thyroiditis.\n4. Viral infections can sometimes trigger autoimmune disorders.\n5. Subacute thyroiditis is believed to be triggered by a combination of environmental and genetic factors.",
    "llama-7b_fact": [
      "Viruses are not involved in the etiology of human subacute thyroiditis.",
      "Subacute thyroiditis is an autoimmune disorder.",
      "The body's immune system attacks the thyroid gland in subacute thyroiditis.",
      "Viral infections can sometimes trigger autoimmune disorders.",
      "Subacute thyroiditis is believed to be triggered by a combination of environmental and genetic factors."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Viruses are believed to be involved in the etiology of human subacute thyroiditis.\n2. FALSE [correction]: Subacute thyroiditis is not primarily classified as an autoimmune disorder; it is often considered to be caused by a viral infection.\n3. FALSE [correction]: While the body's immune system may be involved in the inflammatory response, subacute thyroiditis is not typically characterized by the immune system attacking the thyroid gland as in autoimmune thyroid diseases like Hashimoto's thyroiditis.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-7b_response": "As an AI language model, I do not have personal beliefs or opinions. However, based on the available scientific literature, the answer to the question of whether STAT3 is involved in EIF2AK2-dependent suppression of autophagy is yes.\n\nSTAT3 is a transcription factor that plays a crucial role in various cellular processes, including cell growth, differentiation, and apoptosis. It has been reported that EIF2AK2, also known as eukaryotic initiation factor 2 alpha kinase 2, negatively regulates autophagy by inhibiting the formation of the pre-autophagosomal complex (PAC) through its kinase activity.\n\nFurthermore, recent studies have shown that STAT3 can interact with EIF2AK2 and negatively regulate its autophagy-suppressing activity. Specifically, STAT3 has been found to directly bind to and inhibit the kinase activity of EIF2AK2, thereby preventing it from inhibiting autophagy.\n\nTherefore, it can be concluded that STAT3 is indeed involved in the EIF2AK2-dependent suppression of autophagy.",
    "llama-7b_fact_raw": "1. STAT3 is a transcription factor involved in cell growth, differentiation, and apoptosis.\n2. EIF2AK2, also known as eukaryotic initiation factor 2 alpha kinase 2, negatively regulates autophagy.\n3. EIF2AK2 inhibits the formation of the pre-autophagosomal complex (PAC) through its kinase activity.\n4. STAT3 can interact with EIF2AK2 and negatively regulate its autophagy-suppressing activity.\n5. STAT3 has been found to directly bind to and inhibit the kinase activity of EIF2AK2.",
    "llama-7b_fact": [
      "STAT3 is a transcription factor involved in cell growth, differentiation, and apoptosis.",
      "EIF2AK2, also known as eukaryotic initiation factor 2 alpha kinase 2, negatively regulates autophagy.",
      "EIF2AK2 inhibits the formation of the pre-autophagosomal complex (PAC) through its kinase activity.",
      "STAT3 can interact with EIF2AK2 and negatively regulate its autophagy-suppressing activity.",
      "STAT3 has been found to directly bind to and inhibit the kinase activity of EIF2AK2."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: EIF2AK2, also known as PKR, is involved in the regulation of autophagy, but it does not inhibit the formation of the pre-autophagosomal complex (PAC) through its kinase activity. Instead, it is generally known to phosphorylate the alpha subunit of eukaryotic initiation factor 2 (eIF2α), leading to the inhibition of protein synthesis and the activation of autophagy under certain stress conditions.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-7b_response": "The Theatre software tool is used for genomic analysis to help researchers better understand the structure and function of genomes. The software is designed to process and analyze large volumes of genomic data, making it easier for researchers to identify patterns and relationships within the data.\n\nOne of the key features of Theatre is its ability to visualize genomic data in 3D. This allows researchers to better understand the spatial relationships between different genomic elements, such as genes and regulatory regions.\n\nAnother important feature of Theatre is its ability to integrate data from a variety of sources, including next-generation sequencing data, gene expression data, and epigenetic data. This allows researchers to gain a more comprehensive understanding of the genome and how it is regulated.\n\nOverall, the Theatre software tool is an important tool for genomic analysis, helping researchers to better understand the structure and function of genomes and uncover new insights into the genetic basis of disease and other biological processes.",
    "llama-7b_fact_raw": "1. The Theatre software tool is used for genomic analysis.\n2. Theatre is designed to process and analyze large volumes of genomic data.\n3. The software can visualize genomic data in 3D.\n4. Theatre can integrate data from various sources, including next-generation sequencing, gene expression, and epigenetic data.\n5. The tool helps researchers understand the genetic basis of disease and other biological processes.",
    "llama-7b_fact": [
      "The Theatre software tool is used for genomic analysis.",
      "Theatre is designed to process and analyze large volumes of genomic data.",
      "The software can visualize genomic data in 3D.",
      "Theatre can integrate data from various sources, including next-generation sequencing, gene expression, and epigenetic data.",
      "The tool helps researchers understand the genetic basis of disease and other biological processes."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a software tool named \"Theatre\" related to genomic analysis, it is not possible to determine the accuracy of these statements. The statements could be true if there is a genomic analysis tool by that name with those capabilities, but without additional context or information, the veracity of the statements cannot be confirmed.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-7b_response": "The Smith-Waterman algorithm is a local sequence alignment algorithm that compares two sequences and finds the optimal alignment between them. The execution time (complexity) of the Smith-Waterman algorithm depends on various factors such as the length of the sequences, the gap opening and gap extension penalties, and the algorithm's implementation.\n\nIn general, the Smith-Waterman algorithm has a time complexity of O(n^2) where n is the length of the shorter of the two sequences. This is because the algorithm compares each pair of nucleotides or amino acids in the sequences and calculates the cost of aligning them. The cost is a function of the distance between the nucleotides or amino acids and the gap opening and gap extension penalties.\n\nHowever, the time complexity of the Smith-Waterman algorithm can be improved to O(n log n) by using a faster matrix multiplication algorithm such as the Coppersmith-Winograd algorithm. This can result in a significant speedup in the alignment of long sequences.\n\nIn summary, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the length of the sequences, the gap opening and gap extension penalties, and the algorithm's implementation. The time complexity can be improved to O(n log n) by using the Coppersmith-Winograd algorithm.",
    "llama-7b_fact_raw": "1. The Smith-Waterman algorithm is a local sequence alignment algorithm.\n2. The general time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter of the two sequences.\n3. The time complexity of the Smith-Waterman algorithm can be improved to O(n log n) by using a faster matrix multiplication algorithm.\n4. The Coppersmith-Winograd algorithm is an example of a faster matrix multiplication algorithm that can improve the time complexity of the Smith-Waterman algorithm.",
    "llama-7b_fact": [
      "The Smith-Waterman algorithm is a local sequence alignment algorithm.",
      "The general time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter of the two sequences.",
      "The time complexity of the Smith-Waterman algorithm can be improved to O(n log n) by using a faster matrix multiplication algorithm.",
      "The Coppersmith-Winograd algorithm is an example of a faster matrix multiplication algorithm that can improve the time complexity of the Smith-Waterman algorithm."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The time complexity of the Smith-Waterman algorithm is not typically improved to O(n log n) by using a faster matrix multiplication algorithm. The Smith-Waterman algorithm's time complexity is inherently quadratic due to its dynamic programming approach, and while there are optimizations, they generally do not reduce the complexity to O(n log n).\n4. FALSE [correction]: The Coppersmith-Winograd algorithm is indeed a faster matrix multiplication algorithm, but it is not used to improve the time complexity of the Smith-Waterman algorithm, which is based on dynamic programming and not matrix multiplication.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-7b_response": "FLVCR1 is a member of the SLC (Solute Carrier) family. Specifically, it belongs to the SLC25A subfamily of solute carriers. The SLC25A family is composed of solute carriers that are involved in the transport of various organic and inorganic ions, such as sodium, potassium, calcium, magnesium, zinc, and copper. FLVCR1 is specifically known to be involved in the transport of fluoride ions.",
    "llama-7b_fact_raw": "1. FLVCR1 is a member of the SLC (Solute Carrier) family.\n2. FLVCR1 belongs to the SLC25A subfamily of solute carriers.\n3. The SLC25A family includes solute carriers that transport various ions including sodium, potassium, calcium, magnesium, zinc, and copper.\n4. FLVCR1 is involved in the transport of fluoride ions.",
    "llama-7b_fact": [
      "FLVCR1 is a member of the SLC (Solute Carrier) family.",
      "FLVCR1 belongs to the SLC25A subfamily of solute carriers.",
      "The SLC25A family includes solute carriers that transport various ions including sodium, potassium, calcium, magnesium, zinc, and copper.",
      "FLVCR1 is involved in the transport of fluoride ions."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC (Solute Carrier) family; it is a member of the Major Facilitator Superfamily (MFS).\n2. FALSE [correction]: FLVCR1 does not belong to the SLC25A subfamily of solute carriers; it is a heme transporter.\n3. FALSE [correction]: The SLC25A family is primarily known for mitochondrial transporters that transport metabolites across the inner mitochondrial membrane, not various ions like sodium, potassium, calcium, magnesium, zinc, and copper.\n4. FALSE [correction]: FLVCR1 is involved in the transport of heme, not fluoride ions.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-7b_response": "GATA-1 (GATA binding protein 1) is a transcription factor that plays a crucial role in the regulation of various cellular processes, including hematopoiesis, cardiogenesis, and muscle differentiation. GATA-1 interacts with a variety of proteins and molecules to regulate its target genes. Here are some of the interacting partners of GATA-1 that have been discovered using the biotinylation tagging approach:\n\n1. BCL11A: BCL11A is a transcriptional repressor that interacts with GATA-1 to regulate the differentiation of hematopoietic stem cells.\n\n2. FOG-1: FOG-1 is a chromatin remodeling protein that interacts with GATA-1 to regulate the expression of genes involved in hematopoiesis.\n\n3. HDAC1: HDAC1 is a histone deacetylase that interacts with GATA-1 to regulate the acetylation of histones and the transcriptional activity of GATA-1.\n\n4. KLF2: KLF2 is a transcription factor that interacts with GATA-1 to regulate the expression of genes involved in cardiogenesis.\n\n5. MEF2A: MEF2A is a transcription factor that interacts with GATA-1 to regulate the expression of genes involved in muscle differentiation.\n\n6. NCOA1: NCOA1 is a coactivator that interacts with GATA-1 to regulate the transcriptional activity of GATA-1.\n\n7. PBX1: PBX1 is a transcription factor that interacts with GATA-1 to regulate the expression of genes involved in hematopoiesis.\n\nThese interactions are crucial for the proper functioning of GATA-1 and the regulation of its target genes. The biotinylation tagging approach has been instrumental in identifying these interacting partners and understanding their role in various biological processes.",
    "llama-7b_fact_raw": "1. BCL11A is a transcriptional repressor that interacts with GATA-1.\n2. FOG-1 is a chromatin remodeling protein that interacts with GATA-1.\n3. HDAC1 is a histone deacetylase that interacts with GATA-1.\n4. KLF2 is a transcription factor that interacts with GATA-1.\n5. MEF2A is a transcription factor that interacts with GATA-1.",
    "llama-7b_fact": [
      "BCL11A is a transcriptional repressor that interacts with GATA-1.",
      "FOG-1 is a chromatin remodeling protein that interacts with GATA-1.",
      "HDAC1 is a histone deacetylase that interacts with GATA-1.",
      "KLF2 is a transcription factor that interacts with GATA-1.",
      "MEF2A is a transcription factor that interacts with GATA-1."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are true as BCL11A, FOG-1, and HDAC1 are known to interact with GATA-1 in the context of hematopoiesis and gene regulation. However, without specific context or additional information, the interactions of KLF2 and MEF2A with GATA-1 cannot be confirmed as true or false, hence the response is UNKNOWN for statements 4 and 5.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-7b_response": "The outcome of TAF10 interacting with the GATA1 transcription factor depends on the specific interaction between the two proteins and the context in which they interact. In general, the interaction between TAF10 and GATA1 could enhance or inhibit the transcriptional activity of GATA1. \n\nTAF10 is a transcriptional co-activator that belongs to the TAF family of proteins. It has been shown to interact with a variety of transcription factors, including GATA1. The interaction between TAF10 and GATA1 could potentially enhance the ability of GATA1 to bind to DNA and form a stable transcriptional complex. This could lead to an increase in the expression of genes that are targeted by GATA1.\n\nOn the other hand, the interaction between TAF10 and GATA1 could also inhibit the transcriptional activity of GATA1. This could occur if TAF10 competes with other proteins that also interact with GATA1 for a limited number of binding sites on the GATA1 protein. In this case, the interaction between TAF10 and GATA1 could lead to a decrease in the expression of genes that are targeted by GATA1.\n\nOverall, the outcome of TAF10 interacting with the GATA1 transcription factor will depend on the specific context in which they interact and the nature of the interaction itself.",
    "llama-7b_fact_raw": "1. TAF10 is a transcriptional co-activator that belongs to the TAF family of proteins.\n2. TAF10 has been shown to interact with a variety of transcription factors, including GATA1.\n3. The interaction between TAF10 and GATA1 could potentially enhance GATA1's ability to bind to DNA and form a stable transcriptional complex.\n4. An increase in the expression of genes targeted by GATA1 could result from the interaction between TAF10 and GATA1.\n5. The interaction between TAF10 and GATA1 could also inhibit GATA1's transcriptional activity if TAF10 competes with other proteins for binding sites on GATA1.",
    "llama-7b_fact": [
      "TAF10 is a transcriptional co-activator that belongs to the TAF family of proteins.",
      "TAF10 has been shown to interact with a variety of transcription factors, including GATA1.",
      "The interaction between TAF10 and GATA1 could potentially enhance GATA1's ability to bind to DNA and form a stable transcriptional complex.",
      "An increase in the expression of genes targeted by GATA1 could result from the interaction between TAF10 and GATA1.",
      "The interaction between TAF10 and GATA1 could also inhibit GATA1's transcriptional activity if TAF10 competes with other proteins for binding sites on GATA1."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll the statements provided are consistent with general knowledge about transcriptional co-activators and their interactions with transcription factors. TAF10, as a member of the TAF family, is known to interact with various transcription factors, potentially influencing their activity and the expression of target genes. The specific interactions and outcomes (such as enhancement or inhibition of transcriptional activity) would depend on the context and the presence of other regulatory proteins, making the statements plausible. However, without specific experimental evidence provided in the context, the exact nature of the interaction between TAF10 and GATA1 in a given scenario would be unknown.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-7b_response": "Yes, there are decision support systems for chronic pain management. These systems are designed to help healthcare professionals make informed decisions about the treatment of chronic pain.\n\nOne example of a decision support system for chronic pain management is the National Institutes of Health (NIH) Pain Management Guidelines. These guidelines provide evidence-based recommendations for the treatment of chronic pain, including medication management, non-pharmacological therapies, and complementary and alternative medicine.\n\nAnother decision support system is the Clinical Practice Guideline for Opioid Therapy for Chronic Pain, developed by the American Pain Society and the American College of Physicians. This guideline provides recommendations for the use of opioid medications in the treatment of chronic pain, including criteria for initiating and titrating opioid therapy, monitoring for side effects and abuse, and transitioning patients to non-opioid therapies when appropriate.\n\nOverall, decision support systems for chronic pain management provide healthcare professionals with evidence-based recommendations and tools to help them make informed decisions about the treatment of patients with chronic pain.",
    "llama-7b_fact_raw": "1. Decision support systems exist to aid healthcare professionals in managing chronic pain.\n2. The National Institutes of Health (NIH) Pain Management Guidelines are an example of a decision support system for chronic pain management.\n3. The NIH Pain Management Guidelines offer evidence-based recommendations for treating chronic pain.\n4. The Clinical Practice Guideline for Opioid Therapy for Chronic Pain is developed by the American Pain Society and the American College of Physicians.\n5. The Clinical Practice Guideline for Opioid Therapy for Chronic Pain includes recommendations for opioid use, monitoring side effects and abuse, and transitioning to non-opioid therapies.",
    "llama-7b_fact": [
      "Decision support systems exist to aid healthcare professionals in managing chronic pain.",
      "The National Institutes of Health (NIH) Pain Management Guidelines are an example of a decision support system for chronic pain management.",
      "The NIH Pain Management Guidelines offer evidence-based recommendations for treating chronic pain.",
      "The Clinical Practice Guideline for Opioid Therapy for Chronic Pain is developed by the American Pain Society and the American College of Physicians.",
      "The Clinical Practice Guideline for Opioid Therapy for Chronic Pain includes recommendations for opioid use, monitoring side effects and abuse, and transitioning to non-opioid therapies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The National Institutes of Health (NIH) Pain Management Guidelines are not a decision support system; they are guidelines. A decision support system is typically an interactive software-based system intended to help decision-makers compile useful information from raw data, documents, personal knowledge, and/or business models to identify and solve problems and make decisions.\n3. TRUE\n4. FALSE [correction]: The Clinical Practice Guideline for Opioid Therapy for Chronic Pain is developed by the Centers for Disease Control and Prevention (CDC), not the American Pain Society and the American College of Physicians.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-7b_response": "Angiogenin is a protein that has been implicated in the process of angiogenesis, which is the formation of new blood vessels. While the exact subcellular localization of angiogenin can vary depending on the cell type and context, it is generally thought to be located in the nucleus of cells.\n\nIn some cell types, such as endothelial cells (which form the inner lining of blood vessels), angiogenin has been found to be localized to the nucleus and to be involved in the regulation of gene expression related to angiogenesis. In other cell types, such as fibroblasts (which are responsible for creating the extracellular matrix that supports blood vessels), angiogenin has been found to be located both in the nucleus and in the cytoplasm.\n\nIt is important to note that the subcellular localization of angiogenin can also be influenced by various factors, such as the stage of angiogenesis, the presence of other molecules, and the cellular context. Therefore, further research is needed to fully understand the precise localization and function of angiogenin in different cell types and under different conditions.",
    "llama-7b_fact_raw": "1. Angiogenin is a protein implicated in the process of angiogenesis.\n2. Angiogenin is generally thought to be located in the nucleus of cells.\n3. In endothelial cells, angiogenin is localized to the nucleus and involved in the regulation of gene expression related to angiogenesis.\n4. In fibroblasts, angiogenin has been found to be located both in the nucleus and in the cytoplasm.\n5. The subcellular localization of angiogenin can be influenced by factors such as the stage of angiogenesis, the presence of other molecules, and the cellular context.",
    "llama-7b_fact": [
      "Angiogenin is a protein implicated in the process of angiogenesis.",
      "Angiogenin is generally thought to be located in the nucleus of cells.",
      "In endothelial cells, angiogenin is localized to the nucleus and involved in the regulation of gene expression related to angiogenesis.",
      "In fibroblasts, angiogenin has been found to be located both in the nucleus and in the cytoplasm.",
      "The subcellular localization of angiogenin can be influenced by factors such as the stage of angiogenesis, the presence of other molecules, and the cellular context."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Angiogenin is not generally thought to be located in the nucleus of cells; it is found in various cellular compartments and its localization can be cell-type specific.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-7b_response": "Ranolazine is a drug that is commonly used to treat chronic angina, a condition characterized by chest pain caused by inadequate blood flow to the heart. The exact mechanism by which ranolazine works is not fully understood, but it is thought to interfere with the activity of certain enzymes involved in cellular signaling pathways.\n\nOne of the key enzymes that ranolazine interacts with is the voltage-gated potassium channel (Kv1.5), which is responsible for regulating the electrical activity of heart cells. By inhibiting the activity of Kv1.5, ranolazine reduces the influx of potassium ions into heart cells, which in turn slows down the heart rate and reduces the demand for oxygen in the heart muscle.\n\nIn addition to its effects on the Kv1.5 channel, ranolazine has also been shown to inhibit the activity of several other enzymes involved in kinase signaling pathways, including protein kinase A (PKA), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK). These enzymes play important roles in regulating the activity of other proteins involved in cardiac muscle contraction and relaxation, and by inhibiting their activity, ranolazine may help to improve blood flow to the heart and reduce the risk of angina attacks.\n\nOverall, the exact mechanisms by which ranolazine affects kinase signaling activation in the heart are not fully understood, but its ability to interfere with the activity of multiple enzymes involved in cellular signaling pathways suggests that it may have a complex and multifaceted effect on cardiac function.",
    "llama-7b_fact_raw": "1. Ranolazine is used to treat chronic angina, which is characterized by chest pain due to inadequate blood flow to the heart.\n2. Ranolazine is thought to interfere with the activity of certain enzymes involved in cellular signaling pathways.\n3. Ranolazine inhibits the activity of the voltage-gated potassium channel (Kv1.5) in heart cells.\n4. By inhibiting Kv1.5, ranolazine reduces the influx of potassium ions into heart cells, which can slow down the heart rate.\n5. Ranolazine has been shown to inhibit the activity of enzymes such as protein kinase A (PKA), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK).",
    "llama-7b_fact": [
      "Ranolazine is used to treat chronic angina, which is characterized by chest pain due to inadequate blood flow to the heart.",
      "Ranolazine is thought to interfere with the activity of certain enzymes involved in cellular signaling pathways.",
      "Ranolazine inhibits the activity of the voltage-gated potassium channel (Kv1.5) in heart cells.",
      "By inhibiting Kv1.5, ranolazine reduces the influx of potassium ions into heart cells, which can slow down the heart rate.",
      "Ranolazine has been shown to inhibit the activity of enzymes such as protein kinase A (PKA), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Ranolazine is thought to work by modulating the late phase of the inward sodium current (INa) in heart cells, not by interfering with enzymes involved in cellular signaling pathways.\n3. FALSE [correction]: Ranolazine is known to inhibit the late phase of the inward sodium channel (INa), not the voltage-gated potassium channel (Kv1.5).\n4. FALSE [correction]: By inhibiting the late phase of the inward sodium current, ranolazine reduces sodium-dependent calcium overload in heart cells, which can help to improve cardiac function and reduce chest pain. It does not reduce the influx of potassium ions into heart cells to slow down the heart rate.\n5. FALSE [correction]: Ranolazine's primary known action is on the late phase of the inward sodium current (INa) in heart cells, and there is no well-established evidence that it directly inhibits the activity of enzymes such as protein kinase A (PKA), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK).",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-7b_response": "The regulation of Vsr endonuclease in bacteria is not necessarily independent of the growth phase. While Vsr endonuclease is known to play a role in bacterial virulence and antibiotic resistance, the exact mechanisms governing its expression and activity are not fully understood.\n\nStudies have shown that Vsr endonuclease activity can be induced or repressed in response to various environmental cues, including nutrient availability, pH, temperature, and the presence of antibiotics or other stressors. In some cases, the expression of vsr genes has been shown to be phase-variable, meaning that it varies over time in a predictable pattern that corresponds to the growth cycle of the bacterium.\n\nHowever, it is important to note that the regulation of Vsr endonuclease is likely complex and multifaceted, and the relationship between growth phase and Vsr activity may vary depending on the specific bacterial strain and environmental conditions. Further research is needed to fully elucidate the mechanisms governing the regulation of Vsr endonuclease in bacteria.",
    "llama-7b_fact_raw": "1. Vsr endonuclease plays a role in bacterial virulence and antibiotic resistance.\n2. The expression and activity of Vsr endonuclease can be induced or repressed in response to environmental cues such as nutrient availability, pH, temperature, and the presence of antibiotics or other stressors.\n3. The expression of vsr genes can be phase-variable, corresponding to the growth cycle of the bacterium.\n4. The regulation of Vsr endonuclease may vary depending on the bacterial strain and environmental conditions.\n5. Further research is needed to fully understand the regulation of Vsr endonuclease in bacteria.",
    "llama-7b_fact": [
      "Vsr endonuclease plays a role in bacterial virulence and antibiotic resistance.",
      "The expression and activity of Vsr endonuclease can be induced or repressed in response to environmental cues such as nutrient availability, pH, temperature, and the presence of antibiotics or other stressors.",
      "The expression of vsr genes can be phase-variable, corresponding to the growth cycle of the bacterium.",
      "The regulation of Vsr endonuclease may vary depending on the bacterial strain and environmental conditions.",
      "Further research is needed to fully understand the regulation of Vsr endonuclease in bacteria."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Vsr endonuclease is involved in DNA mismatch repair, not directly in bacterial virulence and antibiotic resistance.\n2. TRUE: The expression and activity of various bacterial enzymes, including endonucleases, can be regulated in response to environmental cues.\n3. UNKNOWN: The phase variability of vsr gene expression would depend on the specific bacterial species and regulatory mechanisms, which are not universally the same across all bacteria.\n4. TRUE: It is common for the regulation of bacterial enzymes to vary depending on the strain and environmental conditions.\n5. TRUE: As with many biological processes, further research is often needed to fully understand the nuances of regulation, including that of Vsr endonuclease in bacteria.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Some of the commonly used tools are:\n\n1. TMHMM: This is a widely used tool for the prediction of transmembrane proteins. It uses a hidden Markov model to predict beta-barrels in proteins.\n\n2. Beta-Barrel Predictor: This is another popular tool for the prediction of beta-barrel transmembrane proteins. It uses a machine learning approach to predict beta-barrels in proteins.\n\n3. PhyMol: This is a molecular visualization software that can be used to predict beta-barrels in proteins. It uses a color-coding scheme to identify beta-strands and beta-barrels in proteins.\n\n4. SWISS-MODEL: This is a software that can be used to predict the 3D structure of proteins. It can also be used to predict beta-barrels in proteins.\n\n5. PDBsum: This is a database that contains information about protein structures in the Protein Data Bank (PDB). It can be used to identify proteins that have beta-barrel structures.\n\nOverall, these computational tools can be useful in predicting beta-barrel transmembrane proteins, but it is important to note that they are not always accurate and should be used in conjunction with experimental data.",
    "llama-7b_fact_raw": "1. TMHMM is a tool used for the prediction of transmembrane proteins using a hidden Markov model.\n2. Beta-Barrel Predictor is a tool that employs a machine learning approach for predicting beta-barrel transmembrane proteins.\n3. PhyMol is a molecular visualization software that can predict beta-barrels in proteins through a color-coding scheme.\n4. SWISS-MODEL is software capable of predicting the 3D structure of proteins, including beta-barrels.\n5. PDBsum is a database that provides information about protein structures from the Protein Data Bank and can be used to identify beta-barrel structures.",
    "llama-7b_fact": [
      "TMHMM is a tool used for the prediction of transmembrane proteins using a hidden Markov model.",
      "Beta-Barrel Predictor is a tool that employs a machine learning approach for predicting beta-barrel transmembrane proteins.",
      "PhyMol is a molecular visualization software that can predict beta-barrels in proteins through a color-coding scheme.",
      "SWISS-MODEL is software capable of predicting the 3D structure of proteins, including beta-barrels.",
      "PDBsum is a database that provides information about protein structures from the Protein Data Bank and can be used to identify beta-barrel structures."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: PyMOL is a molecular visualization software, but it does not predict beta-barrels in proteins through a color-coding scheme. It is used for viewing, analyzing, and creating molecular visualizations, not for prediction.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-7b_response": "Galassi classification is used for the diagnosis of skeletal dysplasias, a group of genetic disorders characterized by abnormalities in bone growth and development. These disorders can affect the shape, size, and structure of bones, leading to various health problems such as joint pain, limited range of motion, and skeletal deformities. Galassi classification is a system that categorizes skeletal dysplasias based on their clinical features, radiographic findings, and genetic causes. It provides a standardized approach for diagnosing and managing these complex disorders.",
    "llama-7b_fact_raw": "1. Galassi classification is used for the diagnosis of skeletal dysplasias.\n2. Skeletal dysplasias are genetic disorders characterized by abnormalities in bone growth and development.\n3. These disorders can lead to health problems such as joint pain, limited range of motion, and skeletal deformities.\n4. Galassi classification categorizes skeletal dysplasias based on clinical features, radiographic findings, and genetic causes.\n5. The classification provides a standardized approach for diagnosing and managing skeletal dysplasias.",
    "llama-7b_fact": [
      "Galassi classification is used for the diagnosis of skeletal dysplasias.",
      "Skeletal dysplasias are genetic disorders characterized by abnormalities in bone growth and development.",
      "These disorders can lead to health problems such as joint pain, limited range of motion, and skeletal deformities.",
      "Galassi classification categorizes skeletal dysplasias based on clinical features, radiographic findings, and genetic causes.",
      "The classification provides a standardized approach for diagnosing and managing skeletal dysplasias."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Galassi classification is not used for the diagnosis of skeletal dysplasias; it is actually a system used to classify temporal bone pneumatization seen on otologic CT scans.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Since the Galassi classification is not related to skeletal dysplasias, it does not categorize them based on clinical features, radiographic findings, and genetic causes. The correct classification systems for skeletal dysplasias include the International Skeletal Dysplasia Society (ISDS) classification.\n5. FALSE [correction]: The Galassi classification does not provide a standardized approach for diagnosing and managing skeletal dysplasias as it is not related to these disorders. Systems like the ISDS classification would be used for this purpose.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-7b_response": "Shapiro syndrome is a rare genetic disorder characterized by a variety of physical and developmental abnormalities. Some of the common features of Shapiro syndrome include:\n\n1. Intellectual disability: Individuals with Shapiro syndrome often have mild to moderate intellectual disability.\n\n2. Facial abnormalities: People with Shapiro syndrome often have a distinctive facial appearance, including a small head, wide-set eyes, and a flattened nasal bridge.\n\n3. Hearing loss: Approximately 50% of individuals with Shapiro syndrome have some degree of hearing loss.\n\n4. Delayed physical development: Children with Shapiro syndrome may take longer to reach developmental milestones, such as walking and talking.\n\n5. Gastroesophageal reflux: Many individuals with Shapiro syndrome experience gastroesophageal reflux, which is the backflow of stomach acid into the esophagus.\n\n6. Scoliosis: Up to 50% of individuals with Shapiro syndrome develop scoliosis, a curvature of the spine.\n\n7. Renal abnormalities: Some individuals with Shapiro syndrome may have kidney abnormalities, such as hydronephrosis (a buildup of urine in one kidney) or kidney failure.\n\nOverall, Shapiro syndrome is a complex disorder that can affect many different systems in the body. Early diagnosis and intervention can help improve quality of life for individuals with Shapiro syndrome and their families.",
    "llama-7b_fact_raw": "1. Shapiro syndrome is characterized by mild to moderate intellectual disability.\n2. Individuals with Shapiro syndrome often have distinctive facial features, including a small head, wide-set eyes, and a flattened nasal bridge.\n3. Approximately 50% of individuals with Shapiro syndrome have some degree of hearing loss.\n4. Children with Shapiro syndrome may experience delayed physical development, affecting milestones such as walking and talking.\n5. Many individuals with Shapiro syndrome experience gastroesophageal reflux.",
    "llama-7b_fact": [
      "Shapiro syndrome is characterized by mild to moderate intellectual disability.",
      "Individuals with Shapiro syndrome often have distinctive facial features, including a small head, wide-set eyes, and a flattened nasal bridge.",
      "Approximately 50% of individuals with Shapiro syndrome have some degree of hearing loss.",
      "Children with Shapiro syndrome may experience delayed physical development, affecting milestones such as walking and talking.",
      "Many individuals with Shapiro syndrome experience gastroesophageal reflux."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of recurrent episodes of spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum; it does not typically include intellectual disability as a defining feature.\n2. FALSE [correction]: The distinctive facial features described are not associated with Shapiro syndrome but may be indicative of other genetic conditions. Shapiro syndrome does not have a defined set of facial features.\n3. UNKNOWN: There is no widely recognized association between Shapiro syndrome and hearing loss; this may vary among individuals but is not a documented characteristic of the syndrome.\n4. UNKNOWN: While delayed physical development can occur in various conditions, there is no specific information linking it as a common feature of Shapiro syndrome. Each case may present differently.\n5. UNKNOWN: Gastroesophageal reflux is a common condition that can affect many individuals, but there is no specific information suggesting it is a common experience for those with Shapiro syndrome.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-7b_response": "The disease that is linked to mutations within BRAG1 is hereditary breast and ovarian cancer (HBOC). HBOC is a genetic disorder that increases the risk of developing breast and ovarian cancer. Mutations in the BRAG1 gene have been found to be associated with an increased risk of developing HBOC. BRAG1 is a tumor suppressor gene that plays a role in regulating cell growth and division. When the BRAG1 gene mutates, it can no longer function properly, which can lead to the development of cancer.",
    "llama-7b_fact_raw": "1. Mutations within BRAG1 are linked to hereditary breast and ovarian cancer (HBOC).\n2. HBOC is a genetic disorder that increases the risk of developing breast and ovarian cancer.\n3. Mutations in the BRAG1 gene are associated with an increased risk of developing HBOC.\n4. BRAG1 is a tumor suppressor gene.\n5. The BRAG1 gene plays a role in regulating cell growth and division.",
    "llama-7b_fact": [
      "Mutations within BRAG1 are linked to hereditary breast and ovarian cancer (HBOC).",
      "HBOC is a genetic disorder that increases the risk of developing breast and ovarian cancer.",
      "Mutations in the BRAG1 gene are associated with an increased risk of developing HBOC.",
      "BRAG1 is a tumor suppressor gene.",
      "The BRAG1 gene plays a role in regulating cell growth and division."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations within BRCA1 are linked to hereditary breast and ovarian cancer (HBOC).\n2. TRUE\n3. FALSE [correction]: Mutations in the BRCA1 gene are associated with an increased risk of developing HBOC.\n4. TRUE [clarification]: While BRAG1 is not a recognized gene, assuming this is a typographical error and the intended gene is BRCA1, then BRCA1 is indeed a tumor suppressor gene.\n5. TRUE [clarification]: Again, assuming BRAG1 is a typo for BRCA1, the BRCA1 gene does play a role in regulating cell growth and division by repairing DNA damage.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-7b_response": "The main inhibitor of protein phosphatase 1 (PP1) is a protein called \"protein inhibitor of activated STAT (PIAS)\" or \"protein inhibitor of activated STAT1 (PIAS1)\". PIAS1 is a ubiquitously expressed protein that binds to and inhibits the activity of several protein phosphatases, including PP1, PP2A, and PP2B. PIAS1 is activated by tyrosine phosphorylation in response to various extracellular and intracellular stimuli, which leads to its association with PP1 and inhibition of its enzymatic activity. PIAS1 is a key regulator of signaling pathways involved in cell growth, differentiation, and apoptosis, and its dysregulation has been implicated in various human diseases, including cancer.",
    "llama-7b_fact_raw": "1. Protein inhibitor of activated STAT (PIAS) or protein inhibitor of activated STAT1 (PIAS1) is the main inhibitor of protein phosphatase 1 (PP1).\n2. PIAS1 binds to and inhibits the activity of several protein phosphatases, including PP1, PP2A, and PP2B.\n3. PIAS1 is ubiquitously expressed.\n4. PIAS1 is activated by tyrosine phosphorylation in response to various extracellular and intracellular stimuli.\n5. Dysregulation of PIAS1 has been implicated in various human diseases, including cancer.",
    "llama-7b_fact": [
      "Protein inhibitor of activated STAT (PIAS) or protein inhibitor of activated STAT1 (PIAS1) is the main inhibitor of protein phosphatase 1 (PP1).",
      "PIAS1 binds to and inhibits the activity of several protein phosphatases, including PP1, PP2A, and PP2B.",
      "PIAS1 is ubiquitously expressed.",
      "PIAS1 is activated by tyrosine phosphorylation in response to various extracellular and intracellular stimuli.",
      "Dysregulation of PIAS1 has been implicated in various human diseases, including cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Protein inhibitor of activated STAT (PIAS) proteins, including PIAS1, are not the main inhibitors of protein phosphatase 1 (PP1). Instead, they primarily function as regulators of the STAT (Signal Transducers and Activators of Transcription) family of transcription factors.\n2. FALSE [correction]: PIAS1 does not bind to and inhibit the activity of protein phosphatases like PP1, PP2A, and PP2B. PIAS1 mainly modulates the activity of various transcription factors, including STAT proteins, by mechanisms such as SUMOylation.\n3. TRUE: PIAS1 is indeed ubiquitously expressed in various tissues throughout the body.\n4. TRUE: PIAS1 can be activated by tyrosine phosphorylation in response to different stimuli, which is part of the mechanism by which it regulates the activity of its target proteins.\n5. TRUE: Dysregulation of PIAS1 has been implicated in the pathogenesis of various human diseases, including cancer, due to its role in modulating the activity of transcription factors and other proteins involved in cell growth, apoptosis, and immune responses.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process in which Bacillus subtilis cells undergo a high frequency of spontaneous mutations during the stationary phase of growth. The mechanisms that underlie adaptive mutagenesis in B. subtilis include:\n\n1. DNA damage: During the stationary phase of growth, B. subtilis cells are exposed to a variety of environmental stressors, such as low nutrient availability and oxidative stress. These stressors can cause DNA damage, which can lead to mutations.\n\n2. DNA repair: B. subtilis cells have several mechanisms to repair DNA damage, such as homologous recombination, non-homologous end joining, and error-prone repair. However, these mechanisms are not perfect, and some DNA damage can go unrepaired, leading to mutations.\n\n3. Replication stress: During the stationary phase of growth, B. subtilis cells replicate their DNA more slowly than during the log phase of growth. This slower replication can lead to replication stress, which can cause DNA damage and mutations.\n\n4. Transcriptional regulation: B. subtilis cells have a complex transcriptional regulatory network that controls the expression of genes involved in DNA replication, repair, and recombination. Mutations in these genes can affect the ability of the cell to respond to DNA damage and replication stress, leading to adaptive mutagenesis.\n\nOverall, adaptive mutagenesis in B. subtilis is a complex process that involves multiple mechanisms, including DNA damage, DNA repair, replication stress, and transcriptional regulation. These mechanisms work together to allow the cell to respond to environmental stressors and undergo high frequencies of spontaneous mutations during the stationary phase of growth.",
    "llama-7b_fact_raw": "1. Bacillus subtilis cells undergo a high frequency of spontaneous mutations during the stationary phase of growth.\n2. Environmental stressors such as low nutrient availability and oxidative stress can cause DNA damage in B. subtilis cells during the stationary phase.\n3. B. subtilis cells have DNA repair mechanisms including homologous recombination, non-homologous end joining, and error-prone repair.\n4. During the stationary phase, B. subtilis cells replicate their DNA more slowly, which can lead to replication stress and mutations.\n5. B. subtilis cells have a transcriptional regulatory network that controls the expression of genes involved in DNA replication, repair, and recombination.",
    "llama-7b_fact": [
      "Bacillus subtilis cells undergo a high frequency of spontaneous mutations during the stationary phase of growth.",
      "Environmental stressors such as low nutrient availability and oxidative stress can cause DNA damage in B. subtilis cells during the stationary phase.",
      "B. subtilis cells have DNA repair mechanisms including homologous recombination, non-homologous end joining, and error-prone repair.",
      "During the stationary phase, B. subtilis cells replicate their DNA more slowly, which can lead to replication stress and mutations.",
      "B. subtilis cells have a transcriptional regulatory network that controls the expression of genes involved in DNA replication, repair, and recombination."
    ],
    "llama-7b_judge_raw": "1. TRUE: Bacillus subtilis cells are known to undergo a high frequency of spontaneous mutations during the stationary phase of growth, which is a phase where the cells have stopped growing due to limitations in nutrients or other factors.\n2. TRUE: Environmental stressors such as low nutrient availability and oxidative stress can indeed cause DNA damage in B. subtilis cells during the stationary phase.\n3. TRUE: B. subtilis cells possess DNA repair mechanisms including homologous recombination and error-prone repair. However, non-homologous end joining is not typically found in B. subtilis, which is a bacterium; this mechanism is more common in eukaryotic cells.\n4. FALSE [correction]: During the stationary phase, B. subtilis cells do not replicate their DNA, as cell division is largely halted due to the lack of nutrients and other growth-limiting conditions. Therefore, replication stress related to DNA replication is not a typical feature of the stationary phase.\n5. TRUE: B. subtilis cells have a complex transcriptional regulatory network that controls the expression of genes involved in various cellular processes, including DNA replication, repair, and recombination, to respond to different environmental conditions and stressors.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-7b_response": "Erucism, also known as eruption hives or urticaria, is a skin condition characterized by the appearance of hives or welts on the skin. The exact cause of erucism is not fully understood, but it is believed to be triggered by a combination of environmental and genetic factors.\n\nEnvironmental factors that can trigger erucism include:\n\n1. Allergens: Inhaling or coming into contact with certain allergens, such as pollen, food, or medication, can cause the release of histamine and other inflammatory mediators, leading to hives.\n\n2. Infections: Bacterial or viral infections, including the common cold, flu, and certain types of fungal infections, can trigger erucism.\n\n3. Heat: Exposure to hot water, sunlight, or other sources of heat can also trigger hives in some people.\n\nGenetic factors that may contribute to erucism include:\n\n1. Heredity: Erucism tends to run in families, suggesting that there is a genetic component to the condition.\n\n2. Immune system function: Some people with erucism have an overactive immune system, which leads to an exaggerated response to allergens and other triggers.\n\n3. Chromosomal abnormalities: Certain chromosomal abnormalities, such as Turner syndrome or Klinefelter syndrome, may be associated with a higher risk of erucism.\n\nIn summary, the exact cause of erucism is complex and involves a combination of environmental and genetic factors. While there is no cure for erucism, treatments such as antihistamines and corticosteroids can help manage symptoms and reduce discomfort.",
    "llama-7b_fact_raw": "1. Erucism is a skin condition characterized by the appearance of hives or welts on the skin.\n2. Environmental factors such as allergens, infections, and heat can trigger erucism.\n3. Genetic factors, including heredity and immune system function, may contribute to erucism.\n4. Erucism tends to run in families, indicating a possible genetic component.\n5. Treatments for erucism include antihistamines and corticosteroids to manage symptoms.",
    "llama-7b_fact": [
      "Erucism is a skin condition characterized by the appearance of hives or welts on the skin.",
      "Environmental factors such as allergens, infections, and heat can trigger erucism.",
      "Genetic factors, including heredity and immune system function, may contribute to erucism.",
      "Erucism tends to run in families, indicating a possible genetic component.",
      "Treatments for erucism include antihistamines and corticosteroids to manage symptoms."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Erucism is not a skin condition; it is a reaction caused by contact with the hairs or bristles of certain caterpillars.\n2. FALSE [correction]: While environmental factors can trigger skin conditions, erucism is specifically caused by contact with caterpillar hairs or bristles, not by allergens, infections, and heat in general.\n3. UNKNOWN: Without specific context, it's unclear whether genetic factors contribute to susceptibility to erucism. Generally, genetic factors can influence reactions to toxins or irritants, but erucism is not a condition widely recognized for its genetic components.\n4. UNKNOWN: Similar to statement 3, without specific context, it's unclear whether erucism runs in families due to a genetic component. It is a reaction to an external irritant rather than a hereditary skin condition.\n5. TRUE: Treatments for reactions caused by caterpillar hairs or bristles (erucism) may include antihistamines and corticosteroids to manage symptoms such as itching and swelling.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-7b_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat high blood pressure (hypertension) and fluid retention in people with congestive heart failure, liver disease, or kidney disease. It works by increasing the amount of urine produced by the kidneys, which helps to reduce blood pressure and remove excess fluid from the body.\n\nIn addition to these indications, hydrochlorothiazide may also be used to treat other conditions as determined by a healthcare provider, such as:\n\n1. Diabetes insipidus - a condition that causes increased thirst and urination due to a lack of antidiuretic hormone.\n\n2. Hypokalemia - a low level of potassium in the blood, which can be caused by certain medications, kidney disease, or other conditions. Hydrochlorothiazide can help to increase potassium levels in the blood.\n\n3. Hypertension during pregnancy - hydrochlorothiazide can be used to treat high blood pressure during pregnancy (gestational hypertension) to reduce the risk of complications such as preeclampsia and premature delivery.\n\nIt is important to note that hydrochlorothiazide should not be used in place of other medications for high blood pressure or fluid retention, and it may not be appropriate for everyone. People with certain medical conditions or taking certain medications should consult with their healthcare provider before taking hydrochlorothiazide.",
    "llama-7b_fact_raw": "1. Hydrochlorothiazide is used to treat high blood pressure (hypertension).\n2. Hydrochlorothiazide is used to treat fluid retention in people with congestive heart failure, liver disease, or kidney disease.\n3. Hydrochlorothiazide works by increasing the amount of urine produced by the kidneys.\n4. Hydrochlorothiazide may be used to treat diabetes insipidus.\n5. Hydrochlorothiazide can be used to treat hypokalemia by helping to increase potassium levels in the blood.",
    "llama-7b_fact": [
      "Hydrochlorothiazide is used to treat high blood pressure (hypertension).",
      "Hydrochlorothiazide is used to treat fluid retention in people with congestive heart failure, liver disease, or kidney disease.",
      "Hydrochlorothiazide works by increasing the amount of urine produced by the kidneys.",
      "Hydrochlorothiazide may be used to treat diabetes insipidus.",
      "Hydrochlorothiazide can be used to treat hypokalemia by helping to increase potassium levels in the blood."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Hydrochlorothiazide can cause hypokalemia by increasing the excretion of potassium in the urine, not increase potassium levels in the blood.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-7b_response": "No, silicon has not been used in the treatment of incontinence. Silicon is a chemical element that is commonly used in the manufacturing of various products such as electronics, solar panels, and medical devices. However, there are no known medical applications for silicon in the treatment of incontinence. \n\nIncontinence is a medical condition that affects millions of people worldwide. There are several treatment options available for incontinence, including lifestyle changes, medications, and surgical procedures. These treatments are aimed at managing the symptoms of incontinence and improving the quality of life of the affected individuals. \n\nIt is important to note that any medical treatment for incontinence should be prescribed by a qualified healthcare professional who has assessed the individual's condition and identified the underlying cause of their incontinence.",
    "llama-7b_fact_raw": "1. Silicon has not been used in the treatment of incontinence.\n2. Silicon is commonly used in the manufacturing of electronics, solar panels, and medical devices.\n3. There are no known medical applications for silicon in the treatment of incontinence.\n4. Treatment options for incontinence include lifestyle changes, medications, and surgical procedures.\n5. Incontinence affects millions of people worldwide.",
    "llama-7b_fact": [
      "Silicon has not been used in the treatment of incontinence.",
      "Silicon is commonly used in the manufacturing of electronics, solar panels, and medical devices.",
      "There are no known medical applications for silicon in the treatment of incontinence.",
      "Treatment options for incontinence include lifestyle changes, medications, and surgical procedures.",
      "Incontinence affects millions of people worldwide."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Silicon has been used in the treatment of incontinence, for example, in the form of silicone-based urethral bulking agents.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-7b_response": "There is no definitive association between the moon cycle and the rupture risk of intracranial aneurysms. Several studies have been conducted on this topic, and the results have been inconclusive. \n\nSome studies have suggested that there may be a slight increase in the rupture risk of intracranial aneurysms during the full moon and the new moon phases. However, other studies have failed to find any significant association between the moon cycle and the rupture risk of aneurysms. \n\nIt is important to note that intracranial aneurysms are unpredictable and can rupture at any time, regardless of the phase of the moon. Therefore, it is not advisable to base any medical decisions on the belief that the moon cycle affects the rupture risk of aneurysms. \n\nFurther research is needed to determine the true association, if any, between the moon cycle and the rupture risk of intracranial aneurysms.",
    "llama-7b_fact_raw": "1. There is no definitive association between the moon cycle and the rupture risk of intracranial aneurysms.\n2. Some studies suggest a slight increase in rupture risk of intracranial aneurysms during the full moon and new moon phases.\n3. Other studies have not found a significant association between the moon cycle and the rupture risk of aneurysms.\n4. Intracranial aneurysms can rupture at any time, regardless of the moon phase.\n5. Further research is needed to determine any true association between the moon cycle and the rupture risk of intracranial aneurysms.",
    "llama-7b_fact": [
      "There is no definitive association between the moon cycle and the rupture risk of intracranial aneurysms.",
      "Some studies suggest a slight increase in rupture risk of intracranial aneurysms during the full moon and new moon phases.",
      "Other studies have not found a significant association between the moon cycle and the rupture risk of aneurysms.",
      "Intracranial aneurysms can rupture at any time, regardless of the moon phase.",
      "Further research is needed to determine any true association between the moon cycle and the rupture risk of intracranial aneurysms."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-7b_response": "Yes, HuR protein has been shown to regulate the splicing process. HuR is a ubiquitous protein that binds to small nuclear RNA (snRNA) and regulates alternative splicing of messenger RNA (mRNA) by promoting the formation of a spliceosome, the complex that catalyzes the removal of intronic sequences from pre-mRNA to form mature mRNA. \n\nHuR has been implicated in various biological processes, including cell proliferation, differentiation, and apoptosis. It has also been shown to regulate the expression of several genes involved in cancer development, including those involved in cell cycle regulation, angiogenesis, and metastasis. \n\nStudies have shown that HuR protein levels are upregulated in several types of cancer, including breast, lung, and colon cancer. This upregulation is thought to contribute to the development and progression of these cancers. \n\nIn summary, HuR protein plays an important role in regulating the splicing process and has been implicated in various biological processes, including cancer development. Further research is needed to fully understand the mechanisms by which HuR regulates splicing and its role in cancer progression.",
    "llama-7b_fact_raw": "1. HuR protein regulates the splicing process by promoting the formation of a spliceosome.\n2. HuR protein binds to small nuclear RNA (snRNA).\n3. HuR protein is involved in cell proliferation, differentiation, and apoptosis.\n4. HuR protein regulates the expression of genes involved in cancer development.\n5. HuR protein levels are upregulated in several types of cancer, including breast, lung, and colon cancer.",
    "llama-7b_fact": [
      "HuR protein regulates the splicing process by promoting the formation of a spliceosome.",
      "HuR protein binds to small nuclear RNA (snRNA).",
      "HuR protein is involved in cell proliferation, differentiation, and apoptosis.",
      "HuR protein regulates the expression of genes involved in cancer development.",
      "HuR protein levels are upregulated in several types of cancer, including breast, lung, and colon cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: HuR protein does not directly regulate the splicing process by promoting the formation of a spliceosome. It is primarily involved in mRNA stability and translation regulation.\n2. FALSE [correction]: HuR protein typically binds to AU-rich elements in the 3' untranslated region (UTR) of mRNA, not to small nuclear RNA (snRNA).\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-7b_response": "The prothymosin alpha c-terminal peptide, also known as PTMA-CTP, is a 24-amino acid peptide that is derived from the larger prothymosin alpha protein. The exact function of PTMA-CTP is not fully understood, but it is known to have several important biological activities.\n\nOne of the primary functions of PTMA-CTP is to act as a signaling molecule that can interact with a variety of cell surface receptors. This interaction can lead to the activation of intracellular signaling pathways that regulate cell growth, differentiation, and apoptosis. For example, PTMA-CTP has been shown to bind to the epidermal growth factor receptor (EGFR) and the insulin receptor, which can lead to the activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways.\n\nPTMA-CTP is also known to have anti-inflammatory properties. It has been shown to inhibit the production of pro-inflammatory cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), which can help to reduce inflammation and prevent tissue damage.\n\nFinally, PTMA-CTP has been shown to have anti-cancer properties. It has been shown to inhibit the growth and proliferation of several different types of cancer cells, including breast, colon, and lung cancer cells. This may be due to its ability to interact with and inhibit key signaling pathways involved in cancer cell growth and survival.\n\nOverall, the prothymosin alpha c-terminal peptide is a complex and multifunctional signaling molecule that plays an important role in a variety of biological processes, including cell growth, differentiation, inflammation, and cancer.",
    "llama-7b_fact_raw": "1. The prothymosin alpha c-terminal peptide (PTMA-CTP) is a 24-amino acid peptide derived from the larger prothymosin alpha protein.\n2. PTMA-CTP acts as a signaling molecule that can interact with cell surface receptors such as the epidermal growth factor receptor (EGFR) and the insulin receptor.\n3. The interaction of PTMA-CTP with cell surface receptors can activate intracellular signaling pathways like the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways.\n4. PTMA-CTP has been shown to have anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha).\n5. PTMA-CTP has demonstrated anti-cancer properties by inhibiting the growth and proliferation of various cancer cells, including breast, colon, and lung cancer cells.",
    "llama-7b_fact": [
      "The prothymosin alpha c-terminal peptide (PTMA-CTP) is a 24-amino acid peptide derived from the larger prothymosin alpha protein.",
      "PTMA-CTP acts as a signaling molecule that can interact with cell surface receptors such as the epidermal growth factor receptor (EGFR) and the insulin receptor.",
      "The interaction of PTMA-CTP with cell surface receptors can activate intracellular signaling pathways like the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways.",
      "PTMA-CTP has been shown to have anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha).",
      "PTMA-CTP has demonstrated anti-cancer properties by inhibiting the growth and proliferation of various cancer cells, including breast, colon, and lung cancer cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is a factual claim about the peptide PTMA-CTP, which can be verified if the specific scientific literature on the subject is available. However, the subsequent statements (2-5) involve specific biological functions and effects of PTMA-CTP that require detailed scientific knowledge or research evidence to confirm. Without access to the relevant scientific studies or literature, it is not possible to determine the truthfulness of these claims. Therefore, the responses to statements 2 through 5 are \"UNKNOWN\".",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-7b_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the C-terminal domain (CTD) of cystatin C. Cystatin C is a cysteine protease inhibitor that is found in various tissues and fluids in the body, including the kidneys, lungs, and blood. The CTD of cystatin C is responsible for its ability to bind to and inhibit cysteine proteases, including cathepsins B and L, which are involved in the degradation of proteins and play a role in various physiological and pathological processes.\n\nHowever, under certain conditions, such as low pH or high concentrations of calcium ions, the CTD of cystatin C can undergo a conformational change that leads to its fibrilization. This process involves the formation of a beta-sheet structure within the CTD, which further aggregates to form fibrils. These fibrils can accumulate in various tissues and organs, leading to the development of cystatin C-associated fibrosis.\n\nTherefore, the CTD of cystatin C plays a crucial role in the regulation of cysteine proteases and the maintenance of normal physiological processes. However, under certain conditions, its fibrilization can lead to the development of pathological processes, including cystatin C-associated fibrosis.",
    "llama-7b_fact_raw": "1. The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.\n2. Cystatin C is a cysteine protease inhibitor found in various tissues and fluids in the body, such as the kidneys, lungs, and blood.\n3. The CTD of cystatin C is responsible for binding to and inhibiting cysteine proteases, including cathepsins B and L.\n4. Under conditions like low pH or high concentrations of calcium ions, the CTD of cystatin C can undergo a conformational change leading to fibrilization.\n5. Fibrilization of the CTD of cystatin C can lead to the accumulation of fibrils in tissues and organs, resulting in cystatin C-associated fibrosis.",
    "llama-7b_fact": [
      "The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.",
      "Cystatin C is a cysteine protease inhibitor found in various tissues and fluids in the body, such as the kidneys, lungs, and blood.",
      "The CTD of cystatin C is responsible for binding to and inhibiting cysteine proteases, including cathepsins B and L.",
      "Under conditions like low pH or high concentrations of calcium ions, the CTD of cystatin C can undergo a conformational change leading to fibrilization.",
      "Fibrilization of the CTD of cystatin C can lead to the accumulation of fibrils in tissues and organs, resulting in cystatin C-associated fibrosis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The C-terminal domain (CTD) of cystatin C is not responsible for the inhibitory activity; it is the main body of the protein that binds to and inhibits cysteine proteases.\n4. TRUE\n5. FALSE [correction]: Fibrilization of cystatin C can lead to the accumulation of amyloid fibrils in tissues and organs, resulting in amyloidosis, not specifically \"cystatin C-associated fibrosis.\"",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-7b_response": "As an AI language model, I do not have access to the latest research studies or clinical data on the effect of amifostine (ethyol) on the concentration of protein HIF-1α. However, it is known that amifostine is a cytoprotective prodrug that is used in cancer chemotherapy to protect healthy cells from the toxic effects of chemotherapy drugs. It is also known that hypoxia-inducible factor-1α (HIF-1α) is a key transcription factor involved in the response of cells to hypoxia (low oxygen levels). \n\nTherefore, it is plausible that the administration of amifostine may lead to an increase in the concentration of protein HIF-1α in cells under conditions of hypoxia. However, further research is needed to confirm this hypothesis and to elucidate the exact mechanism of action of amifostine on HIF-1α protein concentration.",
    "llama-7b_fact_raw": "1. Amifostine is a cytoprotective prodrug used in cancer chemotherapy.\n2. Amifostine is used to protect healthy cells from the toxic effects of chemotherapy drugs.\n3. Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor involved in the cellular response to hypoxia.\n4. There is a hypothesis that the administration of amifostine may lead to an increase in the concentration of protein HIF-1α under hypoxic conditions.",
    "llama-7b_fact": [
      "Amifostine is a cytoprotective prodrug used in cancer chemotherapy.",
      "Amifostine is used to protect healthy cells from the toxic effects of chemotherapy drugs.",
      "Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor involved in the cellular response to hypoxia.",
      "There is a hypothesis that the administration of amifostine may lead to an increase in the concentration of protein HIF-1α under hypoxic conditions."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-7b_response": "Set7 is a histone lysine methyltransferase that adds a trimethyl group to lysine 9 of histone H3 (H3K9me3). This mark is associated with transcriptional repression and is often found at the promoters of developmentally regulated genes. Set7 has also been shown to methylate other histones, such as H3K79 and H4K20, but its role in these modifications is less clear. Overall, Set7 plays an important role in the regulation of gene expression during cellular differentiation and development.",
    "llama-7b_fact_raw": "1. Set7 is a histone lysine methyltransferase.\n2. Set7 adds a trimethyl group to lysine 9 of histone H3 (H3K9me3).\n3. The H3K9me3 mark is associated with transcriptional repression.\n4. The H3K9me3 mark is often found at the promoters of developmentally regulated genes.\n5. Set7 has been shown to methylate other histones, such as H3K79 and H4K20.",
    "llama-7b_fact": [
      "Set7 is a histone lysine methyltransferase.",
      "Set7 adds a trimethyl group to lysine 9 of histone H3 (H3K9me3).",
      "The H3K9me3 mark is associated with transcriptional repression.",
      "The H3K9me3 mark is often found at the promoters of developmentally regulated genes.",
      "Set7 has been shown to methylate other histones, such as H3K79 and H4K20."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 specifically adds a monomethyl group to lysine 4 of histone H3 (H3K4me1), not a trimethyl group to lysine 9.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Set7 is known for its specificity to lysine 4 of histone H3 (H3K4me1) and does not typically methylate H3K79 or H4K20. Other enzymes are responsible for methylation at those sites.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-7b_response": "Hepcidin is a small, cysteine-rich peptide hormone that plays a crucial role in the regulation of iron metabolism in mammals. Hepcidin is synthesized and stored in hepatocytes and is released into the bloodstream in response to iron deficiency or inflammation.\n\nHepcidin contains two disulfide bridges, which are essential for its biological activity. The first disulfide bridge is formed between the cysteine residues at positions 2 and 3, while the second disulfide bridge is formed between the cysteine residues at positions 14 and 15. These disulfide bridges help to stabilize the structure of hepcidin and prevent it from being degraded by proteases.\n\nIn summary, hepcidin has two disulfide bridges, namely at positions 2-3 and 14-15.",
    "llama-7b_fact_raw": "1. Hepcidin is a peptide hormone that regulates iron metabolism in mammals.\n2. Hepcidin is synthesized and stored in hepatocytes.\n3. Hepcidin contains two disulfide bridges.\n4. The first disulfide bridge in hepcidin is between cysteine residues at positions 2 and 3.\n5. The second disulfide bridge in hepcidin is between cysteine residues at positions 14 and 15.",
    "llama-7b_fact": [
      "Hepcidin is a peptide hormone that regulates iron metabolism in mammals.",
      "Hepcidin is synthesized and stored in hepatocytes.",
      "Hepcidin contains two disulfide bridges.",
      "The first disulfide bridge in hepcidin is between cysteine residues at positions 2 and 3.",
      "The second disulfide bridge in hepcidin is between cysteine residues at positions 14 and 15."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The first disulfide bridge in hepcidin is typically between cysteine residues at positions 7 and 23.\n5. FALSE [correction]: The second disulfide bridge in hepcidin is typically between cysteine residues at positions 10 and 13. However, the exact positions of the disulfide bridges can vary depending on the species and the specific form of hepcidin being referred to.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-7b_response": "The protein encoded by the DNAJC11 gene is localized to the endoplasmic reticulum (ER) membrane in mammalian cells. The DNAJC11 protein is a member of the DNAJ family of proteins, which are thought to play a role in protein folding and trafficking within the ER membrane. The DNAJC11 protein has been shown to interact with other ER resident proteins, including calreticulin and protein disulfide isomerase, suggesting that it may play a role in ER stress response pathways. Additionally, studies have shown that DNAJC11 is upregulated in certain types of cancer, including breast and colon cancer, suggesting that it may have oncogenic potential. Overall, further research is needed to fully elucidate the function of DNAJC11 in mammalian cells.",
    "llama-7b_fact_raw": "1. The protein encoded by the DNAJC11 gene is localized to the endoplasmic reticulum (ER) membrane in mammalian cells.\n2. The DNAJC11 protein is a member of the DNAJ family of proteins.\n3. DNAJC11 protein interacts with other ER resident proteins, including calreticulin and protein disulfide isomerase.\n4. DNAJC11 is upregulated in certain types of cancer, such as breast and colon cancer.\n5. The DNAJC11 protein is thought to play a role in protein folding and trafficking within the ER membrane.",
    "llama-7b_fact": [
      "The protein encoded by the DNAJC11 gene is localized to the endoplasmic reticulum (ER) membrane in mammalian cells.",
      "The DNAJC11 protein is a member of the DNAJ family of proteins.",
      "DNAJC11 protein interacts with other ER resident proteins, including calreticulin and protein disulfide isomerase.",
      "DNAJC11 is upregulated in certain types of cancer, such as breast and colon cancer.",
      "The DNAJC11 protein is thought to play a role in protein folding and trafficking within the ER membrane."
    ],
    "llama-7b_judge_raw": "1. TRUE: The protein encoded by the DNAJC11 gene is indeed localized to the endoplasmic reticulum (ER) membrane in mammalian cells.\n2. TRUE: The DNAJC11 protein is a member of the DNAJ/Hsp40 family of proteins, which are characterized by the presence of a J-domain.\n3. UNKNOWN: Without specific scientific references, it is difficult to confirm whether the DNAJC11 protein interacts with calreticulin and protein disulfide isomerase, although it is plausible given its localization and function.\n4. UNKNOWN: The statement about DNAJC11 being upregulated in certain types of cancer would require specific scientific studies to confirm, and without that information, the truth of this statement cannot be determined.\n5. TRUE: The DNAJC11 protein, as a member of the DNAJ/Hsp40 family, is indeed thought to play a role in protein folding and trafficking within the ER membrane.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-7b_response": "As an AI language model, I do not have personal beliefs or opinions. However, I can provide an objective answer to your question based on the available scientific literature.\n\nUltraconserved elements (UCEs) are regions of the genome that are highly conserved across evolutionary time and across different species. UCEs are believed to be important for the regulation of gene expression and the maintenance of genome stability.\n\nCopy number variants (CNVs) are genetic abnormalities that involve changes in the number of copies of a particular gene or set of genes. CNVs can occur spontaneously during embryonic development or be inherited from one or both parents.\n\nThe relationship between UCEs and CNVs is an active area of research. Some studies have reported that UCEs are enriched among CNVs, suggesting that CNVs may disrupt the function of UCEs and contribute to genomic instability.\n\nHowever, other studies have found that UCEs are not significantly depleted among CNVs, suggesting that UCEs may be more resistant to disruption by CNVs than previously thought.\n\nOverall, the current evidence suggests that UCEs are not consistently depleted among CNVs, but further research is needed to fully understand the relationship between these two genomic features.",
    "llama-7b_fact_raw": "1. Ultraconserved elements (UCEs) are regions of the genome that are highly conserved across different species.\n2. UCEs are believed to be important for the regulation of gene expression and the maintenance of genome stability.\n3. Copy number variants (CNVs) are genetic abnormalities that involve changes in the number of copies of a particular gene or set of genes.\n4. Some studies have reported that UCEs are enriched among CNVs, which may disrupt the function of UCEs and contribute to genomic instability.\n5. Other studies have found that UCEs are not significantly depleted among CNVs, indicating that UCEs may be more resistant to disruption by CNVs than previously thought.",
    "llama-7b_fact": [
      "Ultraconserved elements (UCEs) are regions of the genome that are highly conserved across different species.",
      "UCEs are believed to be important for the regulation of gene expression and the maintenance of genome stability.",
      "Copy number variants (CNVs) are genetic abnormalities that involve changes in the number of copies of a particular gene or set of genes.",
      "Some studies have reported that UCEs are enriched among CNVs, which may disrupt the function of UCEs and contribute to genomic instability.",
      "Other studies have found that UCEs are not significantly depleted among CNVs, indicating that UCEs may be more resistant to disruption by CNVs than previously thought."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Studies have reported that UCEs are generally depleted among CNVs, suggesting that UCEs are resistant to such variations and that their disruption can contribute to disease.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-7b_response": "As an AI language model, I do not have personal beliefs or opinions. However, according to scientific research, the haspin kinase substrate during mitosis is not yet fully understood. Some studies suggest that microtubules are the primary substrate for haspin kinase during mitosis, while others suggest that actin filaments may also be involved. It is also possible that both microtubules and actin filaments serve as substrates for haspin kinase during different stages of mitosis. Further research is needed to determine the exact substrate(s) of haspin kinase during mitosis.",
    "llama-7b_fact_raw": "1. The substrate of haspin kinase during mitosis is not yet fully understood.\n2. Some studies suggest that microtubules are the primary substrate for haspin kinase during mitosis.\n3. Other studies suggest that actin filaments may also be involved as a substrate for haspin kinase during mitosis.\n4. It is possible that both microtubules and actin filaments serve as substrates for haspin kinase during different stages of mitosis.",
    "llama-7b_fact": [
      "The substrate of haspin kinase during mitosis is not yet fully understood.",
      "Some studies suggest that microtubules are the primary substrate for haspin kinase during mitosis.",
      "Other studies suggest that actin filaments may also be involved as a substrate for haspin kinase during mitosis.",
      "It is possible that both microtubules and actin filaments serve as substrates for haspin kinase during different stages of mitosis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Some studies suggest that histone H3 is the primary substrate for haspin kinase during mitosis.\n3. FALSE [correction]: There is no widespread evidence to suggest that actin filaments serve as a substrate for haspin kinase; the primary substrate is histone H3, particularly at threonine 3 (H3T3) during mitosis.\n4. FALSE [correction]: The primary substrate for haspin kinase is histone H3, not microtubules or actin filaments, although haspin kinase may indirectly affect microtubule dynamics through its regulation of chromosome cohesion and spindle assembly.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-7b_response": "Viroid replication is a unique process that occurs within the host cell without the involvement of either DNA or RNA polymerase enzymes. Viroids are non-coding RNA molecules that can replicate themselves and infect plants. The mechanism of viroid replication involves the following steps:\n\n1. Viroids enter the host cell and associate with the cellular membrane.\n\n2. The viroid RNA is transcribed into a complementary single-stranded RNA molecule by an RNA polymerase-like enzyme that is specific to viroids.\n\n3. The newly synthesized single-stranded RNA molecule is then used as a template to synthesize a complementary double-stranded RNA molecule by the host cell's RNA polymerase enzyme.\n\n4. The newly synthesized double-stranded RNA molecule is then transported to the host cell's nucleus.\n\n5. In the nucleus, the double-stranded RNA molecule is converted into a single-stranded RNA molecule by an RNA helicase enzyme.\n\n6. The single-stranded RNA molecule is then used as a template to synthesize a complementary double-stranded RNA molecule by the host cell's RNA polymerase enzyme.\n\n7. The newly synthesized double-stranded RNA molecule is then transported back to the host cell's cytoplasm.\n\n8. In the cytoplasm, the double-stranded RNA molecule is converted into a single-stranded RNA molecule by an RNA helicase enzyme.\n\n9. The single-stranded RNA molecule is then used as a template to synthesize a complementary double-stranded RNA molecule by the host cell's RNA polymerase enzyme.\n\n10. The newly synthesized double-stranded RNA molecule is then transported back to the host cell's nucleus.\n\n11. In the nucleus, the double-stranded RNA molecule is converted into a",
    "llama-7b_fact_raw": "1. Viroid replication occurs within the host cell without the involvement of either DNA or RNA polymerase enzymes.\n2. Viroids are non-coding RNA molecules that can replicate themselves and infect plants.\n3. The viroid RNA is transcribed into a complementary single-stranded RNA molecule by an RNA polymerase-like enzyme that is specific to viroids.\n4. The newly synthesized single-stranded RNA molecule is used as a template to synthesize a complementary double-stranded RNA molecule by the host cell's RNA polymerase enzyme.\n5. The double-stranded RNA molecule is transported to the host cell's nucleus and converted into a single-stranded RNA molecule by an RNA helicase enzyme.",
    "llama-7b_fact": [
      "Viroid replication occurs within the host cell without the involvement of either DNA or RNA polymerase enzymes.",
      "Viroids are non-coding RNA molecules that can replicate themselves and infect plants.",
      "The viroid RNA is transcribed into a complementary single-stranded RNA molecule by an RNA polymerase-like enzyme that is specific to viroids.",
      "The newly synthesized single-stranded RNA molecule is used as a template to synthesize a complementary double-stranded RNA molecule by the host cell's RNA polymerase enzyme.",
      "The double-stranded RNA molecule is transported to the host cell's nucleus and converted into a single-stranded RNA molecule by an RNA helicase enzyme."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Viroid replication does involve host cell RNA polymerase enzymes. Viroids do not encode proteins and thus rely on the host cell's machinery for replication.\n2. TRUE\n3. FALSE [correction]: The viroid RNA is not transcribed by a viroid-specific enzyme; it is the host cell's RNA polymerase that transcribes the viroid RNA into a complementary RNA molecule.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-7b_response": "As an AI language model, I do not have personal beliefs or opinions. However, based on the available scientific literature, the answer to the question of whether fibronectin constitutes a serum biomarker for Duchenne muscular dystrophy (DMD) is inconclusive.\n\nFibronectin is a protein that plays a role in the development and maintenance of muscle tissue. Studies have suggested that fibronectin levels may be elevated in individuals with DMD. However, other studies have found no significant differences in fibronectin levels between individuals with DMD and healthy controls.\n\nMore research is needed to determine whether fibronectin can be used as a reliable biomarker for DMD. Other factors, such as muscle damage and inflammation, may also contribute to changes in fibronectin levels in individuals with DMD. Therefore, a comprehensive analysis of multiple biomarkers may be necessary to accurately diagnose and monitor the progression of DMD.",
    "llama-7b_fact_raw": "1. Fibronectin is a protein involved in the development and maintenance of muscle tissue.\n2. Some studies have suggested that fibronectin levels may be elevated in individuals with Duchenne muscular dystrophy (DMD).\n3. Other studies have found no significant differences in fibronectin levels between individuals with DMD and healthy controls.\n4. More research is required to determine the reliability of fibronectin as a biomarker for DMD.\n5. Factors such as muscle damage and inflammation may affect fibronectin levels in individuals with DMD.",
    "llama-7b_fact": [
      "Fibronectin is a protein involved in the development and maintenance of muscle tissue.",
      "Some studies have suggested that fibronectin levels may be elevated in individuals with Duchenne muscular dystrophy (DMD).",
      "Other studies have found no significant differences in fibronectin levels between individuals with DMD and healthy controls.",
      "More research is required to determine the reliability of fibronectin as a biomarker for DMD.",
      "Factors such as muscle damage and inflammation may affect fibronectin levels in individuals with DMD."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Fibronectin is a protein that is involved in cell adhesion, growth, migration, and wound healing, but it is not specifically involved in the development and maintenance of muscle tissue.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-7b_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects. Some of the notable projects that have contributed data to the server include:\n\n1. Encyclopedia of DNA Elements (ENCODE) Project: This is a large-scale project that aims to identify and characterize all the functional elements in the human genome. The ENCODE project has generated a vast amount of data on epigenetic modifications, such as DNA methylation, histone modifications, and non-coding RNAs.\n\n2. Roadmap Epigenomics Project: This is another large-scale project that aims to identify and characterize epigenetic changes in various tissues and cell types. The project has generated data on DNA methylation, histone modifications, and non-coding RNAs across multiple species, including humans, mice, and zebrafish.\n\n3. Epigenomics of Common Disorders Initiative (ECDI): This project aims to identify epigenetic changes associated with common diseases, such as cancer, neurodegenerative disorders, and cardiovascular diseases. The project has generated data on DNA methylation, histone modifications, and non-coding RNAs in various disease models.\n\n4. International Human Epigenome Consortium (IHEC): This is a collaborative project that aims to generate a comprehensive map of the human epigenome. The project has generated data on DNA methylation, histone modifications, and non-coding RNAs in various tissues and cell types.\n\nThese are just a few examples of the major epigenome projects that have contributed data to the DeepBlue epigenomic data server. The server also contains data from many other smaller-scale projects and individual studies.",
    "llama-7b_fact_raw": "1. The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) Project.\n2. The Roadmap Epigenomics Project has contributed data to the DeepBlue epigenomic data server.\n3. Data from the Epigenomics of Common Disorders Initiative (ECDI) is included in the DeepBlue epigenomic data server.\n4. The International Human Epigenome Consortium (IHEC) has generated data that is available on the DeepBlue epigenomic data server.\n5. The DeepBlue epigenomic data server includes data on DNA methylation, histone modifications, and non-coding RNAs.",
    "llama-7b_fact": [
      "The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) Project.",
      "The Roadmap Epigenomics Project has contributed data to the DeepBlue epigenomic data server.",
      "Data from the Epigenomics of Common Disorders Initiative (ECDI) is included in the DeepBlue epigenomic data server.",
      "The International Human Epigenome Consortium (IHEC) has generated data that is available on the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server includes data on DNA methylation, histone modifications, and non-coding RNAs."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-7b_response": "The tool that employs Self-Organizing Maps (SOM) for analyzing synonymous codon usage is called \"CodonW\" (pronounced as \"Ko-don Wah\"). CodonW is a bioinformatics tool that is used to analyze synonymous codon usage in DNA sequences. SOM is a type of artificial neural network that is used in CodonW for analyzing codon usage patterns in DNA sequences. CodonW uses SOM to identify the most frequently used codons for a given amino acid and to compare the codon usage patterns between different organisms. CodonW is a widely used tool in the field of molecular biology and genetics for analyzing synonymous codon usage.",
    "llama-7b_fact_raw": "1. CodonW employs Self-Organizing Maps (SOM) for analyzing synonymous codon usage.\n2. CodonW is a bioinformatics tool used to analyze synonymous codon usage in DNA sequences.\n3. Self-Organizing Maps (SOM) is a type of artificial neural network used in CodonW.\n4. CodonW can identify the most frequently used codons for a given amino acid.\n5. CodonW is used to compare codon usage patterns between different organisms.",
    "llama-7b_fact": [
      "CodonW employs Self-Organizing Maps (SOM) for analyzing synonymous codon usage.",
      "CodonW is a bioinformatics tool used to analyze synonymous codon usage in DNA sequences.",
      "Self-Organizing Maps (SOM) is a type of artificial neural network used in CodonW.",
      "CodonW can identify the most frequently used codons for a given amino acid.",
      "CodonW is used to compare codon usage patterns between different organisms."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: CodonW does not employ Self-Organizing Maps (SOM); it uses statistical methods to analyze synonymous codon usage.\n2. TRUE\n3. FALSE [correction]: Self-Organizing Maps (SOM) is a type of artificial neural network, but it is not used in CodonW.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-7b_response": "I'm sorry, but I cannot provide a detailed answer to the question \"What is MINDY-1?\" as I am an AI language model and I do not have access to information that is not publicly available on the internet. However, I can tell you that MINDY-1 may refer to a variety of things, such as a person's nickname or a fictional character in a book, movie, or video game. Without more context, it is difficult to provide a specific answer.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-7b_response": "There are several software packages available for the analysis of conserved genomic loci. Some of the popular ones are:\n\n1. BLAST (Basic Local Alignment Search Tool): BLAST is a widely used software for sequence alignment. It can be used to compare a query sequence against a database of known sequences to identify homologous sequences. BLAST can also be used to identify conserved genomic loci.\n\n2. MEGA (Molecular Evolutionary Genetics Analysis): MEGA is a software package used for molecular phylogenetics and evolutionary analysis. It can be used to align sequences, construct phylogenetic trees, and identify conserved genomic loci.\n\n3. Conserved Domain Database (CDD): CDD is a database that contains information about protein domains that are conserved across different species. It can be used to identify conserved genomic loci that contain specific protein domains.\n\n4. InterProScan: InterProScan is a software package that can be used to identify protein domains and motifs in a protein sequence. It can be used to identify conserved genomic loci that contain protein domains or motifs.\n\n5. RepeatMasker: RepeatMasker is a software package that can be used to identify repetitive elements in a genomic sequence. It can be used to identify conserved genomic loci that contain repetitive elements.\n\nThese are just a few examples of software packages that are available for the analysis of conserved genomic loci. The choice of software package depends on the specific requirements of the research project.",
    "llama-7b_fact_raw": "1. BLAST (Basic Local Alignment Search Tool) is used for sequence alignment and can identify conserved genomic loci.\n2. MEGA (Molecular Evolutionary Genetics Analysis) is used for molecular phylogenetics and evolutionary analysis, including the identification of conserved genomic loci.\n3. The Conserved Domain Database (CDD) contains information about protein domains conserved across species and can be used to identify conserved genomic loci.\n4. InterProScan identifies protein domains and motifs in protein sequences and can be used to identify conserved genomic loci.\n5. RepeatMasker identifies repetitive elements in genomic sequences and can be used to identify conserved genomic loci.",
    "llama-7b_fact": [
      "BLAST (Basic Local Alignment Search Tool) is used for sequence alignment and can identify conserved genomic loci.",
      "MEGA (Molecular Evolutionary Genetics Analysis) is used for molecular phylogenetics and evolutionary analysis, including the identification of conserved genomic loci.",
      "The Conserved Domain Database (CDD) contains information about protein domains conserved across species and can be used to identify conserved genomic loci.",
      "InterProScan identifies protein domains and motifs in protein sequences and can be used to identify conserved genomic loci.",
      "RepeatMasker identifies repetitive elements in genomic sequences and can be used to identify conserved genomic loci."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: RepeatMasker identifies repetitive elements in genomic sequences, but it is primarily used to mask out repetitive DNA to aid in the annotation of genes, rather than to identify conserved genomic loci.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-7b_response": "As an AI language model, I do not have the ability to browse the internet or access external databases. However, I can tell you that the PIEZO2 gene is associated with several diseases, including hereditary hemorrhagic telangiectasia (HHT), Loeys-Dietz syndrome, and Marfan syndrome. HHT is a genetic disorder that affects the blood vessels, causing them to bleed excessively. Loeys-Dietz syndrome is a genetic disorder that affects the aorta and other blood vessels, increasing the risk of aortic aneurysms and dissection. Marfan syndrome is a genetic disorder that affects the connective tissue, causing abnormalities in the eyes, skeletal system, and cardiovascular system, including an increased risk of aortic aneurysms and dissection.",
    "llama-7b_fact_raw": "1. The PIEZO2 gene is associated with hereditary hemorrhagic telangiectasia (HHT).\n2. The PIEZO2 gene is associated with Loeys-Dietz syndrome.\n3. The PIEZO2 gene is associated with Marfan syndrome.",
    "llama-7b_fact": [
      "The PIEZO2 gene is associated with hereditary hemorrhagic telangiectasia (HHT).",
      "The PIEZO2 gene is associated with Loeys-Dietz syndrome.",
      "The PIEZO2 gene is associated with Marfan syndrome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The PIEZO2 gene is not associated with hereditary hemorrhagic telangiectasia (HHT); instead, genes commonly associated with HHT include ENG, ACVRL1, and SMAD4.\n2. FALSE [correction]: The PIEZO2 gene is not associated with Loeys-Dietz syndrome; Loeys-Dietz syndrome is associated with mutations in the TGFBR1, TGFBR2, SMAD3, TGFB2, and TGFB3 genes.\n3. FALSE [correction]: The PIEZO2 gene is not associated with Marfan syndrome; Marfan syndrome is typically caused by mutations in the FBN1 gene, and in some cases, mutations in the TGFBR1 and TGFBR2 genes.",
    "llama-7b_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-7b_response": "ERAP1-ERAP2 dimerization is a critical step in the processing and presentation of antigenic peptides by the major histocompatibility complex (MHC) class I pathway. ERAP1 and ERAP2 are two essential proteins involved in the formation of a peptide-loading complex (PLC) that loads antigenic peptides onto MHC class I molecules for presentation to cytotoxic T lymphocytes (CTLs).\n\nThe dimerization of ERAP1 and ERAP2 is crucial for the proper functioning of the PLC. ERAP1 and ERAP2 interact with each other through their C-terminal domains, forming a stable dimer that is required for the efficient loading of peptides onto MHC class I molecules. The dimerization of ERAP1 and ERAP2 also plays a critical role in the processing of peptides, as it facilitates the formation of a peptide-binding groove on the surface of the PLC.\n\nFurthermore, ERAP1-ERAP2 dimerization is important for the regulation of the MHC class I pathway. The dimerization of ERAP1 and ERAP2 is negatively regulated by the ubiquitin-proteasome system (UPS), which targets ERAP1 and ERAP2 for degradation. This negative regulation of ERAP1-ERAP2 dimerization ensures that the MHC class I pathway is tightly controlled and only activated when necessary.\n\nIn summary, ERAP1-ERAP2 dimerization is essential for the proper functioning of the MHC class I pathway, as it facilitates the loading of antigenic peptides onto MHC class I molecules and the formation of a peptide-binding groove on the surface of the PLC. The dimerization of ERAP1 and ERAP2 is also important for the regulation of the MHC class I pathway, as it ensures that the pathway is only activated when necessary.",
    "llama-7b_fact_raw": "1. ERAP1-ERAP2 dimerization is involved in the processing and presentation of antigenic peptides by the major histocompatibility complex (MHC) class I pathway.\n2. ERAP1 and ERAP2 form a peptide-loading complex (PLC) that loads antigenic peptides onto MHC class I molecules for presentation to cytotoxic T lymphocytes (CTLs).\n3. The dimerization of ERAP1 and ERAP2 is crucial for the efficient loading of peptides onto MHC class I molecules.\n4. ERAP1 and ERAP2 interact through their C-terminal domains to form a stable dimer.\n5. The ubiquitin-proteasome system (UPS) negatively regulates the dimerization of ERAP1 and ERAP2 by targeting them for degradation.",
    "llama-7b_fact": [
      "ERAP1-ERAP2 dimerization is involved in the processing and presentation of antigenic peptides by the major histocompatibility complex (MHC) class I pathway.",
      "ERAP1 and ERAP2 form a peptide-loading complex (PLC) that loads antigenic peptides onto MHC class I molecules for presentation to cytotoxic T lymphocytes (CTLs).",
      "The dimerization of ERAP1 and ERAP2 is crucial for the efficient loading of peptides onto MHC class I molecules.",
      "ERAP1 and ERAP2 interact through their C-terminal domains to form a stable dimer.",
      "The ubiquitin-proteasome system (UPS) negatively regulates the dimerization of ERAP1 and ERAP2 by targeting them for degradation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are consistent with the known roles of ERAP1 and ERAP2 in antigen processing and presentation via the MHC class I pathway. However, the specific details of their interaction, such as whether they interact through their C-terminal domains to form a stable dimer (statement 4), and the role of the ubiquitin-proteasome system in regulating their dimerization (statement 5), are not provided in the context and may require specific scientific knowledge or literature to confirm.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-7b_response": "R-spondin 1 and noggin are two proteins that play important roles in the development and maintenance of the gallbladder. \n\nR-spondin 1 is a member of the TGF-beta superfamily of proteins and is involved in the regulation of bone formation and cartilage development. In the gallbladder, R-spondin 1 is thought to regulate the proliferation and differentiation of gallbladder smooth muscle cells, which are responsible for the contraction of the gallbladder during the digestion of fats.\n\nNoggin, on the other hand, is a member of the BMP (bone morphogenetic protein) family of proteins and is involved in the regulation of embryonic development. In the gallbladder, noggin is thought to inhibit the activity of bone morphogenetic proteins (BMPs), which are signaling molecules that are involved in the formation of the gallbladder and other organs during embryonic development.\n\nIn non-damaged gallbladders, R-spondin 1 and noggin work together to maintain the normal structure and function of the gallbladder. They help to regulate the growth and differentiation of gallbladder smooth muscle cells, ensuring that the gallbladder is able to contract properly during the digestion of fats. Without these proteins, the gallbladder may not be able to function properly, leading to problems with digestion and potentially even gallstones.",
    "llama-7b_fact_raw": "1. R-spondin 1 is involved in the regulation of bone formation and cartilage development.\n2. In the gallbladder, R-spondin 1 is thought to regulate the proliferation and differentiation of gallbladder smooth muscle cells.\n3. Noggin is a member of the BMP family of proteins and is involved in the regulation of embryonic development.\n4. In the gallbladder, noggin is thought to inhibit the activity of bone morphogenetic proteins during embryonic development.\n5. R-spondin 1 and noggin work together to maintain the normal structure and function of the gallbladder in non-damaged gallbladders.",
    "llama-7b_fact": [
      "R-spondin 1 is involved in the regulation of bone formation and cartilage development.",
      "In the gallbladder, R-spondin 1 is thought to regulate the proliferation and differentiation of gallbladder smooth muscle cells.",
      "Noggin is a member of the BMP family of proteins and is involved in the regulation of embryonic development.",
      "In the gallbladder, noggin is thought to inhibit the activity of bone morphogenetic proteins during embryonic development.",
      "R-spondin 1 and noggin work together to maintain the normal structure and function of the gallbladder in non-damaged gallbladders."
    ],
    "llama-7b_judge_raw": "1. TRUE: R-spondin 1 is known to be involved in the regulation of bone formation and cartilage development.\n2. UNKNOWN: While R-spondin 1 is involved in various developmental processes, its specific role in the regulation of gallbladder smooth muscle cells is not well-established or may vary depending on the source.\n3. FALSE [correction]: Noggin is not a member of the BMP family of proteins; rather, it is an antagonist that inhibits the activity of BMPs and is involved in the regulation of embryonic development.\n4. TRUE: Noggin is known to inhibit the activity of bone morphogenetic proteins (BMPs) during embryonic development, which is consistent with its role as a BMP antagonist.\n5. UNKNOWN: The specific interaction between R-spondin 1 and noggin in maintaining the normal structure and function of the gallbladder in non-damaged gallbladders is not well-documented in the literature and may require more specific research to confirm.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-7b_response": "Yes, NADPH oxidase 5 (NOX5) requires several subunits for its proper function. NOX5 is a member of the NOX family of NADPH oxidases, which are enzymes that generate reactive oxygen species (ROS) as a secondary messenger in response to various stimuli.\n\nNOX5 is a homodimer composed of two identical subunits, NOX5a and NOX5b. The NOX5a subunit is responsible for the catalytic activity of the enzyme, while the NOX5b subunit serves as a regulatory subunit that controls the activity and localization of NOX5.\n\nIn addition to NOX5a and NOX5b, several other subunits have been identified as components of the NOX5 complex. These include p47phox, p67phox, p40phox, and Rac2. p47phox, p67phox, and p40phox are structural and regulatory subunits that form the catalytic core of NOX, while Rac2 is a small GTPase that interacts with NOX5 and regulates its activity.\n\nThe interaction between NOX5 and its subunits is crucial for the enzyme's function. The NOX5a subunit interacts with p47phox, p67phox, and p40phox to form the catalytic core of the enzyme, while the NOX5b subunit interacts with Rac2 to regulate NOX5 activity and localization.\n\nIn summary, NOX5 requires several subunits, including NOX5a, NOX5b, p47phox, p67phox, p40phox, and Rac2, for its proper function.",
    "llama-7b_fact_raw": "1. NADPH oxidase 5 (NOX5) is a member of the NOX family of NADPH oxidases.\n2. NOX5 is a homodimer composed of two identical subunits, NOX5a and NOX5b.\n3. The NOX5a subunit is responsible for the catalytic activity of the enzyme.\n4. The NOX5b subunit serves as a regulatory subunit that controls the activity and localization of NOX5.\n5. Subunits identified as components of the NOX5 complex include p47phox, p67phox, p40phox, and Rac2.",
    "llama-7b_fact": [
      "NADPH oxidase 5 (NOX5) is a member of the NOX family of NADPH oxidases.",
      "NOX5 is a homodimer composed of two identical subunits, NOX5a and NOX5b.",
      "The NOX5a subunit is responsible for the catalytic activity of the enzyme.",
      "The NOX5b subunit serves as a regulatory subunit that controls the activity and localization of NOX5.",
      "Subunits identified as components of the NOX5 complex include p47phox, p67phox, p40phox, and Rac2."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: NOX5 is not known to form homodimers composed of NOX5a and NOX5b subunits. Instead, NOX5 exists as a single polypeptide chain with various isoforms, including NOX5α and NOX5β, which are generated by alternative splicing.\n3. TRUE [assuming the context implies that NOX5a is an isoform with catalytic activity, which is typical for NOX enzymes]\n4. FALSE [correction]: The statement about NOX5b serving as a regulatory subunit is incorrect. NOX5 isoforms, including NOX5β, have catalytic activity, and there is no evidence that NOX5β serves as a regulatory subunit in the manner described.\n5. FALSE [correction]: The subunits p47phox, p67phox, p40phox, and Rac2 are components of the NOX2 complex, not NOX5. NOX5 does not require these subunits for its activity and is regulated differently.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-7b_response": "Furin and hepcidin have a direct connection in the regulation of iron metabolism in the body. Furin is an enzyme that plays a crucial role in the processing and activation of hepcidin, a hormone that regulates the level of iron absorption in the body. Hepcidin is produced by hepatocytes in the liver and is released into the bloodstream. It binds to the iron transporter protein, ferroportin, located on the surface of enterocytes in the intestine, and prevents the release of iron into the circulation.\n\nFurin is responsible for the cleavage of prohepcidin, a precursor of hepcidin, into its active form. Prohepcidin is produced in the liver and circulates in the bloodstream. It is then cleaved by furin into hepcidin, which is released into the bloodstream. The cleavage of prohepcidin by furin is a rate-limiting step in the regulation of hepcidin production.\n\nTherefore, the connection between furin and hepcidin is crucial in the regulation of iron metabolism in the body. Dysregulation of this connection can lead to abnormalities in iron metabolism, such as iron overload or iron deficiency.",
    "llama-7b_fact_raw": "1. Furin is an enzyme that plays a role in the processing and activation of hepcidin.\n2. Hepcidin is a hormone that regulates iron absorption in the body.\n3. Hepcidin is produced by hepatocytes in the liver.\n4. Hepcidin binds to the iron transporter protein, ferroportin, on the surface of enterocytes in the intestine.\n5. The cleavage of prohepcidin by furin into hepcidin is a rate-limiting step in the regulation of hepcidin production.",
    "llama-7b_fact": [
      "Furin is an enzyme that plays a role in the processing and activation of hepcidin.",
      "Hepcidin is a hormone that regulates iron absorption in the body.",
      "Hepcidin is produced by hepatocytes in the liver.",
      "Hepcidin binds to the iron transporter protein, ferroportin, on the surface of enterocytes in the intestine.",
      "The cleavage of prohepcidin by furin into hepcidin is a rate-limiting step in the regulation of hepcidin production."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Furin is an enzyme that plays a role in the processing and activation of various proteins, but it is not directly involved in the processing and activation of hepcidin. Prohormone convertase (PCSK6) is more directly involved in the activation of hepcidin.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The cleavage of prohepcidin into hepcidin is a crucial step, but it is not solely a rate-limiting step as there are multiple regulatory mechanisms involved in the regulation of hepcidin production, including iron levels, inflammation, and erythropoiesis.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-7b_response": "The largest metabolic gene cluster in yeast is the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cluster. This cluster is responsible for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, which plays a crucial role in glycolysis, the process by which glucose is broken down into pyruvate. The Pichia pastoris GAPDH cluster consists of 13 genes that are transcribed as a single polycistronic mRNA, which is then processed to produce individual mRNAs for each of the 13 genes. The cluster is located on a single chromosome and is highly conserved across different yeast species. The large size of the Pichia pastoris GAPDH cluster makes it a valuable tool for studying the regulation of gene expression in yeast and for engineering yeast for industrial applications.",
    "llama-7b_fact_raw": "1. The largest metabolic gene cluster in yeast is the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cluster.\n2. The Pichia pastoris GAPDH cluster is involved in glycolysis, specifically in the conversion of glucose to pyruvate.\n3. The Pichia pastoris GAPDH cluster consists of 13 genes.\n4. These 13 genes are transcribed as a single polycistronic mRNA.\n5. The GAPDH cluster is highly conserved across different yeast species.",
    "llama-7b_fact": [
      "The largest metabolic gene cluster in yeast is the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cluster.",
      "The Pichia pastoris GAPDH cluster is involved in glycolysis, specifically in the conversion of glucose to pyruvate.",
      "The Pichia pastoris GAPDH cluster consists of 13 genes.",
      "These 13 genes are transcribed as a single polycistronic mRNA.",
      "The GAPDH cluster is highly conserved across different yeast species."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The statement about the size of the metabolic gene cluster in yeast being the largest for Pichia pastoris GAPDH is specific and would require specialized knowledge or a specific source to confirm its accuracy.\n2. TRUE: GAPDH (glyceraldehyde-3-phosphate dehydrogenase) is an enzyme that is indeed involved in glycolysis, which is the metabolic pathway that converts glucose into pyruvate.\n3. UNKNOWN: The specific number of genes in the Pichia pastoris GAPDH cluster is a detail that would require specialized knowledge or a specific source to confirm.\n4. FALSE [correction]: In eukaryotes like yeast, genes are typically transcribed as monocistronic mRNAs, meaning each mRNA molecule corresponds to a single gene, not polycistronic.\n5. UNKNOWN: The conservation of the GAPDH cluster across different yeast species is a specific detail that would require specialized knowledge or a specific source to confirm. While GAPDH itself is a highly conserved enzyme, the statement about the entire cluster's conservation cannot be confirmed without additional information.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-7b_response": "LIMT lncRNA, also known as long intergenic non-coding RNA, is a type of non-coding RNA molecule that has been found to play a crucial role in various biological processes, including cell differentiation, proliferation, and apoptosis.\n\nStudies have shown that LIMT lncRNA is highly expressed in various types of cancer cells, including breast, lung, and colon cancer cells. It has been suggested that the overexpression of LIMT lncRNA contributes to the development and progression of cancer by promoting cell growth, invasion, and metastasis.\n\nFurthermore, LIMT lncRNA has also been found to regulate the activity of tumor suppressor genes, such as TP53 and PTEN, by binding to their promoter regions and preventing them from suppressing cell growth and division.\n\nOverall, LIMT lncRNA appears to play a crucial role in cancer development by promoting cell growth, invasion, and metastasis, and by suppressing the activity of tumor suppressor genes. Therefore, understanding the role of LIMT lncRNA in cancer may help in the development of new therapeutic strategies for cancer treatment.",
    "llama-7b_fact_raw": "1. LIMT lncRNA is a type of long intergenic non-coding RNA molecule.\n2. LIMT lncRNA is involved in biological processes such as cell differentiation, proliferation, and apoptosis.\n3. LIMT lncRNA is highly expressed in various types of cancer cells, including breast, lung, and colon cancer cells.\n4. Overexpression of LIMT lncRNA is suggested to contribute to the development and progression of cancer.\n5. LIMT lncRNA can regulate the activity of tumor suppressor genes like TP53 and PTEN by binding to their promoter regions.",
    "llama-7b_fact": [
      "LIMT lncRNA is a type of long intergenic non-coding RNA molecule.",
      "LIMT lncRNA is involved in biological processes such as cell differentiation, proliferation, and apoptosis.",
      "LIMT lncRNA is highly expressed in various types of cancer cells, including breast, lung, and colon cancer cells.",
      "Overexpression of LIMT lncRNA is suggested to contribute to the development and progression of cancer.",
      "LIMT lncRNA can regulate the activity of tumor suppressor genes like TP53 and PTEN by binding to their promoter regions."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements are true as LIMT lncRNA is indeed a type of long intergenic non-coding RNA molecule, and such molecules are known to be involved in various biological processes including cell differentiation, proliferation, and apoptosis. However, without specific scientific references or context, it is not possible to confirm the accuracy of statements 3, 4, and 5 regarding the expression of LIMT lncRNA in various cancer cells, its contribution to cancer development and progression, or its regulatory interactions with tumor suppressor genes. These would require specific empirical evidence from scientific studies.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-7b_response": "The R / bioconductor package that is commonly used for performing SNP enrichment analysis is called \"GSEA\". It stands for Gene Set Enrichment Analysis and is designed to help researchers identify differentially expressed gene sets that are associated with specific biological processes, pathways, and diseases. GSEA is particularly useful for analyzing large-scale genomic data sets, such as those obtained from genome-wide association studies (GWAS) or transcriptomics experiments. The GSEA package is available for download from the R / bioconductor website and can be easily integrated into R scripts for performing SNP enrichment analysis.",
    "llama-7b_fact_raw": "1. The R / bioconductor package used for performing SNP enrichment analysis is called \"GSEA\".\n2. GSEA stands for Gene Set Enrichment Analysis.\n3. GSEA is designed to identify differentially expressed gene sets associated with specific biological processes, pathways, and diseases.\n4. GSEA is useful for analyzing large-scale genomic data sets from genome-wide association studies (GWAS) or transcriptomics experiments.\n5. The GSEA package can be downloaded from the R / bioconductor website.",
    "llama-7b_fact": [
      "The R / bioconductor package used for performing SNP enrichment analysis is called \"GSEA\".",
      "GSEA stands for Gene Set Enrichment Analysis.",
      "GSEA is designed to identify differentially expressed gene sets associated with specific biological processes, pathways, and diseases.",
      "GSEA is useful for analyzing large-scale genomic data sets from genome-wide association studies (GWAS) or transcriptomics experiments.",
      "The GSEA package can be downloaded from the R / bioconductor website."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The R / bioconductor package used for performing SNP enrichment analysis is not called \"GSEA\". There are different packages available for SNP enrichment analysis on Bioconductor, and GSEA is a separate method for gene set enrichment analysis.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN: While GSEA software can be downloaded from its own website, it is not clear if there is a specific package named \"GSEA\" on the R / bioconductor website without additional context. Bioconductor does host various packages for gene set enrichment analysis, but the statement is vague regarding the exact package name.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-7b_response": "Radial glial specification to ependymal cells is a complex process that involves several key players. Here are some of the important players involved in this process:\n\n1. Sonic hedgehog (Shh): Shh is a critical signaling molecule that is produced by neural crest cells during embryonic development. It plays a crucial role in the specification of radial glial cells and their differentiation into ependymal cells.\n\n2. Notch signaling pathway: The Notch signaling pathway is involved in the regulation of cell fate decisions during embryonic development. It plays a key role in the differentiation of radial glial cells into ependymal cells.\n\n3. Wnt signaling pathway: The Wnt signaling pathway is involved in the regulation of cell proliferation and differentiation during embryonic development. It plays a role in the specification of radial glial cells and their differentiation into ependymal cells.\n\n4. Brachyury: Brachyury is a transcription factor that is essential for the development of the notochord during embryonic development. It also plays a role in the specification of radial glial cells and their differentiation into ependymal cells.\n\n5. TGF-beta signaling pathway: The TGF-beta signaling pathway is involved in the regulation of cell proliferation and differentiation during embryonic development. It plays a role in the specification of radial glial cells and their differentiation into ependymal cells.\n\nOverall, these key players work together to specify radial glial cells to ependymal cells during embryonic development.",
    "llama-7b_fact_raw": "1. Sonic hedgehog (Shh) is produced by neural crest cells during embryonic development and is involved in the specification of radial glial cells to ependymal cells.\n2. The Notch signaling pathway regulates cell fate decisions during embryonic development and is key in the differentiation of radial glial cells into ependymal cells.\n3. The Wnt signaling pathway is involved in cell proliferation and differentiation during embryonic development and plays a role in the specification of radial glial cells to ependymal cells.\n4. Brachyury is a transcription factor essential for notochord development and is involved in the specification of radial glial cells to ependymal cells.\n5. The TGF-beta signaling pathway regulates cell proliferation and differentiation during embryonic development and is involved in the specification of radial glial cells to ependymal cells.",
    "llama-7b_fact": [
      "Sonic hedgehog (Shh) is produced by neural crest cells during embryonic development and is involved in the specification of radial glial cells to ependymal cells.",
      "The Notch signaling pathway regulates cell fate decisions during embryonic development and is key in the differentiation of radial glial cells into ependymal cells.",
      "The Wnt signaling pathway is involved in cell proliferation and differentiation during embryonic development and plays a role in the specification of radial glial cells to ependymal cells.",
      "Brachyury is a transcription factor essential for notochord development and is involved in the specification of radial glial cells to ependymal cells.",
      "The TGF-beta signaling pathway regulates cell proliferation and differentiation during embryonic development and is involved in the specification of radial glial cells to ependymal cells."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Sonic hedgehog (Shh) is not produced by neural crest cells; it is secreted by the notochord and floor plate during embryonic development and is involved in the patterning of the neural tube and the development of the brain and spinal cord, not specifically in the specification of radial glial cells to ependymal cells.\n2. TRUE: The Notch signaling pathway does regulate cell fate decisions during embryonic development and is key in the differentiation of neural stem cells, which can include radial glial cells, into various cell types, including ependymal cells.\n3. TRUE: The Wnt signaling pathway is involved in cell proliferation and differentiation during embryonic development and does play a role in the specification of various cell types, including the fate of radial glial cells.\n4. FALSE [correction]: Brachyury is a transcription factor essential for notochord development, but it is not directly involved in the specification of radial glial cells to ependymal cells.\n5. TRUE: The TGF-beta signaling pathway does regulate cell proliferation and differentiation during embryonic development and can be involved in various cell fate decisions, including the specification of radial glial cells to ependymal cells.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-7b_response": "Triple negative gliomas (TNGs) are a type of central nervous system tumor that is characterized by the absence of three key cellular markers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This means that TNGs do not respond to treatments that target these receptors, such as hormone therapy or targeted therapy with Herceptin.\n\nIn addition to the absence of these receptors, TNGs are also characterized by their aggressive growth pattern and tendency to invade surrounding tissue. They are typically diagnosed in adults between the ages of 20 and 40, although they can occur in younger or older individuals.\n\nThe diagnosis of TNG is typically made through a combination of imaging studies (such as MRI or CT scans) and biopsy of the tumor. Once diagnosed, treatment typically involves a combination of surgery (to remove as much of the tumor as possible), radiation therapy, and chemotherapy.\n\nOverall, TNGs are challenging to treat due to their aggressive nature and lack of effective targeted therapies. However, ongoing research in this area may lead to new treatments that can improve outcomes for patients with this type of tumor.",
    "llama-7b_fact_raw": "1. Triple negative gliomas are characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).\n2. Triple negative gliomas do not respond to treatments that target ER, PR, and HER2 receptors.\n3. These tumors are known for their aggressive growth pattern and tendency to invade surrounding tissue.\n4. Triple negative gliomas are typically diagnosed in adults between the ages of 20 and 40.\n5. The diagnosis of triple negative gliomas is made through imaging studies and biopsy, and treatment usually involves surgery, radiation therapy, and chemotherapy.",
    "llama-7b_fact": [
      "Triple negative gliomas are characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).",
      "Triple negative gliomas do not respond to treatments that target ER, PR, and HER2 receptors.",
      "These tumors are known for their aggressive growth pattern and tendency to invade surrounding tissue.",
      "Triple negative gliomas are typically diagnosed in adults between the ages of 20 and 40.",
      "The diagnosis of triple negative gliomas is made through imaging studies and biopsy, and treatment usually involves surgery, radiation therapy, and chemotherapy."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Triple negative gliomas are not characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Instead, triple negative refers to breast cancer that lacks these receptors.\n2. TRUE (assuming the context is triple negative breast cancer, as gliomas are not classified by these receptors)\n3. TRUE (assuming the context is triple negative breast cancer, as gliomas are not classified by these receptors)\n4. FALSE [correction]: Triple negative breast cancer can be diagnosed in adults of various ages, not specifically between the ages of 20 and 40. The age range for diagnosis can be broader.\n5. TRUE (assuming the context is triple negative breast cancer, as gliomas are not classified by these receptors and the diagnosis and treatment of gliomas may differ)",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-7b_response": "TOPAZ1 is a cryptocurrency that was launched in 2017. It is a privacy-focused cryptocurrency that aims to provide users with greater anonymity and security when making transactions. TOPAZ1 is based on the CryptoNight hashing algorithm and uses a proof-of-work consensus mechanism. It is one of several privacy-focused cryptocurrencies, also known as privacy coins, that have emerged in recent years in response to concerns about government surveillance and data privacy. TOPAZ1 is traded on several cryptocurrency exchanges and has a market capitalization of over $1 billion.",
    "llama-7b_fact_raw": "1. TOPAZ1 is a cryptocurrency that was launched in 2017.\n2. TOPAZ1 aims to provide users with greater anonymity and security for transactions.\n3. The cryptocurrency is based on the CryptoNight hashing algorithm.\n4. TOPAZ1 uses a proof-of-work consensus mechanism.\n5. TOPAZ1 has a market capitalization of over $1 billion.",
    "llama-7b_fact": [
      "TOPAZ1 is a cryptocurrency that was launched in 2017.",
      "TOPAZ1 aims to provide users with greater anonymity and security for transactions.",
      "The cryptocurrency is based on the CryptoNight hashing algorithm.",
      "TOPAZ1 uses a proof-of-work consensus mechanism.",
      "TOPAZ1 has a market capitalization of over $1 billion."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a cryptocurrency named TOPAZ1, it is not possible to verify these statements. The cryptocurrency market is vast and constantly changing, and without current and accurate data, the status of a specific cryptocurrency like TOPAZ1 cannot be confirmed.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-7b_response": "The gene that controls the expression of GATA-1 isoforms is called the GATA-1 gene. The GATA-1 gene contains the instructions for making the GATA-1 protein, which is a transcription factor that regulates the expression of other genes involved in the development and function of the cardiovascular system. \n\nThe GATA-1 protein is produced as a result of alternative splicing of its mRNA, which leads to the production of different isoforms of the protein. These isoforms have different amino acid sequences and may have different functions. \n\nThe expression of the GATA-1 gene is regulated by a variety of factors, including transcription factors, signaling molecules, and epigenetic modifications. These factors can activate or repress the expression of the GATA-1 gene, leading to the production of different amounts of GATA-1 protein and different isoforms of the protein. \n\nOverall, the GATA-1 gene plays a critical role in the development and function of the cardiovascular system, and its expression is tightly controlled by a complex network of regulatory factors.",
    "llama-7b_fact_raw": "1. The GATA-1 gene controls the expression of GATA-1 isoforms.\n2. The GATA-1 protein is a transcription factor that regulates the expression of genes involved in the development and function of the cardiovascular system.\n3. Alternative splicing of the GATA-1 mRNA leads to the production of different isoforms of the GATA-1 protein.\n4. Isoforms of the GATA-1 protein have different amino acid sequences and may have different functions.\n5. The expression of the GATA-1 gene is regulated by factors such as transcription factors, signaling molecules, and epigenetic modifications.",
    "llama-7b_fact": [
      "The GATA-1 gene controls the expression of GATA-1 isoforms.",
      "The GATA-1 protein is a transcription factor that regulates the expression of genes involved in the development and function of the cardiovascular system.",
      "Alternative splicing of the GATA-1 mRNA leads to the production of different isoforms of the GATA-1 protein.",
      "Isoforms of the GATA-1 protein have different amino acid sequences and may have different functions.",
      "The expression of the GATA-1 gene is regulated by factors such as transcription factors, signaling molecules, and epigenetic modifications."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The GATA-1 protein is a transcription factor that regulates the expression of genes involved in the development and function of erythroid and megakaryocytic lineages, not specifically the cardiovascular system.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-7b_response": "MIRA-seq (Mutually Informative Reads Assembly) is a sequencing-based method for de novo genome assembly that was developed by a group of researchers at the University of California, Berkeley. MIRA-seq differs from other de novo genome assembly methods, such as Illumina sequencing or PacBio sequencing, in that it leverages the information contained in both forward and reverse reads to improve the accuracy and completeness of the assembled genome.\n\nMIRA-seq works by first generating millions of short, paired-end reads using a high-throughput sequencing platform, such as Illumina or PacBio. These reads are then aligned to a reference genome or transcriptome using a pairwise alignment algorithm, such as HISAT2 or STAR. The aligned reads are then sorted into groups based on their similarity to each other, and each group is referred to as a \"mutually informative read\" or MIR.\n\nThe MIRs are then assembled into contigs using a de novo genome assembly algorithm, such as SPAdes or Velvet. Unlike other de novo genome assembly methods, which rely solely on forward or reverse reads, MIRA-seq takes advantage of the information contained in both types of reads to improve the accuracy and completeness of the assembled genome.\n\nOverall, MIRA-seq has been shown to outperform other de novo genome assembly methods in terms of accuracy and completeness, particularly for genomes that are difficult to assemble, such as those of non-model organisms or those with high levels of repetitive sequence.",
    "llama-7b_fact_raw": "1. MIRA-seq stands for Mutually Informative Reads Assembly.\n2. MIRA-seq was developed by researchers at the University of California, Berkeley.\n3. MIRA-seq uses both forward and reverse reads to improve genome assembly accuracy and completeness.\n4. MIRA-seq involves generating millions of short, paired-end reads using high-throughput sequencing platforms like Illumina or PacBio.\n5. MIRA-seq has been shown to outperform other de novo genome assembly methods in terms of accuracy and completeness for certain genomes.",
    "llama-7b_fact": [
      "MIRA-seq stands for Mutually Informative Reads Assembly.",
      "MIRA-seq was developed by researchers at the University of California, Berkeley.",
      "MIRA-seq uses both forward and reverse reads to improve genome assembly accuracy and completeness.",
      "MIRA-seq involves generating millions of short, paired-end reads using high-throughput sequencing platforms like Illumina or PacBio.",
      "MIRA-seq has been shown to outperform other de novo genome assembly methods in terms of accuracy and completeness for certain genomes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MIRA-seq stands for Methylation-based Inference of Regulatory Activity sequencing.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction provided for statement 1 is based on the assumption that MIRA-seq refers to a sequencing method related to methylation and regulatory activity, which is a common context for the acronym. However, without specific context, the statements 2 through 5 cannot be accurately verified as true or false, as they may refer to a specific study or aspect of MIRA-seq that is not universally known or may be part of ongoing research.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-7b_response": "ARCALYST (rilonacept) is a prescription medicine used to treat Cryopyrin-associated periodic syndromes (CAPS) in adults and children who are at least 12 years old. CAPS is a rare genetic disorder that causes episodes of pain, fever, and inflammation. ARCALYST works by blocking a specific protein called interleukin-1 (IL-1) that is involved in the inflammatory response. By blocking IL-1, ARCALYST helps to reduce the symptoms of CAPS. \n\nIt is important to note that ARCALYST is not a cure for CAPS and should not be used to treat other types of inflammatory diseases. Additionally, ARCALYST can cause serious side effects, including an increased risk of infections and cancer. Therefore, patients should be monitored closely while taking ARCALYST and should notify their healthcare provider right away if they develop any new or worsening symptoms.",
    "llama-7b_fact_raw": "1. ARCALYST (rilonacept) is used to treat Cryopyrin-associated periodic syndromes (CAPS) in adults and children aged 12 and older.\n2. CAPS is a rare genetic disorder characterized by episodes of pain, fever, and inflammation.\n3. ARCALYST functions by blocking interleukin-1 (IL-1), a protein involved in the inflammatory response.\n4. ARCALYST is not a cure for CAPS.\n5. ARCALYST can cause serious side effects, including an increased risk of infections and cancer.",
    "llama-7b_fact": [
      "ARCALYST (rilonacept) is used to treat Cryopyrin-associated periodic syndromes (CAPS) in adults and children aged 12 and older.",
      "CAPS is a rare genetic disorder characterized by episodes of pain, fever, and inflammation.",
      "ARCALYST functions by blocking interleukin-1 (IL-1), a protein involved in the inflammatory response.",
      "ARCALYST is not a cure for CAPS.",
      "ARCALYST can cause serious side effects, including an increased risk of infections and cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-7b_response": "Robertsonian translocation is a type of chromosomal abnormality characterized by the exchange of material between two acrocentric chromosomes. In humans, the acrocentric chromosomes are numbered 13, 14, 15, and 16. Therefore, the human acrocentric chromosomes that are involved in Robertsonian translocation are 13, 14, 15, and 16.",
    "llama-7b_fact_raw": "1. Robertsonian translocation is characterized by the exchange of material between two acrocentric chromosomes.\n2. The human acrocentric chromosomes involved in Robertsonian translocation are numbered 13, 14, 15, and 16.",
    "llama-7b_fact": [
      "Robertsonian translocation is characterized by the exchange of material between two acrocentric chromosomes.",
      "The human acrocentric chromosomes involved in Robertsonian translocation are numbered 13, 14, 15, and 16."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The human acrocentric chromosomes involved in Robertsonian translocation are numbered 13, 14, 15, 21, and 22.",
    "llama-7b_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-7b_response": "There is no single R package that can be used for the identification of pediatric brain tumors. This is because brain tumors are a complex medical condition that requires a multidisciplinary approach for diagnosis and treatment. \n\nHowever, there are several R packages that can be used for various aspects of pediatric brain tumor diagnosis and treatment. Here are some examples:\n\n1. R/Bioconductor: This package can be used for analyzing gene expression data from pediatric brain tumors, which can provide insights into the molecular mechanisms driving tumor growth and progression.\n\n2. R/cBio: This package can be used for analyzing clinical data from pediatric brain tumor patients, such as patient demographics, treatment outcomes, and survival rates.\n\n3. R/SPM8: This package can be used for analyzing functional magnetic resonance imaging (fMRI) data from pediatric patients with brain tumors, which can provide insights into brain activation patterns and potential biomarkers for diagnosis and treatment.\n\n4. R/fsl: This package can be used for analyzing structural magnetic resonance imaging (sMRI) data from pediatric brain tumor patients, which can provide insights into tumor location, size, and morphology.\n\nOverall, the choice of R package for pediatric brain tumor diagnosis and treatment will depend on the specific research question and available data.",
    "llama-7b_fact_raw": "1. R/Bioconductor can be used for analyzing gene expression data from pediatric brain tumors.\n2. R/cBio can be used for analyzing clinical data from pediatric brain tumor patients.\n3. R/SPM8 can be used for analyzing functional magnetic resonance imaging (fMRI) data from pediatric patients with brain tumors.\n4. R/fsl can be used for analyzing structural magnetic resonance imaging (sMRI) data from pediatric brain tumor patients.",
    "llama-7b_fact": [
      "R/Bioconductor can be used for analyzing gene expression data from pediatric brain tumors.",
      "R/cBio can be used for analyzing clinical data from pediatric brain tumor patients.",
      "R/SPM8 can be used for analyzing functional magnetic resonance imaging (fMRI) data from pediatric patients with brain tumors.",
      "R/fsl can be used for analyzing structural magnetic resonance imaging (sMRI) data from pediatric brain tumor patients."
    ],
    "llama-7b_judge_raw": "1. TRUE: R/Bioconductor is a collection of software packages that can be used for the analysis of various types of genomic data, including gene expression data, which would be relevant for pediatric brain tumors.\n2. FALSE [correction]: R/cBio is not a recognized software package. However, the cBioPortal for Cancer Genomics provides a web resource for exploring, visualizing, and analyzing multidimensional cancer genomics data, which can be interfaced with R using packages like 'cgdsr' for analyzing clinical data from cancer patients, including those with pediatric brain tumors.\n3. FALSE [correction]: R/SPM8 is not an R package. SPM (Statistical Parametric Mapping) is a standalone software package that is used for the analysis of brain imaging data, including fMRI. It is not part of R but can be used independently for analyzing fMRI data from pediatric patients with brain tumors.\n4. FALSE [correction]: R/fsl is not an R package. FSL (FMRIB Software Library) is a standalone software library that can be used for the analysis of brain imaging data, including structural MRI (sMRI). It is not part of R but can be used independently for analyzing sMRI data from pediatric brain tumor patients.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-7b_response": "Yes, NEMO (NF-kappaB essential modulator) is a zinc finger protein. Zinc finger proteins are named after their ability to bind zinc ions, which is essential for their structure and function. NEMO is a key component of the NF-kappaB signaling pathway, which is involved in regulating the expression of genes involved in immune and inflammatory responses. The zinc finger domain of NEMO interacts with other proteins involved in the NF-kappaB pathway, including IkappaB kinase (IKK) and p65 (RelA), to activate the degradation of IkappaB alpha and the transcription of target genes. Overall, the zinc finger domain of NEMO is critical for the proper functioning of the NF-kappaB pathway.",
    "llama-7b_fact_raw": "1. NEMO (NF-kappaB essential modulator) is a zinc finger protein.\n2. Zinc finger proteins bind zinc ions, which is essential for their structure and function.\n3. NEMO is a key component of the NF-kappaB signaling pathway.\n4. The NF-kappaB signaling pathway is involved in regulating the expression of genes involved in immune and inflammatory responses.\n5. The zinc finger domain of NEMO interacts with IkappaB kinase (IKK) and p65 (RelA) in the NF-kappaB pathway.",
    "llama-7b_fact": [
      "NEMO (NF-kappaB essential modulator) is a zinc finger protein.",
      "Zinc finger proteins bind zinc ions, which is essential for their structure and function.",
      "NEMO is a key component of the NF-kappaB signaling pathway.",
      "The NF-kappaB signaling pathway is involved in regulating the expression of genes involved in immune and inflammatory responses.",
      "The zinc finger domain of NEMO interacts with IkappaB kinase (IKK) and p65 (RelA) in the NF-kappaB pathway."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: NEMO (NF-kappaB essential modulator) is not a zinc finger protein; it is a regulatory subunit of the IKK (IκB kinase) complex.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The zinc finger domain is not a feature of NEMO; instead, NEMO contains a coiled-coil domain and a leucine zipper that are involved in its interactions with the IKK complex and other components of the NF-kappaB pathway.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-7b_response": "Yes, TFIIS does affect nucleosome positioning. TFIIS is a transcription factor that is involved in the initiation of RNA polymerase II-mediated transcription. One of the key functions of TFIIS is to stimulate the unwinding of the DNA double helix around the promoter region of a gene, allowing RNA polymerase II to bind and begin transcription.\n\nHowever, TFIIS also has a role in regulating the positioning of nucleosomes around the promoter region of a gene. Nucleosomes are composed of a histone protein core that is wrapped around a DNA double helix, and they play an important role in regulating access to DNA for transcription factors like TFIIS.\n\nStudies have shown that TFIIS interacts with the histones H2A and H2B, which are components of nucleosomes. These interactions appear to be important for the recruitment of TFIIS to the promoter region of a gene, as well as for the positioning of nucleosomes around the promoter.\n\nIn summary, while TFIIS is primarily involved in stimulating the unwinding of the DNA double helix around the promoter region of a gene, it also appears to have a role in regulating the positioning of nucleosomes around the promoter.",
    "llama-7b_fact_raw": "1. TFIIS is a transcription factor involved in the initiation of RNA polymerase II-mediated transcription.\n2. TFIIS stimulates the unwinding of the DNA double helix around the promoter region of a gene.\n3. TFIIS plays a role in regulating the positioning of nucleosomes around the promoter region of a gene.\n4. Nucleosomes are composed of a histone protein core wrapped around a DNA double helix.\n5. TFIIS interacts with the histones H2A and H2B, which are components of nucleosomes.",
    "llama-7b_fact": [
      "TFIIS is a transcription factor involved in the initiation of RNA polymerase II-mediated transcription.",
      "TFIIS stimulates the unwinding of the DNA double helix around the promoter region of a gene.",
      "TFIIS plays a role in regulating the positioning of nucleosomes around the promoter region of a gene.",
      "Nucleosomes are composed of a histone protein core wrapped around a DNA double helix.",
      "TFIIS interacts with the histones H2A and H2B, which are components of nucleosomes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TFIIS is not a transcription factor involved in the initiation of RNA polymerase II-mediated transcription. It is a transcription elongation factor that helps RNA polymerase II to overcome transcriptional arrest.\n2. FALSE [correction]: TFIIS does not stimulate the unwinding of the DNA double helix around the promoter region of a gene. Its role is associated with the elongation phase of transcription, not the initiation phase.\n3. UNKNOWN: The role of TFIIS in regulating the positioning of nucleosomes around the promoter region of a gene is not well-established and would require specific evidence to confirm.\n4. TRUE: Nucleosomes are indeed composed of a histone protein core around which DNA is wrapped. This core typically consists of histone proteins H2A, H2B, H3, and H4.\n5. UNKNOWN: The specific interaction of TFIIS with histones H2A and H2B is not a well-documented function of TFIIS. TFIIS is known to interact with RNA polymerase II, but its direct interactions with specific histones would require specific evidence to confirm.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-7b_response": "The answer to this question is that the origins of replication close to yeast centromeres do not have a consistent pattern of firing early or late. While some studies have suggested that these origins may fire early during the S phase of the cell cycle, other studies have found that they may also fire late.\n\nThe reason for this discrepancy is that the firing of origins of replication is a complex process that is influenced by a variety of factors, including the cell cycle stage, DNA damage, and the presence of transcription factors. In addition, different yeast strains may have different patterns of origin firing.\n\nOverall, while it is true that origins of replication close to yeast centromeres have been shown to be important for accurate chromosome segregation, the precise timing of their firing is still not fully understood. Further research is needed to clarify this issue and to elucidate the mechanisms that regulate origin firing in these regions.",
    "llama-7b_fact_raw": "1. Origins of replication close to yeast centromeres do not have a consistent pattern of firing early or late.\n2. Some studies suggest that origins of replication near yeast centromeres may fire early during the S phase of the cell cycle.\n3. Other studies have found that origins of replication near yeast centromeres may also fire late.\n4. The firing of origins of replication is influenced by factors such as cell cycle stage, DNA damage, and the presence of transcription factors.\n5. Origins of replication close to yeast centromeres are important for accurate chromosome segregation.",
    "llama-7b_fact": [
      "Origins of replication close to yeast centromeres do not have a consistent pattern of firing early or late.",
      "Some studies suggest that origins of replication near yeast centromeres may fire early during the S phase of the cell cycle.",
      "Other studies have found that origins of replication near yeast centromeres may also fire late.",
      "The firing of origins of replication is influenced by factors such as cell cycle stage, DNA damage, and the presence of transcription factors.",
      "Origins of replication close to yeast centromeres are important for accurate chromosome segregation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the general understanding of yeast centromeres and origins of replication. Origins of replication can indeed have variable timing of activation, and their firing can be influenced by various factors. Additionally, proper function of origins near centromeres is important for chromosome segregation.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-7b_response": "Mammalian GA-sequences are a type of non-coding RNA molecule that is found in the nucleus of mammalian cells. These sequences are approximately 70 nucleotides in length and contain a repeating pattern of four nucleotides, known as the GA-motif.\n\nThe GA-motif is made up of the nucleotides guanine, adenine, and two other nucleotides, which can vary between different GA-sequences. The GA-motif has been shown to be highly conserved across different mammalian species, suggesting that it has important biological functions.\n\nResearch has shown that GA-sequences are involved in the regulation of gene expression, particularly in the control of alternative splicing. Alternative splicing is the process by which a single pre-mRNA molecule can be spliced in different ways to produce different mRNA molecules, each encoding a different protein isoform. GA-sequences have been found to interact with specific proteins involved in alternative splicing, leading to the regulation of splice site selection and the formation of alternative splice isoforms.\n\nIn addition to their role in alternative splicing, GA-sequences have also been implicated in other biological processes, such as cell differentiation, cell cycle regulation, and DNA damage response. Overall, the properties of mammalian GA-sequences suggest that they play important roles in the regulation of gene expression and cellular processes.",
    "llama-7b_fact_raw": "1. Mammalian GA-sequences are non-coding RNA molecules found in the nucleus of mammalian cells.\n2. These sequences are approximately 70 nucleotides in length.\n3. The GA-motif within GA-sequences is highly conserved across different mammalian species.\n4. GA-sequences are involved in the regulation of gene expression, particularly in the control of alternative splicing.\n5. GA-sequences have been implicated in biological processes such as cell differentiation, cell cycle regulation, and DNA damage response.",
    "llama-7b_fact": [
      "Mammalian GA-sequences are non-coding RNA molecules found in the nucleus of mammalian cells.",
      "These sequences are approximately 70 nucleotides in length.",
      "The GA-motif within GA-sequences is highly conserved across different mammalian species.",
      "GA-sequences are involved in the regulation of gene expression, particularly in the control of alternative splicing.",
      "GA-sequences have been implicated in biological processes such as cell differentiation, cell cycle regulation, and DNA damage response."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The term \"GA-sequences\" is not a standard term in molecular biology, and without additional context, it is unclear whether this refers to a specific type of non-coding RNA or is a hypothetical or mislabeled term. Therefore, the truth of this statement cannot be determined.\n2. UNKNOWN: Since the term \"GA-sequences\" is not clearly defined, the length of these sequences cannot be confirmed.\n3. UNKNOWN: Without a clear definition of what \"GA-sequences\" are, it is impossible to determine if the GA-motif is conserved across different mammalian species.\n4. UNKNOWN: The role of \"GA-sequences\" in gene expression regulation and alternative splicing cannot be confirmed without a clear understanding of what these sequences are.\n5. UNKNOWN: The involvement of \"GA-sequences\" in biological processes such as cell differentiation, cell cycle regulation, and DNA damage response cannot be confirmed without additional context or clarification of what these sequences are.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-7b_response": "As an AI language model, I do not have access to the latest information on the number of Groucho-related genes (GRG) contained in the mouse genome. However, I can tell you that Groucho-related genes are a group of genes that play a crucial role in embryonic development and cell-to-cell communication. These genes are named after the character Groucho Marx, who famously said \"Outside of a dog, a book is a man's best friend. Inside of a dog, it's too dark to read.\" The name \"Groucho\" was given to these genes because they were first discovered in the fruit fly Drosophila melanogaster, which is often referred to as \"the fly that Groucho loved.\" As for the number of Groucho-related genes in the mouse genome, I suggest consulting a specialized database or conducting a scientific literature search to obtain the most up-to-date information.",
    "llama-7b_fact_raw": "1. Groucho-related genes (GRG) play a crucial role in embryonic development and cell-to-cell communication.\n2. The name \"Groucho\" for these genes was inspired by the character Groucho Marx.\n3. Groucho-related genes were first discovered in the fruit fly Drosophila melanogaster.",
    "llama-7b_fact": [
      "Groucho-related genes (GRG) play a crucial role in embryonic development and cell-to-cell communication.",
      "The name \"Groucho\" for these genes was inspired by the character Groucho Marx.",
      "Groucho-related genes were first discovered in the fruit fly Drosophila melanogaster."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-7b_response": "The RNA polymerase II subunit that carries RNA cleavage activity is called the RNase III subunit. RNase III is a cytidine deaminase that catalyzes the conversion of adenosine to inosine in RNA. This enzymatic activity is essential for the processing and maturation of certain types of RNA, such as tRNA and siRNA. RNase III also plays a role in the regulation of alternative splicing by removing intronic sequences from pre-mRNA, thereby exposing the exonic regions for splicing. Overall, RNase III is a crucial component of the RNA polymerase II complex and is essential for proper gene expression.",
    "llama-7b_fact_raw": "1. The RNase III subunit of RNA polymerase II carries RNA cleavage activity.\n2. RNase III catalyzes the conversion of adenosine to inosine in RNA.\n3. RNase III is involved in the processing and maturation of tRNA and siRNA.\n4. RNase III plays a role in the regulation of alternative splicing by removing intronic sequences from pre-mRNA.\n5. RNase III is a component of the RNA polymerase II complex and is essential for proper gene expression.",
    "llama-7b_fact": [
      "The RNase III subunit of RNA polymerase II carries RNA cleavage activity.",
      "RNase III catalyzes the conversion of adenosine to inosine in RNA.",
      "RNase III is involved in the processing and maturation of tRNA and siRNA.",
      "RNase III plays a role in the regulation of alternative splicing by removing intronic sequences from pre-mRNA.",
      "RNase III is a component of the RNA polymerase II complex and is essential for proper gene expression."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The RNase III enzyme is not a subunit of RNA polymerase II; it is a type of ribonuclease that processes RNA molecules in various cellular contexts.\n2. FALSE [correction]: The conversion of adenosine to inosine in RNA is catalyzed by the enzyme ADAR (adenosine deaminase acting on RNA), not RNase III.\n3. TRUE\n4. FALSE [correction]: RNase III does not regulate alternative splicing by removing intronic sequences from pre-mRNA. This function is typically associated with the spliceosome. RNase III is involved in the processing of other RNA species, such as rRNA, tRNA, and siRNA.\n5. FALSE [correction]: RNase III is not a component of the RNA polymerase II complex. RNA polymerase II is responsible for transcribing mRNA, while RNase III is involved in the processing of various RNA molecules, but it is not part of the polymerase complex itself.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-7b_response": "Ohdo syndrome is a rare genetic disorder that is caused by mutations in the TP53 gene. The TP53 gene is responsible for producing a protein called p53, which is a tumor suppressor protein that helps to prevent the development of cancer. In individuals with Ohdo syndrome, mutations in the TP53 gene result in the production of a defective p53 protein that is unable to effectively regulate cell growth and division, leading to an increased risk of cancer.\n\nIn addition to an increased risk of cancer, individuals with Ohdo syndrome may also experience a range of other physical and developmental abnormalities. These may include skeletal abnormalities, such as short stature and bowed legs; heart defects; and cognitive and developmental delays.\n\nOverall, the genetic basis of Ohdo syndrome is a mutation in the TP53 gene that results in the production of a defective p53 protein, leading to an increased risk of cancer and a range of other physical and developmental abnormalities.",
    "llama-7b_fact_raw": "1. Ohdo syndrome is a rare genetic disorder caused by mutations in the TP53 gene.\n2. The TP53 gene is responsible for producing the p53 protein.\n3. The p53 protein is a tumor suppressor that helps prevent the development of cancer.\n4. Mutations in the TP53 gene can lead to the production of a defective p53 protein.\n5. Individuals with Ohdo syndrome may experience skeletal abnormalities, heart defects, and cognitive and developmental delays.",
    "llama-7b_fact": [
      "Ohdo syndrome is a rare genetic disorder caused by mutations in the TP53 gene.",
      "The TP53 gene is responsible for producing the p53 protein.",
      "The p53 protein is a tumor suppressor that helps prevent the development of cancer.",
      "Mutations in the TP53 gene can lead to the production of a defective p53 protein.",
      "Individuals with Ohdo syndrome may experience skeletal abnormalities, heart defects, and cognitive and developmental delays."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a rare genetic disorder, but it is not typically caused by mutations in the TP53 gene. It is often associated with mutations in other genes such as MED12 or KAT6B.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-7b_response": "The R/Bioconductor package \"PsychiatricGWAS\" has been developed for the analysis of psychiatric disease genes. It provides a set of tools for analyzing genome-wide association study (GWAS) data to identify genetic variants associated with psychiatric disorders such as depression, anxiety, bipolar disorder, and schizophrenia. The package includes functions for quality control, imputation, genotype association testing, and pathway analysis. It also provides access to a large dataset of GWAS data from the Psychiatric Genomics Consortium.",
    "llama-7b_fact_raw": "1. The R/Bioconductor package \"PsychiatricGWAS\" is developed for the analysis of psychiatric disease genes.\n2. \"PsychiatricGWAS\" includes tools for analyzing genome-wide association study (GWAS) data.\n3. The package is designed to identify genetic variants associated with psychiatric disorders such as depression, anxiety, bipolar disorder, and schizophrenia.\n4. Functions included in \"PsychiatricGWAS\" cover quality control, imputation, genotype association testing, and pathway analysis.\n5. \"PsychiatricGWAS\" provides access to a dataset of GWAS data from the Psychiatric Genomics Consortium.",
    "llama-7b_fact": [
      "The R/Bioconductor package \"PsychiatricGWAS\" is developed for the analysis of psychiatric disease genes.",
      "\"PsychiatricGWAS\" includes tools for analyzing genome-wide association study (GWAS) data.",
      "The package is designed to identify genetic variants associated with psychiatric disorders such as depression, anxiety, bipolar disorder, and schizophrenia.",
      "Functions included in \"PsychiatricGWAS\" cover quality control, imputation, genotype association testing, and pathway analysis.",
      "\"PsychiatricGWAS\" provides access to a dataset of GWAS data from the Psychiatric Genomics Consortium."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information about a package named \"PsychiatricGWAS\" in R/Bioconductor, it is not possible to confirm the accuracy of this statement.\n2. UNKNOWN: Similarly, without specific details about the \"PsychiatricGWAS\" package, it is not possible to confirm whether it includes tools for analyzing GWAS data.\n3. UNKNOWN: The purpose of the \"PsychiatricGWAS\" package cannot be confirmed without additional information.\n4. UNKNOWN: The functions included in the \"PsychiatricGWAS\" package cannot be verified without further details.\n5. UNKNOWN: Whether \"PsychiatricGWAS\" provides access to a dataset from the Psychiatric Genomics Consortium is not verifiable without more information.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-7b_response": "Swirl sign in intracerebral hemorrhage refers to the pattern of blood flow within the brain following the hemorrhage. This sign is seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans and is characterized by a swirling or whirling pattern of blood within the hemorrhage site.\n\nThe swirl sign is caused by the turbulent flow of blood within the brain due to the disruption of blood vessels caused by the hemorrhage. This turbulent flow can cause damage to surrounding brain tissue, leading to further neurological deterioration.\n\nThe swirl sign is considered a poor prognostic indicator as it is associated with a higher risk of death and severe disability in patients with intracerebral hemorrhage. However, it is important to note that not all patients with intracerebral hemorrhage will have a swirl sign on their imaging scans, and the presence of this sign does not necessarily determine the severity of the hemorrhage or the outcome of the patient.",
    "llama-7b_fact_raw": "1. Swirl sign in intracerebral hemorrhage is seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\n2. It is characterized by a swirling or whirling pattern of blood within the hemorrhage site.\n3. The swirl sign is caused by the turbulent flow of blood within the brain due to the disruption of blood vessels.\n4. The presence of the swirl sign is associated with a higher risk of death and severe disability in patients with intracerebral hemorrhage.\n5. Not all patients with intracerebral hemorrhage will have a swirl sign on their imaging scans.",
    "llama-7b_fact": [
      "Swirl sign in intracerebral hemorrhage is seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.",
      "It is characterized by a swirling or whirling pattern of blood within the hemorrhage site.",
      "The swirl sign is caused by the turbulent flow of blood within the brain due to the disruption of blood vessels.",
      "The presence of the swirl sign is associated with a higher risk of death and severe disability in patients with intracerebral hemorrhage.",
      "Not all patients with intracerebral hemorrhage will have a swirl sign on their imaging scans."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The swirl sign is not caused by turbulent flow of blood within the brain; it is an imaging finding that indicates the presence of active or ongoing bleeding within the hemorrhage.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-7b_response": "ROF1 is a member of the ROOT HAIR DEFICIENT1 (RHD1) family of transcription factors in Arabidopsis thaliana. ROF1 expression is induced in response to a variety of environmental and developmental cues.\n\nOne of the earliest known inducers of ROF1 expression is the phytohormone auxin. Auxin is synthesized and transported throughout the plant in a polar manner, and its accumulation in the shoot apical meristem (SAM) leads to the initiation of lateral roots. ROF1 expression is induced in the SAM in response to auxin, and this induction is required for the formation of lateral roots.\n\nAnother inducer of ROF1 expression is the plant hormone cytokinin. Cytokinins promote cell division and differentiation, and their accumulation in the root meristem leads to the formation of root hairs. ROF1 expression is induced in root hair precursor cells in response to cytokinin, and this induction is required for the differentiation of these cells into root hairs.\n\nAdditional inducers of ROF1 expression include abiotic stresses such as drought, salinity, and low temperature, as well as biotic stresses such as fungal infection and herbivory. These inducers trigger the plant's stress response pathways, which lead to the activation of ROF1 expression.\n\nIn summary, ROF1 expression is induced by a variety of environmental and developmental cues, including auxin, cytokinin, abiotic stresses, and biotic stresses. These inducers trigger the plant's stress response pathways, which lead to the activation of ROF1 expression and the formation of lateral roots and root hairs.",
    "llama-7b_fact_raw": "1. ROF1 is a member of the ROOT HAIR DEFICIENT1 (RHD1) family of transcription factors in Arabidopsis thaliana.\n2. Auxin induces ROF1 expression in the shoot apical meristem (SAM) of Arabidopsis thaliana.\n3. The induction of ROF1 expression by auxin is required for the formation of lateral roots in Arabidopsis thaliana.\n4. Cytokinin induces ROF1 expression in root hair precursor cells of Arabidopsis thaliana.\n5. The induction of ROF1 expression by cytokinin is required for the differentiation of root hair precursor cells into root hairs in Arabidopsis thaliana.",
    "llama-7b_fact": [
      "ROF1 is a member of the ROOT HAIR DEFICIENT1 (RHD1) family of transcription factors in Arabidopsis thaliana.",
      "Auxin induces ROF1 expression in the shoot apical meristem (SAM) of Arabidopsis thaliana.",
      "The induction of ROF1 expression by auxin is required for the formation of lateral roots in Arabidopsis thaliana.",
      "Cytokinin induces ROF1 expression in root hair precursor cells of Arabidopsis thaliana.",
      "The induction of ROF1 expression by cytokinin is required for the differentiation of root hair precursor cells into root hairs in Arabidopsis thaliana."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific to the molecular biology and genetics of the plant Arabidopsis thaliana. Without access to the specific scientific literature or studies that these statements are derived from, it is not possible to accurately determine the truthfulness of these statements. They require specialized knowledge in plant biology and the role of specific genes and hormones in plant development.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-7b_response": "The most common protein that causes hereditary renal amyloidosis is transthyretin (TTR). TTR is a plasma protein that is normally present in the bloodstream and is involved in the transport of thyroid hormones and retinol (vitamin A) throughout the body. However, mutations in the TTR gene can lead to the production of abnormal TTR protein, which accumulates in the tissues and organs, including the kidneys, causing amyloidosis. The hereditary form of renal amyloidosis caused by TTR is known as familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).",
    "llama-7b_fact_raw": "1. Transthyretin (TTR) is the most common protein that causes hereditary renal amyloidosis.\n2. TTR is a plasma protein involved in the transport of thyroid hormones and retinol (vitamin A).\n3. Mutations in the TTR gene can lead to the production of abnormal TTR protein.\n4. Abnormal TTR protein can accumulate in tissues and organs, including the kidneys, causing amyloidosis.\n5. The hereditary form of renal amyloidosis caused by TTR is known as familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).",
    "llama-7b_fact": [
      "Transthyretin (TTR) is the most common protein that causes hereditary renal amyloidosis.",
      "TTR is a plasma protein involved in the transport of thyroid hormones and retinol (vitamin A).",
      "Mutations in the TTR gene can lead to the production of abnormal TTR protein.",
      "Abnormal TTR protein can accumulate in tissues and organs, including the kidneys, causing amyloidosis.",
      "The hereditary form of renal amyloidosis caused by TTR is known as familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Transthyretin (TTR) is not the most common protein that causes hereditary renal amyloidosis. The most common form of hereditary amyloidosis is related to the protein fibrinogen, not TTR.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-7b_response": "Yes, the proteome of mice hippocampus has been analysed. Proteomics is the large-scale study of proteins, and the hippocampus is a region of the brain that is involved in learning and memory. Therefore, studying the proteome of the mouse hippocampus can provide insights into the molecular mechanisms underlying these processes.\n\nSeveral studies have used proteomic techniques to identify and quantify the proteins present in the mouse hippocampus. For example, one study used two-dimensional gel electrophoresis to separate and identify over 1000 proteins present in the hippocampus of adult mice. Another study used mass spectrometry to identify over 4000 proteins present in the hippocampus of juvenile mice.\n\nThese studies have provided valuable insights into the functional organization of the hippocampus, and have identified potential targets for therapeutic intervention in diseases such as Alzheimer's disease and epilepsy. Overall, the proteome of mice hippocampus has been extensively studied, and continues to be a topic of active research in the field of neuroscience.",
    "llama-7b_fact_raw": "1. The proteome of mice hippocampus has been analysed.\n2. The hippocampus is a region of the brain involved in learning and memory.\n3. One study identified over 1000 proteins in the hippocampus of adult mice using two-dimensional gel electrophoresis.\n4. Another study identified over 4000 proteins in the hippocampus of juvenile mice using mass spectrometry.\n5. Research on the mouse hippocampus proteome has contributed to understanding diseases like Alzheimer's disease and epilepsy.",
    "llama-7b_fact": [
      "The proteome of mice hippocampus has been analysed.",
      "The hippocampus is a region of the brain involved in learning and memory.",
      "One study identified over 1000 proteins in the hippocampus of adult mice using two-dimensional gel electrophoresis.",
      "Another study identified over 4000 proteins in the hippocampus of juvenile mice using mass spectrometry.",
      "Research on the mouse hippocampus proteome has contributed to understanding diseases like Alzheimer's disease and epilepsy."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-7b_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are chromosomes that have a short arm that is attached to the centromere and a long arm that is much longer than the short arm. In mammals, the sex chromosomes are acrocentric since they have a short arm that is attached to the centromere and a long arm that is much longer than the short arm. However, mouse chromosomes are not classified as sex chromosomes since they do not determine an individual's sex. Instead, mouse chromosomes are autosomes, which are the non-sex chromosomes that determine an individual's traits and characteristics. Therefore, mouse chromosomes are not acrocentric.",
    "llama-7b_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have a short arm attached to the centromere and a long arm that is much longer than the short arm.\n3. In mammals, the sex chromosomes are acrocentric.\n4. Mouse chromosomes are classified as autosomes.\n5. Autosomes are non-sex chromosomes that determine an individual's traits and characteristics.",
    "llama-7b_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have a short arm attached to the centromere and a long arm that is much longer than the short arm.",
      "In mammals, the sex chromosomes are acrocentric.",
      "Mouse chromosomes are classified as autosomes.",
      "Autosomes are non-sex chromosomes that determine an individual's traits and characteristics."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mouse chromosomes are acrocentric.\n2. TRUE\n3. FALSE [correction]: In mammals, the sex chromosomes are not typically acrocentric. For example, in humans, the sex chromosomes (X and Y) are not acrocentric.\n4. FALSE [correction]: Not all mouse chromosomes are classified as autosomes; mice also have sex chromosomes (X and Y).\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-7b_response": "One siRNA-based drug that is currently in clinical trials for the treatment of pancreatic cancer is GDC-0084. It is being developed by Genentech, a subsidiary of Roche. GDC-0084 is a lipid nanoparticle (LNP) encapsulating small interfering RNA (siRNA) targeting the vascular endothelial growth factor (VEGF) gene. VEGF is overexpressed in many types of cancer, including pancreatic cancer, and plays a crucial role in tumor angiogenesis and growth. \n\nGDC-0084 has shown promising results in preclinical studies, leading to its advancement to clinical trials. In a phase I clinical trial, GDC-0084 was found to be safe and well-tolerated when administered intravenously to patients with advanced solid tumors, including pancreatic cancer. The trial also demonstrated evidence of anti-tumor activity, with some patients experiencing partial or complete responses. \n\nFurthermore, GDC-0084 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer, which provides incentives for the development of drugs for rare diseases. \n\nOverall, GDC-0084 has great potential as a targeted therapy for pancreatic cancer and is currently being evaluated in ongoing clinical trials.",
    "llama-7b_fact_raw": "1. GDC-0084 is an siRNA-based drug currently in clinical trials for the treatment of pancreatic cancer.\n2. Genentech, a subsidiary of Roche, is developing GDC-0084.\n3. GDC-0084 targets the vascular endothelial growth factor (VEGF) gene, which is overexpressed in many types of cancer, including pancreatic cancer.\n4. In a phase I clinical trial, GDC-0084 was found to be safe and well-tolerated in patients with advanced solid tumors.\n5. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GDC-0084 for the treatment of pancreatic cancer.",
    "llama-7b_fact": [
      "GDC-0084 is an siRNA-based drug currently in clinical trials for the treatment of pancreatic cancer.",
      "Genentech, a subsidiary of Roche, is developing GDC-0084.",
      "GDC-0084 targets the vascular endothelial growth factor (VEGF) gene, which is overexpressed in many types of cancer, including pancreatic cancer.",
      "In a phase I clinical trial, GDC-0084 was found to be safe and well-tolerated in patients with advanced solid tumors.",
      "The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GDC-0084 for the treatment of pancreatic cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: GDC-0084 is not an siRNA-based drug; it is a small molecule inhibitor of the PI3K pathway, which is being investigated for the treatment of glioblastoma, not pancreatic cancer.\n2. TRUE\n3. FALSE [correction]: GDC-0084 does not target the VEGF gene; it targets the PI3K pathway, which is implicated in the growth and survival of tumor cells, particularly in glioblastoma.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-7b_response": "The HPG pore, also known as the high-pressure gradient pore, is a hypothetical pore that is believed to exist in the membranes of cells. This pore is thought to allow for the selective transport of ions and molecules across the membrane by exploiting the differences in their chemical potentials across the membrane.\n\nThe existence of the HPG pore has been proposed to explain certain phenomena, such as the selective permeability of certain ions and the ability of some cells to generate electricity. However, the pore has not been directly observed yet, and its existence is still the subject of debate among scientists.\n\nIn summary, the HPG pore is a hypothetical pore that is believed to exist in the membranes of cells and is thought to allow for the selective transport of ions and molecules across the membrane by exploiting differences in their chemical potentials.",
    "llama-7b_fact_raw": "1. The HPG pore stands for high-pressure gradient pore.\n2. The HPG pore is a hypothetical structure proposed to exist in cell membranes.\n3. The HPG pore is thought to facilitate selective transport of ions and molecules across the membrane.\n4. The existence of the HPG pore is proposed to explain selective permeability and electricity generation in some cells.\n5. The HPG pore has not been directly observed and is a subject of scientific debate.",
    "llama-7b_fact": [
      "The HPG pore stands for high-pressure gradient pore.",
      "The HPG pore is a hypothetical structure proposed to exist in cell membranes.",
      "The HPG pore is thought to facilitate selective transport of ions and molecules across the membrane.",
      "The existence of the HPG pore is proposed to explain selective permeability and electricity generation in some cells.",
      "The HPG pore has not been directly observed and is a subject of scientific debate."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The HPG pore stands for hypothetical pore gradient.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-7b_response": "The 959 Nematode Genomes initiative is a large-scale project aimed at sequencing and analyzing the genomes of 959 species of roundworms, also known as nematodes. These roundworms are a diverse group of organisms that inhabit a wide range of environments, from soil to water to inside the bodies of other animals.\n\nThe goal of the 959 Nematode Genomes initiative is to create a comprehensive database of nematode genomes that can be used to better understand the evolution, ecology, and biology of these organisms. By analyzing the genetic information contained in these genomes, researchers hope to gain insights into how nematodes adapt to different environments, how they interact with other organisms, and how they evolve over time.\n\nThe project is being carried out by a consortium of researchers from around the world, and is funded in part by the National Institutes of Health and the National Science Foundation. To date, over 500 nematode genomes have been sequenced and annotated as part of this initiative, and the remaining genomes are expected to be completed over the next few years.",
    "llama-7b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms.\n2. The initiative's goal is to create a comprehensive database of nematode genomes.\n3. The project intends to use the genetic information to understand nematode evolution, ecology, and biology.\n4. A consortium of researchers from around the world is carrying out the 959 Nematode Genomes initiative.\n5. The National Institutes of Health and the National Science Foundation are partially funding the initiative.",
    "llama-7b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms.",
      "The initiative's goal is to create a comprehensive database of nematode genomes.",
      "The project intends to use the genetic information to understand nematode evolution, ecology, and biology.",
      "A consortium of researchers from around the world is carrying out the 959 Nematode Genomes initiative.",
      "The National Institutes of Health and the National Science Foundation are partially funding the initiative."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-7b_response": "As an AI language model, I am not aware of any R package that has been specifically developed for analyzing Non-invasive prenatal testing (NIPT) data. However, there are several R packages that can be used for analyzing genetic data in general. Some of the popular R packages for genetic analysis include:\n\n1. Genome-wide association studies (GWAS) - GWASR\n2. Single nucleotide polymorphism (SNP) analysis - snpEFF\n3. Genome annotation - ANNOVAR\n4. Gene expression analysis - edgeR\n5. Population genetics - STRUCTURE\n\nIt is possible that some of these R packages could be used for analyzing NIPT data, but there is no dedicated R package for NIPT analysis specifically.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-7b_response": "Achenbach's syndrome, also known as the Achenbach triad, is a rare genetic disorder characterized by a combination of developmental delay, intellectual disability, and distinctive facial features. The syndrome is caused by mutations in the TP53 gene, which is responsible for regulating cell division and repairing DNA damage.\n\nIndividuals with Achenbach's syndrome may have mild to moderate intellectual disability and delays in physical development, such as walking and talking. They may also have distinctive facial features, such as a small head, widely spaced eyes, and a flattened nasal bridge.\n\nOther potential symptoms of Achenbach's syndrome may include hearing loss, seizures, and behavioral challenges. The severity of symptoms can vary among individuals, and some may have additional health issues related to the TP53 mutation, such as an increased risk of cancer.\n\nThere is no cure for Achenbach's syndrome, but therapies and supportive care can help manage symptoms and improve quality of life. Early intervention services, including speech and language therapy, occupational therapy, and physical therapy, can help individuals with Achenbach's syndrome reach their full potential.",
    "llama-7b_fact_raw": "1. Achenbach's syndrome is characterized by developmental delay, intellectual disability, and distinctive facial features.\n2. The syndrome is caused by mutations in the TP53 gene.\n3. Individuals with Achenbach's syndrome may have a small head, widely spaced eyes, and a flattened nasal bridge.\n4. Symptoms of Achenbach's syndrome can include hearing loss, seizures, and behavioral challenges.\n5. There is no cure for Achenbach's syndrome, but therapies and supportive care can help manage symptoms.",
    "llama-7b_fact": [
      "Achenbach's syndrome is characterized by developmental delay, intellectual disability, and distinctive facial features.",
      "The syndrome is caused by mutations in the TP53 gene.",
      "Individuals with Achenbach's syndrome may have a small head, widely spaced eyes, and a flattened nasal bridge.",
      "Symptoms of Achenbach's syndrome can include hearing loss, seizures, and behavioral challenges.",
      "There is no cure for Achenbach's syndrome, but therapies and supportive care can help manage symptoms."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not characterized by developmental delay, intellectual disability, and distinctive facial features. It is actually a condition involving spontaneous bruising of the hands or fingers.\n2. FALSE [correction]: Achenbach's syndrome is not caused by mutations in the TP53 gene. The cause of Achenbach's syndrome is not well understood, but it is not associated with genetic mutations like those in the TP53 gene.\n3. FALSE [correction]: The description of small head, widely spaced eyes, and a flattened nasal bridge does not pertain to Achenbach's syndrome. These features may describe a different condition, but not Achenbach's syndrome, which involves bruising.\n4. FALSE [correction]: Symptoms such as hearing loss, seizures, and behavioral challenges are not typically associated with Achenbach's syndrome. The primary symptom of Achenbach's syndrome is spontaneous bruising.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-7b_response": "There are several algorithms used for the detection of long repeat expansions, but one of the most commonly used is the Markov chain algorithm.\n\nThe Markov chain algorithm works by analyzing the sequence of nucleotides (A, T, C, and G) and determining the likelihood of the next nucleotide based on the previous nucleotides in the sequence. This is done by constructing a Markov chain model that defines the probability of each nucleotide given the previous nucleotides.\n\nThe algorithm starts by constructing a model that defines the probability of each nucleotide given the previous nucleotides. This is typically done using statistical methods such as maximum likelihood estimation. Once the model is constructed, the algorithm then analyzes the sequence of nucleotides and calculates the probability of each possible nucleotide given the previous nucleotides.\n\nBased on these probabilities, the algorithm can then identify regions of the sequence where the same nucleotide is repeated multiple times in a row. These regions are known as repeat expansions and can be used to identify genetic mutations that cause diseases such as Huntington's disease and myotonic dystrophy.\n\nOverall, the Markov chain algorithm is a powerful tool for the detection of long repeat expansions and has been used extensively in genetic research. However, it is important to note that other algorithms and methods may also be used depending on the specific characteristics of the sequence being analyzed.",
    "llama-7b_fact_raw": "1. The Markov chain algorithm is used for the detection of long repeat expansions.\n2. The Markov chain algorithm analyzes the sequence of nucleotides (A, T, C, and G).\n3. The algorithm determines the likelihood of the next nucleotide based on the previous nucleotides in the sequence.\n4. The Markov chain model is constructed using statistical methods such as maximum likelihood estimation.\n5. The Markov chain algorithm can identify regions where the same nucleotide is repeated multiple times, known as repeat expansions.",
    "llama-7b_fact": [
      "The Markov chain algorithm is used for the detection of long repeat expansions.",
      "The Markov chain algorithm analyzes the sequence of nucleotides (A, T, C, and G).",
      "The algorithm determines the likelihood of the next nucleotide based on the previous nucleotides in the sequence.",
      "The Markov chain model is constructed using statistical methods such as maximum likelihood estimation.",
      "The Markov chain algorithm can identify regions where the same nucleotide is repeated multiple times, known as repeat expansions."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Markov chain algorithm is not specifically used for the detection of long repeat expansions; it is a general probabilistic model used for predicting the sequence of future states (not necessarily nucleotides) based on the current state. There are specialized algorithms for detecting long repeat expansions in genetic sequences.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While Markov chain algorithms can model sequences of nucleotides, they are not specifically designed to identify repeat expansions. Specialized bioinformatics tools are used to detect such repeat regions in DNA sequences.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-7b_response": "Neuroligin-3 is a protein that plays a critical role in the development and function of the nervous system. It is expressed in various regions of the brain, including the cerebral cortex, hippocampus, and olfactory bulb.\n\nStudies have shown that neuroligin-3 is involved in the formation and function of synapses, which are the junctions where neurons communicate with each other. Neuroligin-3 interacts with other proteins, including N-methyl-D-aspartate (NMDA) receptors and neuroligins, to regulate synaptic plasticity and neurotransmitter release.\n\nIn terms of brain tumors, neuroligin-3 has been found to promote the growth and survival of certain types of tumors. For example, studies have shown that the overexpression of neuroligin-3 is associated with poor prognosis in glioblastoma multiforme, an aggressive type of brain tumor that arises from astrocytes.\n\nAdditionally, neuroligin-3 has been found to promote the growth of medulloblastoma, a malignant tumor that arises from embryonal cells in the cerebellum. This suggests that targeting neuroligin-3 may be a promising strategy for treating these types of brain tumors.\n\nHowever, it is worth noting that the role of neuroligin-3 in promoting brain tumors is complex and not fully understood. Other factors, such as genetic mutations and epigenetic changes, may also contribute to tumor growth and progression. Therefore, further research is needed to fully elucidate the role of neuroligin-3 in brain tumor development and identify potential therapeutic targets.",
    "llama-7b_fact_raw": "1. Neuroligin-3 is expressed in various regions of the brain, including the cerebral cortex, hippocampus, and olfactory bulb.\n2. Neuroligin-3 is involved in the formation and function of synapses in the nervous system.\n3. Overexpression of neuroligin-3 is associated with poor prognosis in glioblastoma multiforme.\n4. Neuroligin-3 promotes the growth of medulloblastoma, a malignant tumor in the cerebellum.\n5. Targeting neuroligin-3 may be a potential strategy for treating certain types of brain tumors.",
    "llama-7b_fact": [
      "Neuroligin-3 is expressed in various regions of the brain, including the cerebral cortex, hippocampus, and olfactory bulb.",
      "Neuroligin-3 is involved in the formation and function of synapses in the nervous system.",
      "Overexpression of neuroligin-3 is associated with poor prognosis in glioblastoma multiforme.",
      "Neuroligin-3 promotes the growth of medulloblastoma, a malignant tumor in the cerebellum.",
      "Targeting neuroligin-3 may be a potential strategy for treating certain types of brain tumors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNeuroligin-3 is indeed expressed in various regions of the brain and is involved in synapse formation and function. Overexpression of neuroligin-3 has been associated with poor prognosis in glioblastoma multiforme, and it has been shown to promote the growth of medulloblastoma. Therefore, targeting neuroligin-3 could be a potential strategy for treating certain types of brain tumors.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-7b_response": "Gas vesicles are gas-filled structures found in some bacteria and archaea. They are small, ranging in size from 0.1 to 10 micrometers in diameter. The exact size of gas vesicles can vary depending on the species of bacteria or archaea they are found in, as well as the environmental conditions in which they are found. In some cases, gas vesicles can be as small as 0.1 micrometers in diameter, while in other cases they can reach up to 10 micrometers in diameter. Overall, gas vesicles are a fascinating structure found in many different types of bacteria and archaea, and their size is just one aspect of their unique biology.",
    "llama-7b_fact_raw": "1. Gas vesicles are found in some bacteria and archaea.\n2. Gas vesicles range in size from 0.1 to 10 micrometers in diameter.\n3. The size of gas vesicles can vary depending on the species of bacteria or archaea.\n4. Environmental conditions can affect the size of gas vesicles.\n5. Gas vesicles can be as small as 0.1 micrometers in diameter.",
    "llama-7b_fact": [
      "Gas vesicles are found in some bacteria and archaea.",
      "Gas vesicles range in size from 0.1 to 10 micrometers in diameter.",
      "The size of gas vesicles can vary depending on the species of bacteria or archaea.",
      "Environmental conditions can affect the size of gas vesicles.",
      "Gas vesicles can be as small as 0.1 micrometers in diameter."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Gas vesicles typically range in size from about 45 to 200 nanometers in diameter, not 0.1 to 10 micrometers.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Gas vesicles are typically not as small as 0.1 micrometers (100 nanometers) in diameter; they usually start at about 45 nanometers in diameter.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-7b_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of epigenetic regulators that contain bromodomains and extra-terminal (BET) domains. These proteins are involved in the recognition of acetylated lysine residues on histone tails and non-histone proteins, leading to changes in chromatin structure and transcriptional regulation. Here are some of the BET proteins:\n\n1. BRD2 (Bromodomain and Extra-Terminal domain 2)\n2. BRD3 (Bromodomain and Extra-Terminal domain 3)\n3. BRD4 (Bromodomain and Extra-Terminal domain 4)\n4. BRDT (Bromodomain and Extra-Terminal domain-like protein)\n5. BETL (Bromodomain and Extra-Terminal domain-like protein)\n6. BET2 (Bromodomain and Extra-Terminal domain-like protein 2)\n7. BET3 (Bromodomain and Extra-Terminal domain-like protein 3)\n8. BET4 (Bromodomain and Extra-Terminal domain-like protein 4)\n9. BET5 (Bromodomain and Extra-Terminal domain-like protein 5)\n10. BET6 (Bromodomain and Extra-Terminal domain-like protein 6)\n11. BET7 (Bromodomain and Extra-Terminal domain-like protein 7)\n12. BET8 (Bromodomain and Extra-Terminal domain-like protein 8)\n13. BET9 (Bromodomain and Extra-Terminal domain-like protein 9)\n14. BET10 (Bromodomain and Extra-Terminal domain-like protein 10)\n15. BET11 (Bromodomain and Extra-Terminal domain-like protein 11)\n16. BET12 (Bromodomain and Extra-Terminal domain-like protein 12)\n17. BET13 (Bromod",
    "llama-7b_fact_raw": "1. BET proteins are a family of epigenetic regulators that contain bromodomains and extra-terminal (BET) domains.\n2. BET proteins are involved in the recognition of acetylated lysine residues on histone tails and non-histone proteins.\n3. BRD2 is a member of the BET protein family.\n4. BRD3 is a member of the BET protein family.\n5. BRD4 is a member of the BET protein family.",
    "llama-7b_fact": [
      "BET proteins are a family of epigenetic regulators that contain bromodomains and extra-terminal (BET) domains.",
      "BET proteins are involved in the recognition of acetylated lysine residues on histone tails and non-histone proteins.",
      "BRD2 is a member of the BET protein family.",
      "BRD3 is a member of the BET protein family.",
      "BRD4 is a member of the BET protein family."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-7b_response": "One algorithm that has been developed for the prediction of protein subcellular localization using deep learning is the DeepLoc algorithm. This algorithm was developed by Li et al. in 2018 and uses a convolutional neural network (CNN) to predict the subcellular localization of a protein based on its amino acid sequence. The DeepLoc algorithm has been shown to outperform other machine learning algorithms for predicting protein subcellular localization. The algorithm is trained on a large dataset of known protein subcellular localizations and can accurately predict the subcellular localization of a protein even if it has never been annotated before. Overall, the DeepLoc algorithm is a promising approach for predicting protein subcellular localization using deep learning.",
    "llama-7b_fact_raw": "1. The DeepLoc algorithm is used for predicting protein subcellular localization using deep learning.\n2. The DeepLoc algorithm was developed by Li et al. in 2018.\n3. The DeepLoc algorithm utilizes a convolutional neural network (CNN) for prediction.\n4. The DeepLoc algorithm has been shown to outperform other machine learning algorithms in predicting protein subcellular localization.\n5. The DeepLoc algorithm is trained on a dataset of known protein subcellular localizations.",
    "llama-7b_fact": [
      "The DeepLoc algorithm is used for predicting protein subcellular localization using deep learning.",
      "The DeepLoc algorithm was developed by Li et al. in 2018.",
      "The DeepLoc algorithm utilizes a convolutional neural network (CNN) for prediction.",
      "The DeepLoc algorithm has been shown to outperform other machine learning algorithms in predicting protein subcellular localization.",
      "The DeepLoc algorithm is trained on a dataset of known protein subcellular localizations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The DeepLoc algorithm was developed by Almagro Armenteros et al. in 2017.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-7b_response": "MULTOVL is an acronym that stands for Multi-level Underground Laboratory for Testing and Research. It is a proposed underground research facility that would be located in a deep, stable geological formation, such as a granite mine, in order to provide a secure and stable environment for scientific research. The facility would be designed to accommodate a wide range of scientific experiments, including those related to particle physics, astrophysics, and cosmology. The goal of MULTOVL would be to advance our understanding of the fundamental laws of nature and to explore the potential for new technologies and applications that could benefit society. The construction and operation of MULTOVL would require significant financial and technical resources, as well as collaboration between scientists, engineers, and policymakers from around the world.",
    "llama-7b_fact_raw": "1. MULTOVL stands for Multi-level Underground Laboratory for Testing and Research.\n2. MULTOVL is a proposed underground research facility.\n3. The facility is intended to be located in a deep, stable geological formation, such as a granite mine.\n4. MULTOVL would be designed to accommodate experiments related to particle physics, astrophysics, and cosmology.\n5. The goal of MULTOVL is to advance understanding of the fundamental laws of nature and explore new technologies and applications.",
    "llama-7b_fact": [
      "MULTOVL stands for Multi-level Underground Laboratory for Testing and Research.",
      "MULTOVL is a proposed underground research facility.",
      "The facility is intended to be located in a deep, stable geological formation, such as a granite mine.",
      "MULTOVL would be designed to accommodate experiments related to particle physics, astrophysics, and cosmology.",
      "The goal of MULTOVL is to advance understanding of the fundamental laws of nature and explore new technologies and applications."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MULTOVL stands for Multi-level Underground Laboratory for Testing, Observation, and Validation of Laws.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-7b_response": "GDF15 (growth differentiation factor 15) is a protein that is involved in the regulation of cell growth, differentiation, and apoptosis. Metformin is a medication that is commonly used to treat type 2 diabetes, and it has been shown to have anti-inflammatory and anti-cancer properties.\n\nStudies have suggested that GDF15 may be a biomarker for the effectiveness of metformin treatment. Specifically, research has shown that metformin is able to decrease levels of GDF15 in the blood, which may indicate that the medication is working to improve insulin sensitivity and reduce inflammation in the body.\n\nHowever, it is important to note that GDF15 is just one potential biomarker for the effectiveness of metformin treatment, and other factors such as fasting glucose levels and hemoglobin A1c levels may also be important to consider. Additionally, further research is needed to fully understand the role of GDF15 in metformin treatment and its potential as a biomarker for medication effectiveness.",
    "llama-7b_fact_raw": "1. GDF15 is involved in the regulation of cell growth, differentiation, and apoptosis.\n2. Metformin is commonly used to treat type 2 diabetes.\n3. Metformin has been shown to have anti-inflammatory and anti-cancer properties.\n4. Studies suggest that GDF15 may be a biomarker for the effectiveness of metformin treatment.\n5. Metformin treatment has been shown to decrease levels of GDF15 in the blood.",
    "llama-7b_fact": [
      "GDF15 is involved in the regulation of cell growth, differentiation, and apoptosis.",
      "Metformin is commonly used to treat type 2 diabetes.",
      "Metformin has been shown to have anti-inflammatory and anti-cancer properties.",
      "Studies suggest that GDF15 may be a biomarker for the effectiveness of metformin treatment.",
      "Metformin treatment has been shown to decrease levels of GDF15 in the blood."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Metformin treatment has been shown to increase levels of GDF15 in the blood. GDF15 is thought to mediate some of the beneficial effects of metformin, including its effects on weight loss and glucose homeostasis.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-7b_response": "As an AI language model, I do not have personal beliefs or opinions. However, I can provide some information on the topic.\n\nRecursive splicing is a process in which a spliceosomal intron is spliced back into the mRNA, resulting in a circular RNA molecule. Recursive splicing has been observed in various organisms, including humans, and is thought to play a role in RNA interference (RNAi) and gene regulation.\n\nIn terms of the relationship between recursive splicing and short introns, there is some evidence to suggest that recursive splicing is more common in short introns. This is because short introns are more likely to undergo alternative splicing, which can lead to the formation of circular RNA molecules. Additionally, studies have shown that circular RNAs that result from recursive splicing tend to be shorter than other circular RNAs.\n\nHowever, it is worth noting that the relationship between recursive splicing and short introns is complex and not fully understood. Other factors, such as the structure of the intron and the nature of the spliceosome, may also play a role in determining whether recursive splicing occurs. Therefore, further research is needed to fully elucidate the relationship between recursive splicing and short introns.",
    "llama-7b_fact_raw": "1. Recursive splicing results in the formation of a circular RNA molecule.\n2. Recursive splicing has been observed in various organisms, including humans.\n3. Recursive splicing is thought to play a role in RNA interference (RNAi) and gene regulation.\n4. There is evidence to suggest that recursive splicing is more common in short introns.\n5. Circular RNAs that result from recursive splicing tend to be shorter than other circular RNAs.",
    "llama-7b_fact": [
      "Recursive splicing results in the formation of a circular RNA molecule.",
      "Recursive splicing has been observed in various organisms, including humans.",
      "Recursive splicing is thought to play a role in RNA interference (RNAi) and gene regulation.",
      "There is evidence to suggest that recursive splicing is more common in short introns.",
      "Circular RNAs that result from recursive splicing tend to be shorter than other circular RNAs."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Recursive splicing is not directly involved in RNA interference (RNAi); it is involved in the processing of long introns and can influence gene expression, but RNAi is a separate mechanism.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-7b_response": "The TALE-iD method, also known as Transcription Activator-Like Effector-based ID, is a genome editing technique used to identify and manipulate specific genes in organisms such as plants, animals, and bacteria. The method involves the use of transcription activator-like effector (TALE) proteins, which are engineered to recognize and bind to specific DNA sequences.\n\nOnce the TALE protein binds to the target DNA sequence, it recruits the CRISPR-Cas9 system to make a double-stranded cut at a specific location in the genome. This allows for the insertion, deletion, or replacement of genetic material at the targeted location.\n\nThe TALE-iD method offers several advantages over other genome editing techniques, including its high specificity, efficiency, and versatility. It can be used to create targeted mutations, insertions, or deletions in the genome, as well as to activate or repress specific genes.\n\nOverall, the TALE-iD method is a powerful tool for genetic research and biotechnology applications, allowing scientists to manipulate genes with high precision and accuracy.",
    "llama-7b_fact_raw": "1. The TALE-iD method is a genome editing technique.\n2. It is used to identify and manipulate specific genes in organisms such as plants, animals, and bacteria.\n3. The method uses transcription activator-like effector (TALE) proteins that bind to specific DNA sequences.\n4. The TALE-iD method recruits the CRISPR-Cas9 system to make a double-stranded cut in the genome.\n5. The technique allows for the insertion, deletion, or replacement of genetic material at targeted locations in the genome.",
    "llama-7b_fact": [
      "The TALE-iD method is a genome editing technique.",
      "It is used to identify and manipulate specific genes in organisms such as plants, animals, and bacteria.",
      "The method uses transcription activator-like effector (TALE) proteins that bind to specific DNA sequences.",
      "The TALE-iD method recruits the CRISPR-Cas9 system to make a double-stranded cut in the genome.",
      "The technique allows for the insertion, deletion, or replacement of genetic material at targeted locations in the genome."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The TALE-iD method does not recruit the CRISPR-Cas9 system. TALE-iD uses transcription activator-like effector nucleases (TALENs), which are different from CRISPR-Cas9. TALENs are fusion proteins that can be designed to cut specific DNA sequences but they do not involve the CRISPR-Cas9 system.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-7b_response": "There are several Lisp frameworks that have been developed for image processing, but one of the most popular ones is the Open Image Processing Library (OIPL). OIPL is a free and open-source Lisp library that provides a set of tools for image processing, analysis, and manipulation. It supports a wide range of image formats, including JPEG, PNG, TIFF, and GIF, and offers a variety of algorithms for tasks such as image filtering, segmentation, and morphology. OIPL is written in Lisp and is designed to be easy to use and integrate with other programming languages and frameworks. It has been widely used in research and industry for a variety of image processing applications.",
    "llama-7b_fact_raw": "1. The Open Image Processing Library (OIPL) is a Lisp framework developed for image processing.\n2. OIPL is free and open-source.\n3. The library supports image formats such as JPEG, PNG, TIFF, and GIF.\n4. OIPL provides algorithms for image filtering, segmentation, and morphology.\n5. OIPL is designed to be easy to integrate with other programming languages and frameworks.",
    "llama-7b_fact": [
      "The Open Image Processing Library (OIPL) is a Lisp framework developed for image processing.",
      "OIPL is free and open-source.",
      "The library supports image formats such as JPEG, PNG, TIFF, and GIF.",
      "OIPL provides algorithms for image filtering, segmentation, and morphology.",
      "OIPL is designed to be easy to integrate with other programming languages and frameworks."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: There is no widely recognized library called the Open Image Processing Library (OIPL) associated with Lisp. However, there is an Open Source Computer Vision Library (OpenCV) which is a well-known library for image processing, but it is not specifically a Lisp framework.\n2. UNKNOWN: Since the existence of OIPL is not established, the statement about it being free and open-source cannot be confirmed.\n3. UNKNOWN: Without confirmation of OIPL's existence, the supported image formats cannot be determined.\n4. UNKNOWN: The capabilities of OIPL, such as providing algorithms for image filtering, segmentation, and morphology, cannot be confirmed.\n5. UNKNOWN: The ease of integration of OIPL with other programming languages and frameworks cannot be determined.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-7b_response": "As an AI language model, I do not have access to the most up-to-date information on the exact number of genes in S. cerevisiae that are the result of an ancient whole genome duplication. However, it is widely accepted that the budding yeast Saccharomyces cerevisiae underwent a whole genome duplication (WGD) event early in its evolutionary history, likely around 100 million years ago. This WGD event resulted in the duplication of the entire genome, which then diverged to produce two identical copies of each gene. \n\nIt is estimated that approximately 75% of the S. cerevisiae genome is derived from this ancient WGD event, with the remaining 25% being the result of subsequent gene duplications and losses. Therefore, it can be inferred that the majority of the genes in S. cerevisiae are the result of this ancient WGD event. However, it is important to note that the exact number of genes that are the result of this event is subject to ongoing research and debate among geneticists and evolutionary biologists.",
    "llama-7b_fact_raw": "1. Saccharomyces cerevisiae underwent a whole genome duplication event early in its evolutionary history.\n2. The whole genome duplication event in Saccharomyces cerevisiae likely occurred around 100 million years ago.\n3. The whole genome duplication event resulted in the duplication of the entire genome of Saccharomyces cerevisiae.\n4. Approximately 75% of the Saccharomyces cerevisiae genome is derived from an ancient whole genome duplication event.\n5. The remaining 25% of the Saccharomyces cerevisiae genome is the result of subsequent gene duplications and losses.",
    "llama-7b_fact": [
      "Saccharomyces cerevisiae underwent a whole genome duplication event early in its evolutionary history.",
      "The whole genome duplication event in Saccharomyces cerevisiae likely occurred around 100 million years ago.",
      "The whole genome duplication event resulted in the duplication of the entire genome of Saccharomyces cerevisiae.",
      "Approximately 75% of the Saccharomyces cerevisiae genome is derived from an ancient whole genome duplication event.",
      "The remaining 25% of the Saccharomyces cerevisiae genome is the result of subsequent gene duplications and losses."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The whole genome duplication event in Saccharomyces cerevisiae likely occurred around 100 to 150 million years ago, but the exact timing is still debated among scientists.\n3. TRUE\n4. FALSE [correction]: Approximately 90% of the Saccharomyces cerevisiae genome is derived from an ancient whole genome duplication event.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-7b_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that belongs to the family of nuclear hormone receptors. It is activated by estrogen and other related ligands and plays a crucial role in various physiological processes such as cell growth, differentiation, and apoptosis.\n\nEsrrb is known to be involved in the development and progression of various diseases, including breast cancer. It has been reported that Esrrb can bind to DNA and regulate the expression of target genes involved in cell proliferation, migration, and invasion.\n\nStudies have shown that Esrrb can also be bound by various complexes, including the estrogen receptor complex, the androgen receptor complex, and the progesterone receptor complex. However, the exact nature of the complex bound by Esrrb is still not fully understood.\n\nIn summary, Estrogen-related receptor β (Esrrb) can be bound by various complexes, including the estrogen receptor complex, the androgen receptor complex, and the progesterone receptor complex. However, the exact nature of the complex bound by Esrrb is still not fully understood.",
    "llama-7b_fact_raw": "1. Estrogen-related receptor β (Esrrb) is a nuclear receptor that is part of the nuclear hormone receptors family.\n2. Esrrb is activated by estrogen and other related ligands.\n3. Esrrb plays a role in cell growth, differentiation, and apoptosis.\n4. Esrrb is involved in the development and progression of various diseases, including breast cancer.\n5. Esrrb can bind to DNA and regulate the expression of target genes involved in cell proliferation, migration, and invasion.",
    "llama-7b_fact": [
      "Estrogen-related receptor β (Esrrb) is a nuclear receptor that is part of the nuclear hormone receptors family.",
      "Esrrb is activated by estrogen and other related ligands.",
      "Esrrb plays a role in cell growth, differentiation, and apoptosis.",
      "Esrrb is involved in the development and progression of various diseases, including breast cancer.",
      "Esrrb can bind to DNA and regulate the expression of target genes involved in cell proliferation, migration, and invasion."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Estrogen-related receptor β (Esrrb) is not activated by estrogen; it is an orphan receptor, meaning its endogenous ligand has not been identified.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-7b_response": "ZCCHC17, also known as Zinc finger CCCH-type 17, is a protein that belongs to the CCCH family of zinc finger transcription factors. These proteins are involved in various cellular processes, including transcriptional regulation, DNA repair, and cell cycle progression.\n\nThe exact function of ZCCHC17 is not fully understood, but it is thought to play a role in the regulation of gene expression. Studies have shown that ZCCHC17 is upregulated in several types of cancer, including breast, colon, and lung cancer. It has been suggested that ZCCHC17 may contribute to tumor growth and progression by promoting cell proliferation and inhibiting apoptosis.\n\nIn addition to its role in cancer, ZCCHC17 has also been implicated in other biological processes, such as immune response and development. Further research is needed to fully elucidate the function of this protein and its role in various biological systems.",
    "llama-7b_fact_raw": "1. ZCCHC17 is known as Zinc finger CCCH-type 17.\n2. ZCCHC17 is a protein that belongs to the CCCH family of zinc finger transcription factors.\n3. ZCCHC17 is involved in various cellular processes, including transcriptional regulation, DNA repair, and cell cycle progression.\n4. ZCCHC17 is upregulated in several types of cancer, such as breast, colon, and lung cancer.\n5. ZCCHC17 may contribute to tumor growth and progression by promoting cell proliferation and inhibiting apoptosis.",
    "llama-7b_fact": [
      "ZCCHC17 is known as Zinc finger CCCH-type 17.",
      "ZCCHC17 is a protein that belongs to the CCCH family of zinc finger transcription factors.",
      "ZCCHC17 is involved in various cellular processes, including transcriptional regulation, DNA repair, and cell cycle progression.",
      "ZCCHC17 is upregulated in several types of cancer, such as breast, colon, and lung cancer.",
      "ZCCHC17 may contribute to tumor growth and progression by promoting cell proliferation and inhibiting apoptosis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements are factual and can be verified based on the standard nomenclature for genes and proteins. ZCCHC17 is indeed known as Zinc finger CCCH-type containing 17, and it is a protein that belongs to the CCCH family of zinc finger proteins. However, without specific scientific references or context, it is difficult to confirm the roles of ZCCHC17 in cellular processes, its expression levels in various types of cancer, and its potential contribution to tumor growth and progression. These are areas of active research and can vary based on the study and context.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-7b_response": "The proteins that form the nuclear pore basket in human cells are known as the nucleoporins (Nups). There are 19 different nucleoporins that have been identified in mammals, and they are classified into three main groups: nucleoporin-100 (Nup100), nucleoporin-153 (Nup153), and nucleoporin-180 (Nup180). \n\nNup100 is the most abundant nucleoporin in the nuclear pore basket and is involved in the formation and maintenance of the nuclear pore complex. Nup153 is also involved in the formation and maintenance of the nuclear pore complex and is important for proper nuclear envelope assembly. Nup180 is involved in the transport of molecules through the nuclear pore complex and plays a role in the regulation of gene expression.\n\nIn addition to these three main groups of nucleoporins, there are also other proteins that associate with the nuclear pore complex, such as the lamin proteins, which help to form the structural framework of the nuclear envelope.\n\nOverall, the nuclear pore basket is a complex structure composed of multiple proteins that work together to regulate the transport of molecules between the nucleus and the cytoplasm.",
    "llama-7b_fact_raw": "1. Nucleoporins (Nups) are the proteins that form the nuclear pore basket in human cells.\n2. There are 19 different nucleoporins identified in mammals.\n3. Nucleoporins are classified into three main groups: Nup100, Nup153, and Nup180.\n4. Nup100 is the most abundant nucleoporin in the nuclear pore basket and is involved in the formation and maintenance of the nuclear pore complex.\n5. Lamin proteins associate with the nuclear pore complex and help to form the structural framework of the nuclear envelope.",
    "llama-7b_fact": [
      "Nucleoporins (Nups) are the proteins that form the nuclear pore basket in human cells.",
      "There are 19 different nucleoporins identified in mammals.",
      "Nucleoporins are classified into three main groups: Nup100, Nup153, and Nup180.",
      "Nup100 is the most abundant nucleoporin in the nuclear pore basket and is involved in the formation and maintenance of the nuclear pore complex.",
      "Lamin proteins associate with the nuclear pore complex and help to form the structural framework of the nuclear envelope."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Nucleoporins (Nups) are the proteins that make up the nuclear pore complex, not just the nuclear pore basket. The nuclear pore basket is a structure that extends into the nucleoplasm and is composed of nucleoporins, but nucleoporins are also present in other parts of the nuclear pore complex.\n2. FALSE [correction]: There are around 30 different nucleoporins identified in mammals, not just 19.\n3. FALSE [correction]: Nucleoporins are not classified into groups based on Nup100, Nup153, and Nup180. They are classified based on their location within the nuclear pore complex and other characteristics, such as whether they are part of the structural scaffold, the central channel, or the nuclear basket.\n4. FALSE [correction]: Nup100 is not the most abundant nucleoporin, and the statement incorrectly implies that Nup100 is a specific nucleoporin. In fact, the most abundant nucleoporins are often those that form the structural scaffold of the nuclear pore complex, such as Nup107-160 complex members.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-7b_response": "Gepotidacin is a type of topoisomerase inhibitor that belongs to the class of antitumor agents known as epipodophyllotoxins. It specifically inhibits the activity of topoisomerase II, an enzyme that is essential for the proper functioning of the DNA replication and repair machinery in cells. By binding to the drug-binding site on the topoisomerase II enzyme, gepotidacin prevents the enzyme from catalyzing the breakage and rejoining of DNA strands, thereby interfering with the ability of cells to replicate and repair their DNA. This leads to the accumulation of DNA damage, which ultimately causes cell death. Gepotidacin has shown activity against a range of cancer types, including breast, lung, and colon cancer, and is currently being investigated as a potential anticancer agent in clinical trials.",
    "llama-7b_fact_raw": "1. Gepotidacin is a topoisomerase inhibitor.\n2. It belongs to the class of antitumor agents known as epipodophyllotoxins.\n3. Gepotidacin specifically inhibits the activity of topoisomerase II.\n4. Topoisomerase II is an enzyme essential for DNA replication and repair.\n5. Gepotidacin is being investigated as a potential anticancer agent in clinical trials.",
    "llama-7b_fact": [
      "Gepotidacin is a topoisomerase inhibitor.",
      "It belongs to the class of antitumor agents known as epipodophyllotoxins.",
      "Gepotidacin specifically inhibits the activity of topoisomerase II.",
      "Topoisomerase II is an enzyme essential for DNA replication and repair.",
      "Gepotidacin is being investigated as a potential anticancer agent in clinical trials."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Gepotidacin does not belong to the class of antitumor agents known as epipodophyllotoxins; it is a novel antibacterial agent.\n3. FALSE [correction]: Gepotidacin specifically targets bacterial type II topoisomerases, including DNA gyrase and topoisomerase IV, not human topoisomerase II.\n4. TRUE\n5. FALSE [correction]: Gepotidacin is being investigated as a potential treatment for bacterial infections, not as an anticancer agent.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-7b_response": "Canvas SPW is a cloud-based learning management system (LMS) that allows educators to create, deliver, and manage online courses and assessments. It is designed to be user-friendly and intuitive, making it easy for educators to create engaging and effective online learning experiences for their students.\n\nOne of the key features of Canvas SPW is its robust set of tools for creating and delivering online courses. These tools include a drag-and-drop course builder, which allows educators to easily design and structure their courses, as well as tools for creating and delivering assessments, such as quizzes, tests, and surveys.\n\nAnother key feature of Canvas SPW is its collaboration tools, which allow students and educators to work together more effectively. These tools include discussion forums, group collaboration tools, and messaging features, which allow students to communicate with each other and with their instructors in real-time.\n\nFinally, Canvas SPW is highly customizable, allowing educators to tailor their courses to meet the unique needs of their students. This includes the ability to create custom themes, layouts, and branding for their courses, as well as the ability to integrate third-party applications and tools into their courses.\n\nOverall, Canvas SPW is a powerful and flexible LMS that provides educators with everything they need to create, deliver, and manage online courses and assessments.",
    "llama-7b_fact_raw": "1. Canvas SPW is a cloud-based learning management system (LMS).\n2. Canvas SPW includes a drag-and-drop course builder for designing and structuring online courses.\n3. Canvas SPW offers tools for creating and delivering assessments such as quizzes, tests, and surveys.\n4. Canvas SPW features collaboration tools like discussion forums, group collaboration tools, and messaging features.\n5. Canvas SPW allows for customization, including the creation of custom themes, layouts, and the integration of third-party applications.",
    "llama-7b_fact": [
      "Canvas SPW is a cloud-based learning management system (LMS).",
      "Canvas SPW includes a drag-and-drop course builder for designing and structuring online courses.",
      "Canvas SPW offers tools for creating and delivering assessments such as quizzes, tests, and surveys.",
      "Canvas SPW features collaboration tools like discussion forums, group collaboration tools, and messaging features.",
      "Canvas SPW allows for customization, including the creation of custom themes, layouts, and the integration of third-party applications."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The statement is vague because \"Canvas SPW\" is not a recognized name for a learning management system. The popular LMS is known simply as \"Canvas\" by Instructure. If \"Canvas SPW\" is meant to refer to \"Canvas\" by Instructure, then the statement would be true, as Canvas is indeed a cloud-based LMS. However, without clarification, the accuracy of this statement cannot be determined.\n\n2. TRUE: Assuming \"Canvas SPW\" refers to the Canvas LMS by Instructure, Canvas does include a drag-and-drop course builder for designing and structuring online courses.\n\n3. TRUE: Again, assuming \"Canvas SPW\" refers to the Canvas LMS, it does offer tools for creating and delivering assessments such as quizzes, tests, and surveys.\n\n4. TRUE: Canvas LMS features collaboration tools like discussion forums, group collaboration tools, and messaging features.\n\n5. TRUE: Canvas allows for customization, including the creation of custom themes, layouts, and the integration of third-party applications.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-7b_response": "Sting agonists are molecules that bind to and activate the sting receptor, which is a component of the innate immune system. Here are some examples of sting agonists:\n\n1. Peptidoglycan: This is a component of the cell wall of bacteria, and it can activate the sting receptor on human cells.\n\n2. Lipopolysaccharide (LPS): LPS is a component of the cell wall of gram-negative bacteria, and it can also activate the sting receptor on human cells.\n\n3. Zymosan: Zymosan is a fungal cell wall component that can activate the sting receptor on human cells.\n\n4. Capsaicin: Capsaicin is the active ingredient in chili peppers that makes them spicy. It can activate the sting receptor on human cells.\n\n5. Formyl peptides: Formyl peptides are short chains of amino acids that are released by bacteria. They can activate the sting receptor on human cells.\n\n6. Phosphorylcholine: Phosphorylcholine is a molecule that is found on the surface of many cells, including human cells. It can activate the sting receptor on human cells.\n\n7. Poly(I:C): Poly(I:C) is a synthetic analog of RNA that can activate the sting receptor on human cells.\n\nThese are just a few examples of sting agonists. There are likely many more that have not been discovered yet.",
    "llama-7b_fact_raw": "1. Peptidoglycan can activate the STING receptor on human cells.\n2. Lipopolysaccharide (LPS) can activate the STING receptor on human cells.\n3. Zymosan can activate the STING receptor on human cells.\n4. Capsaicin can activate the STING receptor on human cells.\n5. Formyl peptides can activate the STING receptor on human cells.",
    "llama-7b_fact": [
      "Peptidoglycan can activate the STING receptor on human cells.",
      "Lipopolysaccharide (LPS) can activate the STING receptor on human cells.",
      "Zymosan can activate the STING receptor on human cells.",
      "Capsaicin can activate the STING receptor on human cells.",
      "Formyl peptides can activate the STING receptor on human cells."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Peptidoglycan does not activate the STING receptor; it is recognized by other pattern recognition receptors like NOD-like receptors in human cells.\n2. FALSE [correction]: Lipopolysaccharide (LPS) does not activate the STING receptor; it is recognized by Toll-like receptor 4 (TLR4) in human cells.\n3. UNKNOWN: Zymosan is known to be recognized by dectin-1 and TLR2 receptors, but there is limited information on its interaction with the STING receptor.\n4. FALSE [correction]: Capsaicin does not activate the STING receptor; it activates TRPV1 (transient receptor potential vanilloid 1) receptors in human cells.\n5. UNKNOWN: Formyl peptides are recognized by formyl peptide receptors on human cells, but there is limited information on their interaction with the STING receptor.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-7b_response": "SLIC-CAGE is a tool developed by the National Institute of Standards and Technology (NIST) for analyzing and evaluating the security of cryptographic algorithms and protocols. SLIC stands for Security Labeling Infrastructure for Cryptographic Algorithms and Protocols, while CAGE is the Cryptographic Algorithm Validation Program.\n\nSLIC-CAGE is a comprehensive framework that provides a systematic approach to evaluating the security of cryptographic algorithms and protocols. It consists of several components, including a security labeling infrastructure, a validation program, and a certification authority.\n\nThe security labeling infrastructure is used to assign security labels to cryptographic algorithms and protocols. These labels indicate the level of security assurance provided by the algorithm or protocol, ranging from low to high.\n\nThe validation program uses formal methods and other rigorous techniques to evaluate the security of cryptographic algorithms and protocols. This process involves analyzing the algorithm or protocol to identify potential vulnerabilities and weaknesses, and then verifying that these vulnerabilities and weaknesses cannot be exploited to compromise the security of the system.\n\nThe certification authority is responsible for issuing certificates that attest to the security of cryptographic algorithms and protocols that have been evaluated and validated by the SLIC-CAGE framework. These certificates provide assurance to users that the cryptographic algorithms and protocols they are using are secure and reliable.\n\nOverall, SLIC-CAGE is an important tool for ensuring the security and reliability of cryptographic algorithms and protocols. By providing a systematic and rigorous approach to evaluating and validating the security of these technologies, SLIC-CAGE helps to minimize the risk of security vulnerabilities and weaknesses that could compromise the confidentiality and integrity of sensitive information.",
    "llama-7b_fact_raw": "1. SLIC-CAGE is a tool developed by the National Institute of Standards and Technology (NIST) for analyzing and evaluating the security of cryptographic algorithms and protocols.\n2. SLIC stands for Security Labeling Infrastructure for Cryptographic Algorithms and Protocols.\n3. CAGE is the Cryptographic Algorithm Validation Program.\n4. The security labeling infrastructure within SLIC-CAGE is used to assign security labels to cryptographic algorithms and protocols, indicating their level of security assurance.\n5. The certification authority within SLIC-CAGE issues certificates that attest to the security of cryptographic algorithms and protocols that have been evaluated and validated by the framework.",
    "llama-7b_fact": [
      "SLIC-CAGE is a tool developed by the National Institute of Standards and Technology (NIST) for analyzing and evaluating the security of cryptographic algorithms and protocols.",
      "SLIC stands for Security Labeling Infrastructure for Cryptographic Algorithms and Protocols.",
      "CAGE is the Cryptographic Algorithm Validation Program.",
      "The security labeling infrastructure within SLIC-CAGE is used to assign security labels to cryptographic algorithms and protocols, indicating their level of security assurance.",
      "The certification authority within SLIC-CAGE issues certificates that attest to the security of cryptographic algorithms and protocols that have been evaluated and validated by the framework."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: SLIC-CAGE is not a known tool developed by the National Institute of Standards and Technology (NIST) for analyzing and evaluating the security of cryptographic algorithms and protocols. NIST does have a Cryptographic Algorithm Validation Program (CAVP), but SLIC-CAGE does not appear to be a recognized term or acronym associated with NIST.\n2. FALSE [correction]: Since SLIC-CAGE is not a recognized tool or framework by NIST, the acronym SLIC does not stand for \"Security Labeling Infrastructure for Cryptographic Algorithms and Protocols.\"\n3. TRUE: CAVP does stand for Cryptographic Algorithm Validation Program, which is a program by NIST.\n4. UNKNOWN: Without accurate information on SLIC-CAGE, it is not possible to determine the truth of the statement regarding the security labeling infrastructure within it.\n5. UNKNOWN: Similarly, without accurate information on SLIC-CAGE, it is not possible to determine the truth of the statement regarding a certification authority within it. However, NIST does issue certificates for cryptographic modules validated under the Cryptographic Module Validation Program (CMVP), which is related to CAVP.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-7b_response": "LEM-3, also known as leucine-rich repeat-containing protein 3, is a multifunctional protein that plays various roles in the body. LEM-3 is primarily expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of synapses to change their strength of communication with other neurons.\n\nOne of the main roles of LEM-3 is to regulate the activity of NMDA receptors, which are glutamate receptors involved in synaptic plasticity and memory formation. LEM-3 binds to the NMDA receptors and regulates their activity by controlling the levels of a protein called NR2B, which is one of the subunits of the NMDA receptor. By doing so, LEM-3 helps to fine-tune the strength of communication between neurons and maintain proper synaptic plasticity.\n\nIn addition to its role in synaptic plasticity, LEM-3 has also been implicated in other physiological processes, such as neuroinflammation, neurogenesis, and neurodegeneration. For example, LEM-3 has been shown to play a protective role in models of Alzheimer's disease by reducing inflammation and promoting the survival of neurons.\n\nOverall, LEM-3 is a multifunctional protein with important roles in the regulation of synaptic plasticity and other physiological processes in the brain. Further research is needed to fully understand the functions of LEM-3 and its potential as a therapeutic target for neurological disorders.",
    "llama-7b_fact_raw": "1. LEM-3 is primarily expressed in the brain.\n2. LEM-3 is involved in the regulation of synaptic plasticity.\n3. LEM-3 regulates the activity of NMDA receptors by controlling the levels of NR2B, a subunit of the NMDA receptor.\n4. LEM-3 plays a role in neuroinflammation, neurogenesis, and neurodegeneration.\n5. LEM-3 has been shown to play a protective role in models of Alzheimer's disease.",
    "llama-7b_fact": [
      "LEM-3 is primarily expressed in the brain.",
      "LEM-3 is involved in the regulation of synaptic plasticity.",
      "LEM-3 regulates the activity of NMDA receptors by controlling the levels of NR2B, a subunit of the NMDA receptor.",
      "LEM-3 plays a role in neuroinflammation, neurogenesis, and neurodegeneration.",
      "LEM-3 has been shown to play a protective role in models of Alzheimer's disease."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific and pertain to scientific knowledge about LEM-3, a protein or gene that may be involved in various neurological processes. Without access to the specific scientific literature or studies that discuss LEM-3, it is not possible to accurately verify these statements. Therefore, the truthfulness of these statements remains unknown based on the information provided.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-7b_response": "I apologize, but as an AI language model, I do not have access to real-time data or specific information about the releases of tmVar. However, I can tell you that tmVar is a variable that is commonly used in statistical analysis and time series modeling. It represents the time variable and is often used in conjunction with other variables to analyze trends and patterns in time-based data. The specific releases or updates of tmVar may vary depending on the software or statistical package being used.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-7b_response": "The database of somatic mutations in normal cells is called the Single Nucleotide Polymorphism Database (dbSNP). It is a publicly available database maintained by the National Center for Biotechnology Information (NCBI) that contains information on single nucleotide polymorphisms (SNPs), which are the most common type of genetic variation among humans. dbSNP provides information on SNPs in both coding and non-coding regions of the genome, and includes information on the frequency of each SNP in different populations, as well as information on the functional effects of the SNPs. The database is an important resource for researchers studying the genetics of normal cells and for identifying somatic mutations in cancer cells.",
    "llama-7b_fact_raw": "1. The Single Nucleotide Polymorphism Database (dbSNP) is a database of somatic mutations in normal cells.\n2. The dbSNP is maintained by the National Center for Biotechnology Information (NCBI).\n3. The dbSNP contains information on single nucleotide polymorphisms (SNPs), which are a common type of genetic variation among humans.\n4. The dbSNP includes information on the frequency of each SNP in different populations.\n5. The dbSNP provides information on the functional effects of the SNPs.",
    "llama-7b_fact": [
      "The Single Nucleotide Polymorphism Database (dbSNP) is a database of somatic mutations in normal cells.",
      "The dbSNP is maintained by the National Center for Biotechnology Information (NCBI).",
      "The dbSNP contains information on single nucleotide polymorphisms (SNPs), which are a common type of genetic variation among humans.",
      "The dbSNP includes information on the frequency of each SNP in different populations.",
      "The dbSNP provides information on the functional effects of the SNPs."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Single Nucleotide Polymorphism Database (dbSNP) is a database that catalogs genetic variations such as single nucleotide polymorphisms (SNPs); it is not specifically a database of somatic mutations in normal cells, but rather includes variations found in a wide range of contexts, including both normal and disease states.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-7b_response": "Yes, there are several graph kernel libraries available implemented in JAVA. Some of the popular ones include:\n\n1. Gephi: Gephi is a popular open-source graph visualization and manipulation toolkit that provides a graph kernel API. It supports various graph algorithms such as clustering, shortest paths, and centrality measures.\n\n2. JUNG: JUNG is a Java library for the creation of visualizations of complex networks and graphs. It provides a graph kernel API that can be used to implement various graph algorithms.\n\n3. GraphKernel4j: GraphKernel4j is a Java library that provides a graph kernel API for implementing graph algorithms. It supports various graph kernels such as the betweenness kernel, closeness kernel, and eigenvector centrality kernel.\n\n4. NetworkX: NetworkX is a Python library that provides a graph kernel API for implementing graph algorithms. It can be used to implement various graph kernels such as the betweenness kernel, closeness kernel, and eigenvector centrality kernel.\n\nOverall, JAVA provides a robust platform for implementing graph kernel libraries, and there are several options available for developers to choose from.",
    "llama-7b_fact_raw": "1. Gephi is an open-source graph visualization and manipulation toolkit that provides a graph kernel API.\n2. JUNG is a Java library that allows for the creation of visualizations of complex networks and graphs and provides a graph kernel API.\n3. GraphKernel4j is a Java library that provides a graph kernel API for implementing graph algorithms.\n4. NetworkX is a Python library, not a Java library, that provides a graph kernel API for implementing graph algorithms.\n5. Gephi supports various graph algorithms such as clustering, shortest paths, and centrality measures.",
    "llama-7b_fact": [
      "Gephi is an open-source graph visualization and manipulation toolkit that provides a graph kernel API.",
      "JUNG is a Java library that allows for the creation of visualizations of complex networks and graphs and provides a graph kernel API.",
      "GraphKernel4j is a Java library that provides a graph kernel API for implementing graph algorithms.",
      "NetworkX is a Python library, not a Java library, that provides a graph kernel API for implementing graph algorithms.",
      "Gephi supports various graph algorithms such as clustering, shortest paths, and centrality measures."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no well-known Java library specifically named GraphKernel4j that provides a graph kernel API for implementing graph algorithms. However, JUNG and other libraries like it do provide similar functionalities.\n4. FALSE [correction]: NetworkX is indeed a Python library, but it does not provide a \"graph kernel API.\" It is a library for the creation, manipulation, and study of the structure, dynamics, and functions of complex networks.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-7b_response": "As an AI language model, I do not have access to the latest updates of the SHERLOCKv2 platform. However, based on my knowledge, the advances integrated into the SHERLOCKv2 platform may include:\n\n1. Enhanced Natural Language Processing (NLP) capabilities: SHERLOCKv2 may have improved NLP capabilities that enable it to understand and interpret human language more accurately and efficiently.\n\n2. Real-time data analytics: SHERLOCKv2 may have real-time data analytics capabilities that enable it to process large volumes of data in real-time and provide actionable insights to users.\n\n3. Machine learning algorithms: SHERLOCKv2 may have incorporated advanced machine learning algorithms that enable it to learn and improve its performance over time.\n\n4. User-friendly interface: SHERLOCKv2 may have a more intuitive and user-friendly interface that makes it easier for users to interact with the platform and access its features and functionalities.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-7b_response": "The bartender algorithm is a simple and efficient algorithm that is commonly used in the field of computer science. It is named after the image of a bartender who serves drinks to customers in a bar.\n\nThe bartender algorithm works by maintaining a queue of unserved customers and serving them in the order that they arrived. When a customer finishes their drink, they are removed from the queue and a new customer is added to the front of the queue. This process continues until all customers have been served.\n\nThe key advantage of the bartender algorithm is its simplicity. It is easy to implement and does not require any complex data structures or algorithms. Additionally, it is well-suited to situations where customers arrive in a steady stream and can be served in a first-in-first-out (FIFO) manner.\n\nOverall, the bartender algorithm is a useful tool for anyone working in the field of computer science or anyone looking for an efficient way to serve customers in a queue.",
    "llama-7b_fact_raw": "1. The bartender algorithm is used in the field of computer science.\n2. It operates by maintaining a queue of unserved customers.\n3. Customers are served in the order that they arrived, following a first-in-first-out (FIFO) manner.\n4. When a customer finishes their drink, they are removed from the queue.\n5. The algorithm continues until all customers have been served.",
    "llama-7b_fact": [
      "The bartender algorithm is used in the field of computer science.",
      "It operates by maintaining a queue of unserved customers.",
      "Customers are served in the order that they arrived, following a first-in-first-out (FIFO) manner.",
      "When a customer finishes their drink, they are removed from the queue.",
      "The algorithm continues until all customers have been served."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Explanation]: The \"bartender algorithm\" is not a standard term or widely recognized algorithm in computer science. Without additional context or a definition of what the \"bartender algorithm\" is supposed to be, it is not possible to accurately assess the truth of these statements.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-7b_response": "There are several web-based pedigree editors available that genealogy enthusiasts can use to create and manage their family trees online. Some of the most popular ones include:\n\n1. FamilySearch: FamilySearch is a free web-based pedigree editor that allows users to create and share their family trees with others. It is owned and operated by The Church of Jesus Christ of Latter-day Saints.\n\n2. Geni: Geni is a free web-based pedigree editor that allows users to create and manage their family trees, as well as connect with others who are researching the same family lines.\n\n3. MyHeritage: MyHeritage is a paid web-based pedigree editor that offers a range of features for genealogy enthusiasts, including family tree management, DNA testing, and historical records search.\n\n4. Ancestry: Ancestry is a paid web-based pedigree editor that offers a comprehensive suite of genealogy tools, including family tree management, historical records search, and DNA testing.\n\n5. WeRelate: WeRelate is a free web-based pedigree editor that focuses on collaborative genealogy, allowing users to work together to build and share family trees.\n\nThese are just a few examples of the many web-based pedigree editors available to genealogy enthusiasts. Each one has its own unique features and benefits, so it's important to choose the one that best fits your needs and preferences.",
    "llama-7b_fact_raw": "1. FamilySearch is a free web-based pedigree editor owned and operated by The Church of Jesus Christ of Latter-day Saints.\n2. Geni is a free web-based pedigree editor that allows users to create and manage their family trees.\n3. MyHeritage is a paid web-based pedigree editor that offers DNA testing and historical records search.\n4. Ancestry is a paid web-based pedigree editor that provides family tree management, historical records search, and DNA testing.\n5. WeRelate is a free web-based pedigree editor that emphasizes collaborative genealogy.",
    "llama-7b_fact": [
      "FamilySearch is a free web-based pedigree editor owned and operated by The Church of Jesus Christ of Latter-day Saints.",
      "Geni is a free web-based pedigree editor that allows users to create and manage their family trees.",
      "MyHeritage is a paid web-based pedigree editor that offers DNA testing and historical records search.",
      "Ancestry is a paid web-based pedigree editor that provides family tree management, historical records search, and DNA testing.",
      "WeRelate is a free web-based pedigree editor that emphasizes collaborative genealogy."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MyHeritage offers both free and paid services for their web-based pedigree editor, including DNA testing and historical records search.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-7b_response": "There are several curated databases that exist for spider venom toxins. One of the most well-known and comprehensive databases is the Spider Toxin Database, which is maintained by the National Center for Biotechnology Information (NCBI). This database includes information on the molecular structure, biological activity, and pharmacological effects of various spider venom toxins.\n\nAnother database that focuses specifically on spider venom toxins is the World Spider Catalog's Venom Database. This database includes information on the venomous spiders and their toxins, as well as details on the biological effects of the toxins.\n\nThe Venomous Animals and Their Toxins database, maintained by the University of Arizona, also includes information on spider venom toxins. This database includes information on the toxins produced by various venomous animals, including spiders, snakes, scorpions, and cone snails.\n\nFinally, the Toxinology Database, maintained by the National Institutes of Health, includes information on a wide range of toxins, including spider venom toxins. This database includes information on the chemical structure, biological activity, and pharmacological effects of various toxins, including spider venom toxins.",
    "llama-7b_fact_raw": "1. The Spider Toxin Database is maintained by the National Center for Biotechnology Information (NCBI).\n2. The Spider Toxin Database includes information on the molecular structure, biological activity, and pharmacological effects of spider venom toxins.\n3. The World Spider Catalog's Venom Database focuses specifically on spider venom toxins and includes information on venomous spiders and their toxins.\n4. The Venomous Animals and Their Toxins database is maintained by the University of Arizona and includes information on spider venom toxins.\n5. The Toxinology Database, maintained by the National Institutes of Health, includes information on a wide range of toxins, including spider venom toxins.",
    "llama-7b_fact": [
      "The Spider Toxin Database is maintained by the National Center for Biotechnology Information (NCBI).",
      "The Spider Toxin Database includes information on the molecular structure, biological activity, and pharmacological effects of spider venom toxins.",
      "The World Spider Catalog's Venom Database focuses specifically on spider venom toxins and includes information on venomous spiders and their toxins.",
      "The Venomous Animals and Their Toxins database is maintained by the University of Arizona and includes information on spider venom toxins.",
      "The Toxinology Database, maintained by the National Institutes of Health, includes information on a wide range of toxins, including spider venom toxins."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Spider Toxin Database is not maintained by the National Center for Biotechnology Information (NCBI); it is maintained by other organizations or databases that specialize in toxin information.\n2. TRUE\n3. UNKNOWN: Without specific information about the World Spider Catalog's Venom Database, it is not possible to confirm the details provided in the statement.\n4. UNKNOWN: Without specific information about the Venomous Animals and Their Toxins database and its maintainer, it is not possible to confirm the details provided in the statement.\n5. FALSE [correction]: The Toxinology Database is not maintained by the National Institutes of Health (NIH); it may be maintained by other organizations or institutions that specialize in toxin research. The NIH does support various research and databases, but there is no specific \"Toxinology Database\" maintained by them.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-7b_response": "As an AI language model, I do not have personal beliefs or opinions. However, based on the available scientific literature, the answer to the question \"Does Axitinib prolong survival of Pancreatic Cancer patients?\" is yes.\n\nAxitinib is a targeted therapy drug that has been shown to be effective in prolonging survival in patients with advanced pancreatic cancer. In a clinical trial conducted by the National Cancer Institute, patients who received Axitinib in combination with gemcitabine (a chemotherapy drug) had a median overall survival of 6.7 months, compared to 4.9 months in patients who received only gemcitabine.\n\nFurthermore, a meta-analysis of multiple clinical trials evaluating Axitinib in various cancer types, including pancreatic cancer, found that patients who received Axitinib had a significant improvement in survival compared to those who did not receive the drug.\n\nHowever, it is important to note that survival rates can vary based on the stage and aggressiveness of the cancer, as well as individual patient factors. It is always important to consult with a healthcare provider for personalized treatment recommendations.",
    "llama-7b_fact_raw": "1. Axitinib is a targeted therapy drug used in the treatment of advanced pancreatic cancer.\n2. A clinical trial by the National Cancer Institute showed that patients treated with Axitinib in combination with gemcitabine had a median overall survival of 6.7 months.\n3. Patients who received only gemcitabine had a median overall survival of 4.9 months in the mentioned clinical trial.\n4. A meta-analysis of multiple clinical trials found that Axitinib improved survival in patients with various cancer types, including pancreatic cancer.\n5. Survival rates for patients taking Axitinib can vary based on the stage and aggressiveness of the cancer, as well as individual patient factors.",
    "llama-7b_fact": [
      "Axitinib is a targeted therapy drug used in the treatment of advanced pancreatic cancer.",
      "A clinical trial by the National Cancer Institute showed that patients treated with Axitinib in combination with gemcitabine had a median overall survival of 6.7 months.",
      "Patients who received only gemcitabine had a median overall survival of 4.9 months in the mentioned clinical trial.",
      "A meta-analysis of multiple clinical trials found that Axitinib improved survival in patients with various cancer types, including pancreatic cancer.",
      "Survival rates for patients taking Axitinib can vary based on the stage and aggressiveness of the cancer, as well as individual patient factors."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Axitinib is a targeted therapy drug used in the treatment of advanced renal cell carcinoma, not specifically for pancreatic cancer.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-7b_response": "MLP (Myosin-Light-Chain-Phosphatase) is a protein that plays a crucial role in the regulation of F-actin dynamics. F-actin is a component of the cytoskeleton that provides structural support to the cell and is involved in various cellular processes such as motility, division, and intracellular trafficking.\n\nMLP regulates F-actin dynamics through its interaction with the Arp2/3 complex, which is a key regulator of actin polymerization. The Arp2/3 complex is responsible for the formation of branched actin filaments, which are essential for cell motility and morphology. MLP interacts with the Arp2/3 complex and inhibits its activity, thereby preventing the formation of branched actin filaments.\n\nBy inhibiting actin polymerization, MLP maintains the stability of existing F-actin fibers and prevents their depolymerization. This allows for the proper organization and functioning of the cytoskeleton, which is essential for various cellular processes.\n\nIn summary, MLP regulates F-actin dynamics by interacting with the Arp2/3 complex and inhibiting its activity, thereby maintaining the stability of existing F-actin fibers and preventing their depolymerization.",
    "llama-7b_fact_raw": "1. MLP (Myosin-Light-Chain-Phosphatase) regulates F-actin dynamics.\n2. F-actin is a component of the cytoskeleton that provides structural support to the cell.\n3. MLP interacts with the Arp2/3 complex, which is a key regulator of actin polymerization.\n4. The Arp2/3 complex is responsible for the formation of branched actin filaments.\n5. MLP inhibits the activity of the Arp2/3 complex, preventing the formation of branched actin filaments.",
    "llama-7b_fact": [
      "MLP (Myosin-Light-Chain-Phosphatase) regulates F-actin dynamics.",
      "F-actin is a component of the cytoskeleton that provides structural support to the cell.",
      "MLP interacts with the Arp2/3 complex, which is a key regulator of actin polymerization.",
      "The Arp2/3 complex is responsible for the formation of branched actin filaments.",
      "MLP inhibits the activity of the Arp2/3 complex, preventing the formation of branched actin filaments."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Myosin-Light-Chain-Phosphatase (MLCP) is involved in the regulation of myosin II activity by dephosphorylating the regulatory light chain of myosin II, not directly regulating F-actin dynamics.\n2. TRUE\n3. UNKNOWN: Without specific context or evidence, it is not clear whether MLP interacts directly with the Arp2/3 complex as its primary function is related to myosin II regulation.\n4. TRUE\n5. FALSE [correction]: MLP's known function is to dephosphorylate myosin light chains, which affects muscle contraction and cell motility. It is not typically described as inhibiting the activity of the Arp2/3 complex. The inhibition of the Arp2/3 complex would be a function of other specific proteins or molecules.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-7b_response": "There are 51 pseudokinases in the human kinome. Pseudokinases are proteins that share structural and functional similarities with kinases but lack the ability to phosphorylate proteins. They play various roles in cellular signaling pathways, including as scaffolding proteins, regulators of protein trafficking, and components of multiprotein complexes. While pseudokinases are not true kinases, they are still important components of the kinome and contribute to the regulation of cellular processes.",
    "llama-7b_fact_raw": "1. There are 51 pseudokinases in the human kinome.\n2. Pseudokinases lack the ability to phosphorylate proteins.\n3. Pseudokinases play roles in cellular signaling pathways.\n4. Pseudokinases can act as scaffolding proteins, regulators of protein trafficking, and components of multiprotein complexes.\n5. Pseudokinases are considered important components of the kinome.",
    "llama-7b_fact": [
      "There are 51 pseudokinases in the human kinome.",
      "Pseudokinases lack the ability to phosphorylate proteins.",
      "Pseudokinases play roles in cellular signaling pathways.",
      "Pseudokinases can act as scaffolding proteins, regulators of protein trafficking, and components of multiprotein complexes.",
      "Pseudokinases are considered important components of the kinome."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe number of pseudokinases in the human kinome can vary depending on the source and the criteria used for classification. Without specific context or a reference, it is difficult to confirm the exact number. However, the other statements about the characteristics and roles of pseudokinases are generally true.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-7b_response": "ApoE mimetics are molecules that mimic the function of apoE, a protein that is important for the transport and metabolism of lipids in the body. Here are three examples of apoE mimetics:\n\n1. Pravastatin: Pravastatin is a statin drug that is used to lower cholesterol levels in the blood. It works by inhibiting the enzyme HMG-CoA reductase, which is involved in the synthesis of cholesterol in the liver. Pravastatin has been shown to have apoE-mimetic activity in vitro and in vivo, and it has been proposed as a potential treatment for Alzheimer's disease, which is associated with decreased levels of apoE.\n\n2. Trodusquemine: Trodusquemine is a drug that is currently being developed as a treatment for obesity and type 2 diabetes. It has been shown to have apoE-mimetic activity in vitro and in vivo, and it has been proposed that its apoE-mimetic effects may contribute to its therapeutic effects.\n\n3. Apolipoprotein E: Apolipoprotein E (apoE) is a protein that is naturally present in the blood and is important for the transport and metabolism of lipids. ApoE has been shown to have apoE-mimetic activity in vitro and in vivo, and it has been proposed as a potential treatment for Alzheimer's disease, which is associated with decreased levels of apoE.",
    "llama-7b_fact_raw": "1. Pravastatin is a statin drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase.\n2. Pravastatin has been shown to have apoE-mimetic activity in vitro and in vivo.\n3. Trodusquemine is being developed as a treatment for obesity and type 2 diabetes and has apoE-mimetic activity.\n4. Apolipoprotein E (apoE) is a protein naturally present in the blood, important for lipid transport and metabolism.\n5. Apolipoprotein E has been proposed as a potential treatment for Alzheimer's disease due to its apoE-mimetic activity.",
    "llama-7b_fact": [
      "Pravastatin is a statin drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase.",
      "Pravastatin has been shown to have apoE-mimetic activity in vitro and in vivo.",
      "Trodusquemine is being developed as a treatment for obesity and type 2 diabetes and has apoE-mimetic activity.",
      "Apolipoprotein E (apoE) is a protein naturally present in the blood, important for lipid transport and metabolism.",
      "Apolipoprotein E has been proposed as a potential treatment for Alzheimer's disease due to its apoE-mimetic activity."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Apolipoprotein E (apoE) itself is not proposed as a treatment for Alzheimer's disease. However, therapies that target apoE pathways or have apoE-mimetic activity are being researched as potential treatments for Alzheimer's disease.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-7b_response": "There are sex differences in the activity of SAMHD1, a protein that restricts HIV-1 replication in human cells. SAMHD1 is known to be a potent inhibitor of HIV-1 replication, and its activity is essential for controlling the spread of the virus.\n\nStudies have shown that SAMHD1 activity is higher in females compared to males. This may be due to the fact that females have a higher level of estrogen, a hormone that has been shown to increase the expression of SAMHD1. On the other hand, males have a higher level of testosterone, which has been shown to decrease the expression of SAMHD1.\n\nFurthermore, studies have also shown that SAMHD1 activity is lower in individuals with a certain variant of the SAMHD1 gene. This variant is more common in females, which may explain the higher SAMHD1 activity observed in females with this variant.\n\nIn summary, there are sex differences in SAMHD1 activity, which may be due to differences in hormone levels and variations in the SAMHD1 gene. However, further research is needed to fully understand the underlying mechanisms behind these differences.",
    "llama-7b_fact_raw": "1. SAMHD1 is a protein that restricts HIV-1 replication in human cells.\n2. SAMHD1 activity is higher in females compared to males.\n3. Estrogen, which is higher in females, has been shown to increase the expression of SAMHD1.\n4. Testosterone, which is higher in males, has been shown to decrease the expression of SAMHD1.\n5. A certain variant of the SAMHD1 gene, which is more common in females, is associated with lower SAMHD1 activity.",
    "llama-7b_fact": [
      "SAMHD1 is a protein that restricts HIV-1 replication in human cells.",
      "SAMHD1 activity is higher in females compared to males.",
      "Estrogen, which is higher in females, has been shown to increase the expression of SAMHD1.",
      "Testosterone, which is higher in males, has been shown to decrease the expression of SAMHD1.",
      "A certain variant of the SAMHD1 gene, which is more common in females, is associated with lower SAMHD1 activity."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Typically, if a variant of a gene is associated with lower activity of the protein it encodes, and if this variant were more common in females, it would suggest that SAMHD1 activity could be lower in females, not higher as stated in statement 2. However, without specific data or research findings, the relationship between gender, gene variants, and protein activity levels cannot be accurately determined.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-7b_response": "No, RUNX2 does not inhibit astrocyte differentiation. In fact, RUNX2 has been shown to play a crucial role in the differentiation and maturation of astrocytes, a type of glial cell in the central nervous system.\n\nStudies have demonstrated that RUNX2 is expressed in astrocytes and is required for their normal development and function. Specifically, RUNX2 has been found to regulate the expression of genes involved in astrocyte morphology, ion channel function, and synaptic transmission.\n\nFurthermore, knockdown of RUNX2 in astrocyte cultures has been shown to result in decreased differentiation and maturation of these cells, suggesting that RUNX2 is necessary for the normal differentiation of astrocytes.\n\nOverall, while RUNX2 has been implicated in the differentiation and maturation of several cell types, including astrocytes, it does not appear to inhibit astrocyte differentiation but rather plays a crucial role in regulating astrocyte function.",
    "llama-7b_fact_raw": "1. RUNX2 plays a crucial role in the differentiation and maturation of astrocytes.\n2. RUNX2 is expressed in astrocytes and is required for their normal development and function.\n3. RUNX2 regulates the expression of genes involved in astrocyte morphology, ion channel function, and synaptic transmission.\n4. Knockdown of RUNX2 in astrocyte cultures results in decreased differentiation and maturation of these cells.\n5. RUNX2 is necessary for the normal differentiation of astrocytes.",
    "llama-7b_fact": [
      "RUNX2 plays a crucial role in the differentiation and maturation of astrocytes.",
      "RUNX2 is expressed in astrocytes and is required for their normal development and function.",
      "RUNX2 regulates the expression of genes involved in astrocyte morphology, ion channel function, and synaptic transmission.",
      "Knockdown of RUNX2 in astrocyte cultures results in decreased differentiation and maturation of these cells.",
      "RUNX2 is necessary for the normal differentiation of astrocytes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: RUNX2 plays a crucial role in the differentiation and maturation of osteoblasts, not astrocytes.\n2. FALSE [correction]: RUNX2 is expressed in osteoblasts and is required for their normal development and function, not astrocytes.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: RUNX2 is necessary for the normal differentiation of osteoblasts, not astrocytes.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-7b_response": "The Cobb-Stainsby excision arthroplasty would be performed on the knee joint. It is a surgical procedure that is used to treat osteoarthritis of the knee joint. The procedure involves the removal of a wedge-shaped portion of the femur (thigh bone) and tibia (shin bone) to restore the alignment of the knee joint and relieve the symptoms of osteoarthritis. The surgery is usually performed under general anesthesia and requires an incision to be made on the knee joint. The surgeon will then remove the damaged bone and cartilage, and replace it with a graft of healthy bone or a synthetic substitute. After the procedure, the knee will be immobilized with a cast or brace to allow for proper healing. The success of the Cobb-Stainsby excision arthroplasty depends on a variety of factors, including the patient's overall health, the severity of their osteoarthritis, and the skill of the surgeon performing the procedure.",
    "llama-7b_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed on the knee joint.\n2. This surgical procedure is used to treat osteoarthritis of the knee joint.\n3. The procedure involves the removal of a wedge-shaped portion of the femur and tibia.\n4. The Cobb-Stainsby excision arthroplasty is usually performed under general anesthesia.\n5. After the procedure, the knee is typically immobilized with a cast or brace to allow for healing.",
    "llama-7b_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed on the knee joint.",
      "This surgical procedure is used to treat osteoarthritis of the knee joint.",
      "The procedure involves the removal of a wedge-shaped portion of the femur and tibia.",
      "The Cobb-Stainsby excision arthroplasty is usually performed under general anesthesia.",
      "After the procedure, the knee is typically immobilized with a cast or brace to allow for healing."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is performed on the hip joint, not the knee joint.\n2. TRUE\n3. FALSE [correction]: The procedure involves the removal of the femoral head and neck, as well as interposition of soft tissue, not a wedge-shaped portion of the femur and tibia.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-7b_response": "As an AI language model, I do not have personal beliefs or opinions. However, based on the available scientific literature, the answer to your question is no, GRHL2 over-expression does not necessarily lead to EMT (epithelial-to-mesenchymal transition).\n\nGRHL2 is a transcription factor that regulates the expression of genes involved in cell-to-mesenchymal transition (CMT) and EMT. CMT is the process by which epithelial cells lose their cell-to-cell adhesion and acquire a more migratory and fibroblast-like phenotype. EMT, on the other hand, is the process by which epithelial cells lose their cell-to-cell adhesion and acquire a more mesenchymal phenotype, characterized by the expression of mesenchymal markers and the ability to differentiate into various mesenchymal lineages.\n\nWhile GRHL2 has been shown to play a role in CMT, its role in EMT is less clear. Some studies have reported that GRHL2 over-expression can induce EMT in certain cell types, while others have found no association between GRHL2 expression and EMT.\n\nOverall, the answer to whether GRHL2 over-expression leads to EMT depends on the context and cell type in question. Further research is needed to fully understand the role of GRHL2 in EMT and its potential as a therapeutic target in cancer and other diseases.",
    "llama-7b_fact_raw": "1. GRHL2 is a transcription factor that regulates the expression of genes involved in cell-to-mesenchymal transition (CMT) and epithelial-to-mesenchymal transition (EMT).\n2. Cell-to-mesenchymal transition (CMT) is a process where epithelial cells lose their cell-to-cell adhesion and acquire a more migratory and fibroblast-like phenotype.\n3. Epithelial-to-mesenchymal transition (EMT) is a process where epithelial cells lose their cell-to-cell adhesion and acquire a more mesenchymal phenotype, characterized by the expression of mesenchymal markers and the ability to differentiate into various mesenchymal lineages.\n4. Some studies have reported that GRHL2 over-expression can induce EMT in certain cell types.\n5. Other studies have found no association between GRHL2 expression and EMT.",
    "llama-7b_fact": [
      "GRHL2 is a transcription factor that regulates the expression of genes involved in cell-to-mesenchymal transition (CMT) and epithelial-to-mesenchymal transition (EMT).",
      "Cell-to-mesenchymal transition (CMT) is a process where epithelial cells lose their cell-to-cell adhesion and acquire a more migratory and fibroblast-like phenotype.",
      "Epithelial-to-mesenchymal transition (EMT) is a process where epithelial cells lose their cell-to-cell adhesion and acquire a more mesenchymal phenotype, characterized by the expression of mesenchymal markers and the ability to differentiate into various mesenchymal lineages.",
      "Some studies have reported that GRHL2 over-expression can induce EMT in certain cell types.",
      "Other studies have found no association between GRHL2 expression and EMT."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Cell-to-mesenchymal transition (CMT) is not a recognized term in biology. The correct term is epithelial-to-mesenchymal transition (EMT), which is the process described in the statement.\n3. TRUE\n4. FALSE [correction]: GRHL2 is generally associated with the suppression of EMT, not the induction of EMT. Over-expression of GRHL2 is typically linked to the maintenance of the epithelial phenotype and inhibition of EMT.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-7b_response": "There are several T-UCRs that have been implicated in the development and progression of lung cancer. One of the most well-studied T-UCRs in this context is T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3).\n\nTIM-3 is a cell surface receptor that is expressed on activated T cells, and it plays a critical role in regulating T cell function. Recent studies have shown that TIM-3 is upregulated on T cells in lung cancer, and it contributes to immune suppression in the tumor microenvironment.\n\nAnother T-UCR that has been implicated in lung cancer is programmed death-1 (PD-1). PD-1 is a receptor that is expressed on activated T cells, and it plays a critical role in regulating T cell function. Studies have shown that PD-1 is upregulated on T cells in lung cancer, and it contributes to immune suppression in the tumor microenvironment.\n\nAdditionally, T-cell immunoglobulin and mucin domain-containing molecule-1 (TIM-1) has also been implicated in lung cancer. TIM-1 is a cell surface receptor that is expressed on activated T cells, and it plays a critical role in regulating T cell function. Studies have shown that TIM-1 is upregulated on T cells in lung cancer, and it contributes to immune suppression in the tumor microenvironment.\n\nOverall, these T-UCRs play important roles in regulating T cell function, and their upregulation in lung cancer suggests that they may contribute to immune suppression in the tumor microenvironment, which could be a target for therapeutic intervention.",
    "llama-7b_fact_raw": "1. T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) has been implicated in the development and progression of lung cancer.\n2. TIM-3 is expressed on activated T cells and plays a critical role in regulating T cell function.\n3. Studies have shown that TIM-3 is upregulated on T cells in lung cancer and contributes to immune suppression in the tumor microenvironment.\n4. Programmed death-1 (PD-1) has been implicated in lung cancer and is expressed on activated T cells.\n5. T-cell immunoglobulin and mucin domain-containing molecule-1 (TIM-1) is upregulated on T cells in lung cancer and contributes to immune suppression in the tumor microenvironment.",
    "llama-7b_fact": [
      "T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) has been implicated in the development and progression of lung cancer.",
      "TIM-3 is expressed on activated T cells and plays a critical role in regulating T cell function.",
      "Studies have shown that TIM-3 is upregulated on T cells in lung cancer and contributes to immune suppression in the tumor microenvironment.",
      "Programmed death-1 (PD-1) has been implicated in lung cancer and is expressed on activated T cells.",
      "T-cell immunoglobulin and mucin domain-containing molecule-1 (TIM-1) is upregulated on T cells in lung cancer and contributes to immune suppression in the tumor microenvironment."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: It is TIM-3, not TIM-1, that is upregulated on T cells in lung cancer and contributes to immune suppression in the tumor microenvironment, as stated in statement 3.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-7b_response": "GPR151, also known as the orphan receptor G protein-coupled receptor 151, is a protein that belongs to the G protein-coupled receptor family. It was first discovered in 2002 and is primarily expressed in the brain, heart, and placenta. The exact function of GPR151 is still not fully understood, but it is believed to play a role in various physiological processes such as neurotransmitter release, cardiovascular function, and embryonic development. \n\nStudies have shown that GPR151 is involved in the regulation of neurotransmitters such as dopamine, serotonin, and norepinephrine. It has been suggested that GPR151 may play a role in the development of Parkinson's disease, depression, and other neurological disorders. \n\nIn terms of cardiovascular function, GPR151 has been found to play a role in the regulation of blood pressure and heart rate. It has been suggested that GPR151 may be a target for the development of new drugs for the treatment of hypertension and other cardiovascular disorders. \n\nAdditionally, GPR151 has been found to play a role in embryonic development and cell growth. It has been suggested that GPR151 may be involved in the regulation of stem cell differentiation and proliferation. \n\nOverall, while much remains to be discovered about GPR151, it is clear that this orphan receptor plays an important role in a variety of physiological processes and may be a promising target for future drug development.",
    "llama-7b_fact_raw": "1. GPR151 is a protein that belongs to the G protein-coupled receptor family.\n2. GPR151 was first discovered in 2002.\n3. GPR151 is primarily expressed in the brain, heart, and placenta.\n4. GPR151 is involved in the regulation of neurotransmitters such as dopamine, serotonin, and norepinephrine.\n5. GPR151 has been suggested to play a role in the development of Parkinson's disease, depression, and other neurological disorders.",
    "llama-7b_fact": [
      "GPR151 is a protein that belongs to the G protein-coupled receptor family.",
      "GPR151 was first discovered in 2002.",
      "GPR151 is primarily expressed in the brain, heart, and placenta.",
      "GPR151 is involved in the regulation of neurotransmitters such as dopamine, serotonin, and norepinephrine.",
      "GPR151 has been suggested to play a role in the development of Parkinson's disease, depression, and other neurological disorders."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: GPR151 is primarily expressed in the brain, particularly in the central nervous system, but there is no strong evidence to suggest significant expression in the heart and placenta.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-7b_response": "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses, which are:\n\n1. Influenza A virus (H1N1)\n2. Influenza A virus (H3N2)\n3. Influenza B virus (Brisbane strain)\n4. Influenza B virus (Florida strain)\n\nIt is important to note that these viruses have been weakened or \"attenuated\" to the point where they cannot cause severe illness or spread easily from person to person. They are used in vaccines to stimulate the immune system to produce protective antibodies against influenza.",
    "llama-7b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains an attenuated Influenza A virus (H1N1).\n2. The Fluzone intradermal quadrivalent vaccine contains an attenuated Influenza A virus (H3N2).\n3. The Fluzone intradermal quadrivalent vaccine contains an attenuated Influenza B virus (Brisbane strain).\n4. The Fluzone intradermal quadrivalent vaccine contains an attenuated Influenza B virus (Florida strain).\n5. The viruses in the Fluzone intradermal quadrivalent vaccine are weakened to the point where they cannot cause severe illness or spread easily from person to person.",
    "llama-7b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated Influenza A virus (H1N1).",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated Influenza A virus (H3N2).",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated Influenza B virus (Brisbane strain).",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated Influenza B virus (Florida strain).",
      "The viruses in the Fluzone intradermal quadrivalent vaccine are weakened to the point where they cannot cause severe illness or spread easily from person to person."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains an inactivated Influenza A virus (H1N1), not an attenuated one.\n2. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains an inactivated Influenza A virus (H3N2), not an attenuated one.\n3. TRUE: The Fluzone intradermal quadrivalent vaccine typically contains an inactivated Influenza B virus from the Brisbane strain, as part of its formulation to cover two Influenza B lineages.\n4. TRUE: The Fluzone intradermal quadrivalent vaccine typically contains an inactivated Influenza B virus from the Florida strain, as part of its formulation to cover two Influenza B lineages.\n5. TRUE: The viruses in the Fluzone intradermal quadrivalent vaccine are inactivated (killed), which means they cannot cause the flu and cannot spread from person to person.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-7b_response": "The TNFR2 gene, also known as tumor necrosis factor receptor 2 gene, is associated with systemic lupus erythematosus (SLE) through various genetic mechanisms. The TNFR2 gene provides instructions for making a protein that is a key component of the tumor necrosis factor (TNF) receptor complex, which plays a critical role in regulating immune responses.\n\nSeveral genetic variations in the TNFR2 gene have been associated with an increased risk of developing SLE. One of the most well-studied variations is a single nucleotide change in the promoter region of the TNFR2 gene, which leads to decreased expression of the TNFR2 protein. This genetic variation has been found to be more common in individuals of African descent, and it is thought to account for up to 20% of the genetic risk of developing SLE.\n\nAnother genetic variation in the TNFR2 gene that has been associated with SLE is a missense mutation that alters a single amino acid in the TNFR2 protein. This mutation has been found to be more common in individuals of European descent and is thought to account for around 10% of the genetic risk of developing SLE.\n\nOther genetic variations in the TNFR2 gene, such as insertions and deletions, have also been associated with an increased risk of developing SLE. However, the exact role of these variations in the disease is not fully understood.\n\nIn summary, the TNFR2 gene provides instructions for making a protein that is a key component of the TNF receptor complex, and genetic variations in this gene have been associated with an increased risk of developing systemic lupus erythematosus.",
    "llama-7b_fact_raw": "1. The TNFR2 gene is associated with systemic lupus erythematosus (SLE) through various genetic mechanisms.\n2. A single nucleotide change in the promoter region of the TNFR2 gene has been associated with an increased risk of developing SLE.\n3. The genetic variation in the promoter region of the TNFR2 gene leads to decreased expression of the TNFR2 protein.\n4. This genetic variation in the promoter region of the TNFR2 gene is more common in individuals of African descent and may account for up to 20% of the genetic risk of developing SLE.\n5. A missense mutation in the TNFR2 gene that alters a single amino acid in the TNFR2 protein has been found to be more common in individuals of European descent and is thought to account for around 10% of the genetic risk of developing SLE.",
    "llama-7b_fact": [
      "The TNFR2 gene is associated with systemic lupus erythematosus (SLE) through various genetic mechanisms.",
      "A single nucleotide change in the promoter region of the TNFR2 gene has been associated with an increased risk of developing SLE.",
      "The genetic variation in the promoter region of the TNFR2 gene leads to decreased expression of the TNFR2 protein.",
      "This genetic variation in the promoter region of the TNFR2 gene is more common in individuals of African descent and may account for up to 20% of the genetic risk of developing SLE.",
      "A missense mutation in the TNFR2 gene that alters a single amino acid in the TNFR2 protein has been found to be more common in individuals of European descent and is thought to account for around 10% of the genetic risk of developing SLE."
    ],
    "llama-7b_judge_raw": "1. TRUE: The TNFR2 gene has been associated with systemic lupus erythematosus (SLE) through various genetic mechanisms.\n2. TRUE: A single nucleotide change in the promoter region of the TNFR2 gene can be associated with an increased risk of developing SLE.\n3. UNKNOWN: Without specific information on the nature of the genetic variation in the promoter region of the TNFR2 gene, it is not possible to determine whether it leads to decreased expression of the TNFR2 protein.\n4. UNKNOWN: The statement about the genetic variation being more common in individuals of African descent and accounting for up to 20% of the genetic risk of developing SLE is very specific and would require supporting data to verify its accuracy.\n5. UNKNOWN: Similar to statement 4, the claim about a missense mutation in the TNFR2 gene being more common in individuals of European descent and accounting for around 10% of the genetic risk of developing SLE is specific and would need supporting evidence to confirm its truthfulness.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-7b_response": "Yes, there is a vaccine for peanut allergy. The vaccine is called Palforzia and it was approved by the FDA in 2020. Palforzia is a sublingual immunotherapy (SLIT) tablet that contains small amounts of peanut protein. It is designed to gradually increase a person's tolerance to peanut allergens over time.\n\nThe vaccine is recommended for individuals who have severe peanut allergies and are 4 to 17 years old. It is important to note that Palforzia is not a cure for peanut allergy, but it can reduce the risk of a severe allergic reaction (anaphylaxis) if a person accidentally eats or comes into contact with peanuts.\n\nThe vaccine is administered under the supervision of a healthcare provider and requires regular visits for monitoring and dose adjustments. It is important to continue avoiding peanuts during the treatment period and to carry an epinephrine auto-injector in case of a severe allergic reaction.\n\nOverall, Palforzia is a promising development in the treatment of peanut allergy, but it is not suitable for everyone with a peanut allergy and should be discussed with a healthcare provider.",
    "llama-7b_fact_raw": "1. Palforzia is a vaccine for peanut allergy approved by the FDA in 2020.\n2. Palforzia is a sublingual immunotherapy (SLIT) tablet that contains small amounts of peanut protein.\n3. The vaccine is designed to gradually increase a person's tolerance to peanut allergens over time.\n4. Palforzia is recommended for individuals between the ages of 4 to 17 who have severe peanut allergies.\n5. Palforzia is not a cure for peanut allergy but can reduce the risk of severe allergic reactions.",
    "llama-7b_fact": [
      "Palforzia is a vaccine for peanut allergy approved by the FDA in 2020.",
      "Palforzia is a sublingual immunotherapy (SLIT) tablet that contains small amounts of peanut protein.",
      "The vaccine is designed to gradually increase a person's tolerance to peanut allergens over time.",
      "Palforzia is recommended for individuals between the ages of 4 to 17 who have severe peanut allergies.",
      "Palforzia is not a cure for peanut allergy but can reduce the risk of severe allergic reactions."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Palforzia is not a vaccine; it is an oral immunotherapy treatment for peanut allergy approved by the FDA in 2020.\n2. FALSE [correction]: Palforzia is not a sublingual immunotherapy (SLIT) tablet; it is an oral immunotherapy product that is ingested.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-7b_response": "The Fxy gene is located on the X chromosome, which is one of the sex chromosomes. In mammals, including mice, females have two X chromosomes while males have one X chromosome and one Y chromosome. This means that the Fxy gene is present in both males and females, but in different numbers. In females, the Fxy gene is present on both X chromosomes, whereas in males, the Fxy gene is present only on the one X chromosome. The presence of the Fxy gene on the X chromosome is particular because it is one of the genes that is known to be sex-linked, meaning that it is located on a sex chromosome. The location of the Fxy gene on the X chromosome is important because it affects the inheritance of the gene. In females, the Fxy gene is present on both X chromosomes, so it is inherited from the mother. In males, the Fxy gene is present only on one X chromosome, so it is inherited from either the mother or the father.",
    "llama-7b_fact_raw": "1. The Fxy gene is located on the X chromosome.\n2. In mammals, females have two X chromosomes.\n3. In mammals, males have one X chromosome and one Y chromosome.\n4. The Fxy gene is present in both males and females, but in different numbers: two copies in females and one copy in males.\n5. The Fxy gene is sex-linked, meaning it is located on a sex chromosome.",
    "llama-7b_fact": [
      "The Fxy gene is located on the X chromosome.",
      "In mammals, females have two X chromosomes.",
      "In mammals, males have one X chromosome and one Y chromosome.",
      "The Fxy gene is present in both males and females, but in different numbers: two copies in females and one copy in males.",
      "The Fxy gene is sex-linked, meaning it is located on a sex chromosome."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-7b_response": "The basis of the MPE-seq method is the incorporation of methyl-propyl-EDTA (MPE) into DNA during replication. MPE is a non-hydrolyzable analog of adenosine triphosphate (ATP), which is the energy source for DNA replication. The MPE molecule is incorporated into the newly synthesized DNA strand by the enzyme DNA polymerase, replacing the normal nucleotide triphosphate (dATP).\n\nThe MPE-seq method relies on the ability of MPE to specifically bind to single-stranded DNA (ssDNA), which is abundant during replication. The MPE molecules that are incorporated into the newly synthesized DNA strand can then be detected and quantified using mass spectrometry.\n\nThe MPE-seq method has several advantages over other sequencing methods, including high throughput, minimal sample preparation, and the ability to sequence both strands of the DNA simultaneously. It has been used to study DNA replication, DNA damage response pathways, and epigenetic modifications, among other applications.",
    "llama-7b_fact_raw": "1. Methidiumpropyl-EDTA (MPE) is incorporated into DNA during replication in the MPE-seq method.\n2. MPE is a non-hydrolyzable analog of adenosine triphosphate (ATP).\n3. DNA polymerase incorporates MPE into the newly synthesized DNA strand, replacing the normal nucleotide triphosphate (dATP).\n4. MPE specifically binds to single-stranded DNA (ssDNA) during replication.\n5. The MPE molecules incorporated into DNA can be detected and quantified using mass spectrometry.",
    "llama-7b_fact": [
      "Methidiumpropyl-EDTA (MPE) is incorporated into DNA during replication in the MPE-seq method.",
      "MPE is a non-hydrolyzable analog of adenosine triphosphate (ATP).",
      "DNA polymerase incorporates MPE into the newly synthesized DNA strand, replacing the normal nucleotide triphosphate (dATP).",
      "MPE specifically binds to single-stranded DNA (ssDNA) during replication.",
      "The MPE molecules incorporated into DNA can be detected and quantified using mass spectrometry."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Methidiumpropyl-EDTA (MPE) is not incorporated into DNA during replication in the MPE-seq method. Instead, it is a DNA footprinting reagent that binds to DNA and is used to identify protein-DNA interactions.\n2. UNKNOWN: Without specific context or additional information, it is unclear whether MPE is an analog of ATP. MPE is typically known as a DNA-binding agent, not as an analog of nucleotides.\n3. FALSE [correction]: DNA polymerase does not incorporate MPE into the newly synthesized DNA strand as MPE is not a nucleotide or nucleotide analog used during DNA replication.\n4. TRUE: MPE does bind to single-stranded DNA (ssDNA), which is part of its function in footprinting techniques to study DNA-protein interactions.\n5. UNKNOWN: The statement about detection and quantification of MPE molecules using mass spectrometry is not standard knowledge regarding MPE-seq or DNA footprinting techniques. Typically, MPE-seq involves sequencing to identify the binding sites of proteins on DNA, not mass spectrometry. However, without specific context, it is difficult to confirm the accuracy of this statement.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-7b_response": "As an AI language model, I am not aware of any programming language being used for implementing GWAR. GWAR is a heavy metal band from Virginia, USA, known for their elaborate costumes, makeup, and stage shows. They are not related to any programming language or software development.",
    "llama-7b_fact_raw": "1. GWAR is a heavy metal band from Virginia, USA.\n2. GWAR is known for their elaborate costumes, makeup, and stage shows.\n3. GWAR is not related to any programming language or software development.",
    "llama-7b_fact": [
      "GWAR is a heavy metal band from Virginia, USA.",
      "GWAR is known for their elaborate costumes, makeup, and stage shows.",
      "GWAR is not related to any programming language or software development."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-7b_response": "As an AI language model, I do not have personal beliefs or opinions. However, based on the available scientific literature, the answer to the question of whether xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS) is uncertain.\n\nXaliproden is a drug that has been studied in clinical trials for the treatment of ALS. It is a selective agonist of the neuropeptide Y (NPY) receptor, which is thought to play a role in the regulation of motor neuron function and survival.\n\nSeveral small clinical trials have investigated the use of xaliproden in patients with ALS, with mixed results. Some studies have suggested that xaliproden may slow the progression of the disease and prolong survival, while others have found no benefit or even harm from the treatment.\n\nHowever, it is important to note that the evidence for the effectiveness of xaliproden in ALS is limited and inconclusive. More research is needed to determine the true impact of this drug on the prognosis of patients with ALS.",
    "llama-7b_fact_raw": "1. Xaliproden is a drug that has been studied in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS).\n2. Xaliproden is a selective agonist of the neuropeptide Y (NPY) receptor.\n3. The role of the NPY receptor is thought to be related to the regulation of motor neuron function and survival.\n4. Clinical trials on xaliproden for ALS have shown mixed results, with some suggesting potential benefits and others showing no benefit or harm.\n5. The evidence for the effectiveness of xaliproden in improving the prognosis of ALS is limited and inconclusive.",
    "llama-7b_fact": [
      "Xaliproden is a drug that has been studied in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS).",
      "Xaliproden is a selective agonist of the neuropeptide Y (NPY) receptor.",
      "The role of the NPY receptor is thought to be related to the regulation of motor neuron function and survival.",
      "Clinical trials on xaliproden for ALS have shown mixed results, with some suggesting potential benefits and others showing no benefit or harm.",
      "The evidence for the effectiveness of xaliproden in improving the prognosis of ALS is limited and inconclusive."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Xaliproden is not a selective agonist of the neuropeptide Y (NPY) receptor; it is a serotonergic compound that acts as a 5-HT1A receptor agonist.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-7b_response": "As an AI language model, I do not have access to specific information about the LiPS-A3S line. However, in general, transgenes can be inserted into any of the chromosomes in a eukaryotic cell. The specific location and copy number of the transgene can vary depending on the method of transformation or gene editing technique used. It is important to note that the location and stability of transgenes can impact their expression level, regulation, and potential impact on the organism.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-7b_response": "As an AI language model, I am not aware of any specific tool that exists for predicting drug synergy with deep learning. However, there are several machine learning algorithms that can be used for drug discovery and development, including deep learning techniques such as convolutional neural networks (CNNs), long short-term memory (LSTM) networks, and recurrent neural networks (RNNs). These algorithms can be trained on large datasets of drug interactions and molecular properties to predict drug efficacy, toxicity, and synergy or antagonism with other drugs.\n\nOne example of a tool that uses deep learning for drug discovery is the DrugPredict platform, which uses CNNs to predict the binding affinity of small molecules to their target proteins. Another example is the Syndera platform, which uses LSTM networks to predict drug-drug interactions and identify potential drug combinations with synergistic effects.\n\nOverall, while there are no specific tools dedicated to predicting drug synergy with deep learning, this is an active area of research in the field of machine learning for drug discovery, and there are several promising approaches being developed.",
    "llama-7b_fact_raw": "1. Convolutional neural networks (CNNs), long short-term memory (LSTM) networks, and recurrent neural networks (RNNs) are deep learning techniques used in drug discovery and development.\n2. These algorithms can predict drug efficacy, toxicity, and synergy or antagonism with other drugs.\n3. The DrugPredict platform uses CNNs to predict the binding affinity of small molecules to target proteins.\n4. The Syndera platform uses LSTM networks to predict drug-drug interactions and identify potential drug combinations with synergistic effects.\n5. Predicting drug synergy with deep learning is an active area of research in the field of machine learning for drug discovery.",
    "llama-7b_fact": [
      "Convolutional neural networks (CNNs), long short-term memory (LSTM) networks, and recurrent neural networks (RNNs) are deep learning techniques used in drug discovery and development.",
      "These algorithms can predict drug efficacy, toxicity, and synergy or antagonism with other drugs.",
      "The DrugPredict platform uses CNNs to predict the binding affinity of small molecules to target proteins.",
      "The Syndera platform uses LSTM networks to predict drug-drug interactions and identify potential drug combinations with synergistic effects.",
      "Predicting drug synergy with deep learning is an active area of research in the field of machine learning for drug discovery."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-7b_response": "The cloud-based platform developed for comparing GWAS is called the Genome-Wide Association Study (GWAS) Catalog. It is a public database that curates and integrates data from past and ongoing GWAS studies to help researchers identify potential genetic associations with various diseases and traits. The GWAS Catalog is hosted on the Amazon Web Services (AWS) cloud computing platform, which provides scalable and reliable storage and computing resources to support the large-scale data processing and analysis required for GWAS analysis. The GWAS Catalog is accessible through a web interface or programmatic APIs, allowing researchers to easily query and download data for further analysis. Overall, the GWAS Catalog is an important tool for advancing our understanding of the genetic basis of complex diseases and traits.",
    "llama-7b_fact_raw": "1. The Genome-Wide Association Study (GWAS) Catalog is a cloud-based platform developed for comparing GWAS.\n2. The GWAS Catalog is a public database that curates data from past and ongoing GWAS studies.\n3. The GWAS Catalog helps researchers identify potential genetic associations with various diseases and traits.\n4. The GWAS Catalog is hosted on the Amazon Web Services (AWS) cloud computing platform.\n5. The GWAS Catalog provides a web interface and programmatic APIs for researchers to query and download data.",
    "llama-7b_fact": [
      "The Genome-Wide Association Study (GWAS) Catalog is a cloud-based platform developed for comparing GWAS.",
      "The GWAS Catalog is a public database that curates data from past and ongoing GWAS studies.",
      "The GWAS Catalog helps researchers identify potential genetic associations with various diseases and traits.",
      "The GWAS Catalog is hosted on the Amazon Web Services (AWS) cloud computing platform.",
      "The GWAS Catalog provides a web interface and programmatic APIs for researchers to query and download data."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Genome-Wide Association Study (GWAS) Catalog is not specifically described as a cloud-based platform for comparing GWAS; it is a database that collects and curates information from published GWAS.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-7b_response": "CMB305 is a monoclonal antibody that is designed to target and bind to the CD30 protein, which is expressed on the surface of certain types of cancer cells, including sarcomas. Therefore, CMB305 has the potential to be used as a treatment for sarcomas.\n\nIn clinical trials, CMB305 has shown promising results in the treatment of certain types of sarcomas, such as synovial sarcoma and alveolar soft part sarcoma. These trials have demonstrated that CMB305 can induce tumor shrinkage and prolong survival in patients with these types of sarcomas.\n\nHowever, it is important to note that CMB305 may not be effective against all types of sarcomas, and further research is needed to determine its efficacy against other sarcoma subtypes. Additionally, CMB305 may not be effective against sarcomas that have become resistant to other treatments.\n\nOverall, CMB305 has the potential to be an effective treatment for some patients with sarcomas, and further research is needed to determine its role in the treatment of this disease.",
    "llama-7b_fact_raw": "1. CMB305 is a monoclonal antibody designed to target the CD30 protein on the surface of certain cancer cells, including sarcomas.\n2. CMB305 has shown promising results in clinical trials for the treatment of certain types of sarcomas, such as synovial sarcoma and alveolar soft part sarcoma.\n3. Clinical trials have demonstrated that CMB305 can induce tumor shrinkage and prolong survival in patients with certain types of sarcomas.\n4. CMB305 may not be effective against all types of sarcomas.\n5. Further research is needed to determine the efficacy of CMB305 against other sarcoma subtypes and its role in the treatment of sarcomas.",
    "llama-7b_fact": [
      "CMB305 is a monoclonal antibody designed to target the CD30 protein on the surface of certain cancer cells, including sarcomas.",
      "CMB305 has shown promising results in clinical trials for the treatment of certain types of sarcomas, such as synovial sarcoma and alveolar soft part sarcoma.",
      "Clinical trials have demonstrated that CMB305 can induce tumor shrinkage and prolong survival in patients with certain types of sarcomas.",
      "CMB305 may not be effective against all types of sarcomas.",
      "Further research is needed to determine the efficacy of CMB305 against other sarcoma subtypes and its role in the treatment of sarcomas."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-7b_response": "The Saint's Triad is a concept in Hindu mythology that refers to the union of three deities: Brahma, Vishnu, and Shiva. These three deities are considered to be the creator, preserver, and destroyer of the universe, respectively. The manifestations of the Saint's Triad are as follows:\n\n1. Brahma: Brahma is the creator of the universe and is often depicted as a bearded sage with four arms. He is associated with creation, knowledge, and wisdom. Some of the manifestations of Brahma include the creation of the universe, the creation of life, and the creation of knowledge.\n\n2. Vishnu: Vishnu is the preserver of the universe and is often depicted as a blue-skinned avatar with four arms. He is associated with preservation, protection, and sustenance. Some of the manifestations of Vishnu include the preservation of the universe, the protection of life, and the sustenance of all beings.\n\n3. Shiva: Shiva is the destroyer of the universe and is often depicted as a matted-haired sage with a third eye. He is associated with destruction, transformation, and regeneration. Some of the manifestations of Shiva include the destruction of the universe, the transformation of life, and the regeneration of all beings.\n\nIn summary, the manifestations of the Saint's Triad include creation, preservation, and destruction, which are essential for the continuous cycle of life and death in the universe.",
    "llama-7b_fact_raw": "1. In Hindu mythology, the Saint's Triad refers to the union of three deities: Brahma, Vishnu, and Shiva.\n2. Brahma is considered the creator of the universe in Hindu mythology.\n3. Vishnu is regarded as the preserver of the universe in Hindu mythology.\n4. Shiva is associated with the destruction of the universe in Hindu mythology.\n5. The Saint's Triad is associated with the continuous cycle of creation, preservation, and destruction in the universe.",
    "llama-7b_fact": [
      "In Hindu mythology, the Saint's Triad refers to the union of three deities: Brahma, Vishnu, and Shiva.",
      "Brahma is considered the creator of the universe in Hindu mythology.",
      "Vishnu is regarded as the preserver of the universe in Hindu mythology.",
      "Shiva is associated with the destruction of the universe in Hindu mythology.",
      "The Saint's Triad is associated with the continuous cycle of creation, preservation, and destruction in the universe."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: In Hindu mythology, the term \"Trimurti\" refers to the union of three deities: Brahma, Vishnu, and Shiva, not the \"Saint's Triad.\"\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-7b_response": "As an AI language model, I do not have access to the latest research studies or clinical data on non-small cell lung cancer (NSCLC) patients. However, I can provide some general information about LY6K and its potential association with cancer prognosis.\n\nLY6K, also known as CD244, is a protein that belongs to the Ly6/PLAUR family of glycoproteins. It is expressed on the surface of immune cells, including T cells, natural killer cells, and myeloid cells. LY6K has been implicated in various biological processes, such as inflammation, angiogenesis, and tumor progression.\n\nIn recent years, there has been growing interest in the role of LY6K in cancer. Studies have shown that LY6K is overexpressed in various types of cancer, including NSCLC. High levels of LY6K have been associated with poor prognosis in some cancer types, such as breast cancer and melanoma.\n\nHowever, the association between LY6K overexpression and cancer prognosis is complex and depends on several factors, such as the stage of cancer, the molecular profile of the tumor, and the treatment received by the patient. More research is needed to fully understand the role of LY6K in NSCLC and its potential as a prognostic biomarker or therapeutic target.",
    "llama-7b_fact_raw": "1. LY6K, also known as CD244, is a protein that belongs to the Ly6/PLAUR family of glycoproteins.\n2. LY6K is expressed on the surface of immune cells, including T cells, natural killer cells, and myeloid cells.\n3. LY6K has been implicated in various biological processes, such as inflammation, angiogenesis, and tumor progression.\n4. LY6K is overexpressed in various types of cancer, including non-small cell lung cancer (NSCLC).\n5. High levels of LY6K have been associated with poor prognosis in some cancer types, such as breast cancer and melanoma.",
    "llama-7b_fact": [
      "LY6K, also known as CD244, is a protein that belongs to the Ly6/PLAUR family of glycoproteins.",
      "LY6K is expressed on the surface of immune cells, including T cells, natural killer cells, and myeloid cells.",
      "LY6K has been implicated in various biological processes, such as inflammation, angiogenesis, and tumor progression.",
      "LY6K is overexpressed in various types of cancer, including non-small cell lung cancer (NSCLC).",
      "High levels of LY6K have been associated with poor prognosis in some cancer types, such as breast cancer and melanoma."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: LY6K, also known as CD177, is a protein that belongs to the Ly6 family of glycoproteins. CD244 is another protein that belongs to the SLAM family, not the Ly6/PLAUR family.\n2. FALSE [correction]: LY6K is not typically expressed on the surface of immune cells like T cells, natural killer cells, and myeloid cells. Instead, it is often associated with tumor cells. CD244, not LY6K, is expressed on natural killer cells and some T-cell subsets.\n3. TRUE: LY6K has been implicated in various biological processes, including those mentioned.\n4. TRUE: LY6K is known to be overexpressed in various types of cancer, including non-small cell lung cancer.\n5. TRUE: High levels of LY6K expression have been associated with poor prognosis in certain cancer types, including breast cancer and melanoma.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-7b_response": "During cytokinesis, several CDK (cyclin-dependent kinase) targets are dephosphorylated, leading to the separation of the daughter cells. Some of the key CDK targets that are dephosphorylated during cytokinesis are:\n\n1. Microtubule-associated proteins (MAPs): CDKs phosphorylate MAPs such as MAP1A, MAP1B, MAP2, and MAP4, which are important components of the mitotic spindle. During cytokinesis, these MAPs are dephosphorylated, leading to the disassembly of the spindle and the separation of the daughter cells.\n\n2. Actin filaments: CDKs also phosphorylate actin, which is a key component of the contractile ring that forms around the equator of the cell during cytokinesis. The dephosphorylation of actin by CDK inhibitors such as p16INK4a and p18INK4c allows for the disassembly of the contractile ring and the separation of the daughter cells.\n\n3. Kinesin spindle fibers: CDKs also phosphorylate kinesin, a motor protein that transports the spindle fibers towards the poles of the cell during anaphase. The dephosphorylation of kinesin by CDK inhibitors such as p21CIP1/WAF1 and p27KIP1 allows for the detachment of the spindle fibers and the separation of the daughter cells.\n\nOverall, the dephosphorylation of CDK targets during cytokinesis is essential for the separation of the daughter cells and the completion of mitosis.",
    "llama-7b_fact_raw": "1. CDKs phosphorylate Microtubule-associated proteins (MAPs) such as MAP1A, MAP1B, MAP2, and MAP4 during mitosis.\n2. These MAPs are dephosphorylated during cytokinesis, which leads to the disassembly of the mitotic spindle.\n3. Actin, a component of the contractile ring in cytokinesis, is phosphorylated by CDKs.\n4. CDK inhibitors such as p16INK4a and p18INK4c dephosphorylate actin, allowing for the disassembly of the contractile ring.\n5. Kinesin, a motor protein that transports spindle fibers, is phosphorylated by CDKs and dephosphorylated by CDK inhibitors like p21CIP1/WAF1 and p27KIP1 during cytokinesis.",
    "llama-7b_fact": [
      "CDKs phosphorylate Microtubule-associated proteins (MAPs) such as MAP1A, MAP1B, MAP2, and MAP4 during mitosis.",
      "These MAPs are dephosphorylated during cytokinesis, which leads to the disassembly of the mitotic spindle.",
      "Actin, a component of the contractile ring in cytokinesis, is phosphorylated by CDKs.",
      "CDK inhibitors such as p16INK4a and p18INK4c dephosphorylate actin, allowing for the disassembly of the contractile ring.",
      "Kinesin, a motor protein that transports spindle fibers, is phosphorylated by CDKs and dephosphorylated by CDK inhibitors like p21CIP1/WAF1 and p27KIP1 during cytokinesis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Actin is not directly phosphorylated by CDKs; instead, other proteins that regulate actin dynamics during cytokinesis may be phosphorylated by CDKs.\n4. FALSE [correction]: CDK inhibitors such as p16INK4a and p18INK4c do not dephosphorylate actin; they inhibit CDK activity, which can indirectly affect the phosphorylation state of proteins involved in cell cycle regulation.\n5. FALSE [correction]: Kinesin is a motor protein involved in microtubule dynamics, but it is not typically described as being phosphorylated by CDKs. CDK inhibitors like p21CIP1/WAF1 and p27KIP1 inhibit CDK activity and do not directly dephosphorylate proteins.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-7b_response": "Xanamem is a prescription medication that is used to treat the symptoms of mild to moderate Alzheimer's disease. It belongs to a class of drugs called cholinesterase inhibitors, which work by increasing the levels of a neurotransmitter called acetylcholine in the brain. Acetylcholine is important for memory and cognitive function.\n\nXanamem works by preventing the breakdown of acetylcholine, which helps to maintain higher levels of this neurotransmitter in the brain. This can improve memory, attention, and other cognitive abilities in people with Alzheimer's disease.\n\nXanamem is taken orally in the form of a tablet, usually once daily. It may take several weeks to see an improvement in symptoms, and it is important to continue taking the medication even if there is no improvement or if symptoms worsen.\n\nSide effects of Xanamem can include nausea, vomiting, diarrhea, and constipation. It is important to let your healthcare provider know if you experience any side effects while taking the medication.\n\nIt is important to note that Xanamem is not a cure for Alzheimer's disease and will not stop the progression of the disease. However, it can help improve quality of life by reducing symptoms and allowing patients to continue living independently for a longer period of time.",
    "llama-7b_fact_raw": "1. Xanamem is used to treat symptoms of mild to moderate Alzheimer's disease.\n2. Xanamem belongs to a class of drugs called cholinesterase inhibitors.\n3. Cholinesterase inhibitors, like Xanamem, work by increasing levels of acetylcholine in the brain.\n4. Xanamem is administered orally in tablet form, typically once daily.\n5. Side effects of Xanamem can include nausea, vomiting, diarrhea, and constipation.",
    "llama-7b_fact": [
      "Xanamem is used to treat symptoms of mild to moderate Alzheimer's disease.",
      "Xanamem belongs to a class of drugs called cholinesterase inhibitors.",
      "Cholinesterase inhibitors, like Xanamem, work by increasing levels of acetylcholine in the brain.",
      "Xanamem is administered orally in tablet form, typically once daily.",
      "Side effects of Xanamem can include nausea, vomiting, diarrhea, and constipation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Xanamem is not a cholinesterase inhibitor; it is designed to block the production of excess cortisol by inhibiting the activity of the enzyme 11β-HSD1.\n3. FALSE [correction]: Cholinesterase inhibitors work by increasing levels of acetylcholine in the brain, but Xanamem does not belong to this class of drugs; it targets cortisol production.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: As of my knowledge cutoff date in early 2023, Xanamem (also known as XanADu) is a drug that was under investigation for the treatment of Alzheimer's disease. It is not a cholinesterase inhibitor but rather is designed to inhibit the enzyme 11β-HSD1 to reduce the production of cortisol in the brain. The administration method, dosing frequency, and side effects would need to be confirmed with current medical guidelines or clinical trial results.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-7b_response": "The Hof1-Cyk3 interaction plays a crucial role in regulating the cell cycle progression in yeast. Hof1 is a protein kinase that is involved in the phosphorylation of numerous proteins involved in various cellular processes, including the cell cycle. Cyk3, on the other hand, is a protein that interacts with Hof1 and regulates its activity.\n\nThe Hof1-Cyk3 interaction is important for the initiation of DNA replication, which is the first step in the cell cycle. Cyk3 interacts with the Cdc6 protein, which is a key regulator of DNA replication. Cdc6 interacts with Hof1, which then phosphorylates Cyk3, preventing it from interacting with other proteins and inhibiting DNA replication.\n\nFurthermore, the Hof1-Cyk3 interaction is also important for the G2/M phase transition of the cell cycle. During this phase, Cyk3 interacts with the Cdc20 protein, which is a regulator of mitosis. Cdc20 interacts with Hof1, which then phosphorylates Cyk3, allowing it to interact with Cdc20 and promote the separation of sister chromatids during mitosis.\n\nIn summary, the Hof1-Cyk3 interaction plays a crucial role in regulating the cell cycle progression in yeast by controlling the activity of key proteins involved in DNA replication and mitosis. Without this interaction, the cell cycle would be disrupted, leading to cellular dysfunction and potentially cell death.",
    "llama-7b_fact_raw": "1. The Hof1-Cyk3 interaction regulates cell cycle progression in yeast.\n2. Hof1 is a protein kinase involved in the phosphorylation of proteins related to the cell cycle.\n3. Cyk3 is a protein that regulates the activity of Hof1.\n4. The Hof1-Cyk3 interaction is important for the initiation of DNA replication in yeast.\n5. The Hof1-Cyk3 interaction is also important for the G2/M phase transition of the cell cycle in yeast.",
    "llama-7b_fact": [
      "The Hof1-Cyk3 interaction regulates cell cycle progression in yeast.",
      "Hof1 is a protein kinase involved in the phosphorylation of proteins related to the cell cycle.",
      "Cyk3 is a protein that regulates the activity of Hof1.",
      "The Hof1-Cyk3 interaction is important for the initiation of DNA replication in yeast.",
      "The Hof1-Cyk3 interaction is also important for the G2/M phase transition of the cell cycle in yeast."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Hof1 is not a protein kinase; it is a protein involved in cytokinesis, but it does not have kinase activity.\n3. TRUE\n4. FALSE [correction]: The Hof1-Cyk3 interaction is not directly involved in the initiation of DNA replication; it is important for cytokinesis during the late stages of the cell cycle.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-7b_response": "There are several T-UCRs that have been implicated in gastric cancer. These include:\n\n1. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): TRAIL is a cytokine that induces apoptosis in cancer cells. Studies have shown that TRAIL can inhibit the growth of gastric cancer cells in vitro and in vivo.\n\n2. Interleukin-1 beta (IL-1β): IL-1β is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-1β have been found in the stomach tissue of patients with gastric cancer.\n\n3. Interleukin-6 (IL-6): IL-6 is another pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-6 have been found in the stomach tissue of patients with gastric cancer.\n\n4. Interleukin-8 (IL-8): IL-8 is a chemokine that promotes inflammation and angiogenesis. Studies have shown that IL-8 can stimulate the growth of gastric cancer cells in vitro and in vivo.\n\n5. Interleukin-18 (IL-18): IL-18 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-18 have been found in the stomach tissue of patients with gastric cancer.\n\nOverall, these T-UCRs play an important role in the development and progression of gastric cancer and may represent potential targets for cancer therapy.",
    "llama-7b_fact_raw": "1. TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) has been shown to inhibit the growth of gastric cancer cells in vitro and in vivo.\n2. High levels of Interleukin-1 beta (IL-1β) have been found in the stomach tissue of patients with gastric cancer.\n3. High levels of Interleukin-6 (IL-6) have been found in the stomach tissue of patients with gastric cancer.\n4. Studies have indicated that Interleukin-8 (IL-8) can stimulate the growth of gastric cancer cells in vitro and in vivo.\n5. High levels of Interleukin-18 (IL-18) have been found in the stomach tissue of patients with gastric cancer.",
    "llama-7b_fact": [
      "TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) has been shown to inhibit the growth of gastric cancer cells in vitro and in vivo.",
      "High levels of Interleukin-1 beta (IL-1β) have been found in the stomach tissue of patients with gastric cancer.",
      "High levels of Interleukin-6 (IL-6) have been found in the stomach tissue of patients with gastric cancer.",
      "Studies have indicated that Interleukin-8 (IL-8) can stimulate the growth of gastric cancer cells in vitro and in vivo.",
      "High levels of Interleukin-18 (IL-18) have been found in the stomach tissue of patients with gastric cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE: TRAIL has been investigated for its role in inducing apoptosis in various cancer cells, including gastric cancer cells, and has shown potential in inhibiting their growth both in vitro (in the lab) and in vivo (in living organisms).\n2. TRUE: Elevated levels of Interleukin-1 beta (IL-1β) have been associated with various types of cancer, including gastric cancer, and have been found in the stomach tissue of patients with this disease.\n3. TRUE: Interleukin-6 (IL-6) is a cytokine that plays a role in inflammation and is often found at high levels in the stomach tissue of patients with gastric cancer, where it can contribute to tumor growth and progression.\n4. TRUE: Interleukin-8 (IL-8) is known to have pro-angiogenic and pro-tumorigenic effects, and studies have indicated that it can stimulate the growth of gastric cancer cells both in vitro and in vivo.\n5. TRUE: Interleukin-18 (IL-18) is involved in the immune response and has been found at high levels in the stomach tissue of patients with gastric cancer, although its exact role in cancer progression can be complex and context-dependent.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-7b_response": "The Lupus Severity Index (LSI) is a tool used to measure the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various organs and systems in the body. The LSI was developed in the 1980s and is based on a combination of clinical and laboratory criteria.\n\nThe LSI consists of a total score that ranges from 0 to 100, with higher scores indicating more severe disease activity. The score is calculated based on the following criteria:\n\n1. Malar rash (facial rash) - 10 points\n2. Discoid rash - 5 points\n3. Oral ulcers - 10 points\n4. Photosensitivity - 10 points\n5. Arthritis - 20 points\n6. Serositis - 20 points\n7. Renal involvement - 20 points\n8. Hematologic abnormalities - 10 points\n9. Central nervous system involvement - 10 points\n10. Cardiovascular involvement - 10 points\n\nIn addition to the above criteria, the LSI also takes into account the patient's age, sex, and race, as these factors can affect the severity of lupus.\n\nThe LSI is a useful tool for clinicians to monitor the disease activity and response to treatment in patients with SLE. However, it is important to note that the LSI is not a perfect measure of disease severity and should be used in conjunction with other clinical and laboratory parameters.",
    "llama-7b_fact_raw": "1. The Lupus Severity Index (LSI) is used to measure the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed in the 1980s.\n3. The LSI score ranges from 0 to 100, with higher scores indicating more severe disease activity.\n4. The LSI score is calculated based on a combination of clinical and laboratory criteria, including malar rash, discoid rash, and renal involvement, among others.\n5. The LSI takes into account the patient's age, sex, and race as factors that can affect the severity of lupus.",
    "llama-7b_fact": [
      "The Lupus Severity Index (LSI) is used to measure the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed in the 1980s.",
      "The LSI score ranges from 0 to 100, with higher scores indicating more severe disease activity.",
      "The LSI score is calculated based on a combination of clinical and laboratory criteria, including malar rash, discoid rash, and renal involvement, among others.",
      "The LSI takes into account the patient's age, sex, and race as factors that can affect the severity of lupus."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The existence of a specific \"Lupus Severity Index\" (LSI) is not a widely recognized term in medical literature. There are several indices used to measure the severity of systemic lupus erythematosus (SLE), such as the SLE Disease Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) index, but without more context, it's unclear whether \"LSI\" refers to a real and specific index or is a fictional or less common term.\n\n2. UNKNOWN: Since the existence of the LSI as a specific index is not established, the time of its development cannot be determined.\n\n3. UNKNOWN: Without confirmation of the LSI's existence and its use, the score range cannot be verified.\n\n4. UNKNOWN: The criteria for calculating the score of the LSI cannot be confirmed without knowing if the LSI is a recognized medical index.\n\n5. UNKNOWN: Without valid information on the LSI, it is not possible to confirm whether it takes into account demographic factors such as age, sex, and race.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-7b_response": "I'm sorry, but I cannot provide a detailed answer to this question as there is no information available on the specific disorders caused by de novo mutations in ZSWIM6. De novo mutations are genetic mutations that occur spontaneously in a person's DNA and are not inherited from their parents. ZSWIM6 is a gene that has not been extensively studied in the context of disease causation. Therefore, it is not possible to say with certainty which disorders are caused by de novo mutations in this gene. It is important to note that de novo mutations can affect many different genes and can potentially cause a wide range of disorders. Further research is needed to determine the specific disorders caused by de novo mutations in ZSWIM6.",
    "llama-7b_fact_raw": "1. De novo mutations are genetic mutations that occur spontaneously in a person's DNA.\n2. De novo mutations are not inherited from the parents.\n3. ZSWIM6 is a gene that has not been extensively studied in the context of disease causation.\n4. It is not possible to say with certainty which disorders are caused by de novo mutations in ZSWIM6.\n5. Further research is needed to determine the specific disorders caused by de novo mutations in ZSWIM6.",
    "llama-7b_fact": [
      "De novo mutations are genetic mutations that occur spontaneously in a person's DNA.",
      "De novo mutations are not inherited from the parents.",
      "ZSWIM6 is a gene that has not been extensively studied in the context of disease causation.",
      "It is not possible to say with certainty which disorders are caused by de novo mutations in ZSWIM6.",
      "Further research is needed to determine the specific disorders caused by de novo mutations in ZSWIM6."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-7b_response": "The Koos Classification is a system used to classify spinal deformities in children and adolescents. It was developed by Dr. Willem Koos, a Dutch orthopedic surgeon, in the 1960s. The classification system categorizes spinal deformities based on their cause, location, and severity.\n\nOne disease that can be classified using the Koos Classification is idiopathic scoliosis. Idiopathic scoliosis is a spinal deformity that occurs in children and adolescents, usually between the ages of 10 and 15 years. It is a sideways curvature of the spine that is usually greater on one side than the other. The cause of idiopathic scoliosis is unknown, but it is thought to be due to a combination of genetic and environmental factors.\n\nThe Koos Classification system categorizes idiopathic scoliosis into different types based on the location and severity of the deformity. For example, the most common type of idiopathic scoliosis is type I, which is a single curve of the spine. Type II scoliosis is when there are two curves in the spine, and type III scoliosis is when there are three or more curves in the spine. The severity of the scoliosis is categorized into grades, with grade 1 being the mildest and grade 4 being the most severe.\n\nOverall, the Koos Classification system is an important tool for orthopedic surgeons to accurately diagnose and treat spinal deformities in children and adolescents, including idiopathic scoliosis.",
    "llama-7b_fact_raw": "1. The Koos Classification is used to classify spinal deformities in children and adolescents.\n2. Dr. Willem Koos, a Dutch orthopedic surgeon, developed the Koos Classification in the 1960s.\n3. Idiopathic scoliosis, a disease that can be classified using the Koos Classification, typically occurs in children and adolescents between the ages of 10 and 15 years.\n4. Idiopathic scoliosis is characterized by a sideways curvature of the spine.\n5. The Koos Classification system categorizes idiopathic scoliosis into different types based on the location and severity of the deformity.",
    "llama-7b_fact": [
      "The Koos Classification is used to classify spinal deformities in children and adolescents.",
      "Dr. Willem Koos, a Dutch orthopedic surgeon, developed the Koos Classification in the 1960s.",
      "Idiopathic scoliosis, a disease that can be classified using the Koos Classification, typically occurs in children and adolescents between the ages of 10 and 15 years.",
      "Idiopathic scoliosis is characterized by a sideways curvature of the spine.",
      "The Koos Classification system categorizes idiopathic scoliosis into different types based on the location and severity of the deformity."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The correct classification system for spinal deformities in children and adolescents is the Cobb method, not the Koos Classification.\n2. FALSE [correction]: Since the Koos Classification does not exist for spinal deformities, Dr. Willem Koos did not develop it. The Cobb method was developed by Dr. John Robert Cobb.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The statement refers to a classification system for idiopathic scoliosis, which is likely the Cobb method, not the Koos Classification. The Cobb method categorizes the severity of the scoliosis by measuring the degree of spinal curvature.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-7b_response": "AZD8601 is a small molecule inhibitor of the PI3K/mTOR pathway that has shown promising results in preclinical models of cancer. In vivo studies have demonstrated that AZD8601 can effectively inhibit the growth and proliferation of various types of cancer, including breast, colon, and lung cancer.\n\nOne of the key mechanisms by which AZD8601 exerts its anticancer effects is by blocking the activation of the PI3K/mTOR pathway, which is frequently aberrantly activated in cancer cells. By inhibiting this pathway, AZD8601 can suppress the proliferation and survival of cancer cells, as well as induce apoptosis or cell death.\n\nAdditionally, AZD8601 has been shown to have anti-angiogenic effects, which may contribute to its anticancer activity. By inhibiting the formation of new blood vessels that supply tumors with oxygen and nutrients, AZD8601 can starve tumors of the nutrients they need to grow and survive.\n\nOverall, the in vivo effects of AZD8601 are promising and suggest that this agent may be an effective treatment for a range of solid tumor types. However, further clinical trials are needed to fully evaluate the safety and efficacy of this agent in patients with cancer.",
    "llama-7b_fact_raw": "1. AZD8601 is a small molecule inhibitor of the PI3K/mTOR pathway.\n2. In vivo studies have shown that AZD8601 can inhibit the growth and proliferation of various types of cancer, including breast, colon, and lung cancer.\n3. AZD8601 works by blocking the activation of the PI3K/mTOR pathway, which is often aberrantly activated in cancer cells.\n4. AZD8601 has been observed to induce apoptosis or cell death in cancer cells.\n5. AZD8601 has anti-angiogenic effects, which means it can inhibit the formation of new blood vessels that supply tumors.",
    "llama-7b_fact": [
      "AZD8601 is a small molecule inhibitor of the PI3K/mTOR pathway.",
      "In vivo studies have shown that AZD8601 can inhibit the growth and proliferation of various types of cancer, including breast, colon, and lung cancer.",
      "AZD8601 works by blocking the activation of the PI3K/mTOR pathway, which is often aberrantly activated in cancer cells.",
      "AZD8601 has been observed to induce apoptosis or cell death in cancer cells.",
      "AZD8601 has anti-angiogenic effects, which means it can inhibit the formation of new blood vessels that supply tumors."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: AZD8601 is not a small molecule inhibitor; it is an mRNA-based therapy that encodes for a protein called VEGF-A, which is involved in the restoration of blood vessels and cardiovascular tissues.\n2. UNKNOWN\n3. FALSE [correction]: AZD8601 does not block the activation of the PI3K/mTOR pathway. Instead, it functions by delivering the mRNA that encodes for VEGF-A to stimulate the restoration of blood vessels.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-7b_response": "SAHFS, or Self-Assembled Hybrid Nanostructures, are created through a process called \"templated self-assembly.\" This process involves the use of a template, such as a gold nanoparticle, to guide the self-assembly of a second material, such as a block copolymer.\n\nThe block copolymer is a polymer made up of two or more different segments, each with distinct chemical or physical properties. In the case of SAHFS, the block copolymer is designed to self-assemble into a repeating pattern of nanostructures, such as cylinders, spheres, or lamellae.\n\nThe template serves as a guide for the block copolymer to align and organize itself into the desired nanostructure pattern. The interaction between the template and the block copolymer is governed by Van der Waals forces, electrostatic interactions, and hydrogen bonding.\n\nOnce the template has guided the self-assembly of the block copolymer, it can be removed, leaving behind the SAHFS. The resulting nanostructures can have a wide range of applications, including in electronics, energy storage, and biomedicine.",
    "llama-7b_fact_raw": "1. SAHFS, or Self-Assembled Hybrid Nanostructures, are created through a process called \"templated self-assembly.\"\n2. A template, such as a gold nanoparticle, is used to guide the self-assembly of a second material, like a block copolymer.\n3. Block copolymers used in SAHFS are polymers made up of two or more different segments with distinct chemical or physical properties.\n4. The interaction between the template and the block copolymer during SAHFS creation is governed by Van der Waals forces, electrostatic interactions, and hydrogen bonding.\n5. The template can be removed after guiding the self-assembly of the block copolymer, leaving behind the SAHFS.",
    "llama-7b_fact": [
      "SAHFS, or Self-Assembled Hybrid Nanostructures, are created through a process called \"templated self-assembly.\"",
      "A template, such as a gold nanoparticle, is used to guide the self-assembly of a second material, like a block copolymer.",
      "Block copolymers used in SAHFS are polymers made up of two or more different segments with distinct chemical or physical properties.",
      "The interaction between the template and the block copolymer during SAHFS creation is governed by Van der Waals forces, electrostatic interactions, and hydrogen bonding.",
      "The template can be removed after guiding the self-assembly of the block copolymer, leaving behind the SAHFS."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with general knowledge about self-assembled hybrid nanostructures (SAHFS) and the processes involved in their creation. However, it should be noted that the specifics of the interactions and the ability to remove the template can vary depending on the particular materials and methods used.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-7b_response": "The PDZ (PSD-95/Dlg/ZO-1) domain in SATB1 (Sry-related HMG-box 1) is a small protein-binding motif consisting of approximately 80 amino acids. The PDZ domain is a common feature of scaffolding proteins and is involved in the formation of multiprotein complexes that regulate various cellular processes, including signal transduction, cytoskeletal organization, and gene expression.\n\nIn the case of SATB1, the PDZ domain is thought to play a crucial role in the regulation of gene expression. SATB1 is a transcriptional regulator that binds to DNA and regulates the expression of target genes involved in cell proliferation, differentiation, and migration. The PDZ domain in SATB1 interacts with a variety of proteins involved in these processes, including ion channels, cytoskeletal proteins, and signaling molecules. These interactions help to localize SATB1 to specific subcellular compartments, such as the nucleus and the cell membrane, and to regulate its activity.\n\nOverall, the PDZ domain in SATB1 plays a critical role in the regulation of gene expression and cellular processes by facilitating the formation of multiprotein complexes and regulating the localization and activity of SATB1.",
    "llama-7b_fact_raw": "1. The PDZ domain in SATB1 consists of approximately 80 amino acids.\n2. The PDZ domain is involved in the formation of multiprotein complexes that regulate various cellular processes.\n3. SATB1 is a transcriptional regulator that binds to DNA and regulates the expression of target genes.\n4. The PDZ domain in SATB1 interacts with proteins involved in cell proliferation, differentiation, and migration.\n5. The PDZ domain helps to localize SATB1 to specific subcellular compartments, such as the nucleus and the cell membrane.",
    "llama-7b_fact": [
      "The PDZ domain in SATB1 consists of approximately 80 amino acids.",
      "The PDZ domain is involved in the formation of multiprotein complexes that regulate various cellular processes.",
      "SATB1 is a transcriptional regulator that binds to DNA and regulates the expression of target genes.",
      "The PDZ domain in SATB1 interacts with proteins involved in cell proliferation, differentiation, and migration.",
      "The PDZ domain helps to localize SATB1 to specific subcellular compartments, such as the nucleus and the cell membrane."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: The PDZ domain typically helps to localize proteins to specific subcellular compartments, but SATB1 localization is primarily due to its nuclear localization signal and its ability to bind to specific DNA sequences, not its PDZ domain.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-7b_response": "The BLISS technique is based on the principle of bilateral stimulation, which involves stimulating both the left and right sides of the brain simultaneously. This is achieved through the use of binaural beats, which are auditory stimuli that are created by using two different frequencies that are played in each ear.\n\nThe idea behind bilateral stimulation is that it can help to activate both hemispheres of the brain, which can lead to enhanced cognitive function, creativity, and emotional regulation. By stimulating both sides of the brain, the BLISS technique aims to create a state of coherence between the two hemispheres, which can help to improve overall brain function and well-being.\n\nIn addition to binaural beats, the BLISS technique also incorporates guided meditation and visualization, which are used to help individuals access a state of deep relaxation and inner peace. By combining these different elements, the BLISS technique aims to create a powerful tool for self-discovery, personal growth, and spiritual development.",
    "llama-7b_fact_raw": "1. The BLISS technique is based on the principle of bilateral stimulation.\n2. Bilateral stimulation involves stimulating both the left and right sides of the brain simultaneously.\n3. Binaural beats are used in the BLISS technique, which are auditory stimuli created by using two different frequencies played in each ear.\n4. The BLISS technique aims to create a state of coherence between the two hemispheres of the brain.\n5. The BLISS technique incorporates guided meditation and visualization in addition to binaural beats.",
    "llama-7b_fact": [
      "The BLISS technique is based on the principle of bilateral stimulation.",
      "Bilateral stimulation involves stimulating both the left and right sides of the brain simultaneously.",
      "Binaural beats are used in the BLISS technique, which are auditory stimuli created by using two different frequencies played in each ear.",
      "The BLISS technique aims to create a state of coherence between the two hemispheres of the brain.",
      "The BLISS technique incorporates guided meditation and visualization in addition to binaural beats."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-7b_response": "Sure, here are 3 NK3R antagonists:\n\n1. APD334 - It is a selective and potent NK3R antagonist that is being developed for the treatment of schizophrenia and other central nervous system disorders.\n\n2. SB-277991 - It is another selective and potent NK3R antagonist that is being developed for the treatment of depression, anxiety, and other central nervous system disorders.\n\n3. TC-5214 - It is a non-selective and less potent NK3R antagonist that is being developed for the treatment of Parkinson's disease and other movement disorders.",
    "llama-7b_fact_raw": "1. APD334 is being developed for the treatment of schizophrenia and other central nervous system disorders.\n2. SB-277991 is being developed for the treatment of depression, anxiety, and other central nervous system disorders.\n3. TC-5214 is being developed for the treatment of Parkinson's disease and other movement disorders.",
    "llama-7b_fact": [
      "APD334 is being developed for the treatment of schizophrenia and other central nervous system disorders.",
      "SB-277991 is being developed for the treatment of depression, anxiety, and other central nervous system disorders.",
      "TC-5214 is being developed for the treatment of Parkinson's disease and other movement disorders."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific and current information about the development status and intended uses of the compounds APD334, SB-277991, and TC-5214, it is not possible to determine the accuracy of these statements. The development of pharmaceuticals is a complex process with many compounds being investigated for various conditions, and without up-to-date knowledge or a specific reference to these compounds, their intended treatments cannot be confirmed.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-7b_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is known as dapagliflozin. It was developed by Bristol-Myers Squibb and AstraZeneca and was approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of type 2 diabetes. Dapagliflozin works by inhibiting the activity of the sodium-glucose co-transporter 2 (SGLT2) protein, which is responsible for reabsorbing glucose in the kidneys. By blocking this reabsorption, dapagliflozin increases the excretion of glucose in the urine, resulting in lower blood glucose levels. Additionally, dapagliflozin has been shown to lower blood pressure and improve glycemic control in patients with type 2 diabetes.",
    "llama-7b_fact_raw": "1. Dapagliflozin is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. Bristol-Myers Squibb and AstraZeneca developed dapagliflozin.\n3. The U.S. Food and Drug Administration approved dapagliflozin in 2014.\n4. Dapagliflozin inhibits the activity of the sodium-glucose co-transporter 2 (SGLT2) protein.\n5. Dapagliflozin was approved for the treatment of type 2 diabetes.",
    "llama-7b_fact": [
      "Dapagliflozin is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "Bristol-Myers Squibb and AstraZeneca developed dapagliflozin.",
      "The U.S. Food and Drug Administration approved dapagliflozin in 2014.",
      "Dapagliflozin inhibits the activity of the sodium-glucose co-transporter 2 (SGLT2) protein.",
      "Dapagliflozin was approved for the treatment of type 2 diabetes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Dapagliflozin is not a ghrelin receptor inverse agonist; it is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-7b_response": "Vaxchora is a vaccine that is approved for the prevention of cholera in adults 18 years of age and older. The protective efficacy of Vaxchora against moderate to severe cholera has been demonstrated in clinical trials.\n\nIn a study conducted in Bangladesh, Vaxchora was found to be 76% effective in preventing severe cholera in adults. The vaccine was also found to be 86% effective in preventing hospitalization due to cholera.\n\nIn another study conducted in Haiti, Vaxchora was found to be 56% effective in preventing severe cholera in adults. However, the vaccine was not found to be effective in preventing hospitalization due to cholera.\n\nOverall, the protective efficacy of Vaxchora against moderate to severe cholera varies depending on the study and the population being vaccinated. However, it is clear that Vaxchora provides some protection against cholera and can be an effective tool in preventing severe cases of the disease.",
    "llama-7b_fact_raw": "1. Vaxchora is approved for the prevention of cholera in adults 18 years of age and older.\n2. In a study conducted in Bangladesh, Vaxchora was 76% effective in preventing severe cholera in adults.\n3. The same study in Bangladesh found Vaxchora to be 86% effective in preventing hospitalization due to cholera.\n4. In a study conducted in Haiti, Vaxchora was 56% effective in preventing severe cholera in adults.\n5. The study in Haiti found that Vaxchora was not effective in preventing hospitalization due to cholera.",
    "llama-7b_fact": [
      "Vaxchora is approved for the prevention of cholera in adults 18 years of age and older.",
      "In a study conducted in Bangladesh, Vaxchora was 76% effective in preventing severe cholera in adults.",
      "The same study in Bangladesh found Vaxchora to be 86% effective in preventing hospitalization due to cholera.",
      "In a study conducted in Haiti, Vaxchora was 56% effective in preventing severe cholera in adults.",
      "The study in Haiti found that Vaxchora was not effective in preventing hospitalization due to cholera."
    ],
    "llama-7b_judge_raw": "1. TRUE: Vaxchora is indeed approved for the prevention of cholera in adults 18 years of age and older.\n2. UNKNOWN: Without specific details of the study conducted in Bangladesh, the effectiveness rate of 76% for Vaxchora in preventing severe cholera in adults cannot be verified.\n3. UNKNOWN: Similarly, without specific details of the study, the effectiveness rate of 86% for preventing hospitalization due to cholera cannot be verified.\n4. UNKNOWN: The effectiveness rate of 56% in a study conducted in Haiti cannot be verified without specific details of the study.\n5. UNKNOWN: The claim that Vaxchora was not effective in preventing hospitalization due to cholera in the Haiti study cannot be verified without specific details of the study.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-7b_response": "The first cholera vaccine approved in the US was the Dukoral vaccine, which was approved by the Food and Drug Administration (FDA) in 2005. Dukoral is a live attenuated oral vaccine that is safe and effective for the prevention of cholera caused by Vibrio cholerae serogroup Ogawa and Inaba. It is approved for use in adults and children above the age of 1 year. The vaccine is administered orally in the form of a powder that is mixed with water and drunk like a fruit juice. Dukoral does not require refrigeration and can be stored at room temperature. It provides long-lasting protection against cholera and can be used as a travel vaccine for individuals traveling to areas with a high risk of cholera.",
    "llama-7b_fact_raw": "1. The Dukoral vaccine was the first cholera vaccine approved in the US.\n2. The Dukoral vaccine was approved by the Food and Drug Administration (FDA) in 2005.\n3. Dukoral is a live attenuated oral vaccine indicated for the prevention of cholera caused by Vibrio cholerae serogroup Ogawa and Inaba.\n4. The Dukoral vaccine is approved for use in adults and children above the age of 1 year.\n5. Dukoral can be stored at room temperature and does not require refrigeration.",
    "llama-7b_fact": [
      "The Dukoral vaccine was the first cholera vaccine approved in the US.",
      "The Dukoral vaccine was approved by the Food and Drug Administration (FDA) in 2005.",
      "Dukoral is a live attenuated oral vaccine indicated for the prevention of cholera caused by Vibrio cholerae serogroup Ogawa and Inaba.",
      "The Dukoral vaccine is approved for use in adults and children above the age of 1 year.",
      "Dukoral can be stored at room temperature and does not require refrigeration."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Dukoral vaccine was not the first cholera vaccine approved in the US. Vaxchora, approved in 2016, is the only cholera vaccine approved by the FDA for use in the United States.\n2. FALSE [correction]: The Dukoral vaccine has not been approved by the Food and Drug Administration (FDA) for use in the United States as of my knowledge cutoff in 2023.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Dukoral must be stored in a refrigerator at 2°C to 8°C (35°F to 46°F) and should not be frozen. It does not have a formulation that allows it to be stored at room temperature.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-7b_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is the autosomal recessive mutation in the gene encoding the common acute lymphoblastic leukemia/lymphoma 1 (CALLA1) protein. This mutation accounts for approximately 20-30% of cases of CVID in European populations. The CALLA1 protein is involved in the regulation of B cell development and function, and mutations in this gene can result in impaired B cell development and reduced levels of immunoglobulin production. Treatment for CVID caused by CALLA1 mutations typically involves immunoglobulin replacement therapy. However, it is important to note that there are likely other genetic and environmental factors that contribute to the development of CVID, and not all cases of CVID are due to mutations in the CALLA1 gene.",
    "llama-7b_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the gene encoding the CALLA1 protein.\n2. This mutation accounts for approximately 20-30% of cases of CVID in European populations.\n3. The CALLA1 protein is involved in the regulation of B cell development and function.\n4. Mutations in the CALLA1 gene can result in impaired B cell development and reduced levels of immunoglobulin production.\n5. Treatment for CVID caused by CALLA1 mutations typically involves immunoglobulin replacement therapy.",
    "llama-7b_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the gene encoding the CALLA1 protein.",
      "This mutation accounts for approximately 20-30% of cases of CVID in European populations.",
      "The CALLA1 protein is involved in the regulation of B cell development and function.",
      "Mutations in the CALLA1 gene can result in impaired B cell development and reduced levels of immunoglobulin production.",
      "Treatment for CVID caused by CALLA1 mutations typically involves immunoglobulin replacement therapy."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is not a mutation in the gene encoding the CALLA1 protein. It is mutations in the TNFRSF13B gene, encoding the TACI protein, that are most commonly associated with CVID in Europeans.\n2. FALSE [correction]: Since the first statement is incorrect, the percentage of cases of CVID in European populations attributed to CALLA1 mutations is also incorrect. Mutations in the TNFRSF13B gene account for about 10% of CVID cases in Europeans.\n3. UNKNOWN: The statement about the CALLA1 protein is vague because there is no well-known protein by that name associated with CVID. The protein commonly associated with CVID is TACI, encoded by the TNFRSF13B gene.\n4. UNKNOWN: Since the CALLA1 protein is not established in the context of CVID, the effects of mutations in a gene encoding this protein on B cell development and immunoglobulin production cannot be confirmed.\n5. TRUE: Treatment for CVID, regardless of the specific genetic mutation, typically involves immunoglobulin replacement therapy to compensate for the reduced levels of immunoglobulin production.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-7b_response": "The IFIT1 gene, also known as interferon-induced protein with tetratricopeptide repeats 1, plays a crucial role in the development and progression of Systemic Lupus Erythematosus (SLE). The IFIT1 protein is a type I interferon (IFN) inducible antiviral factor that regulates the expression of various genes involved in the innate immune response.\n\nStudies have shown that the IFIT1 gene is upregulated in SLE patients compared to healthy individuals. This upregulation is thought to be due to the activation of IFN signaling pathways in SLE, which are dysregulated in the disease. The IFIT1 protein has been shown to inhibit the replication of various viruses, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV).\n\nFurthermore, IFIT1 has been shown to regulate the expression of various genes involved in autoimmunity, inflammation, and tissue damage in SLE. It has been suggested that the dysregulation of IFIT1 expression contributes to the development of autoantibodies and tissue damage in SLE.\n\nIn summary, the IFIT1 gene plays a crucial role in the development and progression of SLE by regulating the expression of various genes involved in the innate immune response and autoimmunity. Dysregulation of IFIT1 expression may contribute to the development of autoantibodies and tissue damage in SLE.",
    "llama-7b_fact_raw": "1. The IFIT1 gene is also known as interferon-induced protein with tetratricopeptide repeats 1.\n2. The IFIT1 protein is a type I interferon inducible antiviral factor.\n3. The IFIT1 gene is upregulated in patients with Systemic Lupus Erythematosus (SLE) compared to healthy individuals.\n4. The IFIT1 protein inhibits the replication of various viruses, including HIV, HCV, and HBV.\n5. Dysregulation of IFIT1 expression is suggested to contribute to the development of autoantibodies and tissue damage in SLE.",
    "llama-7b_fact": [
      "The IFIT1 gene is also known as interferon-induced protein with tetratricopeptide repeats 1.",
      "The IFIT1 protein is a type I interferon inducible antiviral factor.",
      "The IFIT1 gene is upregulated in patients with Systemic Lupus Erythematosus (SLE) compared to healthy individuals.",
      "The IFIT1 protein inhibits the replication of various viruses, including HIV, HCV, and HBV.",
      "Dysregulation of IFIT1 expression is suggested to contribute to the development of autoantibodies and tissue damage in SLE."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - The IFIT1 gene is known to be upregulated in patients with Systemic Lupus Erythematosus (SLE) compared to healthy individuals, as part of the interferon signature associated with the disease.\n4. TRUE - The IFIT1 protein is known to inhibit the replication of various viruses, although the specific range of viruses it affects can depend on the context and the study. It is generally involved in the antiviral response.\n5. TRUE - Dysregulation of IFIT1 and other interferon-inducible genes is thought to contribute to the pathogenesis of SLE, including the development of autoantibodies and tissue damage.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-7b_response": "The Liverpool Elbow Score (LES) is a clinical scoring system used to assess the severity of elbow injuries, particularly those involving the lateral epicondyle. It was developed by a group of physicians at the Liverpool Hospital in Australia in the 1990s and has since become a widely used tool in the evaluation and management of elbow injuries.\n\nThe LES takes into account several factors related to the patient's symptoms, physical examination findings, and imaging studies. The score ranges from 0 to 10, with higher scores indicating more severe injuries. A score of 0-3 indicates a minor injury, 4-6 indicates a moderate injury, and 7-10 indicates a severe injury.\n\nThe LES has several advantages over other scoring systems, including its simplicity, ease of use, and reliability. It is also widely available and has been validated in multiple studies.\n\nIn summary, the Liverpool Elbow Score is a useful tool for assessing the severity of elbow injuries, particularly those involving the lateral epicondyle. It helps clinicians determine the appropriate management plan, which may include rest, physical therapy, or surgery.",
    "llama-7b_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow injuries.\n2. The LES was developed by physicians at the Liverpool Hospital in Australia in the 1990s.\n3. The score ranges from 0 to 10, with higher scores indicating more severe injuries.\n4. A score of 0-3 on the LES indicates a minor injury, 4-6 indicates a moderate injury, and 7-10 indicates a severe injury.\n5. The Liverpool Elbow Score has been validated in multiple studies.",
    "llama-7b_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow injuries.",
      "The LES was developed by physicians at the Liverpool Hospital in Australia in the 1990s.",
      "The score ranges from 0 to 10, with higher scores indicating more severe injuries.",
      "A score of 0-3 on the LES indicates a minor injury, 4-6 indicates a moderate injury, and 7-10 indicates a severe injury.",
      "The Liverpool Elbow Score has been validated in multiple studies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The Liverpool Elbow Score (LES) was developed by physicians at the Royal Liverpool Hospital in the United Kingdom, not Australia.\n3. FALSE [correction]: The score actually ranges from 0 to 100, with higher scores indicating better function, not more severe injuries.\n4. FALSE [correction]: Since the LES ranges from 0 to 100 and higher scores indicate better function, the interpretation of the scores provided is incorrect. A higher score reflects a better outcome or less disability.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-7b_response": "The 100,000 Genomes Project is a groundbreaking initiative launched by the UK government in 2012 with the aim of sequencing the genomes of 100,000 patients with rare diseases or cancers. One of the rare cancers targeted by the project is sarcoma, a type of cancer that affects soft tissues such as muscles, tendons, and ligaments, as well as bone and cartilage.\n\nThe project has made significant efforts to include sarcoma patients in its research, with the aim of improving diagnosis, treatment, and outcomes for patients. To date, over 100 sarcoma patients have had their genomes sequenced as part of the project.\n\nOne of the key benefits of the 100,000 Genomes Project for sarcoma patients is that it has enabled researchers to identify new genetic mutations associated with the disease. These mutations can help clinicians to diagnose sarcoma earlier and more accurately, as well as identify patients who may be at a higher risk of developing the disease.\n\nIn addition, the project has enabled researchers to identify potential targets for new treatments, including targeted therapies that can specifically target the genetic mutations driving the disease. This has the potential to significantly improve outcomes for sarcoma patients, many of whom currently have a poor prognosis.\n\nOverall, the 100,000 Genomes Project has made significant efforts to include sarcoma patients in its research, with the aim of improving diagnosis, treatment, and outcomes for patients. As the project continues to analyze more genomes, it is hoped that even more insights will be gained into the genetic drivers of sarcoma, leading to more effective treatments and better patient outcomes.",
    "llama-7b_fact_raw": "1. The 100,000 Genomes Project was launched by the UK government in 2012.\n2. The project aims to sequence the genomes of 100,000 patients with rare diseases or cancers, including sarcoma.\n3. Over 100 sarcoma patients have had their genomes sequenced as part of the 100,000 Genomes Project.\n4. The project has identified new genetic mutations associated with sarcoma.\n5. The 100,000 Genomes Project has enabled researchers to identify potential targets for new treatments for sarcoma.",
    "llama-7b_fact": [
      "The 100,000 Genomes Project was launched by the UK government in 2012.",
      "The project aims to sequence the genomes of 100,000 patients with rare diseases or cancers, including sarcoma.",
      "Over 100 sarcoma patients have had their genomes sequenced as part of the 100,000 Genomes Project.",
      "The project has identified new genetic mutations associated with sarcoma.",
      "The 100,000 Genomes Project has enabled researchers to identify potential targets for new treatments for sarcoma."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched by the UK government in 2013.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe 100,000 Genomes Project was indeed launched with the aim of sequencing 100,000 genomes from patients with rare diseases and cancers, including sarcoma. The project has sequenced the genomes of over 100 sarcoma patients and has identified new genetic mutations associated with sarcoma. These findings have the potential to help researchers identify targets for new treatments.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-7b_response": "Yes, protein ALEX1 does contain armadillo repeats. The ALEX1 protein is a component of the SWI/SNF chromatin remodeling complex, which is involved in the regulation of gene expression. The armadillo repeat domain of ALEX1 is responsible for interacting with other components of the SWI/SNF complex, as well as with other proteins involved in chromatin remodeling and transcriptional regulation. The armadillo repeats in ALEX1 are composed of a series of tandem repeats of a small, approximately 60 amino acid motif known as the armadillo repeat domain. These repeats are thought to contribute to the stability and flexibility of the ALEX1 protein, as well as its ability to interact with other proteins. Overall, the presence of armadillo repeats in ALEX1 is crucial for its role in regulating gene expression and shaping the three-dimensional structure of chromatin.",
    "llama-7b_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. The ALEX1 protein is a component of the SWI/SNF chromatin remodeling complex.\n3. The armadillo repeat domain of ALEX1 interacts with other components of the SWI/SNF complex and proteins involved in chromatin remodeling and transcriptional regulation.\n4. Armadillo repeats in ALEX1 are composed of a series of tandem repeats of approximately 60 amino acid motifs.\n5. The presence of armadillo repeats in ALEX1 is important for its role in regulating gene expression and shaping the three-dimensional structure of chromatin.",
    "llama-7b_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "The ALEX1 protein is a component of the SWI/SNF chromatin remodeling complex.",
      "The armadillo repeat domain of ALEX1 interacts with other components of the SWI/SNF complex and proteins involved in chromatin remodeling and transcriptional regulation.",
      "Armadillo repeats in ALEX1 are composed of a series of tandem repeats of approximately 60 amino acid motifs.",
      "The presence of armadillo repeats in ALEX1 is important for its role in regulating gene expression and shaping the three-dimensional structure of chromatin."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE - Armadillo repeats are indeed composed of tandem repeats of approximately 42 to 45 amino acids, which can be rounded to approximately 60 for a generalized description.\n5. UNKNOWN\n\nThe statements regarding ALEX1 protein, its functions, and interactions are highly specific and would require access to current and detailed scientific literature or databases to verify. Without such access or specific knowledge, the truthfulness of these statements cannot be determined.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-7b_response": "There are several enzymes that remove histone modifications, including:\n\n1. Histone deacetylases (HDACs): These enzymes remove acetyl groups from lysine residues in the N-terminal tails of histones. This leads to the condensation of chromatin and the repression of gene expression.\n\n2. Histone methyltransferases (HMTs): These enzymes add methyl groups to lysine residues in the N-terminal tails of histones. This can lead to either the activation or repression of gene expression, depending on the specific residue modified and the presence of other modifications.\n\n3. Histone demethylases (HDMs): These enzymes remove methyl groups from lysine residues in the N-terminal tails of histones. This can lead to the activation or repression of gene expression, depending on the specific residue modified and the presence of other modifications.\n\n4. Lysine-specific demethylase 1 (LSD1): This enzyme removes methyl groups from lysine 9 of histone H3, leading to the activation of gene expression.\n\n5. Jumonji C (JmjC) domain-containing histone demethylases: These enzymes remove methyl groups from lysine residues in the N-terminal tails of histones. There are several subfamilies of JmjC domain-containing enzymes, which can either activate or repress gene expression depending on the specific residue modified.\n\nOverall, these enzymes play an important role in regulating gene expression by modifying histones, which in turn affects the accessibility of DNA to transcription factors and RNA polymerase.",
    "llama-7b_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from lysine residues in the N-terminal tails of histones.\n2. Histone demethylases (HDMs) remove methyl groups from lysine residues in the N-terminal tails of histones.\n3. Lysine-specific demethylase 1 (LSD1) removes methyl groups from lysine 9 of histone H3.\n4. Jumonji C (JmjC) domain-containing histone demethylases remove methyl groups from lysine residues in the N-terminal tails of histones.\n5. The removal of histone modifications by these enzymes can lead to the activation or repression of gene expression.",
    "llama-7b_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from lysine residues in the N-terminal tails of histones.",
      "Histone demethylases (HDMs) remove methyl groups from lysine residues in the N-terminal tails of histones.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from lysine 9 of histone H3.",
      "Jumonji C (JmjC) domain-containing histone demethylases remove methyl groups from lysine residues in the N-terminal tails of histones.",
      "The removal of histone modifications by these enzymes can lead to the activation or repression of gene expression."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-7b_response": "The answer to the question \"does head CT increase brain tumor risk?\" is complex and depends on several factors.\n\nA head CT (computed tomography) scan is a medical imaging test that uses X-rays and computer technology to create detailed images of the head. It is often used to diagnose and treat a variety of medical conditions, including brain tumors.\n\nWhile head CT scans are generally considered safe and effective, there is some concern that repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor. This is particularly true for children and young adults, who are more susceptible to the effects of radiation.\n\nHowever, it is important to note that the risk of developing a brain tumor from a single head CT scan is extremely low. In fact, most experts believe that the benefits of using head CT scans outweigh the potential risks.\n\nThat being said, it is always a good idea to minimize exposure to radiation whenever possible. If you are concerned about the risks associated with head CT scans, be sure to discuss your concerns with your healthcare provider. They can help you weigh the benefits and risks of this diagnostic tool and determine the best course of action for your individual situation.",
    "llama-7b_fact_raw": "1. A head CT scan uses X-rays and computer technology to create detailed images of the head.\n2. Head CT scans are used to diagnose and treat a variety of medical conditions, including brain tumors.\n3. Repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor, especially in children and young adults.\n4. The risk of developing a brain tumor from a single head CT scan is considered extremely low.\n5. Experts generally believe that the benefits of using head CT scans outweigh the potential risks.",
    "llama-7b_fact": [
      "A head CT scan uses X-rays and computer technology to create detailed images of the head.",
      "Head CT scans are used to diagnose and treat a variety of medical conditions, including brain tumors.",
      "Repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor, especially in children and young adults.",
      "The risk of developing a brain tumor from a single head CT scan is considered extremely low.",
      "Experts generally believe that the benefits of using head CT scans outweigh the potential risks."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-7b_response": "Otx2 is associated with the embryonic stem cell pluripotency. Otx2 is a transcription factor that plays a crucial role in the regulation of embryonic stem cell self-renewal and differentiation. Otx2 is expressed in the inner cell mass of the blastocyst, which is the source of embryonic stem cells. The expression of Otx2 in embryonic stem cells is essential for the maintenance of pluripotency and the differentiation of embryonic stem cells into various cell types. Therefore, Otx2 is strongly associated with embryonic stem cell pluripotency.",
    "llama-7b_fact_raw": "1. Otx2 is associated with embryonic stem cell pluripotency.\n2. Otx2 is a transcription factor involved in the regulation of embryonic stem cell self-renewal and differentiation.\n3. Otx2 is expressed in the inner cell mass of the blastocyst.\n4. The inner cell mass of the blastocyst is the source of embryonic stem cells.\n5. The expression of Otx2 is essential for the maintenance of pluripotency in embryonic stem cells.",
    "llama-7b_fact": [
      "Otx2 is associated with embryonic stem cell pluripotency.",
      "Otx2 is a transcription factor involved in the regulation of embryonic stem cell self-renewal and differentiation.",
      "Otx2 is expressed in the inner cell mass of the blastocyst.",
      "The inner cell mass of the blastocyst is the source of embryonic stem cells.",
      "The expression of Otx2 is essential for the maintenance of pluripotency in embryonic stem cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nOtx2 is indeed associated with embryonic stem cell pluripotency and is a transcription factor that plays a role in the regulation of stem cell self-renewal and differentiation. It is expressed in the inner cell mass of the blastocyst, which is the source of embryonic stem cells. The expression of Otx2 is considered essential for the maintenance of pluripotency in these cells.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-7b_response": "The murine beta globin locus region contains several DNaseI hypersensitive sites, also known as DHS. The exact number of DHS that mark the murine beta globin locus region is difficult to determine as it varies depending on the study and the method used to identify DHS. However, several studies have reported that the murine beta globin locus region contains between 10 and 20 DHS. \n\nFor example, a study by Zhang et al. (2004) identified 16 DHS in the murine beta globin locus region using a chromatin immunoprecipitation assay combined with DNaseI hypersensitivity testing. Another study by Liu et al. (2008) identified 18 DHS in the murine beta globin locus region using a similar approach. \n\nTherefore, it is fair to say that the murine beta globin locus region contains between 10 and 20 DHS. However, it is important to note that this number may vary depending on the experimental conditions and the method used to identify DHS.",
    "llama-7b_fact_raw": "1. The murine beta globin locus region contains several DNaseI hypersensitive sites (DHS).\n2. The number of DHS marking the murine beta globin locus region varies between studies.\n3. Studies have reported that the murine beta globin locus region contains between 10 and 20 DHS.\n4. Zhang et al. (2004) identified 16 DHS in the murine beta globin locus region.\n5. Liu et al. (2008) identified 18 DHS in the murine beta globin locus region.",
    "llama-7b_fact": [
      "The murine beta globin locus region contains several DNaseI hypersensitive sites (DHS).",
      "The number of DHS marking the murine beta globin locus region varies between studies.",
      "Studies have reported that the murine beta globin locus region contains between 10 and 20 DHS.",
      "Zhang et al. (2004) identified 16 DHS in the murine beta globin locus region.",
      "Liu et al. (2008) identified 18 DHS in the murine beta globin locus region."
    ],
    "llama-7b_judge_raw": "1. TRUE: The murine beta globin locus region does contain several DNaseI hypersensitive sites (DHS), which are indicative of regions of open chromatin that are accessible to transcription factors.\n2. TRUE: It is plausible that the number of DHS marking the murine beta globin locus region varies between studies due to differences in experimental conditions, techniques, or interpretations of data.\n3. UNKNOWN: Without specific references to studies, it is difficult to confirm the exact range of DHS reported for the murine beta globin locus region.\n4. UNKNOWN: Without access to the specific study by Zhang et al. (2004), the accuracy of the statement cannot be confirmed.\n5. UNKNOWN: Similarly, without access to the specific study by Liu et al. (2008), the accuracy of the statement cannot be confirmed.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-7b_response": "There are several European influenza vaccines available, including:\n\n1. Fluarix: This is an inactivated influenza vaccine that is manufactured by GlaxoSmithKline. It is approved for use in adults and children above the age of 3 years.\n\n2. FluLaval: This is another inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children above the age of 6 months.\n\n3. FluMist: This is a live attenuated influenza vaccine that is manufactured by MedImmune. It is approved for use in healthy individuals between the ages of 2 and 49 years.\n\n4. Afluria: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults and children above the age of 18 years.\n\n5. Fluzone: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children above the age of 6 months.\n\n6. Fluzone High-Dose: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults aged 65 years and older.\n\n7. Fluarix Quadrivalent: This is an inactivated influenza vaccine that is manufactured by GlaxoSmithKline. It is approved for use in adults and children above the age of 3 years.\n\n8. FluLaval Quadrivalent: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children above the age of 6 months.\n\n9. FluMist Quadrivalent: This is a live attenuated influenza vaccine that is manufactured by MedImmune. It is approved for use in healthy individuals between the ages of 2 and 49 years.\n\n10. Afluria Quadrivalent: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved",
    "llama-7b_fact_raw": "1. Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline, approved for use in adults and children over 3 years old.\n2. FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur, approved for use in adults and children over 6 months old.\n3. FluMist is a live attenuated influenza vaccine manufactured by MedImmune, approved for use in healthy individuals between 2 and 49 years old.\n4. Afluria is an inactivated influenza vaccine manufactured by Seqirus, approved for use in adults and children over 18 years old.\n5. Fluzone High-Dose is an inactivated influenza vaccine manufactured by Sanofi Pasteur, approved for use in adults aged 65 years and older.",
    "llama-7b_fact": [
      "Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline, approved for use in adults and children over 3 years old.",
      "FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur, approved for use in adults and children over 6 months old.",
      "FluMist is a live attenuated influenza vaccine manufactured by MedImmune, approved for use in healthy individuals between 2 and 49 years old.",
      "Afluria is an inactivated influenza vaccine manufactured by Seqirus, approved for use in adults and children over 18 years old.",
      "Fluzone High-Dose is an inactivated influenza vaccine manufactured by Sanofi Pasteur, approved for use in adults aged 65 years and older."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: FluLaval is an inactivated influenza vaccine manufactured by GlaxoSmithKline, approved for use in adults and children over 6 months old.\n3. TRUE\n4. FALSE [correction]: Afluria is an inactivated influenza vaccine manufactured by Seqirus, approved for use in individuals 6 months of age and older.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-7b_response": "Yes, the Paramyxovirus geneome segmented, negative-sense RNA. \n\nParamyxoviruses are a family of viruses that cause a wide range of diseases in humans and animals. These viruses have a single-stranded, negative-sense RNA genome that is segmented into eight separate genetic segments. Each segment is encapsidated by the viral protein VP1 and then assembled into a complete viral particle. \n\nThe negative-sense RNA means that the RNA strand is read in the opposite direction to the usual sense of mRNA, which is positive-sense. This is important for the replication of the virus, as it allows the viral RNA to be complementary to the mRNA of the host cell. \n\nThe segmented nature of the Paramyxovirus genome means that there are eight separate genes, each encoding a specific protein necessary for viral replication and/or function. These genes are arranged in a specific order, with each segment containing a portion of one or more of the genes. \n\nOverall, the segmented, negative-sense RNA genome of Paramyxoviruses is crucial for their ability to infect host cells and replicate their genetic material.",
    "llama-7b_fact_raw": "1. Paramyxoviruses have a single-stranded, negative-sense RNA genome.\n2. The Paramyxovirus genome is segmented into eight separate genetic segments.\n3. Each segment of the Paramyxovirus genome is encapsidated by the viral protein VP1.\n4. The RNA of Paramyxoviruses is read in the opposite direction to the usual sense of mRNA.\n5. Each of the eight segments of the Paramyxovirus genome encodes a specific protein necessary for viral replication and/or function.",
    "llama-7b_fact": [
      "Paramyxoviruses have a single-stranded, negative-sense RNA genome.",
      "The Paramyxovirus genome is segmented into eight separate genetic segments.",
      "Each segment of the Paramyxovirus genome is encapsidated by the viral protein VP1.",
      "The RNA of Paramyxoviruses is read in the opposite direction to the usual sense of mRNA.",
      "Each of the eight segments of the Paramyxovirus genome encodes a specific protein necessary for viral replication and/or function."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The Paramyxovirus genome is non-segmented, not divided into separate segments.\n3. FALSE [correction]: Paramyxoviruses do not have a VP1 protein that encapsidates their genome; instead, the nucleocapsid protein (N) encapsidates the RNA genome.\n4. TRUE\n5. FALSE [correction]: Since the Paramyxovirus genome is non-segmented, it does not have eight separate segments; therefore, it does not have eight segments each encoding a specific protein. The genome encodes multiple proteins, but not in a one-segment-one-protein manner.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-7b_response": "Roflumilast cream is a prescription medication that is used to treat a certain type of lung disease called chronic obstructive pulmonary disease (COPD). COPD is a progressive disease that makes it difficult to breathe and is caused by damage to the airways and lungs. Roflumilast cream works by reducing inflammation and improving the function of the airways, which can help improve symptoms of COPD such as shortness of breath, wheezing, and coughing. However, it is not a cure for COPD and should be used in combination with other medications as directed by a healthcare provider. It is important to note that roflumilast cream should not be used by people who have asthma or severe allergies.",
    "llama-7b_fact_raw": "1. Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).\n2. COPD is a progressive disease that makes it difficult to breathe.\n3. Roflumilast cream works by reducing inflammation and improving the function of the airways.\n4. Roflumilast cream is not a cure for COPD.\n5. Roflumilast cream should not be used by people who have asthma or severe allergies.",
    "llama-7b_fact": [
      "Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).",
      "COPD is a progressive disease that makes it difficult to breathe.",
      "Roflumilast cream works by reducing inflammation and improving the function of the airways.",
      "Roflumilast cream is not a cure for COPD.",
      "Roflumilast cream should not be used by people who have asthma or severe allergies."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Roflumilast is available as a pill or tablet for the treatment of chronic obstructive pulmonary disease (COPD); it is not typically formulated as a cream.\n2. TRUE\n3. TRUE, but the statement is more accurate for the pill or tablet form of roflumilast, which is taken orally to reduce inflammation and improve lung function in COPD.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-7b_response": "There are several tools that have been developed for identifying and visualising ncRNA promoters. Here are some of the most popular ones:\n\n1. RNAhyplot: RNAhyplot is a web-based tool that allows users to visualize and compare the hybridization patterns of different RNA molecules. It can be used to identify ncRNA promoters by comparing the hybridization patterns of the promoter region with those of other regions of the same ncRNA molecule.\n\n2. PROMO: PROMO is a database and web-based tool that contains information on promoters of various types of RNA molecules, including ncRNA promoters. It allows users to search for promoters based on various criteria, such as the type of RNA molecule, the location of the promoter, and the type of transcription factor that binds to the promoter.\n\n3. PITA: PITA is a web-based tool that allows users to search for and visualize promoters of various types of RNA molecules, including ncRNA promoters. It provides information on the location of the promoter, the transcription factors that bind to the promoter, and the regulatory elements that are involved in the regulation of the promoter.\n\n4. NCPromoter: NCPromoter is a database and web-based tool that contains information on promoters of ncRNA molecules. It allows users to search for promoters based on various criteria, such as the type of ncRNA molecule, the location of the promoter, and the type of transcription factor that binds to the promoter.\n\nOverall, these tools provide valuable resources for identifying and visualizing ncRNA promoters, and they are essential for understanding the regulatory mechanisms that control the expression of these non-coding RNA molecules.",
    "llama-7b_fact_raw": "1. RNAhyplot is a web-based tool designed to visualize and compare the hybridization patterns of RNA molecules.\n2. PROMO is a database and web-based tool that contains information on promoters for various types of RNA molecules, including ncRNA promoters.\n3. PITA is a web-based tool that provides information on the location of promoters and the transcription factors that bind to them for various types of RNA molecules.\n4. NCPromoter is a database and web-based tool that contains information specifically on promoters of ncRNA molecules.",
    "llama-7b_fact": [
      "RNAhyplot is a web-based tool designed to visualize and compare the hybridization patterns of RNA molecules.",
      "PROMO is a database and web-based tool that contains information on promoters for various types of RNA molecules, including ncRNA promoters.",
      "PITA is a web-based tool that provides information on the location of promoters and the transcription factors that bind to them for various types of RNA molecules.",
      "NCPromoter is a database and web-based tool that contains information specifically on promoters of ncRNA molecules."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: PROMO is a tool designed for the identification of transcription factor binding sites in DNA sequences, not specifically for RNA molecules or ncRNA promoters.\n3. FALSE [correction]: PITA is a tool designed to predict microRNA targets by analyzing the hybridization between microRNAs and potential target sites, not for providing information on promoters and transcription factors.\n4. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-7b_response": "I apologize, but as an AI language model, I do not have access to the specific data or information on genes identified by the SWIM tool for glioblastoma. However, I can provide a general overview of how the SWIM tool works and how it identifies down-regulated genes in glioblastoma.\n\nThe SWIM tool is a bioinformatics tool that uses gene expression data to identify differentially expressed genes in glioblastoma. The tool analyzes gene expression profiles of glioblastoma samples and compares them to normal brain samples to identify genes that are down-regulated in glioblastoma.\n\nSome examples of genes that may be identified by the SWIM tool as being down-regulated in glioblastoma include:\n\n1. TP53: TP53 is a tumor suppressor gene that is frequently mutated in glioblastoma. The SWIM tool may identify TP53 as being down-regulated in glioblastoma.\n\n2. PTEN: PTEN is a tumor suppressor gene that is also frequently mutated in glioblastoma. The SWIM tool may identify PTEN as being down-regulated in glioblastoma.\n\n3. CDKN2A: CDKN2A is another tumor suppressor gene that is frequently mutated in glioblastoma. The SWIM tool may identify CDKN2A as being down-regulated in glioblastoma.\n\n4. EGFR: EGFR is a receptor tyrosine kinase that is frequently overexpressed in glioblastoma. The SWIM tool may identify EGFR as being down-regulated in glioblastoma.\n\n5. PDGFRA: PDGFRA is another receptor tyrosine kinase that is frequently overexpressed in glioblastoma. The SWIM tool may identify PDGFRA as being down-regulated in glioblastoma.\n\nThese are just a few examples of genes that may be identified by the SWIM tool as being down-regulated in glioblastoma. It is important to note that the specific genes identified by the SWIM tool may vary depending on the dataset used and the analysis performed.",
    "llama-7b_fact_raw": "1. TP53 is a tumor suppressor gene that can be down-regulated in glioblastoma.\n2. PTEN is a tumor suppressor gene that can be down-regulated in glioblastoma.\n3. CDKN2A is a tumor suppressor gene that can be down-regulated in glioblastoma.\n4. EGFR is a receptor tyrosine kinase that can be down-regulated in glioblastoma.\n5. PDGFRA is a receptor tyrosine kinase that can be down-regulated in glioblastoma.",
    "llama-7b_fact": [
      "TP53 is a tumor suppressor gene that can be down-regulated in glioblastoma.",
      "PTEN is a tumor suppressor gene that can be down-regulated in glioblastoma.",
      "CDKN2A is a tumor suppressor gene that can be down-regulated in glioblastoma.",
      "EGFR is a receptor tyrosine kinase that can be down-regulated in glioblastoma.",
      "PDGFRA is a receptor tyrosine kinase that can be down-regulated in glioblastoma."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: EGFR is a receptor tyrosine kinase that is often up-regulated or mutated in glioblastoma, not down-regulated.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-7b_response": "There are several R packages that have been developed for studying TADs (TADs stands for Transcriptional Activation Domains). Here are some of the most notable ones:\n\n1. TADMatrix: TADMatrix is a widely used R package for studying TADs. It provides a comprehensive set of tools for analyzing and visualizing TADs, including tools for identifying TAD boundaries, measuring TAD enrichment, and visualizing TAD structures.\n\n2. TADtools: TADtools is another popular R package for studying TADs. It provides a suite of tools for analyzing and visualizing TADs, including tools for identifying TAD boundaries, measuring TAD enrichment, and visualizing TAD structures.\n\n3. TADSeq: TADSeq is an R package for analyzing TADs using RNA-seq data. It provides tools for identifying TAD boundaries in RNA-seq data, measuring TAD enrichment, and visualizing TAD structures.\n\n4. TADFinder: TADFinder is an R package for identifying TADs in genomic data. It uses a machine learning approach to identify TAD boundaries in genomic data, and provides tools for measuring TAD enrichment and visualizing TAD structures.\n\n5. TADProfiler: TADProfiler is an R package for analyzing TADs using ChIP-seq data. It provides tools for identifying TAD boundaries in ChIP-seq data, measuring TAD enrichment, and visualizing TAD structures.\n\nThese are just a few of the many R packages that have been developed for studying TADs. Each of these packages provides a unique set of tools for analyzing and visualizing TADs, and can be used together to gain a comprehensive understanding of TAD structure and function.",
    "llama-7b_fact_raw": "1. TADMatrix is an R package used for analyzing and visualizing Transcriptional Activation Domains (TADs).\n2. TADtools is an R package that provides tools for studying TADs, including identifying TAD boundaries and visualizing TAD structures.\n3. TADSeq is an R package designed for analyzing TADs using RNA-seq data.\n4. TADFinder is an R package that employs a machine learning approach to identify TAD boundaries in genomic data.\n5. TADProfiler is an R package for analyzing TADs using ChIP-seq data.",
    "llama-7b_fact": [
      "TADMatrix is an R package used for analyzing and visualizing Transcriptional Activation Domains (TADs).",
      "TADtools is an R package that provides tools for studying TADs, including identifying TAD boundaries and visualizing TAD structures.",
      "TADSeq is an R package designed for analyzing TADs using RNA-seq data.",
      "TADFinder is an R package that employs a machine learning approach to identify TAD boundaries in genomic data.",
      "TADProfiler is an R package for analyzing TADs using ChIP-seq data."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information about a package named \"TADMatrix,\" it is not possible to confirm its purpose. There is no widely recognized R package by this name known for analyzing and visualizing Transcriptional Activation Domains (TADs) as of my knowledge cutoff date.\n2. TRUE: TADtools is indeed an R package that provides tools for studying TADs, including identifying TAD boundaries and visualizing TAD structures.\n3. FALSE [correction]: TADSeq does not seem to be a recognized R package for analyzing TADs using RNA-seq data. There might be confusion with other tools or packages designed for TAD analysis, but \"TADSeq\" is not known for this purpose.\n4. UNKNOWN: Without specific information about a package named \"TADFinder,\" it is not possible to confirm its purpose or whether it uses a machine learning approach to identify TAD boundaries in genomic data. There is no widely recognized R package by this name known for such a purpose as of my knowledge cutoff date.\n5. UNKNOWN: Without specific information about a package named \"TADProfiler,\" it is not possible to confirm its purpose. There is no widely recognized R package by this name known for analyzing TADs using ChIP-seq data as of my knowledge cutoff date.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-7b_response": "One bioconductor tool that has been developed for accessing bacterial regulatory networks is the \"Bacterial Regulatory Networks\" package. This package provides a set of tools for analyzing bacterial regulatory networks, including tools for identifying regulatory interactions, predicting the effects of mutations on regulatory networks, and visualizing regulatory interactions. The package is based on a variety of data sources, including genomic sequence data, transcriptomic data, and proteomic data. The \"Bacterial Regulatory Networks\" package has been used to study a variety of bacterial species, including E. coli, Salmonella, and Pseudomonas.",
    "llama-7b_fact_raw": "1. The \"Bacterial Regulatory Networks\" package is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. The package includes tools for identifying regulatory interactions.\n3. It also provides tools for predicting the effects of mutations on regulatory networks.\n4. The package allows for visualization of regulatory interactions.\n5. It has been used to study bacterial species such as E. coli, Salmonella, and Pseudomonas.",
    "llama-7b_fact": [
      "The \"Bacterial Regulatory Networks\" package is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "The package includes tools for identifying regulatory interactions.",
      "It also provides tools for predicting the effects of mutations on regulatory networks.",
      "The package allows for visualization of regulatory interactions.",
      "It has been used to study bacterial species such as E. coli, Salmonella, and Pseudomonas."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-7b_response": "The shikimate pathway is a series of biochemical reactions that occur in plants, bacteria, and some fungi. It is involved in the synthesis of aromatic amino acids, which are essential building blocks for the biosynthesis of various secondary metabolites, such as plant hormones, antibiotics, and defense compounds.\n\nThe end products of the shikimate pathway are the aromatic amino acids: phenylalanine, tyrosine, and tryptophan. These amino acids are crucial building blocks for the biosynthesis of various secondary metabolites, including plant hormones such as auxin and gibberellins, antibiotics such as Streptomyces antibiotics, and defense compounds such as alkaloids and phenolics.\n\nPhenylalanine can be converted into tyrosine, which can be further converted into L-dopa, a precursor for the biosynthesis of dopamine, norepinephrine, and epinephrine. Tryptophan can be converted into serotonin, which is an important neurotransmitter involved in regulating mood, appetite, and sleep.\n\nIn summary, the end products of the shikimate pathway are aromatic amino acids that are essential building blocks for the biosynthesis of various secondary metabolites, which have important biological functions in plants, bacteria, and some fungi.",
    "llama-7b_fact_raw": "1. The shikimate pathway occurs in plants, bacteria, and some fungi.\n2. The end products of the shikimate pathway are the aromatic amino acids: phenylalanine, tyrosine, and tryptophan.\n3. Aromatic amino acids are used for the biosynthesis of secondary metabolites such as plant hormones, antibiotics, and defense compounds.\n4. Phenylalanine can be converted into tyrosine, which can be further converted into L-dopa.\n5. Tryptophan can be converted into serotonin, an important neurotransmitter.",
    "llama-7b_fact": [
      "The shikimate pathway occurs in plants, bacteria, and some fungi.",
      "The end products of the shikimate pathway are the aromatic amino acids: phenylalanine, tyrosine, and tryptophan.",
      "Aromatic amino acids are used for the biosynthesis of secondary metabolites such as plant hormones, antibiotics, and defense compounds.",
      "Phenylalanine can be converted into tyrosine, which can be further converted into L-dopa.",
      "Tryptophan can be converted into serotonin, an important neurotransmitter."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-7b_response": "No, cabergoline is not typically used for the treatment of Nelson's syndrome. Nelson's syndrome is a rare condition that occurs when prostate cancer spreads to the pituitary gland and causes it to produce too much growth hormone. Cabergoline is typically used to treat hyperprolactinemia, a condition in which the pituitary gland produces too much prolactin, the hormone responsible for breast milk production. However, cabergoline may be used off-label to treat Nelson's syndrome in some cases, but it is not a first-line treatment for this condition. Other treatments for Nelson's syndrome may include surgery to remove the pituitary gland or radiation therapy to the pituitary gland.",
    "llama-7b_fact_raw": "1. Cabergoline is not typically used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is a condition that occurs when cancer spreads to the pituitary gland, causing it to produce too much growth hormone.\n3. Cabergoline is typically used to treat hyperprolactinemia, a condition where the pituitary gland produces too much prolactin.\n4. Surgery to remove the pituitary gland or radiation therapy to the pituitary gland are treatments for Nelson's syndrome.",
    "llama-7b_fact": [
      "Cabergoline is not typically used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is a condition that occurs when cancer spreads to the pituitary gland, causing it to produce too much growth hormone.",
      "Cabergoline is typically used to treat hyperprolactinemia, a condition where the pituitary gland produces too much prolactin.",
      "Surgery to remove the pituitary gland or radiation therapy to the pituitary gland are treatments for Nelson's syndrome."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Nelson's syndrome is a condition that occurs following the removal of the adrenal glands, causing the pituitary gland to produce too much adrenocorticotropic hormone (ACTH).\n3. TRUE\n4. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-7b_response": "Liebenberg syndrome is a rare genetic disorder that affects the development and functioning of the nervous system. The main manifestation of Liebenberg syndrome is intellectual disability, which can range from mild to severe. Intellectual disability is characterized by limitations in cognitive, social, and adaptive skills, which can make it difficult for individuals to function independently in daily life.\n\nAdditionally, individuals with Liebenberg syndrome may have delayed motor development, speech and language delays, and behavioral challenges. They may also experience seizures, sleep disturbances, and sensory processing issues.\n\nThe severity of symptoms can vary among individuals with Liebenberg syndrome, and some may also have other health issues such as vision and hearing impairments, gastroesophageal reflux disease, and sleep apnea.\n\nOverall, the main manifestation of Liebenberg syndrome is a combination of intellectual disability, developmental delays, and behavioral challenges, which can impact an individual's quality of life and require ongoing support and intervention.",
    "llama-7b_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder that affects the development and functioning of the nervous system.\n2. The main manifestation of Liebenberg syndrome is intellectual disability.\n3. Individuals with Liebenberg syndrome may experience delayed motor development, speech and language delays, and behavioral challenges.\n4. Seizures, sleep disturbances, and sensory processing issues can occur in individuals with Liebenberg syndrome.\n5. Some individuals with Liebenberg syndrome may have additional health issues such as vision and hearing impairments, gastroesophageal reflux disease, and sleep apnea.",
    "llama-7b_fact": [
      "Liebenberg syndrome is a rare genetic disorder that affects the development and functioning of the nervous system.",
      "The main manifestation of Liebenberg syndrome is intellectual disability.",
      "Individuals with Liebenberg syndrome may experience delayed motor development, speech and language delays, and behavioral challenges.",
      "Seizures, sleep disturbances, and sensory processing issues can occur in individuals with Liebenberg syndrome.",
      "Some individuals with Liebenberg syndrome may have additional health issues such as vision and hearing impairments, gastroesophageal reflux disease, and sleep apnea."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Liebenberg syndrome is not a recognized medical condition. It appears to be a fictitious or mistaken name. Therefore, any statements regarding its symptoms or manifestations cannot be verified.\n2. FALSE [correction]: Since Liebenberg syndrome is not a recognized medical condition, the statement about its main manifestation cannot be accurate.\n3. FALSE [correction]: As Liebenberg syndrome is not a recognized medical condition, statements about associated developmental delays cannot be verified.\n4. FALSE [correction]: Without recognition of Liebenberg syndrome as a medical condition, any claims about seizures, sleep disturbances, and sensory processing issues cannot be substantiated.\n5. FALSE [correction]: Since Liebenberg syndrome is not an established medical condition, any statements about additional health issues are not verifiable.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-7b_response": "There are currently no FDA-approved oral MPS1 kinase inhibitors. However, there are several clinical candidates in various stages of development. Some examples include:\n\n1. GSK2879552: This is a selective and potent oral MPS1 kinase inhibitor that is being developed by GlaxoSmithKline. It has shown promising results in preclinical studies and is currently being tested in phase 1 clinical trials.\n\n2. BMS-986156: This is another selective and potent oral MPS1 kinase inhibitor that is being developed by Bristol-Myers Squibb. It has also shown promising results in preclinical studies and is currently being tested in phase 1 clinical trials.\n\n3. AZD1208: This is a selective and potent oral MPS1 kinase inhibitor that is being developed by AstraZeneca. It has also shown promising results in preclinical studies and is currently being tested in phase 1 clinical trials.\n\n4. GSK2630671: This is a selective and potent oral MPS1 kinase inhibitor that is being developed by GlaxoSmithKline. It has shown promising results in preclinical studies and is currently being tested in phase 1 clinical trials.\n\nIt is important to note that these inhibitors are still in development and may not receive FDA approval. However, they offer hope for the treatment of MPS1-related diseases such as cancer and neurodegenerative disorders.",
    "llama-7b_fact_raw": "1. GSK2879552 is an oral MPS1 kinase inhibitor developed by GlaxoSmithKline.\n2. GSK2879552 is currently being tested in phase 1 clinical trials.\n3. BMS-986156 is an oral MPS1 kinase inhibitor developed by Bristol-Myers Squibb.\n4. BMS-986156 is currently being tested in phase 1 clinical trials.\n5. AZD1208 is an oral MPS1 kinase inhibitor developed by AstraZeneca and is currently being tested in phase 1 clinical trials.",
    "llama-7b_fact": [
      "GSK2879552 is an oral MPS1 kinase inhibitor developed by GlaxoSmithKline.",
      "GSK2879552 is currently being tested in phase 1 clinical trials.",
      "BMS-986156 is an oral MPS1 kinase inhibitor developed by Bristol-Myers Squibb.",
      "BMS-986156 is currently being tested in phase 1 clinical trials.",
      "AZD1208 is an oral MPS1 kinase inhibitor developed by AstraZeneca and is currently being tested in phase 1 clinical trials."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: GSK2879552 is an oral LSD1 inhibitor developed by GlaxoSmithKline.\n2. UNKNOWN\n3. FALSE [correction]: BMS-986156 is not an MPS1 kinase inhibitor; it is a GITR agonist developed by Bristol-Myers Squibb.\n4. UNKNOWN\n5. FALSE [correction]: AZD1208 is a PIM kinase inhibitor developed by AstraZeneca, not an MPS1 kinase inhibitor. The current phase of clinical trials for AZD1208 is unknown based on the provided statements.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-7b_response": "Golimumab, also known as Simponi, is a medication that is primarily used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is a tumor necrosis factor (TNF) inhibitor that works by blocking the activity of TNF, a protein that plays a key role in inflammation.\n\nHowever, golimumab has not been specifically tested or approved for the treatment of diabetes. Its role in managing diabetes is limited to the fact that it may help reduce inflammation in the body, which can be beneficial for people with diabetes who experience inflammation in their joints or other parts of their body.\n\nIt is important to note that golimumab should not be used to treat diabetes alone, as it is not a substitute for insulin or other diabetes medications. People with diabetes should continue to take their prescribed medications as directed by their healthcare provider.",
    "llama-7b_fact_raw": "1. Golimumab is used primarily to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n2. Golimumab is a tumor necrosis factor (TNF) inhibitor.\n3. Golimumab works by blocking the activity of TNF, a protein involved in inflammation.\n4. Golimumab has not been specifically tested or approved for the treatment of diabetes.\n5. Golimumab is not a substitute for insulin or other diabetes medications.",
    "llama-7b_fact": [
      "Golimumab is used primarily to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "Golimumab is a tumor necrosis factor (TNF) inhibitor.",
      "Golimumab works by blocking the activity of TNF, a protein involved in inflammation.",
      "Golimumab has not been specifically tested or approved for the treatment of diabetes.",
      "Golimumab is not a substitute for insulin or other diabetes medications."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-7b_response": "No, progeria is not caused by an autosomal recessive gene. Progeria is a rare genetic disorder that is caused by a mutation in the LMNA gene, which is located on chromosome 1q21. This mutation results in the production of a defective protein called lamin A, which is essential for the structure and function of the cell's nucleus. The LMNA gene is inherited in an autosomal dominant manner, which means that a single copy of the mutated gene is sufficient to cause the disorder. However, some cases of progeria have been reported to occur spontaneously due to mutations in the LMNA gene, without a family history of the disorder.",
    "llama-7b_fact_raw": "1. Progeria is caused by a mutation in the LMNA gene.\n2. The LMNA gene is located on chromosome 1q21.\n3. The mutation in the LMNA gene results in the production of a defective protein called lamin A.\n4. The LMNA gene is inherited in an autosomal dominant manner.\n5. Some cases of progeria occur spontaneously due to mutations in the LMNA gene without a family history of the disorder.",
    "llama-7b_fact": [
      "Progeria is caused by a mutation in the LMNA gene.",
      "The LMNA gene is located on chromosome 1q21.",
      "The mutation in the LMNA gene results in the production of a defective protein called lamin A.",
      "The LMNA gene is inherited in an autosomal dominant manner.",
      "Some cases of progeria occur spontaneously due to mutations in the LMNA gene without a family history of the disorder."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The LMNA gene mutation that causes progeria is not typically inherited in an autosomal dominant manner; most cases result from a new (de novo) mutation.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-7b_response": "There are several common variants at 12q14 and 12q24 that have been associated with different traits and diseases.\n\nAt 12q14, a common variant in the CDKN2A gene has been associated with an increased risk of melanoma, a type of skin cancer. Another common variant in the CDKN2B gene has been associated with a lower risk of melanoma.\n\nAt 12q24, a common variant in the TP53 gene has been associated with an increased risk of several types of cancer, including breast, ovarian, colorectal, and lung cancer. Additionally, a common variant in the RB1 gene has been associated with an increased risk of retinoblastoma, a type of eye cancer.\n\nOther common variants at 12q14 and 12q24 have been associated with traits such as obesity, type 2 diabetes, and cardiovascular disease.\n\nOverall, these common variants can affect gene expression levels and contribute to the development of various diseases and traits.",
    "llama-7b_fact_raw": "1. A common variant in the CDKN2A gene at 12q14 is associated with an increased risk of melanoma.\n2. A common variant in the CDKN2B gene at 12q14 is associated with a lower risk of melanoma.\n3. A common variant in the TP53 gene at 12q24 is associated with an increased risk of several types of cancer, including breast, ovarian, colorectal, and lung cancer.\n4. A common variant in the RB1 gene at 12q24 is associated with an increased risk of retinoblastoma.\n5. Common variants at 12q14 and 12q24 have been associated with traits such as obesity, type 2 diabetes, and cardiovascular disease.",
    "llama-7b_fact": [
      "A common variant in the CDKN2A gene at 12q14 is associated with an increased risk of melanoma.",
      "A common variant in the CDKN2B gene at 12q14 is associated with a lower risk of melanoma.",
      "A common variant in the TP53 gene at 12q24 is associated with an increased risk of several types of cancer, including breast, ovarian, colorectal, and lung cancer.",
      "A common variant in the RB1 gene at 12q24 is associated with an increased risk of retinoblastoma.",
      "Common variants at 12q14 and 12q24 have been associated with traits such as obesity, type 2 diabetes, and cardiovascular disease."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-7b_response": "The ligands of the Roundabout (Robo) receptors include various proteins and peptides that bind to the extracellular domain of the receptor and regulate its signaling activity. Some of the known ligands of Robo receptors include Robo1, Robo2, Robo3, and Robo4, which are all proteins expressed in various tissues during embryonic development. These ligands interact with the Robo receptors to regulate cell migration, proliferation, and differentiation during embryonic development. Additionally, other proteins such as Netrin-1, Netrin-2, and Sonic hedgehog have also been shown to bind to Robo receptors and regulate their signaling activity. Overall, the ligands of the Roundabout (Robo) receptors play an important role in various physiological processes, including embryonic development and tissue homeostasis.",
    "llama-7b_fact_raw": "1. The ligands of the Roundabout (Robo) receptors include proteins and peptides that bind to the extracellular domain of the receptor.\n2. Robo1, Robo2, Robo3, and Robo4 are known ligands of Robo receptors.\n3. These ligands are expressed in various tissues during embryonic development.\n4. Ligands of Robo receptors regulate cell migration, proliferation, and differentiation during embryonic development.\n5. Netrin-1, Netrin-2, and Sonic hedgehog are proteins that have been shown to bind to Robo receptors.",
    "llama-7b_fact": [
      "The ligands of the Roundabout (Robo) receptors include proteins and peptides that bind to the extracellular domain of the receptor.",
      "Robo1, Robo2, Robo3, and Robo4 are known ligands of Robo receptors.",
      "These ligands are expressed in various tissues during embryonic development.",
      "Ligands of Robo receptors regulate cell migration, proliferation, and differentiation during embryonic development.",
      "Netrin-1, Netrin-2, and Sonic hedgehog are proteins that have been shown to bind to Robo receptors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Robo1, Robo2, Robo3, and Robo4 are not ligands; they are the receptors themselves. Slit proteins are known ligands of Robo receptors.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Netrin-1 and Netrin-2 are known to bind to DCC and UNC-5 receptors, not Robo receptors. Slit proteins are the ligands that bind to Robo receptors. Sonic hedgehog is not a ligand for Robo receptors; it binds to the Patched receptor.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-7b_response": "Yes, there is a role for TFII-I in megakaryopoiesis. TFII-I is a transcription factor that plays a crucial role in the regulation of gene expression during hematopoiesis, including megakaryopoiesis.\n\nTFII-I is expressed in the bone marrow stromal cells that provide the microenvironment for hematopoietic stem cells, including those that give rise to megakaryocytes. TFII-I binds to specific DNA sequences in the promoters of genes involved in megakaryopoiesis, such as GATA1 and GATA2, and activates their transcription.\n\nWithout TFII-I, the expression of these genes would be reduced, leading to a decrease in the number of megakaryocytes produced in the bone marrow. Therefore, TFII-I is essential for the normal development and function of megakaryocytes in the bone marrow.",
    "llama-7b_fact_raw": "1. TFII-I is a transcription factor involved in the regulation of gene expression during hematopoiesis, including megakaryopoiesis.\n2. TFII-I is expressed in bone marrow stromal cells.\n3. Hematopoietic stem cells in the bone marrow, which give rise to megakaryocytes, are supported by stromal cells expressing TFII-I.\n4. TFII-I binds to specific DNA sequences in the promoters of genes such as GATA1 and GATA2.\n5. The absence of TFII-I leads to reduced expression of genes involved in megakaryopoiesis and a decrease in the number of megakaryocytes.",
    "llama-7b_fact": [
      "TFII-I is a transcription factor involved in the regulation of gene expression during hematopoiesis, including megakaryopoiesis.",
      "TFII-I is expressed in bone marrow stromal cells.",
      "Hematopoietic stem cells in the bone marrow, which give rise to megakaryocytes, are supported by stromal cells expressing TFII-I.",
      "TFII-I binds to specific DNA sequences in the promoters of genes such as GATA1 and GATA2.",
      "The absence of TFII-I leads to reduced expression of genes involved in megakaryopoiesis and a decrease in the number of megakaryocytes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known roles of transcription factors like TFII-I in the regulation of gene expression during hematopoiesis, including megakaryopoiesis. TFII-I is known to be expressed in various cell types, including stromal cells, and it can influence the behavior of hematopoietic stem cells indirectly through its effects on the bone marrow microenvironment. TFII-I is known to bind to DNA sequences in the promoters of certain genes, and its absence could indeed lead to reduced expression of genes involved in megakaryopoiesis, potentially resulting in a decrease in the number of megakaryocytes. However, without specific references to scientific literature or a detailed passage providing context, these statements are assumed to be true based on general knowledge of transcription factors and their roles in gene regulation.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-7b_response": "Yes, atenolol is metabolized by the cytochrome P450 (CYP) enzyme CYP2D6. Atenolol is a beta-adrenergic blocker that is used to treat hypertension and angina. CYP2D6 is a key enzyme in the metabolism of many drugs, including beta-blockers such as atenolol. CYP2D6 is responsible for the conversion of atenolol to its active metabolite, tenolol, which has a longer half-life and greater beta-blocking effects. Therefore, CYP2D6 plays an important role in the therapeutic efficacy and safety of atenolol.",
    "llama-7b_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. Atenolol is used to treat hypertension and angina.\n3. CYP2D6 is a key enzyme in the metabolism of many drugs, including beta-blockers.\n4. CYP2D6 converts atenolol to its active metabolite, tenolol.\n5. Tenolol has a longer half-life and greater beta-blocking effects than atenolol.",
    "llama-7b_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "Atenolol is used to treat hypertension and angina.",
      "CYP2D6 is a key enzyme in the metabolism of many drugs, including beta-blockers.",
      "CYP2D6 converts atenolol to its active metabolite, tenolol.",
      "Tenolol has a longer half-life and greater beta-blocking effects than atenolol."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and is excreted primarily in the urine; it is not metabolized by the cytochrome P450 enzyme CYP2D6.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Atenolol does not have an active metabolite called tenolol; it is excreted largely unchanged in the urine.\n5. FALSE [correction]: Since atenolol does not have an active metabolite called tenolol, this statement is incorrect. Atenolol itself is the active drug with beta-blocking effects.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-7b_response": "There are several versions of ExpansionHunter, including:\n\n1. ExpansionHunter Classic: This is the original version of ExpansionHunter, which was released in 2014. It is a turn-based strategy game that focuses on building and expanding your empire.\n\n2. ExpansionHunter Mobile: This is the mobile version of ExpansionHunter, which was released in 2016. It is a free-to-play game that can be played on both iOS and Android devices.\n\n3. ExpansionHunter 2: This is the sequel to ExpansionHunter Classic, which was released in 2016. It is a real-time strategy game that introduces new features, such as resource management and multiplayer battles.\n\n4. ExpansionHunter Online: This is the online version of ExpansionHunter, which was released in 2017. It is a browser-based game that allows players to compete against each other in real-time battles.\n\n5. ExpansionHunter 3: This is the upcoming third installment in the ExpansionHunter series. It is currently in development and is expected to be released in 2021.",
    "llama-7b_fact_raw": "1. ExpansionHunter Classic was released in 2014.\n2. ExpansionHunter Mobile was released in 2016 and is available on iOS and Android devices.\n3. ExpansionHunter 2 was released in 2016 and is a real-time strategy game.\n4. ExpansionHunter Online was released in 2017 and is a browser-based game.\n5. ExpansionHunter 3 was expected to be released in 2021.",
    "llama-7b_fact": [
      "ExpansionHunter Classic was released in 2014.",
      "ExpansionHunter Mobile was released in 2016 and is available on iOS and Android devices.",
      "ExpansionHunter 2 was released in 2016 and is a real-time strategy game.",
      "ExpansionHunter Online was released in 2017 and is a browser-based game.",
      "ExpansionHunter 3 was expected to be released in 2021."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or information about the \"ExpansionHunter\" being referred to, it is not possible to verify the accuracy of these statements. \"ExpansionHunter\" could refer to a software tool, a game, or another product entirely, and without specific knowledge about the release dates and platforms of this product, the truthfulness of these statements cannot be determined.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-7b_response": "Adamts18, also known as aggrecanase-1, is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of proteins. This protein is primarily expressed in the extracellular matrix of various tissues, including bone, cartilage, and blood vessels.\n\nIn the context of hormone receptor signaling, Adamts18 has been shown to play a role in the regulation of estrogen signaling in breast cancer cells. Specifically, research has demonstrated that Adamts18 can cleave and inactivate the estrogen receptor (ER) in breast cancer cells, thereby reducing the ability of estrogen to stimulate cell growth and proliferation.\n\nAdditionally, Adamts18 has been shown to be upregulated in response to other hormones, such as progesterone and testosterone, suggesting that it may play a role in the regulation of hormone signaling more broadly.\n\nOverall, while further research is needed to fully elucidate the role of Adamts18 in hormone receptor signaling, its ability to modulate the activity of key hormone receptors suggests that it may be an important target for therapeutic intervention in certain contexts.",
    "llama-7b_fact_raw": "1. Adamts18 is a member of the ADAMTS family of proteins.\n2. Adamts18 is primarily expressed in the extracellular matrix of various tissues, including bone, cartilage, and blood vessels.\n3. Adamts18 has been shown to play a role in the regulation of estrogen signaling in breast cancer cells.\n4. Adamts18 can cleave and inactivate the estrogen receptor in breast cancer cells.\n5. Adamts18 is upregulated in response to hormones such as progesterone and testosterone.",
    "llama-7b_fact": [
      "Adamts18 is a member of the ADAMTS family of proteins.",
      "Adamts18 is primarily expressed in the extracellular matrix of various tissues, including bone, cartilage, and blood vessels.",
      "Adamts18 has been shown to play a role in the regulation of estrogen signaling in breast cancer cells.",
      "Adamts18 can cleave and inactivate the estrogen receptor in breast cancer cells.",
      "Adamts18 is upregulated in response to hormones such as progesterone and testosterone."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the specific roles and regulation of Adamts18, including its interaction with estrogen signaling and hormone response, would require specific scientific evidence to confirm. Without the context of the passage or access to relevant scientific literature, it is not possible to accurately determine the truthfulness of statements 3, 4, and 5.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-7b_response": "Thiazovivin is a synthetic anticoagulant that works by inhibiting the enzyme thrombin. Thrombin is a key enzyme in the coagulation cascade, which is responsible for the clotting of blood. By inhibiting thrombin, thiazovivin prevents the formation of blood clots, which is beneficial in the treatment of cardiovascular diseases such as deep vein thrombosis and pulmonary embolism.\n\nAdditionally, thiazovivin also has anti-inflammatory properties, which may contribute to its efficacy in the treatment of certain inflammatory disorders such as rheumatoid arthritis. However, the exact mechanisms by which thiazovivin exerts its anti-inflammatory effects are not fully understood.\n\nOverall, thiazovivin's mode of action involves the inhibition of thrombin, which helps to prevent the formation of blood clots and reduce inflammation.",
    "llama-7b_fact_raw": "1. Thiazovivin is a synthetic anticoagulant.\n2. Thiazovivin works by inhibiting the enzyme thrombin.\n3. Thrombin is a key enzyme in the coagulation cascade responsible for blood clotting.\n4. Thiazovivin is used in the treatment of cardiovascular diseases such as deep vein thrombosis and pulmonary embolism.\n5. Thiazovivin has anti-inflammatory properties.",
    "llama-7b_fact": [
      "Thiazovivin is a synthetic anticoagulant.",
      "Thiazovivin works by inhibiting the enzyme thrombin.",
      "Thrombin is a key enzyme in the coagulation cascade responsible for blood clotting.",
      "Thiazovivin is used in the treatment of cardiovascular diseases such as deep vein thrombosis and pulmonary embolism.",
      "Thiazovivin has anti-inflammatory properties."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is not an anticoagulant; it is a small molecule inhibitor used to enhance the survival of various cells, including stem cells.\n2. FALSE [correction]: Thiazovivin does not work by inhibiting thrombin; it acts by inhibiting the Rho-associated protein kinase (ROCK) pathway.\n3. TRUE\n4. FALSE [correction]: Thiazovivin is not used in the treatment of cardiovascular diseases; it is primarily used in stem cell research.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "unknown"
    ]
  }
]